**REVIEW ARTICLES**

Pharmacotherapy of kidney transplant rejection: A narrative review on current therapy and future aspects  
Naim Kittana, Alaa Hamamri, Lana Zighan, Israa Salama, Suhaib Hattab  

**ORIGINAL ARTICLES**

The frequency of celiac disease in children with chronic constipation  
Yasin Sahin, Derya Aydin Sahin  

Testing the depth of anesthesia in total intravenous and balanced anesthesia  
Vickovic Sanja, Popovic Radmila, Bozic Teodora, Uvelin Arsen, Lukic-Sarkanovic Mirka, Zdravkovic Ranko  

Comparison of diagnostic tests performed in patients with suspected acute osteomyelitis  
Asli Ayan, Mesut Ortatatif  

Comparison of psoriasis area and severity index and physician’s global assessment in determining psoriasis severity  
Ayda Acar, Ada Bozkurt, Gizem Kocabas Yenipazar, Sibel Alper, Can Ceylan  

Case series of pancreas transplant in Kingdom of Saudi Arabia  
Faisal A Alsaif, Mohammed Alsaghier, Mohammad Saad Alqahtani, Mansour Altawfeeq, Khalid Almeshari, Faisal Alalem  

The effect of neutrophil lymphocyte ratio and monocyte HDL ratio in indicating additional arterial disease in patients scheduled to undergo elective coronary bypass operation  
Mesut Engin  

Neutrophil to lymphocyte ratio: An indicator of recurrence in primary spontaneous pneumothorax?  
Serhat Yalcinkaya  

Oral hygiene habits and storage method impact on toothbrush contamination among participants in Kuwait  
Ahmad M AlAli, Norya M Al Maraghi, Qusiyia Y Electricwala, Ali A Dashli  

Arthroscopic Bankart repair by using the antero-superior portal for visualization  
Tahsin Gurpinar, Baris Polat, Tuna Pehlivanoglu, Ayse E Polat, Engin Carkci, Yusuf Ozturkmen  

Relationship with serum bilirubin levels and mortality in critically ill patients  
Belgin Akan, Derya Gokcinar, Guzin Ceran, Isil Ozkocak Turan  

Evaluation of the flexible laryngeal mask airway in 120 patients undergoing tympanoplasty  
Guo Ran, Yan Wu, Lijun Wang, Jie Jia  

Diagnostic value of TIMP-1, TIMP-2, TGF- b1, YKL-40 in the evaluation of liver fibrosis in patients with chronic hepatitis B  
Kader Arslan, Cigdem A Hatipoglu, Cemal Bulut, Mehmet A Gonultas, Sami Kinikli  

**CASE REPORTS**

Can diabetes insipidus be used as a marker for multisystemic and progressive disease in Langerhans cell histiocytosis?  
Nizameddin Koço, Soner Cander, Özen Öz Gul  

Parapharyngeal spindle cell rhabdomyosarcoma presenting as infra-auricular pain with vocal cord paralysis  
Ching-Yuan Wang, Liang-Yu Chen, Teik-Ying Ng  

Treatment of bilateral patellar dislocation after bilateral total knee arthroplasty of a patient with Parkinson’s disease: A case report  
Kursad Aytekin, Cem Zeki Esenycl
Continued from cover

Oliver Sacks syndrome treated with adaptation to hearing aid  
Ebru Sahan, Ismet Kirpınar  
466

Hyalinizing trabecular tumor of the thyroid gland: A case report and review of the literature  
Mohammed Alswayyed  
469

Emergency parathyroidectomy under combined superficial and intermediate cervical plexus block: A fatal case of hypercalcemic crisis due to parathyroid carcinoma  
Erkan Somuncu, Fethi Akyol  
473

BRIEF COMMUNICATION

The experience of Oman with establishing a field hospital during COVID-19 pandemic  
Zainab Al Lawati, Alaa Al Lawati  
477

LETTER TO THE EDITOR

Overview on outbreak investigations of 2019 novel Coronavirus disease  
Asad Khan  
482

SELECTED ABSTRACTS OF ARTICLES PUBLISHED ELSEWHERE BY AUTHORS IN KUWAIT  
485

FORTHCOMING CONFERENCES AND MEETINGS  
487

WHO-FACTS SHEET

1. Brucellosis
2. Children: new threats to health
3. Endometriosis
4. Hepatitis C
5. Meningitis

YEARLY TITLE INDEX  
508

YEARLY AUTHOR INDEX  
511
Open access for articles at
http: www.kmj.org.kw

Indexed and abstracted in:

SCOPUS

EMBASE
(The Excerpta Medica Database)

Science Citation Index Expanded
(also known as SciSearch®)

Journal Citation Reports/Science Edition

IMEMR Current Contents
(Index Medicus for the Eastern Mediterranean Region)
available online at: www.emro.who.int/EMRJorList/online.aspx

THE PUBLICATION OF ADVERTISEMENTS IN THE KUWAIT MEDICAL JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE KUWAIT MEDICAL ASSOCIATION OR THE EDITORIAL BOARD OF THIS JOURNAL, OF THE ADVERTISED PRODUCTS, SERVICES, OR CLAIMS MADE BY THE ADVERTISERS. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE ASSOCIATION.

PUBLISHER: The Kuwait Medical Journal (KU ISSN-0023-5776) is a quarterly publication of THE KUWAIT MEDICAL ASSOCIATION. Address: P.O. Box 1202, 13013 Safat, State of Kuwait; Telephone: 1881181 Fax: 25317972, 25333276. E-mail : kmj@kma.org.kw
COPYRIGHT: The Kuwait Medical Journal. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in Kuwait.
INSTRUCTIONS FOR AUTHORS: Authors may submit manuscripts prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. These Requirements are published in each issue of the Kuwait Medical Journal.
CHANGE OF ADDRESS: Notice should be sent to the Publisher six weeks in advance of the effective date. Include old and new addresses with mail codes.
KUWAIT MEDICAL JOURNAL (previously The Journal of the Kuwait Medical Association) is added to the list of journals adhering to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals”, American College of Physicians, Independence Mall West, Sixth Street at Race, Philadelphia, PA 19106-1572, USA, and can be located at http://www.icmje.org/jrnlist.html

Indexed and abstracted in:

SCOPUS

EMBASE
(The Excerpta Medica Database)

Science Citation Index Expanded
(also known as SciSearch®)

Journal Citation Reports/Science Edition

IMEMR Current Contents
(Index Medicus for the Eastern Mediterranean Region)
available online at: www.emro.who.int/EMRJorList/online.aspx

THE PUBLICATION OF ADVERTISEMENTS IN THE KUWAIT MEDICAL JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE KUWAIT MEDICAL ASSOCIATION OR THE EDITORIAL BOARD OF THIS JOURNAL, OF THE ADVERTISED PRODUCTS, SERVICES, OR CLAIMS MADE BY THE ADVERTISERS. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE ASSOCIATION.
Guidelines for Authors

Formerly known as 'The Journal of the Kuwait Medical Association', the Kuwait Medical Journal (KMJ) was established in the year 1967. It is the official publication of the Kuwait Medical Association and is published quarterly and regularly every March, June, September and December.

KMJ aims to publish peer-reviewed manuscripts of international interest. Submissions on clinical, scientific or laboratory investigations of relevance to medicine and health science come within the scope of its publication. Original articles, case reports, brief communications, book reviews, insights and letters to the editor are all considered. Review articles are solicited. Basic medical science articles are published under the section 'Experimental Medicine'.

The Kuwait Medical Journal follows the guidelines set down in “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” developed by the International Committee of Medical Journal Editors (ICMJE). The official and most recent version of the recommendations are available at www.icmje.org.

Journal Policies

Ethics in Publishing
Where human investigations are part of the study, the research must be conducted ethically in accordance with the Declaration of Helsinki, and the design of the work has to be approved by a local ethics committee and informed written consent must be obtained from all subjects. Documents review and approval from the Institutional Review Board or Ethics Committee must be submitted along with any studies involving people, medical records and human tissues. A relevant statement of approval should be added in the ‘Subjects and Methods’ section of the manuscript.

Authors should also consult guidelines for the reporting of specific study types (e.g., the CONSORT guidelines for the reporting of randomized trials); see http://equator-network.org.

Copyright
The publisher reserves copyright on the Journal’s contents. No part may be reproduced, translated or transmitted in any form by any means, electronic or mechanical, including scanning, photocopying, recording or any other information storage and retrieval system without prior permission from the publisher. The publisher shall not be held responsible for any inaccuracy of the information contained therein.

Conflict of Interest
Potential conflicts of interest for all authors must be identified in a ‘Conflict of interest’ statement at the end of the manuscript. An electronic cover letter from the corresponding author is acceptable. Authors of research articles should disclose any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (e.g., consultancies, employment, expert testimony, honoraria, retainers, stock) that may affect the conduct or reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure. Because reviews and editorials are based on selection and interpretation of the literature, the Journal expects that authors of such articles will not have any financial interest in a company (or its competitor) that makes a product discussed in the article. Information about potential conflict of interest will be made available to reviewers and will be published with the manuscript at the discretion of the editors. If there is no conflict of interest, please state: “The authors declare no conflicts of interest.”

Peer Review
All submitted manuscripts are reviewed by the editorial staff to ensure adherence to the guidelines of the Journal. Manuscripts that are considered suitable for review are sent to a peer in the relevant field of study as part of a double-blinded peer review. The reviewer may recommend the manuscript be accepted as is, undergo revision, or be rejected. If a reviewer recommends revision of a manuscript, the revised version must be re-submitted to the Journal within 3 months from the date when the review report is sent to the corresponding author.

Authors
To be named as an author on a submission, the following four criteria are followed:
1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. Authors should also have confidence in the integrity of the contributions of their co-authors. Specific contributions made by each author to the article must be clearly stated at the end of the document. Those who do not meet all four criteria should be mentioned in the Acknowledgment section of the submission.

Conflict of Interest
Once a paper has been accepted, the Journal does not consider requests to add, delete or rearrange the sequence of the authors. If the corresponding author requests to add, remove or rearrange the authors’ names after manuscript submission, the journal will seek justification for the requested change. Written confirmation signed by all authors, attesting that they agree to the addition, removal, or rearrangement of names is required. In the case of the addition or removal of authors, the author being added or removed must confirm assent. Requests that are not sent by the corresponding author will not be considered.

Fees
Publication in the Kuwait Medical Journal is free of charge.

Plagiarism
The Journal defines plagiarism as the use of others’ published and unpublished ideas or words without prior consent, and presenting them as new and original, whether intentional or not. If an accepted or published paper is found to...
be plagiarised, the manuscript will be retracted and the author will be blacklisted from submitting to the journal.

Preparing your manuscript

Article types

Original Articles: Original Articles include laboratory and clinical investigations as well as research not previously published or being considered for publication elsewhere. The text should contain a Title page, Abstract (in structured format) of not more than 250 words, Key Words (no more than five), Introduction, Subjects (or Materials) and Methods, Results, Discussion, Conclusion, Acknowledgment/s (if any) and References, Figure Legends, Tables, and Figures in this order. Details of the section contents are explained below for further adherence.

Review Articles (solicited only): Review articles should contain separate sections such as Title Page, Abstract (preferably in structured format) of no more than 250 words, Key Words (no more than five), Introduction, Methods/History (if applicable), Literature Review, Conclusion, Acknowledgment/s (if any) and References followed by (if relevant), Legends to figures, Tables, and Figures.

Case Reports: These should contain separate sections such as Title page, Abstract (a short summary of not more than 200 words), Key Words (no more than five), Introduction, Case history/report, Discussion, Conclusion, Acknowledgment/s (if any) and References followed by (if relevant), Legends to figures, Tables, and Figures.

Short Communications: Short communications are concise articles that aim to report new ideas, significant improvements to existing methods, a new practical application, or a new tool or resource. Short communications do not cover in detail background information about the problems treated, rather they provide key pointers to the reader. The work reported needs to be technically sound, innovative and significantly unique, advancing the state of the art. Short communication is not intended to publish preliminary results. Short communications should be similar to a research article, but with briefer Materials and Methods and Discussion.

Letters to the Editor: Letters may comment on recently published KMJ articles, novel cases or topics of current interest as Title page, Abstract (preferably in structured format) of not more than 200 words, Key Words (no more than five), Introduction, Case report, Discussion, Conclusion, Acknowledgment/s (if any) and References followed by (if relevant), Legends to figures, Tables, and Figures.

Structured abstract

A structured abstract (no more than 250 words) is required for studies under the section “Original Articles”. It must provide an overview of the entire paper, and should contain succinct statements on the following, where appropriate: Objective(s), Design, Setting, Subjects, Intervention(s), Main Outcome Measure(s), Result(s), and Conclusion(s). (See: Haynes RB, Mulrow CD, Huth AJ, Altman DG, Gardner MJ. More informative abstracts revisited. Annals of Internal Medicine 1990; 113:69-76). Abstracts for all other category of submissions shall be a short summary followed by Key words and the report or review.

Preparation of the manuscript

The manuscript should be typed as ‘normal text’ with no hyphenation and no hard returns within paragraphs (use automatic wordwrap) on A4 size (29.7 x 21 cm) paper in single column format, preferably in font size 12. Cell format for paragraphs, artwork and/or special effects for the text and/or table(s) are not acceptable. Italics shall be used only for foreign/Latin expressions and/or special terminologies such as names of micro-organisms. Maintain a minimum of 2 cm margin on both sides of the text and a 3 cm margin at the top and bottom of each page. No part of the manuscript other than abbreviations and/or subtitles should be written in upper case. Header/foot notes, end notes, lines drawn to separate the paragraphs or pages etc. are not acceptable. Do not submit articles written/saved in ‘Track-change’ mode.

More than six authors are not appreciated for a research article and if listed, the authors may be asked to justify the contribution of each individual author. For case reports, not more than three authors are acceptable. Regarding contributions of authors over the limit mentioned above, please read the ‘Acknowledgment’ section.

Key words

Key Words (maximum five) should be preferably MeSH terms, and shall not duplicate words already in the manuscript title. MeSH terms can be checked at: http://www.nlm.nih.gov/mesh.

Tables

Tables typed on separate pages using table format (MS Word or Excel) should follow the list of references. Tables must be numbered consecutively using Arabic numerals and provided with appropriate titles. Contents of the table should be simple, and information therein not duplicated, but duly referred to, in the main text. Tables recording only a few values are not appreciated, since such information can be more accurately, usefully and concisely presented in a sentence or two in the manuscript.

Title Page

The title page of the submitted manuscript should provide a clear title of the study followed by full names of all authors, the highest academic degree and affiliations if any, the name and address of the institution(s) where the work was done including the department, the name and complete address of the corresponding author to whom proofs and correspondences shall be sent, duly supported with contacts such as telephone, mobile and the e-mail address. This page must also contain any disclaimers, sources of support and a conflict of interest declaration.

Illustrations

All illustrations including figures should be numbered as Fig 1, Fig 2, etc. in running sequence and submitted as separate attachments along with the manuscript. Photographs should fit within a print area of 164 x 235 mm. In the case of figures where patient’s identity is not concealed, authors need to submit a written consent of the patient or of the patient’s guardian, in the case of minors. Figure legends should be listed separately after the ‘References’ section. If any of the tables, illustrations or photomicrographs have been published elsewhere previously, a written consent for re-production is required from the copyright holder along with the manuscript. When charts are submitted, the numerical data on which they were based should be supplied.
Abbreviations

Except for units of measurement, abbreviations should be defined on their first use in the abstract and in the text and then applied consistently throughout the article. Non-standard abbreviations or those appearing fewer than three times are not accepted. Use abbreviated units of measure, only when used with numbers. Abbreviations used as legends in Tables and/or figures should be duly defined below the respective item.

Numbers and units

Measurements of length, height, weight and volume must be reported in metric units (meter, kilogram, liter etc.) or their decimal multiples. Temperature should be given in degrees Celsius, Blood pressure in mmHg, and hematological and biochemical measurements in Système International (SI) units. For decimal values, use a point, and not a comma, e.g., 5.7. Use a comma for numbers $>1,000$ (i.e., $10^3$) and do not use a comma for numbers $<9,999$, (e.g., 6,542).

Drug names

Non-proprietary (generic) names of product should be employed. If a brand name for a drug is used, the British or international non-proprietary (approved) name should be given in parentheses. The source of any new or experimental preparation should also be given.

Acknowledgment

Contributors who meet fewer than all 4 of the aforementioned criteria for authorship should only be listed in this section. Contributions of others who have involved in the study, such as statisticians, radiologists etc. and/or those who have assisted in the preparation of the manuscript being submitted could also be included in this section. The corresponding author must obtain written permission to be acknowledged from all acknowledged individuals.

References

Indicate references in the text in sequence using Arabic numerals within square brackets and as superscripts (e.g., [1-3] etc.). Do not quote additional data (like part of the title, year of publication etc.) from the references, with citations in the text, unless very important. In the References section, list them in the same sequence as they appeared in the text. Include the names and initials of all authors if not more than six ($<6$). Write the last name of authors followed by the initials with no punctuation other than a comma to separate the names. In references where authorship exceeds six, use et al after six author names. Do not use automatic numbering, end notes or footnotes for references. References to manuscripts either in preparation or submitted for publication, personal communications, unpublished data, etc. are not acceptable.

References should be limited to those relating directly to the contents of the paper and should be set out in the style outlined by the International Committee of Medical Journal Editors (ICMJE), as shown in the examples below. Additional examples are in the ICMJE sample references. https://www.nlm.nih.gov/bsd/uniform_requirements.html

Examples


Manuscript submission

To present your original work for consideration, one complete set of the manuscript written in English, accompanied by tables and one set of figures (if applicable) should be submitted to the Editor by e-mail to "kmj@kma.org.kw" as attachment files.

The manuscript submitted by e-mail should be in MS Word document (.doc) format, together with a scanned copy or PDF version of the signed consent letter of the author(s) (see the section Authorship and Consent Form for details). Figures or photographs, if any, need to be presented as separate attachments in .JPG or .BMP format with a resolution of 300 dpi and illustrations such as graphs, charts etc., as Excel format files. Incomplete/improper submissions will not be processed, and will be returned. Author(s) will receive a formal acknowledgment letter with a permanent reference number towards each successful submission.

Following a peer review process, the corresponding author will be advised of the status; acceptance or recommendation for revision or rejection of the paper, in a formal letter sent through e-mail. A galley proof will be forwarded to the corresponding author by e-mail at the time of publication of the accepted paper, which must be returned to the journal office within 48 hours with specific comments or corrections, if any. Such corrections in the galley proof must be limited to typographical errors or missing contents from the finally accepted version.

Authorship and consent form

All authors must give their signed consent for publication in a letter of submission, which should accompany the manuscript. This letter should contain the following statement: “This manuscript (write the title) is an unpublished work which is not under consideration elsewhere and the results contained in this paper have not been published previously in whole or part, except in abstract form. In consideration of the KMJ accepting my/our submission for publication, the author(s) undersigned hereby assign all copyrights ownership to the KMJ and shall have no right to withdraw its publication. It is expressly certified that I/we, have done/actively participated in this study and agree to the accuracy of contents of this manuscript. It was conducted in accordance with current ethical considerations and meets with the committee’s approval. I/all of us agree to its publication in KMJ and to the authorship as expressed in this declaration and in the title page of our manuscript”.

The consent form must also contain the names of all authors, along with their signatures.

Manuscripts should be submitted to: The Editor, Kuwait Medical Journal P.O. Box: 1202 Code-13013-Safat Kuwait Telephone: (965) 1881181, 25333920 extn. 114 E-mail: kmj@kma.org.kw Website: www.kma.org.kw/KMJ
Pharmacotherapy of kidney transplant rejection: A narrative review on current therapy and future aspects

Naim Kittana¹, Alaa Hamamri², Lana Zighan², Israa Salama², Suhaib Hattab¹
¹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
²Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine

ABSTRACT

Objectives: The current article was designed to review the main clinical and pharmacological data on the currently approved immunosuppressants used for the prevention and treatment of kidney transplant rejection.
Design: A narrative review manuscript
Settings: A comprehensive search for the available literature on renal transplant pharmacotherapy on PubMed, Google, Medline, Scopus, and clinicalTrials.gov.
Subjects: Key related articles published until May 2020
Intervention: Non-interventional
Main outcome measures: The induction therapy should be started with high doses of immunosuppressants immediately after transplantation, followed by gradual dosage reduction in maintenance therapy. It commonly involves thymoglobulin or alemtuzumab. Basiliximab is also approved as an induction agent, especially in recipients with low risk of rejection.
Results: Thymoglobulin is superior in patients on a steroid-free maintenance regimen. The maintenance therapy should be started early after transplantation or even before. It can be made up of different combinations of calcineurin inhibitors (CNIs) like cyclosporine A / tacrolimus, mycophenolate mofetil (MMF), mTOR inhibitors (sirolimus/everolimus) and corticosteroids. Tacrolimus is considered a first-line agent in maintenance therapy and it is associated with a better allograft function. MMF is a major drug in the current maintenance therapy in combination with CNIs, and a main part in CNI-free regimens. Corticosteroids are still a main component in immunosuppressive regimens, despite the current interest in avoiding them due to their various long-term side effects. The rates of transplant loss are still unacceptably high, mainly due to dose-limiting toxicities.
Conclusion: New drugs are being developed to improve the efficacy and safety profile of maintenance therapy. Some of them showed promising results.

KEY WORDS: alemtuzumab, cyclosporine, sirolimus, tacrolimus, thymoglobulin

INTRODUCTION

Chronic kidney disease (CKD) is defined as a decrease in kidney function indicated by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m², presence of kidney damage markers, or both for more than three months, regardless of the underlying cause. The two main causes of CKD are found to be diabetes and hypertension[1].

CKD is a major health care problem. According to a recent study, 13.4% of the population worldwide are CKD patients, which is thought to be more than the prevalence of diabetes mellitus[2]. Treatment of CKD mainly aims to delay the progression towards end-stage renal disease[3], in which the only treatment becomes dialysis or renal transplantation when possible[4]. In the year 2016, renal transplants comprised around 66% of the different total transplants worldwide according to the Global Observatory on Donation and Transplantation[5]. However, this therapeutic option is challenged by the reaction of the immune system against the transplant, which necessitates a chronic control by immunosuppressants[6].

Address correspondence to:
Dr. Naim Kittana, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, An Najah National University, Akademia Street, P.O. Box 7, Nablus, Palestine. Tel: +970 (9) 2345113; Fax: +970 (9) 2345982; E-mail: naim.kittana@najah.edu
Despite the continuous development of immunosuppressive agents over recent decades, renal graft loss as a consequence of rejection response cannot be totally prevented. The United Network for Organ Sharing reported that the probability of new graft rejection from a living donor at one-year post-transplantation is 3% and increases up to 14% at five years\(^7\). Generally, graft survival is affected by different factors including recipient age, the number of human leukocyte antigen mismatches, the onset of graft function after transplantation, donor type (deceased or living) and the presence of infections\(^8\)\textendash\(^10\).

This review discusses the current protocols, the new approaches and potential drug targets that might improve the prevention of renal graft rejection.

There are three types of graft rejection; hyperacute, acute and chronic rejection. Each one has a unique onset and mechanism\(^{11}\).

### Hyperacute rejection

Hyperacute rejection appears only in the vascularized organs. It is a fast response that aims to eliminate foreign intruders. It occurs within the first few minutes to hours of transplantation\(^{11,12}\). In this reaction, the preexisting recipient antidonor antibodies bind to endothelial cells of the graft and activate the complement cascade, which recruits inflammatory cells such as polymorphonuclear cells\(^{11\textendash}14\). The recruited inflammatory cells secrete enzymes that cause injury to the endothelial cells, resulting in the release of von Willebrand factor that stimulates platelet aggregation and thrombus formation, which ultimately leads to graft loss\(^{11,14}\). A high risk for hyperacute rejection occurs if the lymphocytotoxicity crossmatch was positive\(^{15}\).

### Acute rejection

This is the most common type of renal transplant rejection. It reduces the graft half-life by around 34% and accounts for almost 6.2% of the causes of graft loss\(^{12,16,17}\). It is a combination of humoral and cellular responses\(^{13}\). The manifestations of this type begin within a week to three months after transplantation\(^{11,12}\). It involves initially the activation of the innate response against the foreign grafts\(^{18}\). It is triggered as a consequence of a graft tissue injury caused by ischemic reperfusion or infection during transplantation\(^{11}\), where specific substances called damage-associated molecular patterns are released from the site of injury, causing the activation of certain receptors expressed by innate immune cells called pattern-recognition receptors\(^{19}\). Upon activation, these receptors mediate danger signals that initiate the innate response through the activation of dendritic cells (DCs) and the secretion of chemokines and cytokines\(^{11,19}\). Activated DCs migrate to the secondary lymphoid tissues to activate T-cells and induce their migration to the graft area to initiate the adaptive response\(^{11,17}\).

The adaptive response is more specific than the innate one. It plays a major role in the rejection mechanism\(^{11,18}\). This response occurs when T-cells recognize the peptide antigen presented by major histocompatibility complex, which is expressed on the surface of the donor antigen-presenting cells (APC); this process is called direct pathway\(^{11\textendash}13,17,18\). Full activation of T-cells is not only achieved by binding with major histocompatibility complex, but also requires other interactions between molecules on the surface of T-cells and their ligands on the APC, such as CD28: CD80L or CD 86L, CD2: CD58L, CD5: CD72L. APC secret IL-12 that activates the helper T-cells (CD4\(^+\) cells) and induce their differentiation into TH1 cells, which produce interleukin-2 (IL-2) and INFs, both can stimulate the differentiation of cytotoxic T-cells. On the other hand, when CD4\(^+\) cells are activated by DCs expressing CD86, they will be differentiated into TH2 cells and thereby acquire the ability to secrete IL-4, IL-5, IL-9, IL-10, IL-13 and IL-14, which in turn stimulate B-cells to produce antibodies against the graft and to present antigens to T-cells\(^{14,18}\).

### Chronic rejection

It represents the most common reason for graft failure after one year of transplantation. The exact cause of developing chronic rejection is still unknown. It is thought to be a combination of different factors including infections, chronic diseases and immunosuppressant induced nephrotoxicity\(^{19}\). Forty-seven percent of graft loss cases are attributed to this type of rejection\(^{16}\), compared to 6.2% of graft loss by acute rejection as mentioned earlier. This difference in the rejection rate could be due to the response of acute type to current immunosuppressive therapy in contrast with chronic type, which is not adequately controlled by any of the available immunosuppressants until now\(^{17}\).

### METHODS

Combinations of different related keywords were fed to PubMed, Google, Medline Scopus and clinicalTrials.gov. The keywords included terms like “kidney/renal transplant rejection”, “renal transplant therapy” (RTT), “immunosuppressants”, and known drug names like thymoglobulin, tacrolimus, etc. The suggested related articles by PubMed and Google were also investigated. The study considered only the articles published in peer-reviewed journals or websites and lay in the scope of the manuscript. The literature search was performed between October 2019 to April 2020.
LITERATURE REVIEW

Conventional immunosuppressive agents

To ensure successful renal transplantation and long-term survival of the graft, two categories of immunosuppressive agents are used sequentially for induction and maintenance[20]. Induction agents include potent immunosuppressive drugs that are given immediately after transplantation and continued over about 1-10 days to reduce the risk of early acute rejection[20,21]. Thereafter, maintenance therapy is continued life-long in lower doses to maintain long-term survival with the least possible side effects[22,23].

Induction agents

Antithymocyte globulin: Atgam and Thymoglobulin

Antithymocyte globulins (ATG) are polyclonal antibodies produced in horse or rabbit by injecting them with human lymphocytes to act as an immunogen so that anti-lymphocyte serum is produced, from which the most potent portion, immune gamma-globulins, are purified[22,24]. These antibodies mediate immunosuppression by targeting markers on T-cell surfaces that are responsible for the immune-activating signals such as CD2, CD3, CD4, CD8, CD16, CD18, CD25 and CD45[20,24]. Consequently, these antigen-antibody interactions result in complement-mediated lysis of lymphocytes[20,23].

Equine ATG (also known as Atgam, Lymphoglobulin and Thymogam) was indicated for treating and preventing acute rejection after kidney transplantation[20,24]. While rabbit ATG (also known as rATG or thymoglobulin) was initially approved only for treating acute rejection, it later on became the most commonly used agent for induction in the United States[20,21,24,25], as it is associated with lower acute rejection rates and better graft survival[20]. A randomized prospective multicenter six-month-long study assessed the efficacy and safety of using thymoglobulin as an induction agent in combination with tacrolimus or cyclosporine A (CsA), in comparison with tacrolimus-based therapy without induction with thymoglobulin. The patients (n=555) were randomly assigned to tacrolimus triple therapy, ATG induction with tacrolimus or ATG induction with CsA. All three treatment groups also received azathioprine and corticosteroid. This study demonstrated that the rate of biopsy-proven acute rejection (BPAR) in the groups of thymoglobulin-tacrolimus was significantly lower than the other two groups. However, thymoglobulin treatment was associated with a higher incidence of serum sickness, hematological toxicities (thrombocytopenia, leucopenia) and cytomegalovirus infections[20]. Besides these side effects, other studies also reported increased risks for lymphoma and anaphylactic reactions[20,22]. The symptoms of hypersensitivity reactions could be prevented by slow infusion of thymoglobulin (over 4-8 hours) and by pretreatment with antihistamines, glucocorticoids and paracetamol[24]. Recently, in 2017, thymoglobulin has gained US FDA approval for prophylaxis as an induction agent[25].

Interleukin-2 receptor antagonist: Basiliximab

Basiliximab is a chimeric monoclonal antibody developed by DNA recombinant technology. It is a fusion of the variable region of murine immunoglobulin with the constant region of human immunoglobulin to produce an antibody that binds with the alpha chain (CD25) of IL-2 receptor (IL-2R) presented on the surface of the activated helper T-cells so that it blocks its binding with IL-2 and consequently prevents helper T-cell proliferation without causing their lysis, as in the case with the use of ATG[20].

Basiliximab is approved as a prophylaxis against rejection following renal graft transplantation[20]. It is currently recommended to be used in recipients with a low risk of rejection[27]. A systematic study emphasized on the effectiveness of using Basiliximab as an induction agent with an acceptable side effect profile[28]. However, a study that targeted patients at the Organ Procurement and Transplantation Network registry between the years 2000-2012 evaluated the necessity of induction therapy with an IL-2R antagonist in patients receiving living donor renal transplantation, who were treated with tacrolimus/mycophenolic acid with and without steroids. The study demonstrated that the induction with IL-2R antagonist had no advantage over no-induction group in patients receiving a maintenance therapy with tacrolimus/mycophenolic acid/steroid. The study also demonstrated that, in the no-steroid group, thymoglobulin resulted in lower rates of acute rejection compared to IL2-R antagonist[29].

From the author’s point of view, it appears that although current guidelines recommend the use of induction agents regardless of the risk of rejection, corticosteroids use or the constituents of the used maintenance regimen, it seems that future guidelines might restrict the use of induction agents for higher risk groups or when steroids are to be avoided. In such cases, thymoglobulin would be the preferred agent. However, large randomized clinical trials in this concern are needed.

Anti-CD-52 antibodies: Alemtuzumab

Alemtuzumab is a humanized monoclonal antibody that triggers antibody-dependent cell lysis by binding to CD-52 molecule on the surface of T- and B-cells, macrophages and natural killer cells[20]. Although it has an FDA approval only for B-cell lymphocytic leukemia, its use for induction therapy in...
kidney transplantation is increasing since 1998\textsuperscript{30}. For this purpose, it is administered intravenously as a single dose of 30 mg intraoperatively\textsuperscript{31}. Like other monoclonal antibodies, alemtuzumab might cause hematological side effects such as thrombocytopenia, neutropenia and lymphopenia. It may also cause cytokine release syndrome and infusion-related reactions\textsuperscript{20}.

Several trials were published that investigated alemtuzumab’s efficacy and safety in kidney transplantation. Of these, alemtuzumab was compared with basiliximab and thymoglobulin in low and high-risk groups. All groups received tacrolimus, mycophenolate mofetil (MMF) and five-day steroid as maintenance therapy. The study showed that alemtuzumab was superior to basiliximab in reducing the acute rejection rate (10% vs. 22%), but almost similar to thymoglobulin (18% vs. 15%)\textsuperscript{32}. However, another study showed no difference between alemtuzumab and basiliximab on graft and patient survival\textsuperscript{30}. Recently, a systemic review and meta-analysis of randomized controlled trials reported statistically insignificant due to the limited number of the trials\textsuperscript{33}. Therefore, more controlled comparative studies are required to determine the superiority of these drugs.

**Maintenance agents**

**Calcineurin inhibitors: Cyclosporin A and tacrolimus**

CsA and tacrolimus are two of the most widely used immunosuppressive agents. They are considered the mainstay of renal transplant maintenance therapy. They are called calcineurin inhibitors (CNI) due to their ability to inhibit the activity of a protein called calcineurin\textsuperscript{34}, which is a calcium/calmodulin-dependent serine-threonine phosphatase, consisting of two subunits, a catalytic subunit, calcineurin-A and a regulatory calcium-binding subunit, calcineurin-B\textsuperscript{35,36}. It plays a major role in T-cell activation. When an alloantigen is recognized by T-cell receptors, the intracellular calcium concentration increases, this in turn activates calcineurin-B. Once activated, it stimulates calcineurin-A to dephosphorylate a cytoplasmic transcription factor called the cytoplasmic nuclear factor of activated T-cells, allowing its transfer along with the activated calcineurin to the nucleus, where it induces the expression of cytokines and co-stimulatory substances like IL-2, which in turn, upon interaction with their receptors, result in cell activation and proliferation\textsuperscript{36-38}.

CsA and tacrolimus have the same pharmacodynamic activity although they differ in their structures\textsuperscript{34,38}. CNIs bind cytoplasmic proteins called immunophilins, cyclophilin in the case of CsA and FK-binding protein in case of tacrolimus\textsuperscript{39}. This complex then binds to calcineurin, leading to inhibition of its activity\textsuperscript{36,40}.

CNIs are associated with many adverse effects due to their narrow therapeutic window and the presence of their target (calcineurin) in many cell types other than immune cells. The most frequent adverse effect is nephrotoxicity, which can be acute and reversible or chronic and irreversible. Chronic CNIs-induced nephrotoxicity may result in interstitial fibrosis, tubular atrophy or glomerulosclerosis, which contributes to the deterioration of the function of the transplanted kidney with time. Other side effects include new-onset diabetes, dyslipidemia, neurotoxicity, de novo cancers and infections\textsuperscript{41}.

Different studies showed that tacrolimus is superior to CsA in terms of the rates of graft loss, acute rejection and hypercholesterolemia in addition to lower nephrotoxic potential. While CsA is more likely to cause gingival hyperplasia, hirsutism and increased levels of low-density lipoprotein and triglycerides, tacrolimus increases the risk of developing diabetes (dose-dependent) and gastrointestinal upsets. No differences in malignancy and infections were observed\textsuperscript{42,43}.

Currently, tacrolimus is considered a first-line agent in maintenance therapy in renal transplantation\textsuperscript{27,44}. Extended-release tacrolimus formulation is available now as an alternative to the immediate release one with comparable efficacy\textsuperscript{45}.

**Purine synthesis inhibitors: Azathioprine and mycophenolate mofetile**

**Azathioprine**

Azathioprine inhibits purine synthesis as it is converted within cells to its metabolites, mercaptopurine and thioguanine. Mercaptopurine, which is involved in the formation of thioninosinic acid nucleotides, consequently blocks the purine biosynthesis pathway. Besides, these metabolites are incorporated into the DNA, blocking its replication\textsuperscript{46}.

Azathioprine, since its development in the 1960s, was used as a main part of the standard regimens for immunosuppression\textsuperscript{22}. However, lately, it has been replaced by mycophenolic acid\textsuperscript{47}, as this drug was found to be more effective in the prevention of acute rejection\textsuperscript{47}. However, this claim has been challenged by later studies, as discussed in the following section of this manuscript.

The main side effects associated with azathioprine use are bone marrow suppression, mainly in patients who take gout medications, allopurinol or febuxostat. Other side effects are nausea, joint pain and hepatotoxicity\textsuperscript{46,48}. 
Mycophenolate mofetil

MMF is a prodrug of the active agent mycophenolic acid. It is directed against the process of guanosine nucleotides production, mostly through the inhibition of the enzyme inosine monophosphate dehydrogenase that is expressed in T and B lymphocytes, thus negatively affecting their proliferation rate[49]. However, MMF’s ability to inhibit the recruitment of immune cells at the site of rejection and to decrease the proliferation of arterial smooth muscle cells are also considered main mechanisms by which MMF may improve graft survival[50]. MMF is considered a major drug in the current maintenance therapy of renal transplant along with CNIs, and a main part in CNI-free, toxicity sparing regimens that may take a place in the future[51]. Although many studies have shown that MMF may play a role in preventing tubular chronic graft rejection and prolong patient survival[47,52,53], there is a need for additional clinical trials on larger scales to confirm this effect.

In many systematic reviews and randomized controlled clinical trials, MMF was found to be associated with a superior benefit in preventing acute renal graft rejection compared with azathioprine, and with comparable adverse effects profile[47,54]. Therefore, MMF has largely replaced azathioprine in immunosuppression protocols, and it is considered now the first-line agent in RTT[27]. However, this approach was opposed by a prospective, multicenter, randomized parallel group trial published in 2004 by Remuzzi and colleagues, which demonstrated that MMF had no advantages over azathioprine in preventing acute rejection in kidney transplant patients who were on CsA microemulsion and steroid over six months, followed by CsA alone over another 15 months. Interestingly, treatment with MMF was fifteen times more expensive than azathioprine[55]. A follow-up study by the same group followed the patients over five years demonstrated that the clinical outcomes were similar between MMF and azathioprine. In addition, based on the relatively high cost of MMF, they recommended the replacement of MMF with azathioprine in the standard immunosuppression treatment for kidney transplant recipients[56]. In agreement with these recommendations, another review of the respective clinical data in 2013 did not reveal any long-term benefits of MMF over azathioprine[57]. Therefore, we think that caregivers should balance the potential benefits and harms of MMF and azathioprine according to individual patient’s risks and preferences.

Inhibitors of mammalian target of Rapamycin: Sirolimus and everolimus

Sirolimus (also known as rapamycin)

It is a potent antiproliferative immunosuppressive agent. It acts by blocking the action of a protein kinase called the mammalian target of Rapamycin (mTOR), which plays a major role in multiple signal transduction pathways. Sirolimus inhibits the proliferation of T- and B-cells. It also decreases the production of antibodies. This unique mechanism of action, as well as its adverse effect profile, make this drug one of the major agents used in the prevention of acute renal transplant rejection[58].

A synergistic effect was observed when sirolimus was combined with CsA, that is, the risk of developing acute renal rejection was reduced[58,59]. Furthermore, in different studies, when CNI was withdrawn and a CNIs-free maintenance regimen consisting of sirolimus and MMF was introduced, a comparable efficacy (in terms of graft and patient survival) with more safety was observed and maintained for four years post transplantation[60,61].

The advantages of Sirolimus use include the lack of causing severe nephrotoxicity or major organ damage. However, gastrointestinal toxicity, hypertension, hyperglycemia, hyperlipidemias, bone marrow suppression, infections, impaired wound healing, arthralgia, edema and increased risks for certain malignancies remain major side effects by sirolimus that require attention[62,63].

Everolimus

It is an oral sirolimus analog, with improved solubility and oral bioavailability, but similar immunosuppressive efficacy and safety profile[64,65]. As an advantage, everolimus may have an ability to lower the toxicity of CNI on the kidneys, in contrast to sirolimus which potentiates CNI-associated nephrotoxicity. However, this ability is claimed only by expert opinions and clinical trials on limited scales[65,66], and therefore further studies and randomized controlled clinical trials are needed to confirm this observation.

Corticosteroids

For decades, corticosteroids have been used as a major part of immunosuppressive regimens due to their various inhibitory effects on inflammatory and lymphocytic activation processes[67]. Their anti-inflammatory effects include suppression of immune cell migration to inflamed tissues as well as inhibition of the production of inflammatory mediators such as prostaglandins. Steroids also decrease cytokines and interleukins production, thus affecting T- lymphocyte proliferation[68].
Methylprednisolone and prednisolone are the main steroids used for immunosuppression preoperatively and as a part of the triple maintenance therapy consisting of CNI and mycophenolic acid along with corticosteroids. Intravenous methylprednisolone dose is used commonly at induction and tapered postoperatively. At 3-5 days post-transplantation, methylprednisolone is switched to a fixed oral dose of prednisolone.

Unfortunately, long term use of corticosteroids is associated with unfavorable side effects that underlay several major health problems, such as dyslipidemia, hypertension, hyperglycemia and post-transplant diabetes mellitus. To obtain a better side effect profile, current protocols suggest that steroids could be withdrawn in patients with low risk of rejection during the first week after transplantation. However, if steroids are not avoided in the first month after transplantation, prednisolone should be continued with the lowest possible effective dose (5 mg daily).

A recent retrospective cohort study included two groups of patients. All patients received a perioperative dose of basiliximab and a second dose on day 4. They also received a single perioperative dose of methylprednisolone as induction agents. The first group included low-risk patients in whom prednisolone was administered from day 1-7 and then maintained with tacrolimus and MMF. The other group included high-risk patients, who were maintained with tacrolimus, MMF and prednisolone for the first three months, and afterward, they were maintained with tacrolimus and prednisolone. The data demonstrated a close incidence of BPAR between the high and low-risk groups. Moreover, one-year post-transplantation, the rates of graft and patient survival, and the graft function were also similar between the two groups. Interestingly, a systemic review and meta-analysis study advocated the withdrawal or avoidance of steroids, even in high-risk patients, as it was demonstrated in this study as being safe, in terms of graft survival and rejection, and associated with a reduced risk of death and post-transplantation diabetes mellitus. However, the authors recommended future prospective studies to further validate these results.

Guidelines in renal transplant therapy

Traditionally, the goal of therapy during the first six months after transplantation is mainly to prevent acute graft rejection and to prolong its survival. However, lately, the aim has expanded to also include the prevention/treatment of the major complications associated with the use of immunosuppressants such as malignancies and infections, and to improve patient’s adherence and to ultimately preserve a good transplant function. The current guidelines recommend the use of multi-drug regimens in a way that produces a synergistic effect against acute rejection, starting with high doses immediately after transplantation followed by gradual dosage reduction in maintenance therapy.

To prevent hyperacute transplant rejection, immunosuppressive therapy should be started at the time of transplantation. Antibody agents including ATG and IL-2R antagonists represent the cornerstone of the induction therapy in all kidney transplant recipients. The use of ATG is preferred when there is a high risk for rejection or when corticosteroids are avoided early at induction.

Treatment with CNIs like CsA or tacrolimus should be started early after transplantation or even before. Tacrolimus is preferred as it is associated with a lower rate of rejection. The plasma trough level of tacrolimus is not recommended to exceed 4-8 ng/ml. The anti-proliferative agent mycophenolic acid is the drug of choice to be used in combination with CNIs.

The mTOR inhibitors, sirolimus or everolimus, are considered second line drugs to be used when CNIs are causing serious adverse effects including chronic graft disease, tubular atrophy or interstitial fibrosis. CNI induced nephrotoxicity should be confirmed by biopsy.

Despite the recent great interest in corticosteroids avoidance and withdrawal from RTT as better side effect profile could be obtained, corticosteroids, so far, remain a main part in immunosuppressive regimens. Studies showed that avoidance of steroids early after transplantation is associated with an increased risk for acute rejection. However, graft survival and mortality seem not to be affected by the current antibody induction and maintenance regimens used. A recently updated review article revealed that there is a significant increase in acute rejection associated with early steroids avoidance or discontinuation, but graft survival seems to be similar in a time frame of five years. However, further clinical studies are required to assess longer corticosteroid withdrawal effects.

New approaches in renal transplant therapy

Targeting specific cytoplasmic signaling proteins

Tofacitinib (also known as tositinib, CP-690,550) has a unique mechanism of action in immune suppression. It is directed against a family of cytoplasmic signaling proteins called Janus kinases (JAK), mainly JAK2 and JAK3, which mediate the signal from cytokine receptors, especially in this context, the IL-2Rγ. The inhibition of this signaling pathway in B-cells, T-cells and natural killer cells results in their apoptosis. In the year 2012, this drug gained FDA approval to treat rheumatoid arthritis and
recently, in 2018, it has also been approved for the treatment of moderate to severe ulcerative colitis\(^{[77,78]}\).

Clinical trials are being conducted to evaluate the efficacy and safety of its use in renal transplantation, especially as a part of CNIs-free regimens. Tofacitinib has successfully passed animal studies as well as phase 1 clinical trials regarding transplantation\(^{[77]}\). In a phase 1 study, 28 stable kidney transplant patients were included and randomized to receive tofacitinib 5 mg b.i.d, 15 mg b.i.d, 30 mg b.i.d or placebo (n=6, 6, 10 and 6 respectively). The study reported a dose-dependent decrease in hemoglobin, natural killer cell count and mild to moderate viral and bacterial infections, especially with the highest dose of tofacitinib. The study did not report any clinical rejection or renal toxicity\(^{[79]}\).

Another larger pilot study was carried out in the year after. It was a prospective, randomized study over 12 months and involved 61 kidney transplant patients who received induction therapy with basiliximab and concomitant treatment with MMF and corticosteroids. The patients were distributed in three treatment groups; 15 mg tofacitinib twice daily, 30 mg tofacitinib twice daily and tacrolimus (control group). The results showed that the combination therapy of 30 mg tofacitinib twice daily with MMF was associated with over-immunosuppression, while 15 mg tofacitinib twice daily showed efficacy and safety profile that was comparable to the control group (tacrolimus), except that it showed a higher risk for viral infections. A limitation of this study was that the treatment groups did not have equivalent demographics\(^{[80]}\).

Based on the outcome of this study, a larger prospective randomized multicenter phase-IIb trial was carried out on tofacitinib. The study included 331 renal transplant recipient patients with low to moderate risk of rejection. The patients were randomly distributed into three groups. All groups received basiliximab for induction and mycophenolic acid and corticosteroids for maintenance therapy. One group received CsA microemulsion, while the other two groups received tofacitinib with two different intensities; more intensive tofacitinib (15 mg twice daily (b.i.d) in months 1-6, then 10 mg b.i.d in months 7-12), and less intensive tofacitinib group (15 mg b.i.d in months 1-3, then 10 mg b.i.d in months 4-12). After 12 months of post-transplantation therapy, patient and graft survival was similar among the different treatment groups. Despite the advantageous lower rates of chronic nephropathy associated with tofacitinib use as compared to CsA, patients treated with this drug developed more severe side effects in the context of anemia, leucopenia, viral infections and lymphoproliferative disorders, which was believed to be a result of excessive immunosuppression\(^{[81]}\). Similar results were obtained by a more recent study, which assessed the long term effect of tofacitinib in comparison with CsA over three years post-transplantation. The study also concluded an association between the increased risk of serious infections and the use of mycophenolic acid with tofacitinib\(^{[82]}\).

Possible future approaches need to be investigated for the aim of reducing the side effects profile of tofacitinib, which might include serum drug level monitoring to individualize the therapeutic levels of tofacitinib to achieve the lowest possible effective doses or testing tofacitinib-containing regimens that include lower therapeutic doses of MMF. Additionally, tofacitinib could be tested as a part of new CNI-free protocols.

### Targeting co-stimulatory pathways

The interaction between the T-cell receptors and the antigen presented on APCs is not sufficient for full T-cell activation, but other co-stimulatory signals are also needed. A new insight for targeting these signals is currently being conducted to treat solid organ transplantation rejection and autoimmune diseases\(^{[83]}\). The inhibition of co-stimulatory pathways such as CD40-CD154 and CD80/CD86-CD28 negatively affects APCs activation, antibody-production and cytokine releasing processes\(^{[84]}\).

### Anti-CD40 monoclonal antibodies

The interaction between CD40, presented by APCs such as B-cells and DCs, and CD40L (or CD154), presented by T-lymphocytes, plays a major role in T-cell activation\(^{[17]}\). Once CD40 interacts with its ligand, the activated APCs upregulate co-stimulatory proteins leading to T-cell proliferation and differentiation. Likewise, the activation of B-cells by the CD40-CD154 pathway causes their differentiation into memory or plasma cells, which play a major role in chronic renal graft rejection as mentioned earlier in this article\(^{[89]}\).

Recently, different agents directed against the CD40-CD154 pathway were introduced to treat chronic graft rejection and auto-immune diseases, besides some kinds of cancers. Anti-CD154 antibodies were studied and they were considered to have a partial efficacy in renal transplant. They are suggested to be combined with B7/CD28 pathway inhibition for full efficacy in preventing chronic rejection\(^{[86]}\). Moreover, anti-CD154 antibodies are associated with thromboembolic events that are thought to be mediated by anti-CD154 Fc domain-platelets interaction\(^{[87]}\).

### Bleselumab

Bleselumab (ASKP1240) is a fully-humanized IgG4 monoclonal antibody that binds with CD40 on B-cells...
and APCs to block its interaction with CD154 ligand on T-cells, resulting in co-stimulatory pathway inhibition[88]. The mean maximal CD40 receptor occupancy is reached at a dose greater than 0.01 mg/kg and the receptor occupancy did not exceed 87%. After that, any increase in the dose will only prolong the duration of occupancy[89,90].

Regarding the safety of bleselumab, the most commonly reported side effects were procedure pain, hypophosphatemia, hypomagnesemia, nausea, tremor, edema and BK viral infection[88,91]. Unlike some investigational chimeric anti CD40 monoclonal antibodies, it does not cause cytotoxicity and immunogenicity. Also, there were no thromboembolic events caused by this antibody[90].

A phase 2 randomized open-label multicenter study was designed to assess the efficacy and safety of bleselumab combined with immediate-release tacrolimus (IR-TAC) or MMF in comparison with the standard of care treatment, which consisted of IR-TAC and MMF. Basiliximab as an induction treatment and corticosteroids were used in all recipients. The dose of IR-TAC was decreased gradually after 28 days of treatment in the bleselumab + IR-TAC group until a trough level of 2-5ng/ml was reached by four months. The BPAR after 6 and 36 months was 6.3% and 14.6% respectively in standard of care treatment, while it was 37% and 41% in bleselumb + MMF and 9.1% and 9.1% in bleselumab + IR–TAC. These results suggest the noninferiority of bleselumb plus IR-TAC in comparison to SoC in the prevention of BPAR. However, the incidence of new-onset diabetes mellitus was lower in patients treated with iscalimab[95], indicating that this novel drug could be a valuable add-on therapy to the current standard tacrolimus containing regimens. The results need to be confirmed by phase-IIb clinical trials (NCT03663335) that may be completed by 2021[86].

Anti CD80/86 monoclonal antibodies

Belatacept

Belatacept is a CTLA4-Ig fusion protein developed from abatacept by substituting leu104 with glutamic acid and ala29 with tyrosine. It was approved in 2011 for acute rejection prophylaxis in kidney transplant recipients as an alternative for CNIs to reduce their renal and cardiometabolic side effects. Belatacept interacts with CD80/86 on APCs to block its binding to CD28 on T-cells, resulting in the prevention of T-cell activation[97,98].

Belatacept has a volume of distribution of 0.11L/kg, clearance of average 0.49013± mL/kg/h and a terminal half-life of almost 11 days. It is administrated intravenously over 30 minutes with 10 mg/kg on days 1 and 5 and at the end of weeks 2, 4 and 8. After that, 5mg/kg is given on week 16 of transplantation and it is repeated every four weeks. It does not require therapeutic monitoring as its plasma concentration is not affected by renal or hepatic functions, therefore, the doses are adjusted only according to the factor of bodyweight[99,100].

The most common adverse effects related to belatacept are infusion-related reactions, anemia, headache, peripheral edema and infections[97]. Also, the FDA puts a black box warning about the post-transplant lymphoproliferative diseases, especially in Epstein-Barr virus seronegative recipients, which contraindicates its use in this group of patients[99,101].

The two major clinical trials that evaluated belatacept efficacy and safety are Belatacept Evaluation of Nephroprotection and Efficacy as a First-line Immunosuppression Trial (BENEFIT) and the BENEFIT–Extended Criteria Donors Trial that followed the patients with extended criteria donor kidney transplant. In these studies, patients were randomized into three groups, more intensive belatacept, low intensive belatacept and CsA. All recipients were given induction with basiliximab and maintenance with MMF and corticosteroids. In BENEFIT, after 12 months, both the graft and patient survival rates were not significantly different between the groups (95% more intensive vs. 97% low intensive vs. 93% CsA respectively)[97]. Concerning safety, belatacept groups had a higher renal function than
Selective CD28 blockade

In contrast to belatacept, selective CD28 blockers inhibit CD28 co-stimulatory effects, while preserving the co-inhibitory effect of the CTLA-4 pathway. Therefore, they are considered to be more effective in inhibiting T-cell activation and proliferation. FR104, a novel humanized pegylated CD28 antagonist that is being developed for the treatment of graft rejection. A nonhuman primate study was conducted to evaluate its efficacy for the aim of allowing the minimization of steroids and CNI use. The results were promising as the combination of FR104 and low doses of tacrolimus with no steroid exposure significantly improved graft survival. FR104 was also found to be effective in preventing alloimmunization and in decreasing the development of donor-specific alloantibodies. CNI-free regimens showed different results as (FR104/MMF/Steroids) was associated with increased risk for acute rejection, but the combination between FR104 and sirolimus prevented acute rejection and showed improvement in graft survival. Later evidence for synergistic effect between FR104 and mTOR inhibitors was demonstrated in a recent study that showed a significant inhibition for T-cell activation, resulting in more immunosuppression and more infectious complications. The first-in-human phase 1 clinical study in 64 healthy volunteers to assess the efficacy and safety of FR104 was conducted in 2016. With all tested doses, FR104 was found to be safe and clinically efficacious, supporting further studies to determine ideal dosage regimens.

Summary

The prevention of kidney transplant rejection requires a short-term induction therapy, as prophylaxis against early acute rejection, and a life-long maintenance therapy against chronic rejection.

The induction therapy should be started with high doses immediately after transplantation, followed by gradual dosage reduction in maintenance therapy. It commonly involves thymoglobulin (ATG), which targets several surface antigens on T-lymphocytes, resulting in complement-mediated lysis of these cells. It is also commonly used for the treatment of acute rejection. Alemtuzumab is another induction agent that causes antibody-dependent immune cell lysis. It demonstrated some statistically insignificant beneficial effects over thymoglobulin, therefore, more controlled comparative studies are required to determine the superiority of these two drugs. Both drugs are associated mainly with hematological toxicities. On the other hand, basiliximab is an IL-2R antagonist that targets activated helper T-cells and prevents their proliferation without causing their lysis. It is approved as an induction agent, especially in recipients with low risk of rejection. However, thymoglobulin might be superior in patients on a steroid-free maintenance regimen.

The maintenance therapy should be started early after transplantation or even before. It can be made up of different combinations of CNIs (CsA/tacrolimus), MMF, mTOR inhibitors (sirolimus/everolimus) and corticosteroids. Tacrolimus is considered a first-line agent in maintenance therapy in renal transplantation. Studies showed that tacrolimus has lower nephrotoxic potential than CsA and it is associated with a better allograft function. CNIs are generally associated with cardiovascular, metabolic and immunosuppression-related side effects, as well as nephrotoxicity, which is the most frequent. MMF is also considered a major drug in the current maintenance therapy of renal transplant along with CNIs, and a main part in CNI-
free regimens that may take a place in the future, although some studies recommended its replacement with azathioprine based on cost-effectiveness data. Sirolimus (rapamycin) and everolimus inhibit the proliferation of T- and B-cells and decrease the production of antibodies. They can produce a synergistic effect in combination with CNI and in CNI-free maintenance regimens along with MMF. They are considered second-line drugs to be used when CNIs are causing serious adverse effects. The inhibitors of mTOR are associated with cardiovascular, metabolic and immunosuppression related side effects. Until now, corticosteroids are considered a main part in immunosuppressive regimens, despite the current interest in avoiding them due to their various side effects.

New drugs are being developed to improve the efficacy and safety profile of maintenance therapy. A promising one is tofacitinib that inhibits JAK signaling pathways resulting in lymphocytes apoptosis. It showed comparable anti-rejection activity to CsA with a lower risk of nephropathy, but more hematological toxicity and increased risk for infections and lymphoproliferative disorders. Other drug classes are being developed, some of them target co-stimulatory pathways like belatacept and iscalimab that targets CD40 antigens on B-cells, another one targets CD80/86 on APC like belatacept, and finally the recent selective CD28 blockers like FR104. These classes are still in clinical trials to assess their efficacy and safety profile in comparison to the currently approved drugs. Some of them showed some promising results.

CONCLUSION

Induction therapy is most commonly achieved by ATG and Alemtuzumab. The maintenance therapy can be made up of different combinations of CNIs, MMF, mTOR inhibitors and corticosteroids. Tacrolimus is considered a first-line agent in maintenance therapy in renal transplantation. MMF is another major drug that is used in combination with CNIs and is being investigated as a main part in future CNI-free regimens. New promising drugs are being developed to improve the efficacy and safety profile of the maintenance therapy.

ACKNOWLEDGMENT

The authors have no conflict of interest to declare. We declare that all of the listed authors effectively participated in the preparation of this manuscript.

Naim Kittana designed the idea of the manuscript, supervised the writing process, wrote the abstract and summary section, proofread and verified the scientific content, improved the scientific language of the text and approved the final version. Alaa Hamamri wrote the introduction and the section on the induction agents. She also verified the scientific content and approved the final version. Lana Zighan wrote the sections on the new approaches in RTT and participated in the writing of the section on guidelines in RTT. She also verified the scientific content and approved the final version. Israa Salama wrote the sections on maintenance agents and the guidelines in RTT. Suhaib Hattab proofread and verified the scientific content, improved the language of the text, assisted in the organization of the manuscript, verified the cited articles and approved the final version. This work did not receive any kind of funding.

REFERENCES


84. Malvezzi P, Jouve T, Rostaing L. Costimulation blockade
83. van der Zwan M, Hesselink DA, van den Hoogen MWF,
82. Busque S, Vincenti FG, Tedesco Silva H, O'Connell PJ,
81. Vincenti F, Tedesco Silva H, Busque S, O'Connell P,
80. Busque S, Leventhal J, Brennan DC, Steinberg S,
79. van Gurp E, Weimar W, Gaston R, Brennan D, Mendez
78. Tran V, Shammas RM, Sauk JS, Padua D. Evaluating
tofacitinib citrate in the treatment of moderate-to-severe
active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;
12:179-191.
79. van Gurp E, Weimar W, Gaston R, Brennan D, Mendez
Pirsch J, et al. Phase 1 dose-escalation study of CP-690
550 in stable renal allograft recipients: preliminary
findings of safety, tolerability, effects on lymphocyte
subsets and pharmacokinetics. Am J Transplant 2008;
8(8):1711-1718.
80. Busque S, Leventhal J, Brennan DC, Steinberg S,
immunosuppression based on the JAK inhibitor CP-
690,550: a pilot study in de novo kidney allograft
81. Vinicenti F, Tedesco Silva H, Busque S, O’Connell P,
Friedewald J, Cibrik D, et al. Randomized phase 2b trial
of tofacitinib (CP-690,550) in de novo kidney transplant
patients: efficacy, renal function and safety at 1 year. Am
82. Busque S, Vinicenti FG, Tedesco Silva H, O’Connell PJ,
Yoshida A, Friedewald JJ, et al. Efficacy and safety of a
tofacitinib-based immunosuppressive regimen after
kidney transplantation: Results From a long-term
83. van der Zwan M, Hesselink DA, van den Hoogen MWF,
Baan CC. Costimulation blockade in kidney transplant
84. Malvezzi P, Jouve T, Rostaing L. Costimulation blockade
in kidney transplantation: An update. Transplantation
2016; 100(11):2315-2323.
85. Law CL, Grewal IS. Therapeutic interventions targeting
CD40-CD154 interaction in kidney transplantation. Am
86. Harland RC, Klintmalm G, Jensik S, Yang H, Bromberg J,
Nashan B, Tedesco-Silva H, van den Hoogen M,
Berger S, Cibrik D, Mulgaonkar S, et al. CD40 inhibition with
CFZ533 - A new, fully human, non-depleting, Fc silent
mAb - improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in
de-novo CNI-free kidney transplant recipients.
Transplantation 2018; 102:S366.
87. Xu Y, Song G. The role of CD40-CD154 interaction in
343.
88. Yamada A, Sayegh MH. The CD154-CD40 costimulatory
pathway in transplantation. Transplantation 2002; 73(1
89. Law CL, Grewal IS. Therapeutic interventions targeting
CD40L (CD154) and CD40: the opportunities and
90. Harland RC, Klintmalm G, Jensik S, Yang H, Bromberg J,
Holman J, et al. Efficacy and safety of a
tofacitinib-based immunosuppressive regimen after
kidney transplantation: Results From a long-term
91. Vincenti F, Klintmalm G, Yang H, Ram Peddi V, Blahunka
P, Conkle A, et al. A randomized, phase 1b study of the
pharmacokinetics, pharmacodynamics, safety, and
tolerability of bleselumab, a fully human, anti-CD40
monoclonal antibody, in kidney transplantation. Am
92. Ristov J, Espie P, Ulrich P, Sickert D, Flandre T,
Dimitrova M, et al. Characterization of the in vitro and
in vivo properties of CFZ533, a blocking and non-
depleting anti-CD40 monoclonal antibody. Am J
Transplant 2018; 18(12):2895-2904.
93. Pinelli DF, Ford ML. Novel insights into anti-CD40/
CD154 immunotherapy in transplant tolerance.
94. Nashan B, Tedesco H, van den Hoogen M, Berger S,
Cibrik D, Mulgaonkar S, et al. CD40 inhibition with
CFZ533 - A new, fully human, non-depleting, Fc silent
mAb - improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in
de-novo CNI-free kidney transplant recipients.
Transplantation 2018; 102:S366.
95. Farkash E, Naik A, Tedesco-Silva H, Nashan B, Witzke
O, van den Hoogen M, et al. CNI-free therapy with
iscalimab (anti-CD40 mAb) preserves allograft
histology compared to standard of care after kidney
96. Novartis (Novartis Pharmaceuticals). Study of efficacy,
safety, tolerability, pharmacokinetic (PK) and
pharmacodynamic (PD) of an anti-CD40 monoclonal
antibody, CFZ533, in kidney transplant recipients
1]; Available from: https://clinicaltrials.gov/ct2/show/
NCT03663335#wrapper.
97. Kumar D, LeCorchick S, Gupta G. Belatacept as an
alternative to calcineurin inhibitors in patients with
solid organ transplants. Front Med (Lausanne) 2017;
4:60.
98. Wojciechowski D, Vincenti F. Belatacept in kidney
transplantation. Curr Opin Organ Transplant 2012;
17(6):640-647.
new biologic and its role in kidney transplantation.
100. Hardinger KL, Sunderland D, Wiederrich JA.
Belatacept for the prophylaxis of organ rejection in kidney
transplant patients: an evidence-based review of
its place in therapy. Int J Nephrol Renovasc Dis 2016;
9:139-150.
101. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S,
Gaite L, et al. Belatacept and long-term outcomes in
343.
102. de Graav GN, Baan CC, Claahsen-van Groningen MC,
Characterization of the in vitro and
pharmacodynamic (PD) of an anti-CD40 monoclonal
antibody, CFZ533, in kidney transplant recipients
1]; Available from: https://clinicaltrials.gov/ct2/show/
NCT03663335#wrapper.
103. Hehenberger K, Heilborn JD, Brismar K, Hansson A.
Calcineurin-inhibitor-free therapy with
belatacept vs. tacrolimus in de-novo CNI-free kidney
104. de Graav GN, Baan CC, Claahsen-van Groningen MC,
Characterization of ASKP1240, a fully
human antibody targeting human CD40 with potent
immunosuppressive effects. Am J Transplant 2019;
19(suppl 3).
105. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S,
Gaite L, et al. Belatacept and long-term outcomes in
343.


The frequency of celiac disease in children with chronic constipation

Yasin Sahin¹, Derya Aydin Sahin²

¹Clinics of Pediatric Gastroenterology, Mersin City Training and Research Hospital, Mersin, Turkey
²Clinics of Pediatrics, Mersin City Training and Research Hospital, Mersin, Turkey


ABSTRACT

Objective: To investigate the frequency of celiac disease (CD) in children with chronic constipation unresponsive to conventional treatment

Design: A retrospective study

Setting: Clinics of Pediatric Gastroenterology, Mersin City Training and Research Hospital, Mersin, Turkey

Subjects: Six hundred and sixty-two pediatric patients between the ages of 2 and 18 who were diagnosed with chronic constipation according to Rome III criteria and did not respond to conservative treatments were included in the study.

Interventions: All patients underwent tissue transglutaminase antibody (tTG) IgA and total IgA tests. The cut-off value of tTG IgA is 20 U/ml. Esophago-gastroduodenoscopy was performed on all patients with tTG positivity.

Main outcome measure: All patients were evaluated in regards to celiac disease.

Results: Of the 662 patients (341 girls), the mean age was 6.48±4.32 years. The mean tTG IgA value was 7.07±17.33 U/ml and the mean total IgA value was 107.37±64.74 mg/dl. tTG positivity was detected in 22 patients (3.32%) and six of them refused endoscopy. Gastroduodenoscopy was performed to the other patients. The pathological biopsy results of nine patients (1.36%) were consistent with Marsh 3 classification score and those were diagnosed with CD. The pathological biopsy results of the other seven patients were consistent with Marsh 0 classification score.

Conclusion: We found that the prevalence of CD was three times higher in children with functional constipation than in the general population. Therefore, we suggest that serologic tests for CD should be considered in children with functional constipation unresponsive to conventional treatment.

Address correspondence to:
Yasin Sahin, Limonluk Mah. 2453 sok. Florya evler sitesi No: 2, K: 3, D: 6, Yenişehir, Mersin, Turkey. Tel: +90 5326021063; Fax: +90 3242251011; E-mail: ysahin977@gmail.com

INTRODUCTION

Chronic constipation is one of the most common problems of childhood and mostly functional. Its prevalence is estimated to be 3% worldwide. In addition, it may be found as a sign of other organic diseases such as celiac disease (CD). According to the Rome III criteria, chronic constipation is defined as a decrease in the frequency of defecation or painful defecation for at least two months[1-4].

CD is an immune-mediated systemic disease triggered by gluten intake in genetically susceptible individuals. It is one of the most common life-long diseases and its prevalence is estimated to be approximately 1% worldwide[5]. With the development of sensitive and specific serologic tests and increased awareness of CD, its prevalence has increased during the recent years.

The clinical manifestations of CD can vary extensively in clinical findings ranging from classical malabsorption symptoms including chronic diarrhea, weight loss, vitamin deficiencies and growth delay to extra-intestinal findings such as osteopenia, isolated short stature, iron deficiency anemia, neurological diseases and elevated liver enzymes[6-8].

The clinical findings of CD have changed over recent years. Instead of classical malabsorption symptoms, atypical symptoms such as abdominal pain and chronic constipation may be the only sign of CD[8].

Chronic constipation is one of the most common presenting causes of pediatric gastroenterology and
general pediatric outpatient clinics. It is mostly functional; most cases have no identifiable organic lesions or disorders. A small number of children with chronic constipation do not respond to medical treatment and may create an inescapable situation for physicians and parents. According to the latest guidelines of ESPGHAN and NASPGHAN, although the routine screening test for organic causes such as CD is not recommended in the absence of alarming symptoms, most physicians apply these tests to exclude organic causes at the first application.

There are a few studies about the prevalence of CD in children with chronic constipation. In the current study, we aimed to investigate the frequency of CD in children with chronic constipation unresponsive to conventional treatment.

SUBJECTS AND METHODS

The present cross-sectional study was carried out between March 2017 and October 2018. Six hundred and sixty-two pediatric patients between the ages of 2 and 18 who were diagnosed with chronic constipation according to Rome III criteria and did not respond to conservative treatments were included in the study.

Patients with any organic disease such as CD, neurologic disease, thyroid dysfunction and hypercalcemia were excluded from the study. Gluten-free patients were also excluded from the study. The current study was approved by the Ethics Committee of Mersin University.

All patients underwent tissue transglutaminase antibody (tTG) IgA and total IgA tests. The cut-off value of tTG IgA is 20 U/ml. tTG IgG test was analysed in patients with selective IgA deficiency. Esophagogastroduodenoscopy was offered to all patients with tTG positivity, and then endoscopy was performed to those patients who accepted. At least four biopsies from duodenum and two biopsies from bulbus were obtained. The endoscopic mucosal biopsies were evaluated according to the modified Marsh classification.

Statistical evaluation

Statistical analysis was performed using SPSS software version 13.0 (SPAA Inc, Chicago IL, USA). Categorical data were reported as percentages and

<table>
<thead>
<tr>
<th>Variable</th>
<th>Children diagnosed with chronic constipation (n=653)</th>
<th>Children diagnosed with celiac disease (n=9)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>5.00 (IQR 6.00)</td>
<td>6.00 (IQR 7.00)</td>
<td>.321</td>
</tr>
<tr>
<td>Hemoglobine (g/dl)*</td>
<td>12.36±1.13</td>
<td>12.27±1.14</td>
<td>.815</td>
</tr>
<tr>
<td>tTG IgA (U/ml)*</td>
<td>3.90 (IQR 2.00)</td>
<td>95.00 (IQR 124.00)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total IgA</td>
<td>92.00 (IQR 84.00)</td>
<td>110.00 (IQR 73.00)</td>
<td>.316</td>
</tr>
<tr>
<td>Duration of constipation (months)*</td>
<td>7.00 (IQR 21.00)</td>
<td>24.00 (IQR 24.00)</td>
<td>.006</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Children diagnosed with chronic constipation (n=653)</th>
<th>Children diagnosed with celiac disease (n=9)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)*</td>
<td>5.00 (IQR 6.00)</td>
<td>6.00 (IQR 7.00)</td>
<td>.321</td>
</tr>
<tr>
<td>Hemoglobine (g/dl)*</td>
<td>12.36±1.13</td>
<td>12.27±1.14</td>
<td>.815</td>
</tr>
<tr>
<td>tTG IgA (U/ml)*</td>
<td>3.90 (IQR 2.00)</td>
<td>95.00 (IQR 124.00)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Total IgA*</td>
<td>92.00 (IQR 84.00)</td>
<td>110.00 (IQR 73.00)</td>
<td>.316</td>
</tr>
<tr>
<td>Duration of constipation (months)*</td>
<td>7.00 (IQR 21.00)</td>
<td>24.00 (IQR 24.00)</td>
<td>.006</td>
</tr>
</tbody>
</table>

tTG: tissue transglutaminase antibody; IQR: interquartile range; *data are presented as mean ± standard deviation; *data are presented as median (interquartile range)
continuous data as mean standard deviation or median (range). Mann Whitney U test was used for the parameters which did not show a normal distribution.

RESULTS
Of the 662 patients (341 girls), the mean age was 6.48±4.32 years. The mean value of tTG IgA was 7.07±17.33 U/ml and the mean value of total IgA was 107.37±64.74 mg/dl. The median duration of constipation in children with chronic constipation and CD were 7.00 (IQR 21.00) and 24.00 (IQR 24.00) months respectively (P <.05; Table 1). Two patients had selective IgA deficiency. tTG IgA positivity was detected in 22 patients (3.32%) and six of them refused endoscopy. Esophago-gastroduodenoscopy was performed for the other patients. The pathological biopsy results of nine patients (1.36%) were consistent with Marsh 3 classification score and those were diagnosed with CD. The duration of constipation ranged from 12-72 months in all patients with CD. The age of onset of constipation ranged from 1-11 years. There was no difference in regard to the age of presentation and the severity of chronic constipation between children with CD and functional chronic constipation. The pathological biopsy results of the other seven patients were consistent with Marsh 0 classification score (Table 2).

Seven of nine celiac patients had anemia and one of them also had folate deficiency. Six patients had low vitamin D levels. B12 deficiency was detected in two patients. In addition to that, two patients had growth retardation.

DISCUSSION
Chronic constipation is a very common and extremely troublesome disorder and has a negative impact on quality of life[18-20]. The relationship between chronic constipation and CD was first reported in 1972[21]. In this study, 12 patients (10.7%) were diagnosed with constipation before the diagnosis of CD.

The clinical findings of CD change over time. Atypical symptoms such as abdominal pain and chronic constipation instead of classical malabsorption symptoms may be the only sign of CD. Abdominal pain and constipation are one of the most common presenting complaints in pediatric gastroenterology outpatient clinics, and are often considered to be functional abdominal pain in the absence of alarming symptoms. Those symptoms are common with CD findings[7,22]. CD is not routinely excluded in patients with chronic constipation because of the identification of functional diseases, and routine testing for CD is also not recommended[1,12,22-25].

The rate of patients admitted only with constipation and then diagnosed with CD to all patients diagnosed with CD was reported between 6.8% to 38.9%[7,26-28].

There are only limited studies investigating the prevalence of CD in children with chronic constipation. The prevalence of CD in children with chronic constipation is reported to be 0.99-7.2%[3,10,14,23,29].

In a study including 370 patients, the prevalence of biopsy-proven CD was found to be 1.9%[22]. The authors recommend that serological tests for CD should be performed to patients with constipation unresponsive to medical treatment.

In another study involving 550 pediatric patients with chronic functional constipation, tTG positivity was found in 42 patients (7.6%), and 40 (7.2%) of them were diagnosed with CD by an intestinal biopsy[29].

In a recent study including 1046 children in Turkey, the prevalence of biopsy-proven CD was found to be 1/28 in children with constipation. Authors recommended that screening tests for CD should be considered in children with conventional treatment-resistant constipation[9].

In contrast, there are studies reporting that the prevalence of CD is not much higher in patients with constipation than in the general population[10,12,23,27]. For this reason, the authors do not recommend screening tests for CD in children with chronic constipation.

In a study conducted in Turkey including 313 children with chronic constipation, tTG positivity was found to be 2.5% in children with chronic constipation[10]. Eight patients with tTG positivity underwent gastroduodenoscopy. The pathological results of five patients were Marsh 1 and the other was Marsh 0, and those cases were evaluated as potential CD. In that study, serological evaluation of CD is not recommended in children with chronic constipation because a majority of the patients had negative serologic tests for CD.

In the present study, nine of the patients (1.36%) with chronic constipation were diagnosed with CD. All the patients with CD were closely monitored. Two patients were incompatible with gluten-free diet; they were still complaining of constipation. We have recommended psychiatric support for these patients. After adherence to gluten-free diet, constipation symptoms disappeared in the other seven patients in six months (2-6 months).

The prevalence of CD in adults and children were found to be 0.39% and 0.47% in our country respectively[30,31]. In the current study, the prevalence of biopsy-proven CD was found to be 1.36%. In accordance with some literature, we found that the prevalence of CD was approximately three times higher in children with functional constipation than in the general population.
Limitations
The major limitations of our study was that six patients with tTG positivity refused the process of gastroduodenoscopy. If they had accepted the endoscopy, the biopsy-proven prevalence of CD would be higher. Hence, the effectiveness of the current study may be weak. Second, HLA-DQ2/8 analysis could not be performed to patients due to the high costs of HLA analysis. Third, because CD can be diagnosed at all stages in life, the follow-up period may be short. Therefore, we may have detected a lesser prevalence of CD than expected.

CONCLUSION
We found that the prevalence of CD was three times higher in children with chronic constipation than in the general population. Therefore, we suggest that serological screening tests for CD be considered in children with chronic constipation unresponsive to conventional treatment.

ACKNOWLEDGMENTS
I would like to thank all pediatricians referring patients with chronic constipation to the Clinics of Pediatric Gastroenterology and the pathologists who evaluated the histopathologic findings of the patients who underwent gastroduodenoscopy.

Funding: None

Conflict of Interest: None

REFERENCES
20. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011; 106(9):1582-1591.


Testing the depth of anesthesia in total intravenous and balanced anesthesia

Vickovic Sanja1,2, Popovic Radmila1,2, Bozic Teodora1,2, Uvelin Arsen1,2, Lukic-Sarkanovic Mirka1,2, Zdravkovic Ranko3
1Department of Anesthesiology and Intensive Care, Clinical Center of Vojvodina, Novi Sad, Serbia
2University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
3Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia

December 2021; 53 (4): 388 - 394

ABSTRACT

Objective(s): Monitoring the depth of anesthesia during general balanced and total intravenous anesthesia using bispectral index (BIS) values and exploring potential occurrence of intraoperative awareness episodes as related to the applied anesthesia modality

Design: Randomized prospective study

Setting: Clinical Center of Vojvodina, Novi Sad, Serbia

Subjects: The study included 40 patients, 20 who received propofol anesthesia, while the other 20 received sevoflurane.

Intervention(s): Patient monitoring involved BIS values and hemodynamic parameters. After surgical intervention, the subjects were interviewed applying modified Brice questionnaire.

Main Outcome Measure(s): Modified Brice questionnaire was used to identify the episodes of intraoperative awareness. The questionnaire consisted of six questions to which multiple answers were offered.

Result(s): There was no difference in the depth of anesthesia between the two groups. There is a relationship between body weight and BIS value during the induction to anesthesia. Anesthetic dosage to maintain BIS values between 40 and 60 achieved an adequate depth of anesthesia in all patients, none of the patients reported that he/she has been awake during surgery. The patients who received propofol stated anxiety as the worst experience of surgery, while pain was reported as the worst experience by those who received sevoflurane.

Conclusion(s): Regardless of the type of anesthetic used (inhalation or intravenous), compliance with the principles of good anesthesiology practice results in no differences in the anesthetic depth and awareness during anesthesia is rare.

INTRODUCTION

The fear of being awake under anesthesia is one of the greatest anxieties among patients facing a surgical procedure. The incidence of anesthesia awareness ranges from 0.1 to 0.3% of anesthetized patients[1,2]. Although such situations occur only occasionally, anesthesiologists take this matter very seriously because of the correlation of shallow anesthesia with the occurrence of post-traumatic stress disorder, which can be subject to a medico legal responsibility of the anesthesiologist[3,4].

The assessment of anesthetic depth is routinely performed by monitoring and analyzing arterial blood pressure, heart rate, frequency and rhythm of breathing, muscle tone, eye tearing and perspiration. These signs are indirect and non-specific. Considering that awareness, i.e, patient’s subjective sensation of being awake, needed to be objectively interpreted, the technology of Electroencephalogram Bispectral Analysis was introduced about 20 years ago as a direct measurement of intraoperative consciousness.

Bispectral index (BIS) is a Continuous Electroencephalogram (EEG)-derived technology used to monitor the depth of anesthesia[5]. The method relies on continuous EEG analysis of the frontal area of the brain reflecting the level of hypnosis. BIS represents a direct measure of the effects of anesthetics and sedatives on the brain, thereby enabling...
Testing the depth of anesthesia in total intravenous and balanced anesthesia

Anesthesiologists need to accurately manage anesthesia and monitor the status of the patient during surgical procedure and react adequately to any change of his clinical condition. Calculation of BIS value integrates the four diverse EEG parameters. Each of these parameters correlates with the relevant level of anesthetic depth. The data for each parameter are processed, analyzed and combined using appropriate software to obtain the final figure – BIS value. BIS values can range between 0 and 100. BIS values greater than 80 indicate that the patient is awake[6], whereas values between 40 and 60 are considered to provide optimal anesthetic depth during surgery[7].

BIS monitor is portable and easy to interpret, and prevents unpleasant episodes of intraoperative awareness. Optimal dosage of anesthetics allows less adverse effects and faster recovery after anesthesia[8].

The basic objective of this study was monitoring the depth of anesthesia during general balanced inhalational and total intravenous anesthesia using BIS values and exploring potential occurrence of intraoperative awareness episodes as related to the applied anesthesia modality.

SUBJECTS AND METHODS

According to the approval of the Ethics Committee of the Clinical Center of Vojvodina, the research was conducted at the Clinic for Anesthesia and Intensive Therapy of the Clinical Center of Vojvodina as a randomized prospective clinical study. The research included 40 patients of both sexes, older than 18, and categorized as American Society of Anesthesiologists group I and II according to its physical status classification system. The patients were informed about the objective of the study and written informed consent was obtained from all participants. The patients were subjected to different surgical procedures.

In line with the aims of the research, the patients were randomly distributed into two groups of 20

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group S</th>
<th>Average value</th>
<th>Standard deviation</th>
<th>Minimum value</th>
<th>Maximum value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>P</td>
<td>58.10</td>
<td>15.00</td>
<td>22</td>
<td>87</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>S</td>
<td>76.73</td>
<td>12.08</td>
<td>53</td>
<td>100</td>
</tr>
<tr>
<td>Body height (cm)</td>
<td></td>
<td>171.85</td>
<td>8.04</td>
<td>152</td>
<td>189</td>
</tr>
<tr>
<td>Systolic arterial pressure (mmHg)</td>
<td>P</td>
<td>142.60</td>
<td>22.70</td>
<td>98</td>
<td>189</td>
</tr>
<tr>
<td>Diastolic arterial pressure (mmHg)</td>
<td>S</td>
<td>79.63</td>
<td>10.49</td>
<td>54</td>
<td>101</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td></td>
<td>105.40</td>
<td>16.71</td>
<td>69</td>
<td>144</td>
</tr>
<tr>
<td>Heart rate (beats per minute)</td>
<td></td>
<td>75.47</td>
<td>13.18</td>
<td>48</td>
<td>100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group P</th>
<th>Average value</th>
<th>Standard deviation</th>
<th>Minimum value</th>
<th>Maximum value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>P</td>
<td>58.10</td>
<td>15.00</td>
<td>22</td>
<td>87</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>S</td>
<td>76.73</td>
<td>12.08</td>
<td>53</td>
<td>100</td>
</tr>
<tr>
<td>Body height (cm)</td>
<td></td>
<td>171.85</td>
<td>8.04</td>
<td>152</td>
<td>189</td>
</tr>
<tr>
<td>Systolic arterial pressure (mmHg)</td>
<td>P</td>
<td>142.60</td>
<td>22.70</td>
<td>98</td>
<td>189</td>
</tr>
<tr>
<td>Diastolic arterial pressure (mmHg)</td>
<td>S</td>
<td>79.63</td>
<td>10.49</td>
<td>54</td>
<td>101</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td></td>
<td>105.40</td>
<td>16.71</td>
<td>69</td>
<td>144</td>
</tr>
<tr>
<td>Heart rate (beats per minute)</td>
<td></td>
<td>75.47</td>
<td>13.18</td>
<td>48</td>
<td>100</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>Group S</th>
<th>%</th>
<th>Group P</th>
<th>%</th>
<th>χ² test</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>8</td>
<td>40</td>
<td>7</td>
<td>35</td>
<td>0.107</td>
<td>.744</td>
</tr>
<tr>
<td>Males</td>
<td>12</td>
<td>60</td>
<td>13</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>100</td>
<td>20</td>
<td>100</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Descriptive statistics of the investigated anthropometric and hemodynamic parameters

Table 2: Gender distribution according to the type of anesthesia

Table 3: The ratio between age, anthropometric and hemodynamic parameters
individuals. All patients received premedication with midazolam i.v. (0.03 mg/kg). Group S: Induction of anesthesia was performed using intravenous anesthetic propofol (2 mg/kg) and depolarizing neuro-muscular blocker succinylcholine (1 mg/kg). Inhalation anesthetic sevoflurane and opioid analgesic fentanyl were used at the maintenance phase of anesthesia, whereas muscle relaxation during surgery was provided using rocuronium bromide. Group P: Induction of anesthesia was performed using intravenous anesthetic propofol (2 mg/kg) and depolarizing neuro-muscular blocker succinylcholine (1 mg/kg). Maintenance of anesthesia and analgesia was accomplished using propofol and fentanyl, respectively. Rocuronium bromide was administered to provide muscle relaxation during surgery. In both groups, the anesthesia was administered according to standard protocols of routine clinical practice. The dosage of inhalation and intravenous anesthetics used to maintain anesthesia was adjusted guided by the BIS-values to maintain the range between 40 and 60. Anesthetic depth was monitored using BIS technology (BIS modul - Aspect®), whereas vital parameters were monitored using the monitor Infinity Delta® – Dräger. Visualization of BIS-values was possible immediately upon attaching the electrodes on the forehead of the patient. The values were recorded during induction of anesthesia, maintenance phase as well as during termination of anesthesia.

Modified Brice questionnaire (interview method) was used to identify the episodes of intraoperative awareness. The questionnaire consisted of six questions to which multiple answers were offered. The questions pertained to the quality and content of memories before, during and after anesthesia. Moreover, one of the questions applied to patient’s subjective experience of the entire course of surgical procedure. Standard non-invasive clinical monitoring was performed during surgery, including monitoring of systolic, mean and diastolic arterial blood pressure and heart rate at five-minute intervals.

Numerical data description was performed using arithmetic mean, standard deviation and minimum/maximum values, whereas attributive properties were described using percentage and frequency distribution. During preliminary statistical analysis of numerical properties and to the purpose of assessing Gauss distribution, Kolmogorov-Smirnov and the Shapiro-Wilk tests were applied. In cases where the variable deviated from normal distribution range (Kolmogorov-Smirnov and Shapiro-Wilk test \( P < .05 \)), the most adequate transformation was applied to the purpose of using parametric tests. Assessment of the interrelations between independent variables (hemodynamic and anthropometric parameters) and dependent variable (BIS-values) standard parametric (Pearson’s correlation coefficient, Student’s t-test for independent samples, Student’s t-test for paired samples, analysis of variance, multiple linear regression) and non-parametric methods (chi-squared test, Spearman correlation coefficient) were used, depending on the nature of the data. The level of statistical significance was \( P < .05 \).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Average value</th>
<th>Standard deviation</th>
<th>Minimum value</th>
<th>Maximum value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIS - phase before beginning of anesthesia</td>
<td>96.65</td>
<td>3.79</td>
<td>79</td>
<td>100</td>
</tr>
<tr>
<td>BIS – induction phase</td>
<td>54.47</td>
<td>20.56</td>
<td>22</td>
<td>96</td>
</tr>
<tr>
<td>BIS – intubation phase</td>
<td>36.05</td>
<td>12.32</td>
<td>20</td>
<td>67</td>
</tr>
<tr>
<td>BIS – extubation phase</td>
<td>83.37</td>
<td>7.78</td>
<td>62</td>
<td>95</td>
</tr>
</tbody>
</table>

### Table 4: Average BIS-values according to the phase of anesthesia

<table>
<thead>
<tr>
<th>Variable</th>
<th>Average value</th>
<th>95% Confidence Interval for Mean</th>
<th>F</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Lower Bound</td>
<td>Upper Bound</td>
<td></td>
</tr>
<tr>
<td>BIS - phase before beginning of anesthesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>96.08</td>
<td>0.3920</td>
<td>0.6952</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>97.60</td>
<td>0.4281</td>
<td>0.5881</td>
<td></td>
</tr>
<tr>
<td>BIS – induction phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>54.88</td>
<td>45.3791</td>
<td>64.3809</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>53.80</td>
<td>44.7144</td>
<td>62.8856</td>
<td></td>
</tr>
<tr>
<td>BIS – intubation phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>37.28</td>
<td>31.8084</td>
<td>42.7516</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>34.00</td>
<td>28.0614</td>
<td>39.9386</td>
<td></td>
</tr>
<tr>
<td>BIS – extubation phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>84.52</td>
<td>81.4492</td>
<td>87.5908</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>81.46</td>
<td>76.9055</td>
<td>86.0278</td>
<td></td>
</tr>
</tbody>
</table>
Statistical analysis of the data was performed using statistical software package SPSS (Statistical Package for Social Sciences).

RESULTS

Sample population in this research included 62.5% males and 37.5% females with an average age of 58.10±15.00 years, weight of 76.73±12.08 kg and height of 171.85±8.04 cm. Average values of hemodynamic parameters such as systolic, diastolic, mean arterial blood pressure and heart rate were 142.60±22.70 mmHg, 79.63±10.49 mmHg, 105.40±16.71 mmHg and 75.47±13.18 beats per minute, respectively (Table 1).

Distribution according to gender analyzed using $\chi^2$ test did not reveal any statistical significance between groups receiving maintenance anesthesia with sevoflurane (group S) and propofol (group P) ($\chi^2 = 0.107; P > .05$) (Table 2).

Analysis of variance did not establish any statistically significant differences between the groups with respect to age and investigated anthropometric and hemodynamic parameters (Table 3).

In the investigated sample population, the average BIS-values were as following: before anesthesia 96.65±3.79, during induction phase 54.47±20.56, during intubation phase 36.05±12.32, and during extubation phase 83.37±7.78 (Table 4).

The analysis of BIS-values at different phases of anesthesia did not reveal any statistically significant difference with respect to gender distribution ($P > .05$) (Table 5).

The assessment of correlation between anthropometric and hemodynamic parameters and BIS-values revealed statistically significant positive correlation between body weight and BIS-values at the phase of induction to anesthesia ($r = 0.55; P = .01$) (Table 6).

Statistical significance between investigated parameters at other phases of anesthesia was not established by Pearson’s correlation test, irrespective of the applied anesthetic drug (propofol or sevoflurane). The analysis of BIS-values at different phases of anesthesia did not show any statistically significant difference between the group S and group P ($P > .05$) (Table 7).

Regarding the question about the last thing the patient remembered happening before they went to sleep, the analysis of modified Brice questionnaire did not show statistically significant differences between the groups S and P ($P > .05$) (Table 8).

There was no statistically significant difference between the groups regarding the answer to the question about the first thing the patient remembered happening on waking ($P > .05$) (Table 9).

All participants answered negatively when asked if they remembered anything during anesthesia. When asked if they were dreaming during anesthesia and if the dreams were disturbing, the answers did not

<table>
<thead>
<tr>
<th>Questions</th>
<th>Group P</th>
<th>Group S</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>1. Time spent in the pre-op area</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>2. Seeing the operating room</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>3. Time spent with family</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4. Hearing voices</td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>5. Feeling mask on face</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>6. Smell of gas</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7. Burning or stinging in the IV line</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>8. Other</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>100</td>
</tr>
</tbody>
</table>
reveal any statistically significant differences between groups S and P (Table 10).

The answer to the question regarding the patient’s worst experience about the operation did not establish any statistically significance between the groups ($P > .05$). However, if absolute numbers are taken into consideration, larger number of patients from group P reported anxiety as the worst experience, as compared to the patients from group S, where pain was most frequently reported as the worst experience (Table 11).

Table 9: First memories of the patient upon waking up after anesthesia

<table>
<thead>
<tr>
<th>Questions</th>
<th>Group P</th>
<th></th>
<th>Group S</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Question 2. What was the first thing you remembered happening on waking?</td>
<td>13</td>
<td>65</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>1. Hearing voices</td>
<td>1</td>
<td>5</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>2. Feeling breathing tube</td>
<td>1</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3. Feeling mask on face</td>
<td>3</td>
<td>15</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>4. Feeling pain</td>
<td>1</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5. Seeing the operating room</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6. Being in the recovery room</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7. Being with family</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8. Being in ICU</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>9. Nothing</td>
<td>1</td>
<td>5</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>10. Other</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>100</td>
<td>20</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 10: Answers to the question if the patients were dreaming during anesthesia

<table>
<thead>
<tr>
<th>Group</th>
<th>Question 4. Did you dream during your procedure?</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Propofol</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>85</td>
<td>15</td>
</tr>
<tr>
<td>Sevoflurane</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>85</td>
<td>15</td>
</tr>
</tbody>
</table>

Statistically significant difference was established with respect to heart rate during extubation phase. The heart rate values established in group S were significantly higher than those in group P ($P < .05$) (Table 12).

Table 11: Answers to the question regarding the patient’s worst experience

<table>
<thead>
<tr>
<th>Questions</th>
<th>Group P</th>
<th></th>
<th>Group S</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Question 6. What was the worst thing about your operation?</td>
<td>4</td>
<td>20</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>1. Anxiety</td>
<td>6</td>
<td>30</td>
<td>11</td>
<td>55</td>
</tr>
<tr>
<td>2. Pain</td>
<td>2</td>
<td>10</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>3. Recovery process</td>
<td>1</td>
<td>5</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>4. Unable to carry out usual activities</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5. Awareness</td>
<td>7</td>
<td>35</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>6. Other</td>
<td>20</td>
<td>100</td>
<td>20</td>
<td>100</td>
</tr>
</tbody>
</table>

Our research, which encompassed 40 participants of both sexes (62.5% males and 37.5% females) aged around 58 years, did not reveal any statistically significant differences for BIS-values in regard to the gender. Also, there were no statistically significant differences in view of anthropometric and hemodynamic parameters between the investigated groups. Similar results were reported by Ching-Kuo et al.[9].

The analysis of correlation between anthropometric and hemodynamic parameters and BIS-values revealed statistically significant positive correlation of

Table 12: Hemodynamic parameters recorded during extubation phase

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group</th>
<th>F</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic arterial pressure (mm Hg)</td>
<td>S</td>
<td>143.95</td>
<td>0.10</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>144.40</td>
<td></td>
</tr>
<tr>
<td>Diastolic arterial pressure (mm Hg)</td>
<td>S</td>
<td>83.95</td>
<td>0.88</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>86.60</td>
<td></td>
</tr>
<tr>
<td>Mean arterial pressure (mm Hg)</td>
<td>S</td>
<td>109.30</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>108.90</td>
<td></td>
</tr>
<tr>
<td>Heart rate (beats per minute)</td>
<td>S</td>
<td>84.45</td>
<td>0.57</td>
</tr>
<tr>
<td></td>
<td>P</td>
<td>73.70</td>
<td></td>
</tr>
</tbody>
</table>

S: sevoflurane; P: propofol

DISCUSSION

Awareness during anesthesia is one of the biggest fears and distress among patients scheduled for surgical procedure. The occurrence of awareness is determined by a range of factors, mainly the type and dose of the anesthetic, metabolic characteristics of the patient and competence of the anesthesiologist to recognize the signs of awareness. Possible awareness episodes can be associated with subsequent psychical complications such as anxiety, nightmares or insomnia.
body weight and BIS-values, i.e., BIS-values were significantly higher in patients with higher body weight. Consequently, the induction and maintenance of anesthesia in persons with higher body weight require higher doses of anesthetics\textsuperscript{[10]}. Differences in anesthetic depth accomplished with inhalation and total intravenous anesthesia have been reported by Somvanshi \textit{et al}\textsuperscript{[11]}. The study included 50 participants aged 18-60, who were randomly distributed into two groups receiving maintenance anesthesia with propofol and sevoflurane. The authors established faster emergence from anesthesia in sevoflurane group. Our research did not establish any differences in BIS-values during the emergence from anesthesia. Similar results were obtained in a study of Siampaliot\textit{i et al}\textsuperscript{[12]}, which encompassed 100 participants allocated into four groups (sevoflurane, sevoflurane with BIS monitoring, propofol and propofol with BIS monitoring). Considering the relatively small number of participants in our research, Brice questionnaire did not reveal any statistically significant differences between the answers obtained in the two groups. Similar results were reported in a study conducted at the Clinic for Otorhinolaryngology and Maxillofacial Surgery of the Clinical Center of Serbia\textsuperscript{[13]}. The analysis of modified Brice questionnaire regarding the question about the last thing the patient remembered happening before they went to sleep did not show statistically significant differences between the groups. However, if absolute numbers are taken into consideration, the majority of patients from groups P and S reported remembering voices and having a mask on their face, respectively. Anxiety (group P) and pain (group S) were reported by majority of patients as the worst experiences about the operation. In all participants of our study, BIS-values were maintained within a range between 40 and 60. Considering that awareness episodes did not occur in any of the patients, we can confirm that the recommended BIS range is the appropriate level to accomplish adequate anesthetic depth\textsuperscript{[7]}. Do the patients dream during anesthesia? This still remains one of the mysteries behind anesthesia. Our research revealed that the same number of patients from both groups recalled some kind of dreams. Similar research\textsuperscript{[14]} showed that the incidence of dreaming was significantly higher in the group receiving sevoflurane. In a study conducted by Errando \textit{et al}\textsuperscript{[15]}, which encompassed 4001 individuals, dreaming was observed in 52.6% of participants, unlike only 15% of patients who reported dreaming during anesthesia and surgery in our study.

Comparison of hemodynamic parameters during extubation phase revealed statistically significant differences in heart rate values, being higher in participants receiving sevoflurane maintenance anesthesia. Fredman \textit{et al}\textsuperscript{[16]} reported correlation between propofol and consistently higher heart rate values.

CONCLUSION

Hypnosis is the essential component of general anesthesia; however, episodes of awareness may occur in clinical practice. This is a frequently raised concern, which has been receiving growing attention among professionals. Besides the indirect signs of awareness, technologies for direct monitoring of anesthetic depth such as BIS-monitoring system are available to the anesthesiologists. Based on the results of our study, we may conclude that, with strict compliance with the principles of good anesthesiology practice, there are no differences in anesthetic depth irrespective of the type of the applied anesthetic (inhalation or intravenous), and the episodes of anesthetic awareness are extremely rare.

ACKNOWLEDGMENT

Declaration of interest: The authors declare that there is no conflict of interest.

Author’s contributions in the manuscript: Vickovic Sanja participated in the design of the study, data collection, statistical analysis, interpretation of data and results, preparation of manuscript and literature search. Popovic Radmila participated in data systematization, design of manuscript, critical review and final revision of manuscript. Bozic Teodora participated in coordination and assisted to draft the manuscript, data interpretation, statistical analysis and literature search. Uvelin Arsen participated in preparation of manuscript, literature search, critical review and final revision of manuscript. Lukic-Sarkanovic Mirka participated in data collection, data systematization, statistical analysis, literature search and preparation of manuscript. Zdravkovic Ranko participated in data systematization, data interpretation, statistical analysis, preparation of manuscript and literature search.

REFERENCES

Original Article

Comparison of diagnostic tests performed in patients with suspected acute osteomyelitis

Asli Ayan¹, Mesut Ortatatli²,³
¹Department of Nuclear Medicine, Gulhane Training and Research Hospital, Ankara, Turkey
²Department of Infectious Diseases and Clinical Microbiology, Gulhane Training and Research Hospital, Ankara, Turkey
³University of Health Sciences, Department of Medical CBRN Defense, Ankara, Turkey

Kuwait Medical Journal 2021; 53 (4): 395 - 401

ABSTRACT

Objective: Diagnosis of acute osteomyelitis (OM) is a multidisciplinary challenge, and the aim of this study was to assess the effectiveness of diagnostic tests of acute OM performed in our hospital.

Design: Retrospective study

Setting: Gulhane Training and Research Hospital, Turkey

Subjects: The charts of 119 patients with suspected acute OM were retrospectively reviewed.

Intervention: The sensitivity and specificity of Three Phase Bone Scintigraphy (TPBS), Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT), Labeled Leukocyte Scintigraphy (LLS), and Magnetic Resonance Imaging (MRI), microbiological culture results, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined. The clinicians confirmed final diagnosis of OM and non-OM by clinical examinations, consultations and results of all performed tests.

Main outcome measures: Diagnostic value of imaging techniques and laboratory tests regarding their cost effectiveness for diagnosis of OM were evaluated.

Results: The clinicians diagnosed 64 patients as acute OM and 55 as non-OM. The sensitivity and specificity of TPBS, SPECT/CT, LLS, MRI, CRP and ESR were between 80.8-100% and 67.3-100%, respectively. The presence of diabetes mellitus was higher in the OM than in the non-OM group (P=.01), while the level of HbA1c was not significantly different (P=.66). The most grown microorganism was Staphylococcus aureus. The mean cost of diagnosis was 52.07±36.59 USD for the OM group and 44.98±37.19 USD for the non-OM group (P=.016).

Conclusion: Our results support the reliability of TPBS and LLS, particularly when combined with SPECT/CT, as diagnostic tools when MRI is contraindicated or unavailable for evaluating patients with suspected acute OM.

KEY WORDS: acute osteomyelitis, diagnosis, imaging, nuclear medicine

INTRODUCTION

Osteomyelitis (OM) is a progressive infection of bone that can lead to bone devastation, necrosis and deformation due to inflammatory reactions. The disease can be classified as acute or chronic based on the duration of the illness, and as hematogenous or contiguous based on the mechanism[1]. Acute OM is diagnosed when the disease is discovered within two weeks after the initial onset, whereas chronic OM refers to a disease that has existed for several months at the time of diagnosis[2]. Contiguous OM is divided into two categories based on the presence or absence of associated vascular insufficiency[1,3].

Hematogenous OM occurs more frequently in children, with the metaphysis of long bones, particularly the tibia and femur, usually affected. In adults, the most common site is the vertebral bodies[1,4]. Contiguous OM usually spreads from adjacent tissues or following direct inoculation during trauma or surgery in young adults, whereas older adults typically show infection in relation to decubitus ulcers and infected joint arthroplasties. OM due to vascular insufficiency is frequently associated with the presence of underlying diabetes mellitus[2,3].

Address correspondence to:
Mesut Ortatatli, M.D., Ph.D., Specialist of Infectious Diseases and Clinical Microbiology, Department of Infectious Diseases and Clinical Microbiology, Gulhane Training and Research Hospital, Ankara, Turkey. Tel: +90 3123043305; GSM: +90 5332117572; Fax: +90 3123046016; E-mail: mortatatli@gmail.com
Hematogenous OM is generally monomicrobial, whereas contiguous OM may be either monomicrobial or polymicrobial. The most commonly isolated organism is *Staphylococcus aureus* in all types of OM in adults and children. Other common pathogens are coagulase-negative staphylococci, beta-hemolytic streptococci, enterococci, aerobic gram-negative bacilli (including *Pseudomonas* species), *Enterobacter* species and *Escherichia coli*. The identification of the causative microorganism is crucial for both diagnosis and treatment[6,5].

Signs and symptoms may vary depending on the category of infection, the infective organism, the anatomic location and other factors related to the patient. A suspicion of OM arises from the initial history and physical examination findings. Confirmation usually entails a combination of radiologic, biochemical, microbiologic and pathologic tests[3-6].

The most useful imaging techniques are Three Phase Bone Scintigraphy (TPBS), Single Photon Emission Computed Tomography (SPECT), Labeled Leukocyte Scintigraphy (LLS) and Magnetic Resonance Imaging (MRI). Blood cultures should be taken in suspected OM cases, even though they are often negative, except in hematogenous OM. The diagnostic gold standard of OM cases, even though they are often negative, except in hematogenous OM. The diagnostic gold standard of OM is determining a bone biopsy for histopathologic examination and tissue culture[2-4,7]. The诊断 erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels are often elevated. The white blood cell (WBC) count can be normal or elevated[8-10].

Many diagnostic tools are available; however, failure to diagnose and promptly treat OM can lead to chronic OM, whereas early intervention, followed by a proper antibiotic regimen, prevents chronic OM[10].

The aims of the present study were to evaluate the diagnostic tests for OM performed in our hospital, to analyze their performance in diagnosis and to determine their cost effectiveness.

**SUBJECTS AND METHODS**

We retrospectively reviewed the medical charts of 119 patients admitted to the Gulhane Training and Research Hospital with clinically suspected acute OM between January 2017 and December 2018. Patients who had a previous history of both acute and chronic OM were excluded from the study. The hospital records, including laboratory test results and radiodiagnostic and radionuclide-imaging tools, of the remaining patients were used in the study. The tools used for the diagnosis of acute OM, including microbiology (wound and blood culture), biochemistry (WBC, CRP, ESR) tests, radionuclide scanning (TBPS, LLS, SPECT/CT), and radiodiagnostics (MRI), were determined and their diagnostic compatibilities, up to the final clinical diagnosis, were statistically evaluated.

TPBS was performed with technetium-99m-methylene diphosphonate, and the in vitro leukocyte labeling for LLS was done with technetium-99m-hexamethylpropyleneamine oxime.

The clinicians’ definitive diagnoses were made based on their clinical examinations, consultations and the results of all performed tests. Patient history of diabetes mellitus, orthopedic prosthesis, bone surgery and trauma were also recorded. This study was approved by the decisions of the Ethics Committee of the University of Health Sciences (April 26, 2018, numbered 18/110) and The Medical Board of the Gulhane Training and Research Hospital (24 May 2018/799).

**Statistical tests**

The data were statistically analyzed using SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). Categorical data were presented as frequencies and percentages, while continuous data that had a normal distribution were presented as means and standard deviations. The diagnostic tests were analyzed for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). The distribution of variables was controlled using the Kolmogorov-Smirnov test. Continuous values, in cases of normal distribution, were analyzed with Student t-test for two independent groups and with one-way analysis of variance for three or more independent groups. The Mann-Whitney U test was used for the continuous variables that did not show a normal distribution. The Chi-square test was used to compare categorical data. A *P*-value <0.05 between groups was considered statistically significantly.

**RESULTS**

In total, 119 adults (42 women [35.3%], 77 men [64.7%]) who presented with suspected acute OM between January 2017 and December 2018 were included in the study. The cases enrolled in the study were under follow up at different clinics, mainly orthopedics (n=72), infectious disease (n=32), plastic surgery (n=4), internal medicine (n=3) and miscellaneous others (n=8). The age range was 18 to 85 years (52.68±17.63). No statistical difference was noted between the patients with and without a diagnosis of acute osteomyelitis (OM and non-OM, respectively) in terms of age or gender (*P*=.17 and *P*=.72, respectively).

The distributions of the involved regions in patients diagnosed with acute OM were as follows: 52 cases (81.3%) with OM of the lower extremities, nine cases with OM of the upper extremities (14%) and three cases with OM of the cranium. The affected bones in
Comparison of diagnostic tests performed in patients with suspected acute osteomyelitis

The lower extremity were the femur (n=5), tibia (n=10) and feet bones (n=32). The 27 patients with acute OM of the feet also had diabetes mellitus.

TPBS was performed in all patients who were followed up with a preliminary diagnosis of acute OM. SPECT/CT imaging was conducted in 89 (74.8%), LLS in 30 (25.2%) and MRI in 37 (31.1%) patients. The results were summarized in Table 1. Statistical significance was calculated for each of four tests performed in the diagnosis of OM (P<.001). Seven patients underwent all four imaging tests and six of them were diagnosed with acute OM. The CRP and ESR values were significantly higher for the OM than for the non-OM group (P<.001; Fig 1 and 2), whereas the WBC counts were not significantly different (P=.56; Table 2).

The statistical analysis revealed no significant differences between OM and non-OM groups in terms of previous orthopedic surgery, prosthesis and trauma (P=.78). However, the number of patients with diabetes mellitus was significantly higher in the OM than in the non-OM group (P=.01). The glycated hemoglobin (HbA1c) levels did not differ significantly between the two groups (P=.66; Table 3).

Microbiological cultures (50 wound cultures and 15 of which had a synchronous blood culture) were performed in 50 of 119 patients, and 39 wound cultures showed microbial growth (29 monomicrobial, 9

### Table 1: The distribution of radionuclide and radiodiagnostic tools and their diagnostic value in the study groups

<table>
<thead>
<tr>
<th>Final diagnosis</th>
<th>Test results</th>
<th>TPBS</th>
<th>SPECT/CT</th>
<th>LLS</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n %</td>
<td>n %</td>
<td>n %</td>
<td>n %</td>
<td></td>
</tr>
<tr>
<td>OM (n=64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>62 96.9</td>
<td>52 92.9</td>
<td>16 100</td>
<td>21 80.8</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>2 3.1</td>
<td>4 7.1</td>
<td>0 0</td>
<td>5 19.2</td>
<td></td>
</tr>
<tr>
<td>Sum</td>
<td>64 100</td>
<td>56 87.5</td>
<td>16 25.0</td>
<td>26 40.6</td>
<td></td>
</tr>
<tr>
<td>Non-OM (n=55)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>18 32.7</td>
<td>9 27.3</td>
<td>0 0</td>
<td>1 9.1</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>37 67.3</td>
<td>24 72.7</td>
<td>14 100</td>
<td>10 90.9</td>
<td></td>
</tr>
<tr>
<td>Sum</td>
<td>55 100</td>
<td>33 60.0</td>
<td>14 25.5</td>
<td>11 20.0</td>
<td></td>
</tr>
<tr>
<td>P-value</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td></td>
</tr>
<tr>
<td>Sensitivity of high positive</td>
<td>96.9%</td>
<td>92.9%</td>
<td>100%</td>
<td>80.8%</td>
<td></td>
</tr>
<tr>
<td>Specificity</td>
<td>67.3%</td>
<td>72.7%</td>
<td>100%</td>
<td>90.9%</td>
<td></td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td>77.5%</td>
<td>85.2%</td>
<td>100%</td>
<td>95.5%</td>
<td></td>
</tr>
<tr>
<td>Negative Predictive Value</td>
<td>94.9%</td>
<td>85.7%</td>
<td>100%</td>
<td>66.7%</td>
<td></td>
</tr>
</tbody>
</table>

TPBS: Three Phase Bone Scintigraphy; SPECT/CT: Single Photon Emission Computed Tomography/Computed Tomography; LLS: Labelled Leukocyte Scintigraphy; MRI: Magnetic Resonance Imaging; OM: Osteomyelitis; non-OM: Diagnosed as other than osteomyelitis.

### Table 2: The CRP, ESR and WBC values of cases in study groups

<table>
<thead>
<tr>
<th>Final diagnosis</th>
<th>Test results</th>
<th>CRP</th>
<th>ESR</th>
<th>WBC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequency (n)</td>
<td>Mean±SD</td>
<td>Frequency (n)</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>OM (n=64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High positive</td>
<td>50</td>
<td>61.6±40.02</td>
<td>47</td>
<td>78.2±18.70</td>
</tr>
<tr>
<td>Positive</td>
<td>14</td>
<td>11.7±4.04</td>
<td>14</td>
<td>36.5±10.52</td>
</tr>
<tr>
<td>Normal</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>15.6±5.51</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>50.7±14.01</td>
<td>66.19±26.56</td>
<td>8.0±2.81</td>
<td></td>
</tr>
<tr>
<td>Non-OM (n=55)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High positive</td>
<td>7</td>
<td>35.2±12.70</td>
<td>10</td>
<td>62.7±15.70</td>
</tr>
<tr>
<td>Positive</td>
<td>19</td>
<td>11.9±3.57</td>
<td>17</td>
<td>37.8±9.74</td>
</tr>
<tr>
<td>Normal</td>
<td>29</td>
<td>3.2±1.51</td>
<td>28</td>
<td>11.8±6.54</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>10.3±1.45</td>
<td>29.1±21.88</td>
<td>7.9±2.26</td>
<td></td>
</tr>
</tbody>
</table>

P-value | Sensitivity of high positive | Specificity of high positive | PPV of high positive | PPV of positive | NPV of high positive | NPV of positive |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;.001</td>
<td>100%</td>
<td>80.6%</td>
<td>52.7%</td>
<td>71.1%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Sensitivity of positive</td>
<td>100%</td>
<td>95.3%</td>
<td>94.0%</td>
<td>69.3%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
<tr>
<td>Specificity of positive</td>
<td>100%</td>
<td>95.3%</td>
<td>94.0%</td>
<td>69.3%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
<tr>
<td>PPV of high positive</td>
<td>87.7%</td>
<td>82.5%</td>
<td>85.7%</td>
<td>74.4%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
<tr>
<td>PPV of positive</td>
<td>71.1%</td>
<td>69.3%</td>
<td>74.4%</td>
<td>44.4%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
<tr>
<td>NPV of high positive</td>
<td>100%</td>
<td>90.3%</td>
<td>94.4%</td>
<td>66.7%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
<tr>
<td>NPV of positive</td>
<td>100%</td>
<td>90.3%</td>
<td>94.4%</td>
<td>66.7%</td>
<td>90.3%</td>
<td>90.3%</td>
</tr>
</tbody>
</table>

OM: Osteomyelitis; non-OM: Diagnosed as other than osteomyelitis; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; WBC: white blood cells; PPV: positive predictive value; NPV: negative predictive value. High positive describes >20 mg/l for CRP and >50 mm/h for ESR. Positive describes between 5-20 mg/l for CRP, 25-50 mm/h for ESR and >10x103 cells/µl for WBC.
bimicrobial and one trimicrobial), however bacterial growth were observed only in two blood cultures. In the OM group, wound cultures and blood cultures were available for 35 (27 positive) and 13 (1 positive; *Prevotella bivia*) patients, respectively. In the non-OM group, wound cultures and blood cultures were available for 15 (12 positive) and two (one positive; *Pseudomonas aeruginosa*) patients, respectively. The most common Gram-positive organism was *Staphylococcus aureus*, followed in frequency by *Streptococcus* subspecies, and the most common Gram-negative organism was *Pseudomonas aeruginosa* in the wound cultures. Descriptive details of wound culture results are given briefly in Table 4.

We also performed a cost analysis for the patients with suspected acute OM. The mean cost per person was 48.79±36.89 USD. The mean cost of patients diagnosed with OM was 52.07±36.59 USD and this cost was statistically higher than the mean cost of 44.98 ± 37.19 USD for patients whose findings ruled out OM ($P=.016$).

**DISCUSSION**

The many classifications of OM are based on different criteria, such as the location of infection, duration of illness, infection source and the condition

---

**Table 3:** The concomitant findings and diabetes mellitus in patients suspected with osteomyelitis

<table>
<thead>
<tr>
<th>Final diagnosis</th>
<th>Results</th>
<th>Prosthesis</th>
<th>Tr/Op</th>
<th>DM</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>n %</td>
<td>n</td>
<td>n %</td>
<td>n</td>
</tr>
<tr>
<td>OM (n=64)</td>
<td>Yes</td>
<td>16 25.0</td>
<td>16</td>
<td>25.0</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>48 75.0</td>
<td>48</td>
<td>75.0</td>
<td>28</td>
</tr>
<tr>
<td>Non-OM (n=55)</td>
<td>Yes</td>
<td>15 27.3</td>
<td>16</td>
<td>29.1</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>40 72.7</td>
<td>39</td>
<td>70.9</td>
<td>37</td>
</tr>
</tbody>
</table>

*Tr/Op:* Trauma or non-prosthetic orthopedic surgery; *DM:* diabetes mellitus; *HbA1c:* glycated hemoglobin; *OM:* osteomyelitis; *non-OM:* diagnosed as other than osteomyelitis.

---

**Fig 1:** C-reactive protein (CRP) values of the groups ($P<.001$).

**Fig 2:** The erythrocyte sedimentation rate (ESR) values of the study groups ($P<.001$).

**Fig 3:** Diagnostic flow chart used in our hospital for patients with suspected osteomyelitis.

studies[1]. that a diagnosis of OM should be based both on clinical diagnostic work-up. The current guidelines suggest and pathologic tests are frequently necessary for the apparent, so radiologic, microbiologic, biochemical of the host. The diagnosis of OM is not always
4
3
2
1
OSTEOMYELITIS. OM: osteomyelitis; non-OM: diagnosed as other than osteomyelitis.

of the host. The diagnosis of OM is not always apparent, so radiologic, microbiologic, biochemical and pathologic tests are frequently necessary for the diagnostic work-up. The current guidelines suggest that a diagnosis of OM should be based both on clinical examination, microbiological tests and imaging studies[11].

In our study, the 119 adult patients who were pre-diagnosed with acute OM underwent TPBS and SPECT/CT (n=89, 74.8%), LLS (n=30, 25.2%) and MRI (n=37, 31.1%). No association was noted between the departments involved in the follow-up and the examinations performed (P=.138). A diagnostic flowchart is shown in Fig 3. Nineteen patients had only undergone a TPBS and 41 patients had undergone both TPBS and SPECT/CT, without other radiologic or radionuclide scans. In 15 of the 19 patients who had no other tests, acute OM diagnosis was initially ruled out; however, the rest of these patients were diagnosed with acute OM based on clinical findings and laboratory tests. Of the 41 patients who had undergone both TPBS and SPECT/CT, 25 were diagnosed with acute OM, whereas the diagnosis was excluded in 16. The mean cost of diagnosis in 59 patients who underwent either TPBS or TPBS and SPECT/CT was 23.35±8.15 USD, whereas the diagnostic cost for the other 60 patients was 73.81±37.04 USD (P <.001). Consequently, almost half of the patients with a pre-diagnosis of OM would require additional examinations and the associated costs for an accurate clinical decision.

The sensitivity and specificity of TPBS are generally reported as 90% and 25%, respectively. If a TPBS is negative, then OM is very unlikely. However, the findings of TPBS are not specific for OM. The reason for the low specificity is that TPBS has low discrimination when the bony structures are complicated by trauma or surgery because localized uptake in TPBS is observed both in cases of active infection and in all other pathologies that result in increased osteoblastic activity. TPBS also fails to differentiate between soft tissue infection and OM[4,12,13]. An abnormal TPBS result therefore requires further investigation, especially in cases of trauma or prosthesis. Adding SPECT/CT to TPBS enhances the diagnostic performance by providing an exact localization of the increased radionuclide uptake[11,13]. The sensitivity, specificity, PPV and NPV values of TPBS alone were 96.9%, 67.5%, 77.5% and 94.9%, respectively, whereas these values for TPBS with SPECT/CT were 96.9%, 75.8%, 87.1% and 92.6%, indicating an increase in specificity and PPV when compared to TPBS alone.

LLS is related to the accumulation of radiolabeled WBC in areas suspected of infection; therefore, it differs from TPBS, which reflects the status of perfusion and osteoblastic activity[11]. The ranges of sensitivity and specificity of LLS have been reported as 75-100% and 67-100%, respectively[14]. Our groups of cases showed LLS sensitivity, specificity, PPV and NPV values of 100%. In our study, 30/80 patients who had undergone a TPBS were also scanned with LLS. The LLS findings supported OM in 16 of these patients, and OM was excluded in 14. LLS improved the diagnostic evaluation of OM by excluding false positives obtained with TPBS, and our results were consistent with previous studies[15,16].

MRI is considered to be the most useful imaging technique for evaluating suspected acute OM, as it provides anatomic detail, including cortical destruction and soft tissue extension, within three to five days of the disease onset[4,14]. The ranges of sensitivity and specificity of MRI were reported as 78-90% and 60-90%, respectively[4]. In the present study, MRI had a modest sensitivity (80.8%), a high specificity (90.9%) and PPV (95.5%), and a low NPV (66.7%).

The serum inflammatory markers CRP and ESR can be utilized for both the diagnosis and the follow-up of patients with OM. Previous studies suggested that elevated CRP and ESR levels may be used for the diagnosis of OM with a sensitivity and specificity of >70%. However, the sensitivity and specificity of CRP
and ESR for the diagnosis of OM vary depending on the cutoff value, as higher cutoff values decrease the sensitivity and increase the specificity\[16,17,18\]. In our study, when the cutoff value of ESR was accepted as 25 mm/h, the sensitivity and specificity were 95.3% and 50.9%, respectively. When the cutoff value of ESR was increased to 50 mm/h, the sensitivity decreased to 94% and the specificity increased to 73.7%. Similarly, when the cutoff value of CRP was chosen as 5 mg/dl or 20 mg/dl, the specificity values were 52.7% and 80.6%, respectively. The mean CRP and ESR values were 50.71±41.01 mg/dl and 66.19±26.56 mm/h respectively in the acute OM group and 10.34±11.45 mg/dl and 29.10±21.88 mm/h respectively in the non-OM group (Fig 1 and 2). Our results suggest that the mean ESR and CRP levels were significantly higher in the patients who had OM than in those who did not (both \(P <.001\)).

Healthy bone is highly resistant to infection. Most hematogenous OM is monomicrobial, although OM due to trauma or implanted prosthetic material is often polymicrobial (with organisms such as \textit{S. aureus}, coagulase-negative staphylococci and gram-negative enteric bacteria). \textit{S. aureus} is typically the most common pathogen responsible for hematogenous, trauma-related or prosthetic-material-related, and diabetic foot OM. The gold standard technique for obtaining a specimen for microbiological culture is a bone biopsy, although it often does not reflect the OM but purulent material from drainage wounds can be cultured, although it often does not reflect the OM agent and may be confused with a wound infection or contamination by skin flora\[3,4\].

In the present study, microbiological wound cultures were obtained from 50 of the 119 patients with suspected OM. Bacterial growth was observed in 39 patients, and 27 of those patients were diagnosed with OM. In those cases, the microbiological cultures were performed to determine the treatment rather than to confirm the diagnosis of OM. The most frequently isolated bacterium was \textit{S. aureus} in our study, and this result was consistent with previous studies.

Acute hematogenous OM generally originates as a bloodstream infection and occurs predominantly in children, whereas a reason, such as diabetes mellitus, trauma or orthopedic prosthesis, usually underlies OM in adults\[1\]. Our analysis of 64 patients with acute OM revealed 27 (42.2%) diagnoses associated with diabetic feet, 16 (25%) with orthopedic prostheses, and 16 (25%) with extra-prosthetic operations or traumas. A total of 59 (92.2%) patients with OM had an underlying etiology. However, no statistically significant difference was noted between prosthesis, trauma or the presence of any previous operation involving the suspect bone among the groups (\(P =.78\)). Diabetes mellitus, as an important underlying cause of OM, was present in 54 of 119 patients and 36 of them were diagnosed with OM (27 diabetic feet). A statistically significant difference was noted between the two groups regarding the presence of diabetes mellitus (\(P =.01\)), but no significant difference was evident in HbA1c values between groups (\(P =.66\)).

The diagnosis of OM remains a challenge, and all imaging techniques have advantages and disadvantages. Both TPBS and LLS, when used alone, are relatively poor at distinguishing between soft tissue infection and OM because of their reduced spatial resolutions\[19\]. Previous surgical treatment or trauma also reduces the specificity of TPBS. Negative results for most of the imaging techniques virtually ruled out OM, but positives were generally inconclusive for diagnosis\[20\]. SPECT/CT, combined with TPBS or LLS, is helpful for the diagnosis of OM\[16,21,22\]. Our study has also shown that excluding OM is more cost effective and less expensive than diagnosing OM. The mean cost of the patients diagnosed with OM was 52.07±36.59 USD, and the mean cost of diagnostic tests in the cases without OM was 44.98±37.19 USD, and this difference was statistically significant (\(P =.016\)).

CONCLUSION

MRI is the imaging modality of choice for the investigation of suspected OM in the current evidence-based guidelines. Previous studies and our results support that, in cases where MRI is contraindicated or unavailable, TPBS and LLS, particularly when combined with SPECT/CT, are useful diagnostic tools in evaluating patients with suspected OM.

ACKNOWLEDGMENT

Dr. Ortatatli and Dr. Ayan conceived of and designed the study. Dr. Ayan acquired data. Dr. Ortatatli wrote the first version of the article and Dr. Ayan drafted the article.

The authors have no conflicts of interest to declare. The authors declare that this study has received no financial support.

REFERENCES

5. Jorge LS, Chueire AG, Rossit AR. Osteomyelitis: a
Original Article

Comparison of psoriasis area and severity index and physician’s global assessment in determining psoriasis severity

Ayda Acar¹, Ada Bozkurt², Gizem Kocabas Yenipazar³, Sibel Alper⁴, Can Ceylan¹
¹Department of Dermatology, Medical Faculty of Ege University, Izmir, Turkey
²Department of Dermatology, Van Training and Research Hospital, Van, Turkey
³Department of Dermatology, Mus Public Hospital, Mus, Turkey
⁴Department of Dermatology, Medical Faculty of Koc University, Istanbul, Turkey


ABSTRACT

Objective: In clinical studies, it is crucial to assess psoriasis severity accurately and with no substantial variation between different raters. The Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) are the two most commonly used tools for the assessment of psoriasis severity. The aim of this study was to evaluate the intra-rater and inter-rater reliability of these methods and to determine whether inter-rater reliability is affected by rater experience.

Design: An open uncontrolled study

Setting: Dermatology Department of Ege University, Medical Faculty

Subjects: Fifty-five patients with plaque psoriasis who were examined between 15 August 2012 and 15 November 2012 in the dermatology department of Ege University

Interventions: Three dermatology residents with varying experience evaluated the patients individually using both the PASI and PGA for each patient (in that order).

Main Outcome Measure: PASI and PGA

Results: PASI and PGA scores showed high intra-rater correlation for all three residents. Inter-rater reliability for PASI was high between the most experienced and second most experienced resident and between the most experienced and least experienced resident. However, inter-rater reliability for PGA was high between the most experienced and second most experienced residents, but only moderate between the most experienced and least experienced resident.

Conclusions: There were no significant interrater differences between PGA and PASI scores in our study. However, because PGA is more subjective and may be affected by rater experience, PASI is considered to be a more reliable method for assessing severity of psoriasis.

KEY WORDS: physician global assessment, psoriasis area and severity index, psoriasis severity score

INTRODUCTION

Psoriasis is a chronic skin disease which affects people for many years. Many different methods have been used to attempt to treat psoriasis; current treatment options include topical treatments, phototherapy, systemic and biological agents. Treatment is selected based on disease severity[1].

The development of new treatment modalities has enhanced the importance of accurate psoriasis severity evaluation in daily clinical assessment and in clinical trials comparing disease severity before and after treatment to evaluate drug efficacy[2,3]. Psoriasis severity is multidimensional, and there is currently no method that assesses all of these dimensions[4]. Despite the fact that psoriasis severity is the most important determinant of treatment, there is no ideal method which is fully verified or globally accepted[5-7]. Naldi et al reviewed 249 randomized clinical studies on psoriasis treatment conducted from 1977 to 2000 and determined that 44 different scoring systems were used in 171 studies, with the most commonly used being the Psoriasis Area and Severity Index (PASI) (83

Address correspondence to:
Ayda Acar, Department of Dermatology, Ege University of Medical Faculty 35040, Bornova, Izmir, Turkey. Tel: +90 5345906035; Fax: +90 2323399702; E-mail: aydaerbas@yahoo.com
studies, 33.3% [8]. Spuls et al. reviewed psoriasis studies conducted between 2000 and 2007 and discovered that 53 different psoriasis severity assessment methods were used, with PASI again being the most common [7]. Although PASI is the most validated and comprehensive scoring scale [6], it does have certain limitations. The PASI can be difficult to interpret, and does not evaluate the hands, nails, feet, face and genital area, impact on life quality or comorbidities. Furthermore, the sensitivity of the upper part of the scale is low and the upper half of the scale is unnecessary, and it has low sensitivity for mild and moderate psoriasis with low body surface involvement [3,6].

After PASI, the Physician’s Global Assessment (PGA) is the second most commonly used method in clinical trials [2]. Although the PGA is less objective compared to the PASI, the PGA is easier to apply and understand [9].

Due to the continuing uncertainty regarding the best method of assessing psoriasis severity, in the present study, we aimed to investigate the intra-rater correlation between PASI and PGA scores in patients with chronic plaque psoriasis and determine whether inter-rater reliability is affected by rater experience.

**SUBJECTS AND METHODS**

Fifty-five patients with chronic plaque psoriasis who presented to our Dermatology department between August 2012 and November 2012 were included in the study. Permission from local ethics committee was taken. Inclusion criteria for the study were having chronic plaque psoriasis and being over the age of 18. Patients with other forms of psoriasis and those who did not agree to be examined separately by three different dermatologists were excluded from the study. All participants provided written informed consent after a full explanation of the nature and purpose of the study.

The patients were evaluated by three dermatology residents with different levels of experience: Physician A was most experienced with three years of residency; Physician B had two years of residency; and Physician C was the least experienced with one year of residency. Each physician used the PASI and PGA to evaluate the 55 psoriasis patients. The patients’ demographic data and treatments received for psoriasis were recorded by Physician A in their case report forms.

All three residents examined the patients individually. They completed the erythema, induration, scale and area sections of the PASI table (Table 1) and indicated a number for the patient in the PGA table (Table 2) in the patients’ case report forms. Physician A later did the necessary calculations for the PASI scores.

In our study, PGA 0-2 and PASI ≤4 were accepted as mild, PGA 3-4 and PASI 4.1-10 as moderate, and PGA 5-6 and PASI > 10 as severe psoriasis.

Statistical analysis of the study data was done using SPSS 15.0 software. Descriptive continuous variables

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe</td>
<td>Very marked plaque elevation, scale and/or erythema</td>
<td>6</td>
</tr>
<tr>
<td>Moderate to severe</td>
<td>Marked plaque elevation, scale and/or erythema</td>
<td>5</td>
</tr>
<tr>
<td>Moderate</td>
<td>Moderate plaque elevation, scale and/or erythema</td>
<td>4</td>
</tr>
<tr>
<td>Mild to moderate</td>
<td>Mild to moderate plaque elevation, scale and/or erythema</td>
<td>3</td>
</tr>
<tr>
<td>Mild</td>
<td>Mild marked plaque elevation, scale and/or erythema</td>
<td>2</td>
</tr>
<tr>
<td>Almost clear</td>
<td>Intermediate between mild features to clear</td>
<td>1</td>
</tr>
<tr>
<td>Clear</td>
<td>No feature of psoriasis (Post-inflammatory hyperpigmentation can be seen)</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 1: The Psoriasis Area and Severity Index (PASI)

<table>
<thead>
<tr>
<th>PASI</th>
<th>Area coefficient</th>
<th>Erythema</th>
<th>Induration</th>
<th>Scaling</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalp</td>
<td>0.1 x</td>
<td>(</td>
<td>+</td>
<td>+</td>
<td>x</td>
</tr>
<tr>
<td>Body</td>
<td>0.3 x</td>
<td>(</td>
<td>+</td>
<td>+</td>
<td>x</td>
</tr>
<tr>
<td>Upper extremity</td>
<td>0.2 x</td>
<td>(</td>
<td>+</td>
<td>+</td>
<td>x</td>
</tr>
<tr>
<td>Lower extremity</td>
<td>0.4 x</td>
<td>(</td>
<td>+</td>
<td>+</td>
<td>x</td>
</tr>
</tbody>
</table>

Table 2: The Physician’s Global Assessment (PGA)
were expressed as means and standard deviations, and categorical variables were expressed in frequency and percent distribution. Means were compared between two groups using t-test and Spearman correlation analysis.

RESULTS

Fifty-five psoriasis patients who presented to our dermatology clinic between August and November 2012 volunteered to participate in the study. The gender and age distribution of the study participants are given in Table 1. The patient group included 45.5% males and 54.5% females (Table 3). Their mean age was 45.4±14.1 years. In terms of age distribution, 34.5% of the participants were 18-35 years old, 30.9% were 36-50 years old, 17% were 51-65 years old, and only 5.5% of the patients were over 65.

<table>
<thead>
<tr>
<th>Epidemiological characteristics</th>
<th>Variables</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>25</td>
<td>45.5</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>30</td>
<td>54.5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>18-35</td>
<td>16</td>
<td>29.1</td>
</tr>
<tr>
<td></td>
<td>36-50</td>
<td>17</td>
<td>30.9</td>
</tr>
<tr>
<td></td>
<td>51-65</td>
<td>19</td>
<td>34.5</td>
</tr>
<tr>
<td></td>
<td>&gt;65</td>
<td>3</td>
<td>5.5</td>
</tr>
</tbody>
</table>

The distribution of the 55 psoriasis patients in our study according to treatment regimen is evaluated. Systemic therapies were separated into two categories: Group 1 therapies included methotrexate, acitretin and cyclosporine, while group 2 included biological therapies such as adalimumab, infliximab and etanercept. Topical agents were being used by 47.35% of the patients, phototherapy by 12.7%; group 1 systemic therapy by 25.5% and group 2 systemic therapies by 7.3%. Four (7.3%) of the participants were not receiving any treatment for psoriatic lesions.

In our study, patients were evaluated separately by three dermatology residents with different levels of experience. The three physicians assessed each patient using both the PASI and PGA. Physician A was the most experienced, Physician B had an intermediate level of experience and Physician C was the least experienced. Table 4 shows the three residents’ independent PASI and PGA values for psoriasis severity. Physicians A, B and C assigned mean PASI scores of 12.1±8.9, 10.0±8.0 and 12.8±8.6 and mean PGA scores of 2.7±1.3, 2.7±1.5 and 3.4±1.4, respectively (Table 4).

Table 5 presents Spearman correlation analysis of the PASI and PGA scores for the same patient obtained independently by residents with different levels of experience. Correlation coefficient (r) values between 0.25-0.50 are accepted as no to very weak correlation, 0.25-0.50 as moderate correlation, 0.50-0.75 as strong correlation and 0.75-1.00 as very strong correlation. Correlations with P <0.05 were considered statistically significant. The correlation coefficients for Physicians A, B and C were 0.933, 0.941 and 0.889, indicating very strong correlation between PASI and PGA scores for all three residents (P <.001 for all; Table 5).

The patients were grouped by Physician A into three levels of severity using the PASI. Table 6 shows the results of the Spearman correlation analysis between PASI and PGA scores of each resident at different levels of severity. Correlation between PASI and PGA for Physician A was good for mild (r=0.503) and moderate cases (r=0.747) and very good for severe cases (r=0.850). For Physician B, correlation between PASI and PGA scores were good for mild cases (r=0.611) and very good for moderate (r=0.769) and severe cases (r=0.902). For Physician C, correlation was good for mild cases (r=0.562), very good for moderate cases (r=0.789) and good for severe cases (r=0.602) (Table 6).

Table 5: Evaluation of the correlation between independent PASI and PGA scores given the same patient by three different residents with different levels of experience (A-C ranked most to least experienced).

<table>
<thead>
<tr>
<th>Observer</th>
<th>Correlation coefficient (r)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>0.933</td>
<td>0.00</td>
</tr>
<tr>
<td>Physician B</td>
<td>0.941</td>
<td>0.00</td>
</tr>
<tr>
<td>Physician C</td>
<td>0.889</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Table 6: Evaluation of correlation between PASI and PGA scores given independently by three different residents (A-C ranked most to least experienced) to patients grouped according to psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>N</th>
<th>Correlation coefficient (r)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>10</td>
<td>0.503</td>
<td>0.138</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>20</td>
<td>0.747</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>25</td>
<td>0.850</td>
<td>0.000</td>
</tr>
<tr>
<td>Physician B</td>
<td>Mild</td>
<td>10</td>
<td>0.611</td>
<td>0.061</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>20</td>
<td>0.769</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>25</td>
<td>0.902</td>
<td>0.000</td>
</tr>
<tr>
<td>Physician C</td>
<td>Mild</td>
<td>10</td>
<td>0.562</td>
<td>0.091</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>20</td>
<td>0.789</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>25</td>
<td>0.602</td>
<td>0.001</td>
</tr>
</tbody>
</table>

The patients were grouped by Physician A into three levels of severity using the PASI. Table 6 shows the results of the Spearman correlation analysis between PASI and PGA scores of each resident at different levels of severity. Correlation between PASI and PGA for Physician A was good for mild (r=0.503) and moderate cases (r=0.747) and very good for severe cases (r=0.850). For Physician B, correlation between PASI and PGA scores were good for mild cases (r=0.611) and very good for moderate (r=0.769) and severe cases (r=0.902). For Physician C, correlation was good for mild cases (r=0.562), very good for moderate cases (r=0.789) and good for severe cases (r=0.602) (Table 6).
Table 7 shows the results of Spearman correlation analysis of the relationships between PASI and PGA scores given by the most experienced resident and the patients’ treatment for psoriasis lesions. Treatment regimen was not significantly correlated with PASI score ($r=0.227$) or PGA score ($r=0.205$).

<table>
<thead>
<tr>
<th>Severity score</th>
<th>Medical Treatment</th>
<th>$r$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASI</td>
<td>0.227</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td>PGA</td>
<td>0.205</td>
<td>0.134</td>
<td></td>
</tr>
</tbody>
</table>

Table 8: Evaluation of correlation between psoriasis treatment and PASI and PGA scores.

<table>
<thead>
<tr>
<th>Severity score</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.667</td>
<td>0.000</td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.637</td>
<td>0.000</td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Table 9: Assessment of interrater agreement between PGA scores of the most experienced resident (Physician A) and second most experienced resident (Physician B) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.637</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.637</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Table 10: Assessment of interrater agreement between PASI scores of the most experienced resident (Physician A) and least experienced resident (Physician C) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Table 7: Evaluation of correlation between psoriasis treatment and PASI and PGA scores.

<table>
<thead>
<tr>
<th>Severity score</th>
<th>Medical Treatment</th>
<th>$r$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASI</td>
<td>0.227</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td>PGA</td>
<td>0.205</td>
<td>0.134</td>
<td></td>
</tr>
</tbody>
</table>

Table 8: Assessment of interrater agreement between PASI scores of the most experienced resident (Physician A) and second most experienced resident (Physician B) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.667</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.637</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Table 9: Assessment of interrater agreement between PGA scores of the most experienced resident (Physician A) and second most experienced resident (Physician B) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.667</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.637</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Table 10: Assessment of interrater agreement between PASI scores of the most experienced resident (Physician A) and least experienced resident (Physician C) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>$kappa$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician B</td>
<td>Moderate</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Physician C</td>
<td>Severe</td>
<td>0.737</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Cohen’s kappa coefficient was calculated to evaluate the inter-rater agreement between PASI scores given by Physicians A and B for the psoriasis patients at the three different severity levels. Kappa values of 0-0.20 were accepted as poor agreement, 0.20-0.40 as fair, 0.40-0.60 as moderate, 0.60-0.80 as good and >0.80 as very good agreement. There was good agreement between Physicians A and B in severity discrimination using PASI ($kappa=0.667$). The inter-rater agreement in PASI scoring was much higher in patients with mild disease compared to those with moderate disease severity. Agreement was 100% for mild cases, 80% for severe cases and 65% for moderately severe psoriatic lesions (Table 8).

Kappa values were used to evaluate the inter-rater agreement between PGA scores given by Physicians A and B for the psoriasis patients at the three different severity levels (Table 9). There was good agreement between Physicians A and B in severity discrimination using the PGA ($kappa=0.637$). Agreement was 100% for severe cases and 92.3% for mild cases, but was lower (59.3%) for moderate cases.

Table 10 shows kappa values used to evaluate inter-rater agreement between PASI scores assigned by Physicians A and C for the psoriasis patients at three different severity levels. There was good agreement between Physicians A and C in severity discrimination using PASI ($kappa=0.737$). Agreement was 96% for severe cases, 80% for mild cases and 70% for moderately severe psoriatic lesions.

Table 11 shows the kappa values for inter-rater agreement in PGA scores given by Physicians A and C for the psoriasis patients at three different severity levels. There was moderate agreement between the PGA scores of Physicians A and C in the discrimination of psoriasis severity ($kappa=0.442$). Agreement was 100% for severe cases and 69.2% for mild cases, but only 50.0% for moderate cases.
Table 11: Assessment of interrater agreement between PGA scores of the most experienced resident (Physician A) and least experienced resident (Physician C) in patients with different levels of psoriasis severity.

<table>
<thead>
<tr>
<th>Observer</th>
<th>Severity classification</th>
<th>Physician B</th>
<th>kappa</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
<td></td>
</tr>
<tr>
<td>Physician A</td>
<td>Mild</td>
<td>18 (69.2%)</td>
<td>8 (30.8%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>1 (4.2%)</td>
<td>12 (50.0%)</td>
<td>11 (45.8%)</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>5 (100.0%)</td>
</tr>
</tbody>
</table>

DISCUSSION

The PASI, developed in 1978 by Fredericksonn and Petersson[10], rates the severity of psoriasis on a scale from 0 to 72, and is difficult to interpret[6]. Interpretations of the severity indicators, particularly area of involvement, may vary between raters, especially if they are not experienced[9].

The PGA includes static, dynamic, 5-point and 7-point variations. Static PGA classifies severity between ‘clear’ and ‘very severe’. The 7-point PGA is the most commonly used form in clinical studies[3]. It provides an average assessment of all psoriatic lesions based on erythema, scaling and induration[3]. Although it is subjective and provides no information about what proportion of the body is affected, it is easy to apply and understand[8]. PGA allows raters to make an estimate of the severity of psoriasis[2]. Robinson et al stated that while PGA is an appropriate and practical method for community-based studies, but due to its variability, it offers no benefit over the use of PASI alone for assessing the severity of psoriasis in large-scale clinical studies, including patients with medium to severe psoriasis[3]. They also observed in their literature review that there is weaker correlation between PASI and PGA when evaluating early treatment response or less effective treatments[3].

Compared to the r values in our study, PASI and PGA correlation was reported as high (r=0.87) in a study by Langley et al[3], and as moderate (r=0.75) and high (r=0.79) by Berth-Jones et al in 2008[5] and 2006[9] respectively. In our study, PASI and PGA correlation was very high for all three physicians.

Langley et al compared severity measurements made by 17 experienced and inexperienced physicians using PASI, PGA and Lattice System Physician’s General Assessment (LSPGA) with 35 psoriasis patients and reported that inter-rater variation was highest in the PASI. They noted that PASI was affected by experience, whereas the PGA and LSPGA were not. The authors proposed that the high level of variability in the PASI may be related to the fact that area of involvement is difficult to determine accurately, even for experienced physicians[2]. In a study by Berth-Jones et al evaluating the reliability of Copenhagen Psoriasis Severity Index and comparing the PASI and PGA, inter-rater reliability was high for the PASI and moderate for the PGA[9]. In another study by Berth-Jones et al investigating the reliability of PASI, PGA and LSPGA, inter-rater reliability was high for the PASI and LSPGA and moderate for the PGA. They suggested that the contradiction between their results and those of Langley et al may be due to the fact that they familiarized the raters with the scales beforehand, and improved the statistical methods used[9]. In our study, we observed a good level of agreement between both rater pairs for PASI, whereas the PGA showed good agreement between Physicians A and B but only moderate agreement between Physicians A and C. Despite the fact that these three residents had not been involved in any previous psoriasis research, the PASI is used in our clinic to measure psoriasis severity, and all of the residents were trained in its use before they began working, which may explain the high inter-rater agreement.

It has been stated in previous studies that differences in PASI scores may result from body area calculations[3]. Moreover, other severity indicators may be interpreted differently by the raters[8]. The variations among the PASI scores assigned by the residents in our study may be the result of differences in the calculation of body surface area and/or the other PASI components.

Limitations of this study are low total number and dissimilar number of participants in the groups separated by the psoriasis severity.

CONCLUSION

In summary, our results showed higher inter-rater agreement when using the PASI than the PGA. Agreement among both PASI and PGA scores was lower in patients with moderately severe psoriasis. In our study, inter-rater agreement for the PGA was affected by the rater’s experience level. Despite being quick and easy to use and understand, the PGA is subjective and may be interpreted differently by different raters. This may explain the lower inter-rater reliability we observed for PGA in this study.

ACKNOWLEDGMENT

Sources of support: None
Authors declare no conflict of interest.

Author Contribution
Ayda Acar: concept, literature search, clinical study, data acquisition, statistical analysis, manuscript preparation, manuscript editing. Ada Bozkurt and Gizem Kocabas Yenipazar: clinical study, data acquisition. Sibel Alper and Can Ceylan: concept, design, manuscript review.

REFERENCES


Original Article

Case series of pancreas transplant in Kingdom of Saudi Arabia

Faisal A Alsaif1, Mohammed Alsaghier2, Mohammad Saad Alqahtani3, Mansour Altawfeeq3, Khalid Almeshari4, Faisal Alalem1
1Department of Surgery, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia
2Visual Realization Office, Ministry of Health, Riyadh, Kingdom of Saudi Arabia
3Surgery Department/Transplant Surgery Department, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia
4Department of Kidney and Pancreas Transplantation, Organ Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of Saudi Arabia

ABSTRACT

Objectives: To report our experience in a rare complex procedure and graft survival data
Design: Retrospective analysis of a prospectively collected data of patients undergoing pancreas transplant in two centers in Saudi Arabia
Setting: Tertiary care centers in Saudi Arabia
Subject: Patients who underwent pancreas transplant
Intervention: Pancreas transplant
Main Outcome Measure(s): Report our experience in a complex surgical procedure and graft survival
Results: We collected a total of 21 cases of pancreas transplant for type 1 diabetes mellitus (DM) patients (9 females and 12 males). Mean age at transplant was 34.9±7.47 years and mean DM duration was 148±119 months. Out of the 21 cases, four (19%) were pancreas after kidney transplants while the remaining 17 (81%) were simultaneous pancreas-kidney. Regarding the surgical technique, all procedures were standardized to be implanted in right iliac fossa with enteric drainage. The mean cold ischemia time was 591.7±185.82 minutes and mean graft survival was 624±396 months. The mean length of admission was 17.8±15.14 days. Mean graft survival (defined by return to insulin use) was 624±395 months. Unfortunately, data regarding C-peptide level was lacking in our sample size. One patient underwent graft excision after 28 days of acute life-threatening graft rejection.
Conclusion: Despite our initial small numbers, they prove that the procedure is feasible and doable in our centers with good initial graft survival and acceptable morbidity and mortality.

KEY WORDS: diabetes mellitus, insulin, pancreas

INTRODUCTION

Pancreas transplant was first introduced in humans in 1966 aiming to treat insulin dependent diabetes mellitus (DM). The number of transplants were scarce until 2004, when the surgical, medical and immunological control aided in a better outcome. The Kingdom of Saudi Arabia is a 2.1x10^6 km^2 spaced country with a population of around 33 million with an estimated median age of 30.6 years for both genders and with a 73-year life expectancy. DM is a major crisis involving about 30% of the population with a mean age of 55.3±13.1 years as of 2011[1,2]. Having a young population with a huge burden of diabetes makes pancreas transplant a good option to improve the quality of the patient’s life and outcomes. In this study, our aim is to report our experience in pancreas transplant in Saudi Arabia.

SUBJECTS AND METHODS

A retrospective analysis of prospectively collected data of patients undergoing pancreas transplant in two centers in Saudi Arabia operated by Saudi surgeons...
over the period of 2004-2016 was carried out. Written ethical approval was part of the general consent to admission, as this is a retrospective study on clinical data. Ethical approval was acquired from King Khalid University Hospital IRB Committee.

Pre-operative and surgical procedure
All patients underwent the same regimen of immunosuppression using thymoglobulin for induction, tacrolimus, mycophenolic acid and prednisone. The patients underwent standardized surgical procedure. All pancreas organs were transplanted in the right iliac fossa with systemic vascular anastomosis and enteric duct drainage.

RESULTS
We collected a total of 21 cases of pancreas transplant for type 1 DM patients (9 females and 12 males). Mean age at transplant was 34.9±7.47 years and mean DM duration was 148±119 months. Out of the 21 cases, four (19%) were pancreas after kidney transplants while the remaining 17 (81%) were simultaneous pancreas-kidney. Regarding the surgical technique, all procedures were standardized to be implanted in right iliac fossa with enteric drainage. The mean cold ischemia time was 591.7±185.82 minutes and mean graft survival was 624±396 months. The mean length of admission was 17.8±15.14 days. Mean graft survival (defined by return to insulin use) was 624±395 months (Table 1, Fig 1). Unfortunately, data regarding C-peptide level was lacking in our sample size. One patient underwent graft excision after 28 days of acute life-threatening graft rejection. In our series, we had zero 90-day mortality.

DISCUSSION
DM is classically described as two types; type I resulting from loss of pancreas insulin resulting from autoimmune disease and type II, which is a result of increased insulin resistance and demand. The treatment modalities differ according to the type. The whole mark of type I DM is insulin deficiency. Hyperglycemia causes defects in the blood cells, vessels, kidney and nerves. This causes micro and macro vascular disease, nephropathy and peripheral
neuropathy. The role of pancreas transplant has been presented in the literature since 1966\[3,4\]. Pancreas transplant has showed a survival benefit in type I DM. In our patient series, all the patients underwent a standardized diagnostic, pre-operative, surgical technique and post-operative pathway. In our cohort, the role of pancreas transplant is promising, with acceptable complications and graft survival rates reaching the published standards\[3-5\]. However, these results are limited by the small sample size and need further studying. Given our national DM rate among young patients that increase the burden on our health care system, further efforts should be directed toward this modality of treatment as it would improve patient survival and lifestyle.

CONCLUSION
Despite our initial small numbers, they prove that the procedure is feasible and doable in our centers with good initial graft survival and acceptable morbidity and mortality.

ACKNOWLEDGMENT
Author Contributions: Faisal A Al-Saif generated the idea, provided the patient cohort reviewer and supervised the whole project; Mohammed Alsaghier and Mansour Altawfeeq contributed to the patient pool, reviewed and edited the manuscript; Mohammad Saad Alqhtani reviewed and edited the manuscript; Faisal Alalem carried out the data analysis and draft writing.

Conflict of Interest: Authors declare that they have no conflict of interest.

REFERENCES
The effect of neutrophil lymphocyte ratio and monocyte HDL ratio in indicating additional arterial disease in patients scheduled to undergo elective coronary bypass operation

Mesut Engin
Department of Cardiovascular Surgery, University of Health Sciences, Mehmet Akif İnan Training and Research Hospital, Şanlıurfa, Turkey

ABSTRACT

Objective: We aimed to investigate the role of neutrophil / lymphocyte ratio (NLR) and monocyte / high density lipoprotein ratio (MHR) in routine blood tests before surgery in predicting the presence of carotid artery and peripheral artery disease in patients scheduled for coronary artery bypass graft (CABG).

Design: Retrospective study

Setting: Department of Cardiovascular Surgery, University of Health Sciences, Mehmet Akif İnan Training and Research Hospital

Subjects: A total of 354 consecutive patients who were scheduled to undergo elective CABG operation

Intervention: Predictive values of the variables were measured for atherosclerosis extensity.

Main outcome measure(s): The relationship between preoperative NLR-MHR and concomitant arterial disease in patients scheduled to undergo CABG

Results: A total number of 310 patients in Group 1 (without additional arterial disease; 64.5% male, mean age: 59.1±8.7 years) and 44 patients in Group 2 (with additional arterial disease; 72.7% male, mean age: 65.5±12.3 years) were recorded in the study. There was a statistical difference between the two groups in terms of age (P=.003) and presence of diabetes mellitus (P=.032). In multivariate analysis, advanced age, NLR and MHR were identified as an independent predictor of concomitant arterial disease. In ROC curve analysis, a cut-off level of 2.85 for predicting concomitant arterial disease was determined for NLR (96% sensitivity and 46% specificity), and for MHR, a cut-off level of 8.65 was determined (90% sensitivity and 42% specificity).

Conclusion: In this study, we found that simple blood tests may shed light on the detection of additional arterial diseases in patients planned to undergo CABG.

KEY WORDS: carotid artery disease, coronary artery disease, monocyte to HDL ratio, neutrophil to lymphocyte ratio, peripheral artery disease

INTRODUCTION

Nowadays, the diagnosis of atherosclerotic cardiovascular diseases is more frequent with prolonged survival and progressive technology. Coronary artery disease (CAD) is one of the most frequent disease of atherosclerotic cardiovascular diseases. The gold standard treatment method is coronary artery bypass graft (CABG) when coronary artery disease presents as multiple vessel disease[5]. CAD may be accompanied by other system arteriopathies such as peripheral arterial disease (PAD) and carotid artery stenosis (CAS). In patients scheduled for coronary artery bypass surgery, CAS with 50% and more stenosis can be seen in 30% of the patients[2]. Only carotid artery disease is even important because of possible cerebrovascular risks[3]. This situation is not a cause of cerebrovascular disease alone, but it is an important risk factor. Therefore, it is important to make a diagnosis before CABG operation. Preoperative recognition of PAD in patients undergoing CABG is also important. Possible iliac artery stenoses can lead to serious complications during and after surgery[4].

Address correspondence to:
Mesut Engin, MD, Department of Cardiovascular Surgery, University of Health Sciences, Mehmet Akif İnan Training and Research Hospital, Esentepe Town, ertoğrul Street, postal code: 63200, Karaköprü, Şanlıurfa, Turkey. Tel: +90 4143186000; Fax: +90 4143186707; E-mail: mesut_kvc_cor@hotmail.com
Studies have shown that various biomarkers can demonstrate the presence and severity of atherosclerosis. In these studies, some parameters that increased in blood were related to atherosclerotic cardiovascular diseases\(^5,6\).

In our study, we aimed to investigate the predictive value of neutrophil / lymphocyte ratio (NLR) and monocyte / high density lipoprotein ratio (MHR) that can be obtained from routine blood tests before surgery on the presence of carotid artery disease and/or PAD in patients who scheduled to undergo CABG.

MATERIAL AND METHODS

The patients who were hospitalized with CABG between December 2014 and December 2018 were included in the study. The study was approved by the Ethical Committee of Sanliurfa Harran University Faculty of Medicine and was conducted in accordance with the principles of the Declaration of Helsinki. The data of the patients were retrospectively obtained from the hospital data system and archive records. Patients undergoing emergency operations, patients with known systemic inflammatory disease, new myocardial infarction, patients with additional cardiac surgery (aneurysm, valvular heart diseases etc.) except for PAD were excluded from the study. After applying these exclusion criteria, 354 consecutive patients were included in the study.

According to the tests and physical examination data, patients who didn’t have any additional artery disease except for PAD were included in Group 1. Patients having 50% or more stenosis in carotid or peripheral arteries were classified as Group 2. Demographic characteristics (age, sex, hypertension, COPD, smoking, BMI: body mass index; hypertension, smoking, etc.) and preoperative blood tests of all patients were recorded (hemogram, urea, creatinine, etc.).

Diagnosis of additional artery disease

Carotid doppler ultrasonography is performed in all patients routinely in our clinic in the preoperative preparation of coronary bypass operations. Thus, the patients can be diagnosed with a possible stenosis and occlusion. The diagnosis of PAD was made by doppler ultrasonography (in 30 patients), conventional angiography (in five patients) and/or computed tomographic angiography (in nine patients) in patients with pathology on physical examinations. According to these results, patients who had 50% or more stenosis in the peripheral and/or carotid artery system were evaluated as patients with additional artery disease.

Laboratory measurements

Preprandial blood samples were obtained from an antecubital vein of every patient when the patients entered our clinic. The tubes with EDTA were utilized for automatic blood count with reference to the procedures of our hospital. An automated hematological analyzer was used for measuring hematologic parameters (Coulter LH 780 Analyzer, CA, USA). Furthermore, NLR and MHR were assessed.

Statistical analysis

SPSS 21.0 (IBM Statistical Package for the Social Sciences Statistic Inc. version 21.0, Chicago, IL, USA) was utilized for analysis. Descriptive statistics such as mean and standard deviations were calculated for continuous and ordinal variables. The frequencies and percentages of nominal variables were analyzed. In exploring the normality of the data, Kolmogorov-Smirnov test and Shapiro-Wilk tests were performed. For comparing two groups, Student’s t test and Mann-Whitney U test were used for continuous variables with and without normal distribution respectively. Nominal variables were compared via Chi Square test. Predictors of other system arterial disease were defined via binary logistic regression analysis. P-value that was lower than 0.05 was determined as statistically significant. Receiver-operating characteristic (ROC) curve was applied for the prediction of other system arterial disease and the area under the curve (AUC) was calculated for NLR and MHR.

RESULTS

A total number of 310 patients in Group 1 (64.5% male, mean age: 59.1±8.7 years) and 44 patients in Group 2 (72.7% male, mean age: 65.5±12.3 years) were recorded in the study. There were statistical differences between the two groups in terms of age (P=0.003) and presence of diabetes mellitus (P=0.032). However, there was no statistical difference between the two groups in terms of gender, percutaneous coronary intervention history, hypertension, smoking and ejection fraction. The demographic and clinical features of the patients were shown in Table 1.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1 (n=310)</th>
<th>Group 2 (n=44)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean±sd)</td>
<td>59.1±6.7</td>
<td>65.5±12.3</td>
<td>.003</td>
</tr>
<tr>
<td>Male/female (n)</td>
<td>200/110</td>
<td>32/12</td>
<td>.448</td>
</tr>
<tr>
<td>Previous PCI, n(%)</td>
<td>88(28.3%)</td>
<td>18(40.9%)</td>
<td>.230</td>
</tr>
<tr>
<td>Target vessel (% mean±sd)</td>
<td>2.9±1.01</td>
<td>3.4±1.1</td>
<td>.073</td>
</tr>
<tr>
<td>COPD, n(%)</td>
<td>64(20.6%)</td>
<td>8(18.1%)</td>
<td>.786</td>
</tr>
<tr>
<td>Hypertension, n(%)</td>
<td>206(66.4%)</td>
<td>28(63.6%)</td>
<td>.794</td>
</tr>
<tr>
<td>Diabetes mellitus, n(%)</td>
<td>74(23.8%)</td>
<td>20(45.4%)</td>
<td>.032</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.7±4.2</td>
<td>27.6±5.9</td>
<td>.516</td>
</tr>
<tr>
<td>Smoking, n(%)</td>
<td>114(36.7%)</td>
<td>20(45.4%)</td>
<td>.432</td>
</tr>
<tr>
<td>Ejection fraction (% mean±sd)</td>
<td>51.7±7.3</td>
<td>50.9±6.7</td>
<td>.236</td>
</tr>
</tbody>
</table>

PCI: percutaneous coronary intervention; COPD: chronic obstructive pulmonary disease; BMI: body mass index
The comparison of laboratory measurements between two groups were shown in Table 2. Both Group 1 and Group 2 were similar to each other in regard to laboratory findings. Additionally, there were statistically significant differences between the two groups in terms of monocyte count ($P<.001$), NLR ($P=.001$) and MHR ($P<.001$) (Table 2).

Factors related to determine concomitant arterial disease in patients scheduled for CABG were included in univariate logistic regression analysis. In unadjusted univariate logistic regression analysis, the presence of extracardiac arterial disease was significantly correlated with advanced age (odds ratio [OR]: 1.076, 95% confidence interval [CI]: 1.024-1.131, $P=.004$), diabetes mellitus (OR: 0.376, 95% CI: 0.150-0.941, $P=.037$), NLR (OR: 1.434, 95% CI: 1.074-1.914, $P=.015$) and MHR (OR: 3.099, 95% CI: 1.674-5.736, $P<.001$), but was not correlated with gender and target vessel. In multivariate analysis, advanced age, NLR and MHR were identified as an independent predictor of concomitant arterial disease (OR: 1.052, 95% CI: 1.002-1.105, $P=.042$; OR: 1.500, 95% CI: 1.036-2.171, $P=.032$; OR: 3.004, 95% CI: 1.540-5.860, $P<.001$, respectively) (Table 3).

In ROC curve analysis, a cut-off level of 2.85 for predicting concomitant arterial disease was determined for NLR (AUC: 0.722, 95% CI: 0.638-0.806, log rank $P=.001$, 96% sensitivity and 46% specificity), and for MHR, a cut-off level of 8.65 was determined for predicting concomitant arterial disease (AUC: 0.791, 95% CI: 0.703-0.879, log rank $P<.001$, 90% sensitivity and 42% specificity) (Figure 1).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1 (n=310; mean ± SD)</th>
<th>Group 2 (n=44; mean ± SD)</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit (%)</td>
<td>38.9±5.1</td>
<td>37.1±5.9</td>
<td>.483</td>
</tr>
<tr>
<td>White blood cell (10³/µL)</td>
<td>8.9±2.9</td>
<td>9.6±3.1</td>
<td>.339</td>
</tr>
<tr>
<td>Platelet (10⁴/µL)</td>
<td>279.3±73.2</td>
<td>288.7±69.2</td>
<td>.354</td>
</tr>
<tr>
<td>RDW(%)</td>
<td>13.7±1.4</td>
<td>14.4±1.3</td>
<td>.249</td>
</tr>
<tr>
<td>MPV(fL)</td>
<td>8.5±1.2</td>
<td>8.8±1.3</td>
<td>.543</td>
</tr>
<tr>
<td>Neutrophil (10⁹ mL)</td>
<td>6.4±1.2</td>
<td>6.9±1.1</td>
<td>.364</td>
</tr>
<tr>
<td>Lymphocyte (10⁹ mL)</td>
<td>2.9±1.4</td>
<td>2.2±1.2</td>
<td>.456</td>
</tr>
<tr>
<td>Monocyte (10⁹ L)</td>
<td>370±122.8</td>
<td>398±133.2</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>17.9±6.7</td>
<td>19.8±9.7</td>
<td>.124</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.1±0.5</td>
<td>0.9±0.5</td>
<td>.486</td>
</tr>
<tr>
<td>C-reactive protein (mg/dL)</td>
<td>7.8±11.3</td>
<td>10.1±12.6</td>
<td>.146</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>191±68.5</td>
<td>199±53.7</td>
<td>.351</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>126.8±43.7</td>
<td>129.2±38.1</td>
<td>.256</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>41.1±6.9</td>
<td>41.7±9.2</td>
<td>.066</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>184.8±89.6</td>
<td>195.3±67.5</td>
<td>.453</td>
</tr>
<tr>
<td>NLR</td>
<td>3.3±1.3</td>
<td>4.1±1.1</td>
<td>.001</td>
</tr>
<tr>
<td>MHR</td>
<td>7.9±1.5</td>
<td>9.4±0.7</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

RDW: red cell distribution width; MPV: mean platelet volume; BUN: blood urea nitrogen; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; NLR: neutrophil to lymphocyte ratio; MHR: monocyte to HDL ratio

Fig 1: Receiver operation characteristic (ROC) curve and area under the curve (AUC) for neutrophil to lymphocyte ratio (NLR) levels and monocyte to HDL ratio (MHR) levels for predicting to identify concomitant carotid artery disease and peripheral artery disease (NLR: cut-off=2.85, 96% sensitivity, 46% specificity, MHR: cut-off= 8.65, 90% sensitivity, 42% specificity)
**DISCUSSION**

Atherosclerosis is a condition arising out of chronic vascular inflammation. As a result of this inflammation, inflamed cytokines and chemokines penetrate into the inflamed vascular endothelium\[^7\]. The atherosclerotic process progresses within a certain relationship with the entire cardiovascular system\[^8\]. The clinical outcomes of this condition are generally seen as CAD, PAD and CAS. These diseases can be detected separately in the same person or can be seen together. The possible PAD and/or CAS cases should be recognized in the preoperative period, especially in patients undergoing CABG.

Neutrophils in circulation lead to the progression of atherosclerosis by clinging to the damaged vascular endothelial regions. Thus, chemokines come into the region, proliferation develops and atherosclerosis progresses and the vessel wall narrows\[^9\]. Monocyte activation also plays a role in the atherosclerotic process by modulating inflammatory cytokines. By attaching to damaged endothelial sites, monocytes aggregate the inflammatory process and play a role in thrombotic events\[^10\]. By contrast, HDL takes a preventive role in the progression of the atherosclerotic process\[^11\].

In recent years, the relationship between blood parameters and cardiovascular system diseases has been the subject of interest, and various studies have been carried out on this topic. In addition to the diagnostic importance, the prognostic values of these parameters after cardiovascular operations were also investigated. Aykan et al investigated the role of NLR in the severity of PAD. In this study, patients were divided into two groups as Transatlantic Intersociety Consensus (TASC) -A-B and TASC-C-D and NLR was significantly higher in TASC-C-D group. In the ROC analysis, the cut-off of NLR was determined as 3.05 (sensitivity=75.0%, specificity = 62.9%, AUC=0.678, 95% CI=0.688 (0.784, P <.001)\[^12\].

The prognostic significance of NLR in patients undergoing CABG was investigated by Ay et al and the patients were divided into two groups as below 45 years of age and above. Mortality and NLR were found to be significantly higher in the elder patient group and it was stated that NLR may be a predictor of mortality in this study\[^13\]. Arbel and his colleagues investigated the role of NLR in determining the severity of CAD by evaluating 3005 consecutive patients who had coronary angiography. They classified the patients into three groups by their NLR. The first group (30% of patients) consisted of patients whose NLR were below 2, the second one (30% of patients) comprised of patients whose NLR were between 2 and 3 and the last one (40% of patients) included patients whose NLR were more than 3. They found a significant difference in CAD severity among these three groups (P <.001). They also found a positive correlation between higher NLR and CAD severity (P <.001). At the same time, close relationship with adverse events was detected at three-year follow-up\[^14\].

Similarly, MHR was investigated in cardiovascular system diseases. The clinical significance of MHR was evaluated by Cetin et al on 2661 patients with acute coronary syndrome. They determined that MHR showed the severity of CAD. In this study, the mean follow-up period was 31.6 months, and the relationship between increased MHR and major adverse cardiovascular events was determined\[^15\]. Tekkesin et al investigated the effects of MHR on atrial fibrillation in patients undergoing CABG. In this study, preoperative MHR values were significantly higher in patients with atrial fibrillation in the postoperative period\[^16\].

In our study, we aimed to investigate the predictive value of MHR and NLR in addition to the presence of CAS and PAD in patients scheduled for CABG. We divided patients into two groups as patients with CAS or PAD and patients without additional artery disease. As a result of our study, we determined that these parameters obtained from preoperative routine blood tests of the patients may guide us. Although MHR and NLR values have good sensitivity, their overall specificity is poor (42% and 46%).

### Table 3: Logistic regression analysis for predictors to identify other system arterial disease

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P</td>
<td>Exp(B)</td>
</tr>
<tr>
<td>Age</td>
<td>.004</td>
<td>1.076</td>
</tr>
<tr>
<td>Male gender</td>
<td>.450</td>
<td>1.467</td>
</tr>
<tr>
<td>Target vessel</td>
<td>.075</td>
<td>1.526</td>
</tr>
<tr>
<td>DM</td>
<td>.057</td>
<td>0.376</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>.226</td>
<td>1.356</td>
</tr>
<tr>
<td>NLR</td>
<td>.015</td>
<td>1.434</td>
</tr>
<tr>
<td>MHR</td>
<td>&lt;.001</td>
<td>3.099</td>
</tr>
</tbody>
</table>

DM: diabetes mellitus; PCI: percutaneus coronary intervention NLR: neutrophil to lymphocyte ratio MHR: monocyte to HDL ratio

---

\[^7\] The atherosclerotic process progresses within a certain relationship with the entire cardiovascular system.

\[^8\] The clinical significance of MHR was evaluated by Cetin et al on 2661 patients with acute coronary syndrome.

\[^9\] Monocyte activation also plays a role in the atherosclerotic process by modulating inflammatory cytokines.

\[^10\] By attaching to damaged endothelial sites, monocytes aggregate the inflammatory process and play a role in thrombotic events.

\[^11\] By contrast, HDL takes a preventive role in the progression of the atherosclerotic process.

\[^12\] The prognostic significance of NLR in patients undergoing CABG was investigated by Ay et al and the patients were divided into two groups as below 45 years of age and above.

\[^13\] Arbel and his colleagues investigated the role of NLR in determining the severity of CAD by evaluating 3005 consecutive patients who had coronary angiography.

\[^14\] At the same time, close relationship with adverse events was detected at three-year follow-up.

\[^15\] Tekkesin et al investigated the effects of MHR on atrial fibrillation in patients undergoing CABG.

\[^16\] In this study, preoperative MHR values were significantly higher in patients with atrial fibrillation in the postoperative period.
Preoperative preparation of coronary bypass operations is as valuable and important as the surgical technique stage of the operation. In these patient groups, possible lung diseases, uncontrolled diabetes and other systemic diseases may overshadow our technical surgical success. Carotid artery disease and PAD should be detected in the preoperative period and essential precautions should be taken. In particular, in patients with possible iliac artery stenosis, it may be difficult to apply to intra-aortic balloon pump, a very valuable device in the weaning of cardiopulmonary bypass. In this case, it may be necessary to perform more complicated methods than the femoral approach[17]. In addition, it is very important to diagnose the potentially severe CAS at preoperative stage. We may need to make changes in our operation strategies in this clinical situation. In this case, the operation method is determined by considering the clinical evaluation of CAD and CAS[18].

CONCLUSION

In this study, we found that simple blood tests may shed light on the detection of additional arterial diseases in patients who are about to undergo CABG. Misdiagnosing possible severe PAD or CAS disease may lead to catastrophic outcomes in CABG operations, which are a major surgery. According to our study, NLR and MHR can cause us to suspect additional arterial diseases.

Limitations
This study is a retrospective study carried out in homogeneous groups of patients. A smaller number of patients is also the limiting factor of the study. In addition, Group 2 had a smaller number of patients (44 patients).

ACKNOWLEDGMENT

Ethical statement: The material has not been published anywhere. Author of the manuscript has no financial ties to disclose and has met the ethical adherence.

Declaration of authorship: The author has directly participated in the planning, execution, analysis or reporting of this research paper. The author has read and approved the final version of the manuscript.

Conflict of interest: None

REFERENCES


Original Article

Neutrophil to lymphocyte ratio: An indicator of recurrence in primary spontaneous pneumothorax?

Serhat Yalcinkaya
Associate Professor of Thoracic Surgery, Department of Thoracic Surgery, Kutahya Health Sciences University Faculty of Medicine, Kutahya, Turkey

Kuwait Medical Journal 2021; 53 (4): 417 - 420

ABSTRACT

Objective(s): To address the question whether neutrophil to lymphocyte ratio may be an indicator of recurrence in primary spontaneous pneumothorax

Design: Retrospective study

Setting: Bursa Yüksek Ihtisas Hospital for Education and Research, Bursa, Turkey

Subjects: A total number of 124 primary spontaneous pneumothorax patients treated in our hospital between 5th July, 2002 and 30th April, 2015. Patients with only initial episode were enrolled in Group 1 and patients presented with recurrence were enrolled in Group 2.

Intervention(s): Age, gender, cigarette smoking history, bullae presence, pneumothorax side, length of hospital stay and presence of recurrence were noted. Initial complete blood count results were used for neutrophil to lymphocyte ratio calculation.

Main Outcome Measure(s): All data are analyzed statistically for any significant relationships between the variables and recurrence.

Result(s): Statistical analysis using chi-square test revealed a significant relationship between recurrence and neutrophil to lymphocyte ratio ($X^2=62.752$, $P=.000$) and cigarette smoking ($X^2=8.116$, $P=.004$). We did not find any significant relationship between recurrence and presence of bullae or gender.

Conclusion(s): We believe that neutrophil to lymphocyte ratio value higher than 2.48 may be an indicator of recurrence in primary spontaneous pneumothorax patients. Further multicenter studies with larger number of patients, however, are needed to verify this conclusion.

INTRODUCTION

Pneumothorax is defined as the presence of free air between the pleural sheets[1-3]. Primary spontaneous pneumothorax (PSP) constitutes a problem for the physician because of the tendency to recur[3]. Researchers have performed studies in search for the perfect indicator of recurrence without success. Recently, a calculation depending on the physical measurements from the chest x-ray and body mass index named as the Ankara Numune Index has been reported to be of value in predicting recurrence[4]. Neutrophil to lymphocyte ratio (NLR) is a recent factor used in determining the severity of various disorders including seriously ill patients in the intensive care units, tuberculosis, chronic obstructive pulmonary disease (COPD), inflammatory diseases, vascular diseases and malignancies[5-16]. Its role in PSP, however, is not yet studied.

The aim of this study is to assess the relationship between NLR and PSP recurrence within a cohort of patients treated in a single institution.

SUBJECTS AND METHODS

Following the permission granted by the Bursa Clinical Study Ethics Committee (Permission date and number: June the 30th, 2015, 2015-13/17) and Hospital Management following this permission (document date and number: July the 13th, 2015/3313), the archive files of Bursa Yüksek İhtisas Hospital for Education and Research were screened for cases of PSP hospitalized between 2nd July, 2002 and 30th April, 2015. Patients with only an initial episode were...
enrolled in Group 1 and patients who presented with recurrence were enrolled in Group 2. Patients who presented with pneumothorax not leading to tube thoracostomy and due to other causes, *e.g.* trauma or COPD, were excluded. Age, gender, site of pneumothorax, cigarette smoking, presence of bullae, length of hospital stay and presence of recurrence were noted. Neutrophil, lymphocyte and platelet counts from the initial complete blood count results in the emergency room at the time of admittance were recorded as well. NLR was calculated as neutrophil count divided by lymphocyte count as defined earlier[5]. For statistical analysis, MedCalc Statistical Software version 18.6 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018, licensed to the author) was used. Receiver operator characteristics (ROC) curve analysis and chi-square tests were used for statistical evaluation, with a *P*-value less than 0.05 accepted as significant.

**RESULTS**

Within the aforementioned period, a total of 124 patients were admitted to the hospital due to either an initial or a recurrent episode of PSP. Group 1 consisted of 59 patients and there were 65 patients in Group 2. There were 51 male (86.4%) and 8 female (13.6%) patients in Group 1 with an average age of 29.23±6.53 years (range: 19-42). In Group 2, there were 55 male (84.6%) and 10 female (15.4%) patients and the average age was 33.04±6.84 years (range: 20-56). The demographic properties of the two groups are listed in Table 1 in detail.

Using the ROC curve analysis, we determined a cut-off value of 2.48 for NLR (sensitivity: 83.1%, specificity: 88.1%, area under curve (AUC): 0.916 and 95% confidence interval). Statistical analysis using chi-square test revealed significant relationship between recurrence and NLR (*X^2*=62.752, *P*=.000) and cigarette smoking (*X^2*=8.116, *P*=.004). We did not find any significant relationship between recurrence and presence of bullae or gender. Chi-square analysis results are listed in Table 2.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>29.23±6.53</td>
<td>33.04±6.84</td>
</tr>
<tr>
<td>NLR</td>
<td>2.13±0.27</td>
<td>3.16±0.81</td>
</tr>
<tr>
<td>Length of hospital stay (days)</td>
<td>6.01±1.30</td>
<td>7.52±2.64</td>
</tr>
<tr>
<td>Interval until recurrence(months)</td>
<td>NA</td>
<td>5.60±3.45</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>51</td>
<td>55</td>
</tr>
<tr>
<td>Female</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>Affected site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>Right</td>
<td>36</td>
<td>41</td>
</tr>
<tr>
<td>Tobacco</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>31</td>
<td>50</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>28</td>
<td>15</td>
</tr>
<tr>
<td>Bullae</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>27</td>
<td>21</td>
</tr>
<tr>
<td>Present</td>
<td>32</td>
<td>44</td>
</tr>
</tbody>
</table>

**DISCUSSION**

PSP is a benign disorder recurrent in nature[17]. Various studies suggest anatomical measurements such as Numune index and presence of bullae[1,18]. Others advocate tobacco consumption as the primary
Neutrophil to lymphocyte ratio: An indicator of recurrence in primary spontaneous pneumothorax?

December 2021

Neutrophil to lymphocyte ratio has become a popular indicator of poorer outcome in various disorders. In studies published recently, NLR is reported to be related to bad prognosis in seriously ill patients in the intensive care units, tuberculosis, COPD, inflammatory diseases, vascular diseases and malignancies. Dilektasli et al revealed that an NLR greater than 8.19 and 7.92 are independent indicators of in-hospital mortality at days 2 and 5, respectively, in our series, bullae were present in 54.2% in Group 1 and 66.2% in Group 2. We did not find any statistically significant relation between bullae presence and recurrence.

The time interval between the first and the second episode is reported as ranging from 2 to 18 months. In our study, the interval was 5.6±3.45 months (range: 1-18 months). This finding also is similar to former reports.

Neutrophil to lymphocyte ratio has become a popular indicator of poorer outcome in various disorders. In studies published recently, NLR is reported to be related to bad prognosis in seriously ill patients in the intensive care units, tuberculosis, COPD, inflammatory diseases, vascular diseases and malignancies. Dilektasli et al revealed that an NLR greater than 8.19 and 7.92 are independent indicators of in-hospital mortality at days 2 and 5, respectively, in the critically ill trauma patients treated in intensive care units. Gunay et al calculated a NLR value of 1.71±0.65 in control, 2.59±1.79 in stable and 4.28±4.12 in exacerbated COPD patients. Iliaz et al reported that NLR value of 2.55 was effective in distinguishing between tuberculosis and sarcoidosis. Choi et al studied the preoperative NLR levels in lung cancer patients as a predictor of survival in addition to non-steroid anti-inflammatory drug use postoperatively. They reported that preoperative NLR ≥5 is an indicator of shorter overall survival. Takahashi et al studied preoperative NLR as an indicator of prognosis in a selected group of lung cancer patients. Using the ROC curve analysis, they determined a cut off value for NLR as 2.498 with 66.7% sensitivity, 58.5% specificity and AUC=0.684. They used this value to discriminate the preoperative NLR as low, i.e. less than 2.498, and high. They concluded that low NLR values had a chance of 89.2% overall survival calculated using the Kaplan-Meier method. We calculated the NLR values of each patient from the initial complete blood count results from the emergency department. The average NLR values were 2.13±0.27 (range: 1.58-2.85) in Group 1 and 3.16±0.81 (range: 1.83-5.33) in Group 2.

We used ROC analysis to determine the cut-off value in our series as 2.48 with 83.1% sensitivity, 88.1% specificity, AUC=0.916 and 95% confidence interval. The statistical analysis revealed a significant relationship between NLR value and recurrence in PSP patients (X²=62.752, P=.000). This result implies that a NLR value over 2.48 calculated from the complete blood count at the initial episode indicates a recurrence.

CONCLUSION

According to these results, we suggest that NLR may be an indicator of recurrence in PSP. To our knowledge, this is the first study evaluating NLR in relation to recurrence in PSP to be published in literature. The limitations of our study include the limited number of patients in both groups, the presence of various hospitals in the area patients may seek medical assistance from and thus resulting in loss of patients under our clinical surveillance.

We conclude that further multi-center clinical studies including larger number of patients will help to assess the value of NLR as an indicator of recurrence in PSP.

ACKNOWLEDGMENT

This study was not supported in any way by third parties. The author has no conflict of interests.

The result of this study was presented at the 9th Turkish National Congress on Thoracic Surgery held at Antalya in 2017 as oral presentation.

The author wishes to thank Assist. Prof. Recep Serkan Arik, PhD, Kutahya Dumlupinar University, Education Faculty, Department of Measurement and Evaluation for his critical review of statistical analysis.

REFERENCES

Original Article

Oral hygiene habits and storage method impact on toothbrush contamination among participants in Kuwait

Ahmad M AlAli1, Norya M Al Maraghi2, Qudsiya Y Electricwala2, Ali A Dashti2
1Ministry of Health, Kuwait City, Kuwait
2Faculty of Allied Health Sciences, Health Sciences Centre, Kuwait University, Kuwait City, Kuwait

Kuwait Medical Journal 2021; 53 (4): 421 - 428

ABSTRACT

Objective(s): To investigate oral hygiene habits and the impact of different storage methods on bacterial growth on toothbrushes among participants in Kuwait

Design: Prospective controlled study

Setting: Health Science Centre, Kuwait University, and Asnan Tower (private dental clinic) between December 2013 and January 2014

Subjects: The study was conducted among 240 participants (students, staff and patients) that were selected by convenience sampling and allocated randomly into five groups according to storage method.

Intervention(s): Each participant was provided with a new toothbrush to use for five continuous days. A questionnaire regarding the oral hygiene habits was also given.

Main Outcome Measure(s): Oral hygiene habits and bacterial growth on toothbrushes were identified.

Result(s): Of the participants, 38%, 27%, and 25% brush their teeth twice a day, after meals, and once a day (morning) respectively. Most participants store their toothbrushes in the bathroom after use but only 5% store them outside the bathroom. Ten different bacterial strains were isolated from 182 toothbrushes and one type of yeast, Candida Spp. was identified. Neisseria spp. and Staphylococcus epidermidis were shown to be present in all groups regardless of the toothbrush storage method. Streptococcus viridans, Bacillus spp., Klebsiella pneumoniae and Enterobacter agglomerans have been identified solely in specific groups only.

Conclusion(s): The participants showed satisfactory standards of oral hygiene habits and were definitely in need of raising the awareness of implementing better oral health. Soaking the toothbrush in chlorhexidine has shown to be the best storage method in terms of the presence of bacterial strains.

KEY WORDS: microbial contamination, oral hygiene, toothbrushes

INTRODUCTION

The oral cavity contains many different complex surfaces providing various environments for microorganisms’ growth and colonization. These microorganisms usually live in the oral cavity in several habitats, which include the teeth with its supragingival and subgingival surfaces, crevicular epithelium, dorsum of the tongue, buccal mucosa, hard and soft palate, tonsils and prosthodontic and orthodontic appliances, if present[1]. Up to 700 species of bacteria, which are commensals and pathogens, have been identified in the oral cavity[2]. The microorganisms in the oral cavity are the main causes of oral diseases, such as dental caries, gingivitis and periodontitis. Hence, toothbrushing is vital to remove these microorganisms as a part of oral hygiene regime for the prevention of oral diseases. However, it is not about toothbrushing alone, but using fluoridated toothpastes, as its efficacy in preventing dental caries has been shown with clear evidence by a Cochrane systematic review with meta-analyses[3]. Another Cochrane systematic review with meta-analyses also showed that using powered toothbrush may result in 21% reduction in plaque after three months of use and 11% reduction in gingivitis when compared with a manual toothbrush[4]. Although toothbrushing is important to remove plaque and provides good oral hygiene, toothbrushes might be the source of repeated oral infections[5]. Several studies show that toothbrushes serve as a reservoir for bacteria that can be extremely contaminating after use[6].

Address correspondence to:
Ahmad M AlAli, Ministry of Health, Kuwait City, Kuwait. Tel: +965 97972742; E-mail: ahalali@mov.gov.kw
Since the oral cavity could carry several opportunistic pathogens, immunocompromised or elderly people might suffer from serious lung infections\(^7\). Moreover, it has been shown that periodontitis can increase the risk of atherosclerotic cardiovascular diseases, which include fatal and non-fatal coronary heart diseases (angina, myocardial infarction), ischemic cerebrovascular disease (stroke/transient ischemic attack) and peripheral arterial disease\(^8\). Therefore, microorganisms contaminating or accumulating on toothbrushes are not only affecting the oral health, but the general health of an individual as well\(^9\).

The purpose of this study is to investigate the oral hygiene habits and the impact of different storage methods on bacterial growth on toothbrushes.

**SUBJECTS AND METHODS**

**Sampling and allocation of participants**

A convenience sampling method was implemented in this study, followed by allocating the participants randomly into five different groups using a random numbers table. New toothbrushes and toothpastes were distributed to the five groups, each with the same toothbrushing instructions but different storage methods. All participants were advised to use the toothbrush twice a day and rinse them with tap water before and after use, but without using the covering cap. Moreover, participants were asked to brush their teeth surfaces, and tongue if possible, using a pea-sized amount of toothpaste with avoidance of rinsing with water after brushing unless necessary.

Groups were assigned as group A, B, C, D and E. Group A was the control group where toothbrushes were stored on toilet sink and group B stored toothbrushes on bedside tables. Group C stored the toothbrushes in a closed toilet cupboard, whereas group D soaked toothbrushes in oral rinse (without changing it during the whole study period) and stored them on the toilet sink. However, participants in group E were instructed to soak toothbrushes in oral rinse similar to group D, but the oral rinse was changed daily.

All participants were provided with new CURAPROX 5460 ultra soft manual toothbrushes (Curaden International, Kriens, Switzerland), CURAPROX Enzycal toothpaste (Curaden International, Kriens, Switzerland), plastic containers to stand the toothbrush and sterile plastic bags for recollection. Additionally, participants in groups D and E were provided with CURASEPT ADS® chlorhexidine oral rinses to soak the toothbrushes after rinsing them with tap water until next use. The toothbrushes were recollected after five days of use in sterile plastic bags. All samples were collected from staff members and students of the Health Science Centre of Kuwait University. Toothbrush collection was also including the staff members and regular attendees of a private dental clinic in Kuwait, which funded this study.

In addition, a questionnaire was distributed to the participants to investigate their oral hygiene habits, such as the use of toothbrushes and other aspects of dental hygiene, including frequency of dental visits, frequency of brushing teeth, using dental floss and method of toothbrush storage.

**Bacterial/microorganism identification**

Samples were processed at room temperature (~23°C) within 24 hours once collected at the Microbiology Laboratory in the Medical Laboratory Sciences Department, Faculty of Allied Health Sciences, Health Sciences Centre, Kuwait University, Kuwait. Bacterial strains depositing on toothbrushes and rinses were isolated as pure cultures using different media: blood agar, MacConkey agar, chocolate agar and Sabouraud agar (Oxoid Ltd., UK). Blood agar was used for the identification of Gram-positive bacteria, while MacConkey agar was used for identifying Gram-negative bacteria. Moreover, chocolate agar was used for the identification of *Neisseria* and *Hemophilus* spp., whereas Sabouraud agar was used for identifying fungi. All isolates were incubated for 24 hours at 37 °C aerobically and anaerobically. Identification of bacterial species was done at the same laboratory following the “gram stain” flow chart of the Practical Handbook of Microbiology\(^10\). The obtained bacterial colonies were used for gram staining with gram stain solution (Sigma-aldrich Company, Poole, Ltd, UK). Following Gram staining results, identification schemes of target organisms incorporating biochemical tests were followed\(^10\). For gram-positive cocci identification, catalase test was used either via API Staph or API Strep (Oxoid) while identification of gram-negative cocci was accomplished by API NH (Oxoid). Whereas identification of target gram positive bacilli, motility test by hanging drop method was used, gram-negative bacilli was done by oxidase test and API 20E (Oxoid). Confirmation of identification of bacterial strains was done using the automated system MicroScan WalkAway-40 System (Dade Behring, West Sacramento, California, USA).

**Ethical approval**

This study has been granted an ethical approval from Health Sciences Centre Ethical Committee, Kuwait University.
Table 1: The participant’s characteristics and their oral hygiene habits

<table>
<thead>
<tr>
<th>Variable</th>
<th>Male n(%)</th>
<th>Female n(%)</th>
<th>Total n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>16-25</td>
<td>100 (74.6)</td>
<td>68 (68)</td>
</tr>
<tr>
<td></td>
<td>26-35</td>
<td>24 (17.9)</td>
<td>22 (22)</td>
</tr>
<tr>
<td></td>
<td>36-45</td>
<td>10 (7.5)</td>
<td>10 (10)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Last visit to the dentist</td>
<td>Within the last 3 months</td>
<td>62 (46.3)</td>
<td>46 (46)</td>
</tr>
<tr>
<td></td>
<td>Within the last 6 months</td>
<td>30 (22.4)</td>
<td>34 (34)</td>
</tr>
<tr>
<td></td>
<td>Last year or more</td>
<td>42 (31.3)</td>
<td>20 (20)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Smoker</td>
<td>48 (35.8)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Non-smoker</td>
<td>78 (58.2)</td>
<td>92 (92)</td>
</tr>
<tr>
<td></td>
<td>Occasional smoking</td>
<td>8 (6)</td>
<td>8 (8)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Experiencing halitosis (bad breath)</td>
<td>Yes</td>
<td>10 (7.5)</td>
<td>4 (4)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>96 (71.6)</td>
<td>74 (74)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>28 (20.9)</td>
<td>22 (22)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Tongue brushing</td>
<td>Yes</td>
<td>84 (62.7)</td>
<td>58 (58)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>28 (20.9)</td>
<td>26 (26)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>22 (16.4)</td>
<td>16 (16)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Experiencing bleeding during toothbrushing</td>
<td>Yes</td>
<td>34 (25.4)</td>
<td>22 (22)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>62 (46.3)</td>
<td>42 (42)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>38 (28.4)</td>
<td>36 (36)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Do you floss?</td>
<td>Yes – Regularly</td>
<td>26 (19.4)</td>
<td>20 (20)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>64 (47.8)</td>
<td>38 (38)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>44 (32.8)</td>
<td>42 (42)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Mouthwash use</td>
<td>Yes – Regularly</td>
<td>40 (29.9)</td>
<td>20 (20)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>50 (37.3)</td>
<td>46 (46)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>44 (32.8)</td>
<td>34 (34)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Toothbrushing timing</td>
<td>Once (morning)</td>
<td>40 (29.9)</td>
<td>18 (18)</td>
</tr>
<tr>
<td></td>
<td>Once (before sleeping)</td>
<td>14 (10.4)</td>
<td>6 (6)</td>
</tr>
<tr>
<td></td>
<td>Twice a day</td>
<td>44 (32.8)</td>
<td>44 (44)</td>
</tr>
<tr>
<td></td>
<td>After meals</td>
<td>32 (23.9)</td>
<td>32 (32)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>4 (3.0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
<tr>
<td>Placing the toothbrush with other toothbrushes</td>
<td>Yes</td>
<td>74 (55.2)</td>
<td>76 (76)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>52 (38.8)</td>
<td>16 (16)</td>
</tr>
<tr>
<td></td>
<td>Occasionally</td>
<td>8 (6.0)</td>
<td>8 (8)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>134 (57.3)</td>
<td>100 (42.7)</td>
</tr>
</tbody>
</table>

RESULTS

Participants’ characteristics and oral hygiene habits

Two hundred and forty participants were enrolled in the study (n=240) and distributed equally into five different groups (n=48*5). Table 1 shows the participants characteristics and their oral hygiene habits (six participants refused to fill the questionnaire).

Bacterial/microorganism identification

For each group, 48 new toothbrushes were distributed for re-collection after use. However, not all of the participants returned their toothbrushes back. Only 44, 40, 24, 36 and 38 toothbrushes were returned in groups A, B, C, D and E respectively, which in total was 182 toothbrushes. Multiple attempts were made to contact the participants who did not return the toothbrushes by text messages and phone calls. The majority of those participants could not be reached either by providing incorrect contact details or not responding at all, while the rest have lost their provided equipment, no longer want to be included in the study or were not available in Kuwait. Therefore, 58 toothbrushes were not re-collected. Ten different bacterial strains and candida species were isolated from the used toothbrushes (Table 2). These microorganisms were Neisseria spp. (37%), Staphylococcus epidermidis (35.6%), Aerococcus
viridans (5.5%), Pseudomonas aeruginosa (4.1%), Candida spp. (4.1%), Enterobacter cloacae (2.7%), Staphylococcus sciuri (2.7%), Streptococcus viridans (2.7%), Bacillus spp. (1.4%), Enterobacter agglomerans (1.4%), Klebsiella pneumoniae (1.4%) and more than 100 mixed growth (1.4%) as shown in Figure 1. Table 3 shows the number of microorganisms found in each toothbrush according to gender.

<table>
<thead>
<tr>
<th>Group/Microorganism</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neisseria spp.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Aerococcus viridans</td>
<td>✓</td>
<td>X</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Candida spp.</td>
<td>✓</td>
<td>X</td>
<td>✓</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>✓</td>
<td>X</td>
<td>✓</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>✓</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>✓</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Bacillus spp.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Enterobacter agglomerans</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>&gt;100 Mixed growth</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>✓</td>
</tr>
</tbody>
</table>

Table 2: Isolated microorganisms from each group

Neisseria spp. and Staphylococcus epidermidis were the most common and only two microorganisms that have been identified in all of the five groups. As expected, the control group A had the greatest variation of microorganisms harbouring the toothbrushes compared to other groups. However, group D had the least variation of bacterial strains identified in the collected toothbrushes. Some bacterial strains were identified solely in specific groups such as Streptococcus viridans and Bacillus spp. in group A, Klebsiella pneumoniae in group D, and Enterobacter agglomerans in group E. Surprisingly, three different bacterial strains, which are Enterobacter cloacae, Bacillus spp., and Enterobacter agglomerans, were identified only in males’ toothbrushes; while Klebsiella pneumoniae was found only in females’ toothbrushes. (Appendix 1: Detailed microorganisms’ identification in each group according to gender).

DISCUSSION

The use of toothbrushes is considered as an essential part of oral hygiene. However, toothbrushes were repeatedly reported to be a source of various oral infections[4,5]. Microorganisms anchoring the tufts and bristles of toothbrushes can cause different localized and systemic diseases[6,11]. The results obtained from this study support previous studies in terms of bacterial strains, which are contaminating regularly...
APPENDICES

Appendix 1: Detailed microorganisms’ identification in each group according to gender.

1. **Group A: Control**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of microorganisms identified in one toothbrush</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>14</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Total number of toothbrushes</td>
<td>26</td>
<td>18</td>
<td>44</td>
</tr>
</tbody>
</table>

Microorganisms identified:

1. Aerococcus viridans
2. Bacillus spp
3. Candida spp
4. Enterobacter cloacae
5. Neisseria spp
6. Pseudomonas aeruginosa
7. Staphylococcus epidermidis
8. Staphylococcus sciuri
9. Streptococcus viridans

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Frequency of presence [M-F]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No growth</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Neisseria spp</td>
<td>18 [8-10]</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>12 [10-2]</td>
</tr>
<tr>
<td>Aerococcus viridans</td>
<td>4 [2-2]</td>
</tr>
<tr>
<td>Candida spp</td>
<td>4 [2-2]</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>4 [2-2]</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>Bacillus spp</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>Total (9 microorganisms)</td>
<td>50 [32-18]</td>
</tr>
</tbody>
</table>

2. **Group B: Bedside table**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of microorganisms identified in one toothbrush</td>
<td>0</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>6</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Total number of toothbrushes</td>
<td>18</td>
<td>22</td>
<td>40</td>
</tr>
</tbody>
</table>

Microorganisms identified:

1. Staphylococcus epidermidis

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Frequency of presence [M-F]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No growth</td>
<td>16 [4-12]</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>16 [14-2]</td>
</tr>
<tr>
<td>Neisseria spp</td>
<td>6 [0-6]</td>
</tr>
<tr>
<td>Aerococcus viridans</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Total (5 microorganisms)</td>
<td>28 [14-14]</td>
</tr>
</tbody>
</table>
3. **Group C**: Closed cupboard:

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gender</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Number of microorganisms identified in one toothbrush</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total number of toothbrushes</td>
<td>12</td>
<td>12</td>
</tr>
</tbody>
</table>

| Microorganisms identified                  |       |        |
|-------------------------------------------|-------|
| 1. Enterobacter cloacae                   |       |
| 2. Neisseria spp                          |       |
| 3. Staphylococcus epidermidis             |       |
| 1. Candida spp                            |       |
| 2. Neisseria spp                          |       |
| 3. Pseudomonas aeruginosa                 |       |
| 4. Staphylococcus epidermidis             |       |

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Frequency of presence [M-F]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No growth</td>
<td>6 [0-6]</td>
</tr>
<tr>
<td>1. Staphylococcus epidermidis</td>
<td>10 [8-2]</td>
</tr>
<tr>
<td>2. Neisseria spp</td>
<td>4 [2-2]</td>
</tr>
<tr>
<td>3. Enterobacter cloacae</td>
<td>2 [0-0]</td>
</tr>
<tr>
<td>4. Pseudomonas aeruginosa</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>5. Candida spp</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Total (5 microorganisms)</td>
<td>20 [12-8]</td>
</tr>
</tbody>
</table>

4. **Group D**: immersed in mouth wash (same amount):

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gender</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Number of microorganisms identified in one toothbrush</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total number of toothbrushes</td>
<td>20</td>
<td>16</td>
</tr>
</tbody>
</table>

| Microorganisms identified                  |       |        |
|-------------------------------------------|-------|
| 1. Neisseria spp                          |       |
| 2. Staphylococcus epidermidis             |       |
| 1. Klebsiella pneumoniae                  |       |
| 2. Neisseria spp                          |       |

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Frequency of presence [M-F]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No growth</td>
<td>20 [10-10]</td>
</tr>
<tr>
<td>1. Neisseria spp</td>
<td>14 [8-6]</td>
</tr>
<tr>
<td>2. Staphylococcus epidermidis</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>3. Klebsiella pneumoniae</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>Total (5 microorganisms)</td>
<td>18 [10-8]</td>
</tr>
</tbody>
</table>

5. **Group E**: immersed in mouth wash (changed daily):

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gender</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Number of microorganisms identified in one toothbrush</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total number of toothbrushes</td>
<td>20</td>
<td>18</td>
</tr>
</tbody>
</table>

| Microorganisms identified                  |       |        |
|-------------------------------------------|-------|
| 1. Aerococcus viridans                    |       |
| 2. Enterobacter agglomerans               |       |
| 3. Neisseria spp                          |       |
| 4. Staphylococcus epidermidis             |       |
| 1. >100 Mixed growth                      |       |
| 2. Neisseria spp                          |       |
| 3. Staphylococcus epidermidis             |       |

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Frequency of presence [M-F]</th>
</tr>
</thead>
<tbody>
<tr>
<td>No growth</td>
<td>12 [4-8]</td>
</tr>
<tr>
<td>1. Neisseria spp</td>
<td>12 [8-4]</td>
</tr>
<tr>
<td>2. Staphylococcus epidermidis</td>
<td>12 [6-6]</td>
</tr>
<tr>
<td>3- &gt;100 Mixed growth</td>
<td>2 [0-2]</td>
</tr>
<tr>
<td>4. Aerococcus viridans</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>5. Enterobacter agglomerans</td>
<td>2 [2-0]</td>
</tr>
<tr>
<td>Total (5 microorganisms)</td>
<td>30 [18-12]</td>
</tr>
</tbody>
</table>
when using toothbrushes. Some of these strains are of pathogenic nature, such as *K. pneumoniae* and *P. aeruginosa*, while *S. viridans* is an opportunistic strain. Others were reported to be of faecal nature such as *E. cloacae* and *Neisseria* spp. [12,13]. Thereby, toothbrushes can be considered as a possible source of contamination to their users.

In terms of oral hygiene standards, female participants showed more diligence than male participants. This could be concluded from the results of isolating more bacterial strains in males’ toothbrushes, while fewer bacterial strains were isolated in females’ toothbrushes. Nevertheless, the questionnaires reflect that females tend to brush their teeth more often than males. Regarding storage methods, some bacteria such as *Neisseria* spp. and *S. epidermidis* were reported from all groups with different storage means. This might rule out the hypothesis of the transmission of *Neisseria* strains from toilet flushing. It might be transmitted from poor hand hygiene, as supported by the finding of *S. epidermidis*, which is thought to be a part of skin commensals. As for yeasts, *Candida* was isolated from the toothbrushes of both genders, stored on toilet sinks and in females’ toothbrushes that were immersed in unchanged mouthwashes. This could also point out to the existence of these yeasts as normal flora of the mouth and not related to storage means. Another interesting finding from this study is the isolation of fewer bacterial strains from storing the toothbrushes in an unchanged mouthwash compared to those that were stored in a daily changed mouthwash. The detection of bacterial strains in the changed mouthwash might be due to cross contamination of the toothbrushes during handling and changing the mouthwash. This indicates the effectiveness of storing toothbrushes into chlorhexidine and supports previous studies[14,15]. Therefore, we can conclude that soaking toothbrushes in mouthwashes that are not changed on a daily basis after use is good in reducing the number of types of bacteria. Further studies are needed to investigate and to compare between the bacteria that are residing in the oral cavity of healthy individuals and individuals with underlying medical condition such as diabetes, cardiovascular diseases, immunocompromised patients and to evaluate its relationship with dental and periodontal diseases.

### CONCLUSION

In conclusion, oral hygiene performs an integral part of our bodily hygiene. If neglected, different diseases can occur and affect the mouth and other organs of the body. Females were proved to show higher standards of oral hygiene than males, which reflected on bacterial growth in their oral cavities. However, greater bacterial growth on males’ toothbrushes may also indicate a better tooth brushing in which bacteria have been removed properly and sufficiently, compared to females. It is not necessarily that fewer bacteria present on toothbrushes means poor oral hygiene and vice versa. Other biologic factors might play a role in the survival of certain bacterial strains in the oral cavities of different genders. Storing methods of toothbrushes may also contribute to the growth of different bacteria on toothbrushes. This was witnessed in previous reports and further supported in the results obtained from this study, which indicated the better-advised storage method. Nevertheless, the absence of bacterial deposits on the bristles of toothbrushes soaked in chlorhexidine indicated the effectiveness of storage into mouthwash. However, the effect of chlorhexidine

<table>
<thead>
<tr>
<th>Variable/ participant</th>
<th>Gender</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Number of microorganisms (n(%))</td>
<td>18 (18.75%)</td>
<td>38 (44.19%)</td>
</tr>
<tr>
<td>0</td>
<td>70 (72.92%)</td>
<td>36 (41.86%)</td>
</tr>
<tr>
<td>1</td>
<td>8 (8.33%)</td>
<td>12 (13.95%)</td>
</tr>
<tr>
<td>Total</td>
<td>96 (100%)</td>
<td>86 (100%)</td>
</tr>
<tr>
<td>Bacterial strains/microorganisms identified (n)</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Aerococcus viridans</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Bacillus spp.</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Candida spp.</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Enterobacter agglomerans</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Enterobacter cloacae</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>26</td>
<td>28</td>
</tr>
<tr>
<td>Neisseria spp.</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>40</td>
<td>12</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>&gt;100 Mixed growth</td>
<td>38 (44.19%)</td>
<td>36 (41.86%)</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>&gt;100 Mixed growth</td>
<td>56 (30.77%)</td>
<td>106 (58.24%)</td>
</tr>
<tr>
<td>Neisseria spp.</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>40</td>
<td>12</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>&gt;100 Mixed growth</td>
<td>38 (44.19%)</td>
<td>36 (41.86%)</td>
</tr>
<tr>
<td>Staphylococcus epidermidis</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Staphylococcus sciuri</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Streptococcus viridans</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>&gt;100 Mixed growth</td>
<td>56 (30.77%)</td>
<td>106 (58.24%)</td>
</tr>
</tbody>
</table>

**Table 3:** The number of microorganisms found in each toothbrush according to gender.
on toothbrush bristles and its effectiveness was not investigated in this study. More studies should be made focusing on other factors that might play a role in toothbrushes storage and contamination, such as seasons and temperatures.

ACKNOWLEDGMENT

The authors thank Asnan Tower (Kuwaiti dental clinic) for the support by providing the toothbrushes, toothpastes and mouth rinses. The authors also thank participants for the time to take part in this study.

Source of support: Asnan Tower (Private Dental Clinic in Kuwait) by providing the toothbrushes, toothpastes and mouth rinses.

Conflict of interest: None

Authors' contributions: Ahmad M AlAli, Norya M Al Maraghi and Ali A Dashti designed the study. Ahmad M AlAli, Norya M Al Maraghi and Qudsiya Y Electricwala performed the bacterial identification. Ahmad M AlAli analyzed the data. Ahmad M AlAli and Norya M Al Maraghi wrote the manuscript with input from all authors and supervised by Ali A Dashti.

REFERENCES

Arthroscopic Bankart repair by using the antero-superior portal for visualization

Tahsin Gurpinar¹, Baris Polat², Tuna Pehlivanoglu¹, Ayse E Polat³, Engin Carkci¹, Yusuf Ozturkmen¹
¹Department of Orthopedics and Traumatology, Istanbul Training and Research Hospital, 34098, Fatih, Istanbul, Turkey
²Department of Orthopaedics and Traumatology, Kyrenia University Hospital, 99300, Kyrenia, Turkish Republic of Northern Cyprus
³Department of Orthopaedics and Traumatology, Dr. Akcicek Kyrenia State Hospital, 99300, Kyrenia, Turkish Republic of Northern Cyprus


ABSTRACT

Objective: The posterior portal was commonly utilized as the primary visualization portal in Arthroscopic Bankart repair surgery, however the pathology was mainly based on the anterior part of the glenoid. We aimed to evaluate the early results of Bankart lesions repaired by using an anterosuperior portal for visualization.

Design: Retrospective study

Setting: Clinic of Orthopaedics and Traumatology, Istanbul Education and Research Hospital, Istanbul

Subjects: A total of 37 (30 male and seven females with a mean age of 28.4 years (range: 17-45)) consecutive patients with anterior shoulder instability

Intervention: Arthroscopic bankart repair for anterior shoulder instability by using the antero-superior portal for visualization

Main outcome measures: The clinical assessment was based on the evaluation of the shoulder range of motion, shoulder laxity test (Apprehension, Jobe relocation) and clinical outcomes were assessed by using the American Shoulder and Elbow Surgeons (ASES), as well as the Rowe shoulder scoring system.

Results: The mean follow-up period was 32.5 months (range: 24-48). The mean ASES score and Rowe score increased from 71.3±7.0 (range: 59-93) and 43.5±6.5 (range: 30-50) preoperatively, to 92.8±3.1 (range: 85-98) and 92.2±6.2 (range: 75-100) postoperatively respectively (P<.05). Redislocation was observed in two patients.

Conclusions: It was observed that the anterior-superior portal was sufficient and reliable for visualization during the entire procedure as a safe and effective alternative to the generally accepted classic posterior portal visualization.

INTRODUCTION

The shoulder is considered to be the joint with the highest mobility in the human body; however, it is also a fact that this wide range of motion might have the potential to compromise its stability and to make it prone to dislocations[1,2].

Shah et al reported that the incidence of shoulder dislocation was 15.5 in females and 40.4 in males per 100,000 person-years. It was observed that the highest incidence was 80.5 in men per 100,000 person-years between the ages of 16-20 years in the United Kingdom[3].

The majority of dislocations are noted to be in the anterior direction and therefore, anterior structures including the anterior glenoid, labrum, capsule or anterior inferior glenohumeral ligament are mostly torn or injured. The Bankart lesion, which was defined as the detachment of the anteroinferior glenoid labrum from the glenoid, presented in more than 90% of cases with dislocation[4,5]. However, other associated injuries must be identified carefully and addressed appropriately for adequate treatment in order to obtain favorable clinical and functional outcomes. Due to the low rate of complications and satisfactory outcomes, arthroscopic surgery has been widely performed and is recommended for the treatment of Bankart lesions[6,7]. To achieve better results, many technical steps have been published in the literature[8-10]. However, no

Address correspondence to:
Baris Polat, Orthopaedics and Traumatology Department, Kyrenia University Hospital, Sehit Yahya Bakir Sokak, Karakum, Girne, Turkish Republic of Northern Cyprus. Tel: +90 5338444755; E-mail: drbpolat@hotmail.com
single standard technique was reported as the standard treatment of this condition and different surgeons prefer to use variable patient positions, portals, anchors and suture techniques with comparable results [6-12].

The posterior portal was commonly utilized as the primary visualization portal by many authors [9,13-15]. However, since the pathology was mainly based on the anterior part of the glenoid, we believe that direct visualization from the antero-superior portal allows the careful identification of associated injuries and might be a good alternative to the posterior portal during the entire procedure. In the present study, we aimed to evaluate the early results of Bankart lesions repaired by using an antero-superior portal for visualization.

SUBJECTS AND METHODS

A total of 53 consecutive patients who were operated arthroscopically between 2013 and 2015 for anterior instability were retrospectively reviewed. The inclusion criteria comprised having purely anterior instability and having a minimum follow-up duration of 24 months. The exclusion criteria included having a revision surgery prior to operation (two patients), having voluntary or multidirectional instability (two patients) and having pure posterior instability (two patients). Furthermore, five patients were lost to follow-up, three patients refused to participate in the study and re-dislocation was observed in another two patients. After the exclusion of 16 patients, the remaining 37 patients were enrolled in the study. All data was collected in a retrospective manner from the hospital records and the intraoperative data were collected based on surgical reports and video records taken during the surgery. Informed consent was taken from all patients, so that their pre, intra and post-operative data including the photos and videos could be used for publication by ensuring that all identities remained hidden. This retrospective study received the approval of the institutional review board (No. 1436; 28 Sep 2018).

The clinical assessment was based on the evaluation of the shoulder range of motion (ROM) and shoulder hyperlaxity, which were assessed through the Apprehension test and the Jobe Relocation test performed by a senior orthopedic surgeon pre-operatively and post-operatively. Each test was compared to the other shoulder of the patient. Clinical outcomes were assessed by using the American Shoulder and Elbow Surgeons (ASES) scoring system [16], as well as the Rowe shoulder scoring system [17], as validated scoring systems. Both pre-operative and post-operative data at the final follow up were collected and analyzed. Failure was defined as a re-dislocation or a subluxation after the surgery.

Surgical technique

All operations were performed at our clinic by the senior surgeons with different accompanying assistant doctors and specialist surgeons under hypotensive general anesthesia in the beach chair position. Adjusted pressure and flow speed arthropump (Karl Storz) were used at an initial pressure of 40 mmHg. After establishment of the standard posterior portal, a low anterior portal adjacent to the upper border of the subscapularis was opened. Diagnostic arthroscopy was performed and the anterior-superior portal was opened anterior to the supraspinatus and adjacent to the lateral border of the rotator interval (Fig. 1).
The scope was then moved to this antero-superior portal to evaluate the anterior structures. The damaged glenohumeral ligament-labrum complex was mobilized from the glenoid neck as far inferiorty as the 6 to 7 o’clock position with an elevator and a radio frequency ablation device. The preparation of the medial glenoid bone was also performed with an arthroscopic shaver and elevator through the anterior portal while viewing from the antero-superior portal (Fig. 2).

We used a minimum amount of two double loaded bioabsorbable knotless 2.9 suture anchor (mean 3.1±6) starting from the most inferior part of glenoid directed anteriorly. A soft tissue penetrator or an arthroscopic suture passer was used to pass the sutures starting from the inferior aspect. After capsular plication and proximal shift of the capsulolabral complex, a Samsung Medical Centre sliding knot was tied on the capsulolabral side of the repair. Neither rotator interval closure nor remplissage was performed in any of the cases; however, SLAP repair was performed in 7 of 37 shoulders.

Rehabilitation protocol

All patients were immobilized during the first two weeks in a sling and were encouraged to perform pendulum exercises. In the following two weeks, active anterior elevation movements up to 90° flexion were allowed and complete shoulder mobilization was allowed after six weeks. Excessive external rotation was not allowed until the third month postoperatively and return to sport was allowed after the third six postoperative months.

Statistical analysis

Mean, standard deviation, median lowest, highest, frequency and ratio values were used in the descriptive statistics of the data. The distribution of the variables was measured by the Kolmogorov-Smirnov test. The Mann-Whitney U test was used in the analysis of quantitative independent data. The Wilcoxon test was used for the analysis of the dependent quantitative data and the McNemar test was used for the analysis of the dependent qualitative data. Chi-square test was used in the analysis of qualitative independent data. The SPSS 22.0 program was used in all analyses.

RESULTS

There were 30 male and seven female patients, with a mean age of 28.4±7.1 years (range: 17-45) at the time of surgery. A total of 26 patients underwent stabilization of their dominant shoulder (70.3%). In terms of employment status, 17 patients had a sedentary office job, 11 were students and nine were manual workers. The mean time between the first dislocation episode and the surgical procedure was 30.9±26.1 months (range: 1-108). The mean number of instability episodes was 8.0±5.9 (range: 1-30), where 29 patients had more than three episodes. The mean preoperative instability severity index score (ISIS) score was 2.7±1.3 (range: 0-5) (Table 1).

The mean ASES score and Rowe score increased from 71.3±7.0 (range: 59-93) and 43.5±6.5 (range: 30-50) preoperatively to 92.8±3.1 (range: 85-98) and 92.2±6.2 (range: 75-100) postoperatively respectively (P <.05) (Table 2). The shoulder joint function at the final follow-up was rated as excellent, good, fair and poor
Table 1: Patient demographics and intraoperative findings

<table>
<thead>
<tr>
<th>Patient variables</th>
<th>Min-Max</th>
<th>Median</th>
<th>Mean±SD / n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>17, 45</td>
<td>29</td>
<td>28.6±7.152</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>7 (18.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>30 (81.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominant</td>
<td>No</td>
<td>1, 108</td>
<td>30 (29.7)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>0, 5</td>
<td>26 (70.3)</td>
</tr>
<tr>
<td>Work</td>
<td>Office</td>
<td>17 (45.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Student</td>
<td>11 (29.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Worker</td>
<td>1, 30</td>
<td>7 (24.3)</td>
</tr>
<tr>
<td>Time to surgery</td>
<td>30.9±26.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(month)</td>
<td>ISIS Score</td>
<td>28±13.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>3 (8.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>3 (8.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>10 (27)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>9 (24.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>10 (27)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>2 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Instability episode</td>
<td>No</td>
<td>28</td>
<td>73.7</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>9 (24.3)</td>
<td></td>
</tr>
<tr>
<td>X-Ray Hill Sachs</td>
<td>No</td>
<td>28 (73.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>9 (24.3)</td>
<td></td>
</tr>
<tr>
<td>Intra-operative findings</td>
<td>AlpSA</td>
<td>2 (5.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bankart</td>
<td>24 (64.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bankart+Slap I</td>
<td>5 (13.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bankart+Slap II</td>
<td>1 (2.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bankart+Slap IV</td>
<td>1 (2.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Osseous Bankart</td>
<td>4 (10.8)</td>
<td></td>
</tr>
<tr>
<td>Number of anchor</td>
<td>2, 5</td>
<td>3</td>
<td>3.1±0.6</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>5 (13.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>26 (70.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>5 (13.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V</td>
<td>1 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Follow-up time</td>
<td>24, 48</td>
<td>30</td>
<td>32.5±7.2</td>
</tr>
<tr>
<td>(month)</td>
<td>Forward flexion difference</td>
<td>0, 18</td>
<td>7.2±4.1</td>
</tr>
<tr>
<td></td>
<td>External rotation in adduction difference</td>
<td>5, 18</td>
<td>10.2±3.6</td>
</tr>
<tr>
<td></td>
<td>External rotation in 90 abduction difference</td>
<td>7, 20</td>
<td>12.8±3.4</td>
</tr>
</tbody>
</table>

Redislocation was observed in two patients. The first patient was seen after falling down at the 28th month postoperatively, while the second patient was seen after experiencing problems during swimming at the 34th month postoperatively. One of these patients underwent open treatment with the Latarjet method and the other did not accept surgery. The functional outcomes of these two patients were not included in the study. Recurrent dislocation was not observed until the final follow-up. The results of the preoperative and final follow-up clinical examinations are summarized in Table 2.

A SLAP lesion was identified in three of the cases and a small partial rotator cuff tear was seen in one of the cases, which were all repaired. Engaging Hill-Sachs lesions or glenohumeral ligament lesions were not detected. When compared to the results of the contralateral side, a mean loss of 7.2°±4.1° (range: 0-18°) in forward flexion, 10.2°±3.6° (range: 5-18°) in external rotation in adduction and 12.8°±3.4° (range: 7-20°) in external rotation in 90° abduction were detected in the study group at the final follow-up (Table 1). Among the 37 patients included in the series, all patients confirmed that they were subjectively satisfied with the final result.

In the group with Instability Episode <10 and Instability Episode ≥10, the preoperative postoperative ASES and Rowe score did not differ significantly (P >.05) (Table 3). In the group with isolated Bankart and

Table 2: Pre-and post-operative physical examination findings and functional outcome scores

<table>
<thead>
<tr>
<th>Physical examination</th>
<th>Min-Max</th>
<th>Median</th>
<th>Mean±SD / n(%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apprehension Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-Op (-)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-Op (+)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-Op (-)</td>
<td>34 (91.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-Op (+)</td>
<td>3 (8.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jobe Relocation Test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-Op (-)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-Op (+)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-Op (-)</td>
<td>37 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-Op (+)</td>
<td>0 (0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASES</td>
<td>59, 93</td>
<td>71</td>
<td>71.3±7.0</td>
<td></td>
</tr>
<tr>
<td>Post-Op</td>
<td>85, 98</td>
<td>93</td>
<td>92.8±3.1</td>
<td></td>
</tr>
<tr>
<td>Rowe</td>
<td>30, 50</td>
<td>45</td>
<td>43.5±6.5</td>
<td></td>
</tr>
<tr>
<td>Post-Op</td>
<td>75, 100</td>
<td>95</td>
<td>92.2±6.2</td>
<td></td>
</tr>
</tbody>
</table>

* Wilcoxon test; † McNemar test; ASES: American Shoulder and Elbow Surgeons

Table 3: Functional outcome comparison of instability episode <10 and instability episode ≥10 groups of patient

<table>
<thead>
<tr>
<th>Functional outcome</th>
<th>Instability episode &lt;10</th>
<th>Instability episode ≥10</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASES</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>72.6±6.7</td>
<td>73</td>
<td>67.8±6.9</td>
</tr>
<tr>
<td>Post-Op</td>
<td>93.0±2.6</td>
<td>93</td>
<td>92.2±4.3</td>
</tr>
<tr>
<td>Intra Group P</td>
<td>0.000 w</td>
<td>0.008 w</td>
<td></td>
</tr>
<tr>
<td>Rowe</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>44.6±6.0</td>
<td>45</td>
<td>40.5±7.2</td>
</tr>
<tr>
<td>Post-Op</td>
<td>93.1±5.6</td>
<td>95</td>
<td>89.5±7.2</td>
</tr>
<tr>
<td>Intra Group P</td>
<td>0.000 w</td>
<td>0.002 w</td>
<td></td>
</tr>
</tbody>
</table>

* Mann-whitney u test; † Wilcoxon test
shoulder instability using the Rowe score, Park literature[7-10]. To assess the effectiveness of an arthroscopic Bankart repair was reported to be similar to other series in the literature, indicating a high level of motion and excellent functional ability both at work and leisure activity, the Rowe score was reported to be based on stability, motion and function[16,17]. In the present study, the Rowe scores were noted to be improved in all of the cases. Consequently, we detected that if the spectrum of surgical indications for arthroscopic Bankart repair was narrowed down, good clinical outcomes could be obtained. In addition to patient selection, effective surgery with the appropriate technique was reported to be the key factor for successful outcomes. In the literature, important steps with regard to surgical technique have been published by experienced authors[8-10]. Among them, visualization and identification of the lesions were noted to be of paramount importance[21,22]. We believe that direct visualization from the anterior portal might help the surgeon to identify not only a classic Bankart lesion, but also other variants, including a glenolabral articular disruption or anterior labroligamentous periosteal sleeve avulsion or an osseous Bankart lesion, which could also be possible reasons for instability.

DISCUSSION
Arthroscopic treatment of glenohumeral instability has rapidly evolved over the past few years. In most recent series, the results of arthroscopic treatment were noted to be equal or superior compared to the results of open series[11]. The ASES shoulder score and the Rowe scores, which are patient reported validated outcome scales, are frequently used methods of clinical and functional assessment following arthroscopic Bankart repair[16,17]. While the ASES score was reported to primarily focus on pain level and functional ability both at work and leisure activity, the Rowe score was reported to be based on stability, motion and function[16,17]. In the present study, the ASES scores following arthroscopic Bankart repair ranged from 85 to 98, while the Rowe scores ranged from 75 to 100 at a minimum follow-up of two years, indicating a high level of motion and excellent function outcome following arthroscopic repair. This was reported to be similar to other series in the literature[7-10]. To assess the effectiveness of an arthroscopic stabilization procedure for anterior shoulder instability using the Rowe score, Park et al[18] calculated the minimal clinical important difference as 9.7. In our series, the difference was 43.5 and over minimal clinical important difference in all patients.

The major risk factors for failure and re-dislocation following arthroscopic repair consist of the younger age of patients, participation in contact sports activities, presence of an engaging Hill-Sachs or osseous Bankart lesion, ipsilateral rotator cuff or deltoid muscle insufficiency and underlying ligamentous laxity[19,20]. Balgand Boileau proposed an ISIS to determine which patients were good candidates for arthroscopic surgery and advised open procedures in cases with high scores[19]. In the present study, patients with high risk factors such as a large Hill-Sachs lesion, a glenoid defect greater than 25% or a score of more than six points in ISIS were not operated on using arthroscopic bankart repair techniques, but were treated by using the open Latarjet method instead. At the final follow up, just two patients had re-dislocation after surgery, while the functional scores were noted to be improved in all of the cases. Consequently, we detected that if the spectrum of surgical indications for arthroscopic Bankart repair was narrowed down, good clinical outcomes could be obtained. In addition to patient selection, effective surgery with the appropriate technique was reported to be the key factor for successful outcomes. In the literature, important steps with regard to surgical technique have been published by experienced authors[8-10]. Among them, visualization and identification of the lesions were noted to be of paramount importance[21,22]. We believe that direct visualization from the anterior portal might help the surgeon to identify not only a classic Bankart lesion, but also other variants, including a glenolabral articular disruption or anterior labroligamentous periosteal sleeve avulsion or an osseous Bankart lesion, which could also be possible reasons for instability.

Another important technical step is to mobilize the inferior glenohumeral ligament and labrum complex such that it could be shifted superiorly and laterally. Management of the inferior component of the pathology was determined to be critical in order to achieve a successful outcome and could only be performed with impeccable visualization. Additionally, it was also reported that untreated or unrecognized capsular tears and deformation could represent the most common cause of failure after arthroscopic Bankart repair[13,23]. All anterior structures and pathology were better evaluated while viewing through the antero-superior portal in comparison to the view obtained from the posterior portal[24]. Therefore, visualization directly through the anterior superior portal could prevent this kind of failure and give surgeons a better understanding of the lesion[24]. However, in a study conducted on shoulder and elbow surgeons in USA, it was reported that only 7% of them performed arthroscopic Bankart repair while viewing entirely from an anterior portal[25].

Meyer et al[26] reported in their study of 23 patients that there was an average loss of shoulder external rotation in adduction of 14.1° and an average loss of

<table>
<thead>
<tr>
<th>Functional outcome</th>
<th>Bankart</th>
<th>Bankart+SLAP</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASES</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>72.1±7.3</td>
<td>3</td>
<td>67.7±4.1</td>
</tr>
<tr>
<td>Post-Op</td>
<td>92.7±2.9</td>
<td>93</td>
<td>92.9±4.3</td>
</tr>
<tr>
<td>Intra</td>
<td>0.000</td>
<td>0.000</td>
<td>0.008</td>
</tr>
<tr>
<td>Rowe</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>44.5±5.9</td>
<td>45</td>
<td>39.3±7.9</td>
</tr>
<tr>
<td>Post-Op</td>
<td>92.3±6.1</td>
<td>95</td>
<td>91.4±6.9</td>
</tr>
<tr>
<td>Intra</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

**Mann-whitney u test; w Wilcoxon test**

Bankart + SLAP, the preoperative - postoperative ASES and Rowe scores did not differ significantly (P >.05) (Table 4). The number of Anchors used in the Bankart + SLAP group (3.7±0.8) was significantly higher (P <.05) than that of the isolated Bankart group (2.9±0.5).

### Table 4: Comparison of functional outcomes of patients with isolated Bankart lesions and those with Bankart + SLAP

<table>
<thead>
<tr>
<th>Functional outcome</th>
<th>Bankart</th>
<th>Bankart+SLAP</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASES</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>72.1±7.3</td>
<td>3</td>
<td>67.7±4.1</td>
</tr>
<tr>
<td>Post-Op</td>
<td>92.7±2.9</td>
<td>93</td>
<td>92.9±4.3</td>
</tr>
<tr>
<td>Intra</td>
<td>0.000</td>
<td>0.000</td>
<td>0.008</td>
</tr>
<tr>
<td>Rowe</td>
<td>Mean±SD</td>
<td>Median</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>Pre-Op</td>
<td>44.5±5.9</td>
<td>45</td>
<td>39.3±7.9</td>
</tr>
<tr>
<td>Post-Op</td>
<td>92.3±6.1</td>
<td>95</td>
<td>91.4±6.9</td>
</tr>
<tr>
<td>Intra</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>
shoulde.. rotation in 90° of shoulder abduction of 12.8° average 3.3 years after arthroscopic Bankart repair via single anterior portal. In the present study, compared to the contralateral side, patients were detected to have an average loss of 7.2° in forward flexion, 10.2° in external rotation in adduction and 12.8° in external rotation in 90° abduction at the last follow-up. The results of the present study were found to be similar to other single anterior portal series in terms of loss of shoulder ROM[14,15,26]. This study reported that double portal to the anterior does not have a negative effect on the patient’s shoulder ROM. Using both working and viewing portals close to each other might result in obstruction and sticking of the instruments. However, we established in our cases that the anterior superior portal was located much more laterally and far from the location of the standard antero-superior portal. The distance between the anterior portals we used was larger than the distance between the standard portals (Figure 1). In our small series, we had various sizes of shoulders, varying from basketball players to small females; nonetheless, in all cases, we were able to easily establish two anterior portals without any congestion. Therefore, we believe that the anterior-superior lateral portal can be established easily and it may be a reliable arthroscopic technique with regard to visualization during the entire procedure. Some authors reported that in the arthroscopic Bankart procedure, the single anterior portal is superior to the double anterior portal in terms of cosmetics, cost-effectiveness and postoperative analgesia, as well as similar clinical outcomes[14,15]. It may be preferable to obtain similar results with a less invasive procedure, but it should be considered that the posterior portal visualization may cause inadequate evaluation of the entire anterior structures, pathology and inadequate release of the labrum and inferior glenohumeral ligament[24].

Our study demonstrated that the number of instability episodes and accompanying SLAP lesions did not adversely affect the clinical outcomes as emphasized in the literature[8,27,28]. The main weaknesses of this study comprised the retrospective design, absence of a control group and the short duration of follow up. However, since it is a rarely used technique, we aimed to present the short-term preliminary results while the study continues with the aim of presenting the mid to long-term results in the near future. Using the anterior portal for visualization is indeed not a new technique, but this study demonstrates that the usage of the anterior portal during the entire operation was a highly safe and effective method, since the main pathology was located at the anterior part of the glenoid and direct visualization could be achieved by using this technique. CONCLUSION In the current study, it was observed that the anterior-superior portal was sufficient and reliable for visualization during the entire procedure as a safe and effective alternative to the generally accepted classic posterior portal visualization. ACKNOWLEDGMENTS This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Conflicts of interest: None Authors’ contributions: Tahsin Gurpinar contributed to the investigation, methodology, to operate the patients and preparation of the manuscript. Baris Polat and Ayse E Polat contributed to the formal analysis, literature search and preparation of the manuscript. Engin Carkci contributed to the data collection and helped in manuscript preparation. Tuna Pehlivanoglu participated in the statistical analysis. Yusuf Ozturkmen contributed to the visualization of data and contributed to the project administration. Ayse E Polat and Yusuf Ozturkmen edited and reviewed the manuscript. All authors read and approved the final manuscript.

REFERENCES
7. Ikemoto RY, Murachovsky J, Nascimento LGP, Bueno RS, Almeida LHO, Kojima C. Evaluation of surgical...


ABSTRACT

Objectives: To examine associated factors of bilirubin levels at admission to general intensive care unit (ICU) and their effects on outcomes

Design: Retrospective, observational study

Setting: Medical records of patients older than 18 years who were hospitalized during one year (2016-2017) at the general ICU in Ankara Numune Training and Research Hospital, Turkey were reviewed.

Subjects: Identifying the change of serum bilirubin level is important for determination of diagnostic and prognostic strategies in critically ill patients.

Intervention: The study group data was obtained from hospital medical records.

Main Outcome Measure: SOFA and APACHE II scores, total blood bilirubin levels, need for mechanical ventilation and renal replacement therapy, length of hospital and ICU stay, and mortality at ICU were evaluated.

Results: Patients with normal bilirubin levels constituted 79.3% of the study population, whereas those with mild elevation and high levels were found to be less common (14% and 6.7%, respectively). Among patients in the high bilirubin group, 40.9% of patients were admitted to the ICU with primary diagnosis of infection, which was detected as 13% and 21.7% in normal and mildly elevated group (P <.01). Mortality rate was the same in all groups (P >.05).

Conclusions: Patients who were admitted to ICU due to infection were likely to have more elevated bilirubin levels and higher APACHE II and SOFA scores. High levels of bilirubin did not change mortality in ICU patients despite prolonged ICU stay.

INTRODUCTION

Bilirubin is the end-product of heme metabolism and 80% of bilirubin originates from the breakdown of hemoglobin from aged red blood cells in the bloodstream. This is the indirect form of bilirubin, which is transformed into direct bilirubin in the liver and excreted via the biliary route. The sum of direct and indirect bilirubin in serum is called as total bilirubin. In normal healthy adults, serum total bilirubin levels vary from 0.3-1.2 mg/dL. Though bilirubin levels are within normal ranges in critically ill patients at admission to intensive care unit (ICU), hyperbilirubinemia and even hepatic dysfunction may develop during ICU follow-up secondary to several conditions such as sepsis, fluid gap, medications, adverse effects of parenteral nutrition, steatosis and ischemic or sclerosing cholangitis[31]. In fact, hepatic dysfunction and jaundice may lead to sepsis and other critical conditions, further causing ICU complications and prolonged length of stay.

To the best of our knowledge, there exists no specific physiological parameter that helps the early identification of the mortality effects of hepatic dysfunction developed in the ICU. Bilirubin is a well-studied biomarker for hepatic dysfunction. Hyperbilirubinemia may be seen within 2-3 days after hepatic injury[2]. Serial bilirubin measurements may reflect a transient and adaptive condition during critical illness, and it is a prognostic biomarker particularly for existing infection[3]. Therefore, serial
bilirubin measurements have been incorporated into scoring systems that assess organ dysfunction such as Sequential Organ Failure Assessment Score (SOFA), Simplified Acute Physiology Score and Logistic Organ Dysfunction Score[4].

Earlier studies reported elevated serum bilirubin levels to have anti-inflammatory activity, hence exert favorable protective effects against devastating impact of acute hepatic injury and sepsis. It was even suggested that administration of exogenous bilirubin might reduce sepsis mortality[5-8]. Contradictory clinical evidence has been published afterwards. In patients with bilirubin levels higher than 3 mg/dL in the surgical ICU, the risk of infection was reported to be higher, near threefold, compared to that in those with bilirubin level ≤3 mg/dL, as well as relation with sepsis-related hepatic dysfunction and increased risk of infection[9]. However, Pierrakos et al reported that mild or intermediate hyperbilirubinemia was associated with poor prognosis[10].

There have been limited studies assessing the relation between bilirubin levels and mortality in critically ill patients in the general ICU. In this study, we aimed to identify the factors associated with bilirubin levels at admission to ICU and investigate their effects on prognosis.

SUBJECTS AND METHODS

This retrospective study was performed after obtaining the approval from ethics committee of Health Sciences University (approval no: E-17-1521). Medical records of patients older than 18 years who were hospitalized between 1st September, 2016 and 31st August, 2017 at the general ICU were reviewed. Those with a known etiology of hyperbilirubinemia including cirrhosis, acute toxic or alcoholic hepatitis with or without hepatic failure, cholecystitis alone or with cholangitis, acute pancreatitis, known hemolysis, or history of hepatic or pancreatic surgery were excluded from the study. The demographic data of the patients, primary diagnosis at admission to ICU, comorbidities, SOFA and APACHE II scores, total blood bilirubin levels, need for mechanical ventilation and renal replacement therapy, length of hospital and ICU stay, and mortality at ICU were evaluated. Patients were divided into three groups as those with normal bilirubin group (≤1 mg/dL), mildly elevated bilirubin group (1.1-2 mg/dL) and high bilirubin group (2.1-6 mg/dL).

Statistical analysis

IBM SPSS Statistics for Windows v.21.0 (IBM Corp., Armonk, NY) was used. Descriptive statistics were expressed as mean, median, standard deviation, minimum-maximum for numerical variables and as number and percentage for categorical variables. The assumption of normality was examined with the Kolmogorov-Smirnov test, which failed to meet the assumption. Kruskal-Wallis test was used to determine whether there was a difference between bilirubin groups. In the case of differences between the groups, paired comparison tests were used to

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Bilirubin levels ≤1 mg/dL (n=261, 79.3%)</th>
<th>1.1-2 mg/dL (n=46, 14%)</th>
<th>2.1-6 mg/dL (n=22, 6.7%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67.0±18.1</td>
<td>71.9±15.4</td>
<td>70.3±16.8</td>
<td>.2</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>141 (54.0)</td>
<td>22 (47.8)</td>
<td>9 (40.9)</td>
<td>.4</td>
</tr>
<tr>
<td>Male</td>
<td>120 (46.0)</td>
<td>24 (52.2)</td>
<td>13 (59.1)</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>26.2±5.4</td>
<td>25.2±3.8</td>
<td>25.4±3.7</td>
<td>.7</td>
</tr>
<tr>
<td>APACHE II</td>
<td>19.7±11.3</td>
<td>21.3±10.1</td>
<td>28.4±13.1</td>
<td>&lt;.01*</td>
</tr>
<tr>
<td>SOFA</td>
<td>4.95±3.1</td>
<td>6.2±2.9</td>
<td>10.6±4.8</td>
<td>&lt;.01*</td>
</tr>
<tr>
<td>Primary diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central nervous</td>
<td>68 (26.1)</td>
<td>15 (32.6)</td>
<td>4 (18.2)</td>
<td>.4</td>
</tr>
<tr>
<td>Respiratory</td>
<td>48 (18.4)</td>
<td>12 (26.1)</td>
<td>3 (13.6)</td>
<td>.4</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>11 (4.2)</td>
<td>1 (2.2)</td>
<td>0 (0)</td>
<td>.3</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>8 (3.1)</td>
<td>1 (2.2)</td>
<td>1 (4.5)</td>
<td>.9</td>
</tr>
<tr>
<td>Renal</td>
<td>17 (6.5)</td>
<td>1 (2.2)</td>
<td>2 (9.1)</td>
<td>.4</td>
</tr>
<tr>
<td>Infection</td>
<td>34 (13.0)</td>
<td>10 (21.7)</td>
<td>9 (40.9)</td>
<td>&lt;.01*</td>
</tr>
<tr>
<td>Multi-trauma</td>
<td>21 (8.0)</td>
<td>4 (8.7)</td>
<td>1 (4.5)</td>
<td>.8</td>
</tr>
<tr>
<td>Postoperative, general surgery</td>
<td>22 (8.4)</td>
<td>2 (4.3)</td>
<td>0 (0)</td>
<td>.1</td>
</tr>
<tr>
<td>Postoperative, orthopedics</td>
<td>48 (18.4)</td>
<td>6 (13.0)</td>
<td>2 (9.1)</td>
<td>.4</td>
</tr>
<tr>
<td>Drug overdose, suicide</td>
<td>7 (2.7)</td>
<td>2 (4.3)</td>
<td>1 (4.5)</td>
<td>.8</td>
</tr>
<tr>
<td>Others</td>
<td>6 (2.3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>.2</td>
</tr>
</tbody>
</table>

Results are demonstrated as mean ± standard deviation or n (%). SOFA: Sequential Organ Failure Assessment Score
RESULTS
Among the 410 patients internalized to general ICU, 329 patients were found to meet study inclusion criteria. Baseline characteristics of the study population according to their bilirubin level groups is given in Table 1. Patients with normal bilirubin levels constituted 79.3% of the study population, whereas those with mild elevation and high bilirubin level were found to be less common (14% and 6.7%, respectively). Mean ages in these groups were 67±18.1, 71.9±15.4 and 70.3±16.8, respectively. Mean age, sex and body mass index did not significantly differ by bilirubin level groups of patients (P >0.05; Table 1).

Mean APACHE II within the first 24 hours of ICU admission was significantly higher (28.4±13.1) in high bilirubin group, compared to those in mild (21.3±11.0) and normal bilirubin groups (19.7±11.3; P <0.01). Similarly, those in high bilirubin group had significantly higher mean SOFA score (10.6±4.8) compared to those in mild (6.2±2.9) and normal bilirubin groups (4.95±3.10; P <0.01). Among patients in the high bilirubin group, 40.9% of patients were admitted to the general ICU with primary diagnosis of infection, which was detected as 13% and 21.7% in normal and mild bilirubin group (P <0.01; Table 1).

There was no statistically significant difference among different groups of bilirubin in terms of comorbidities at admission to ICU. Mechanical ventilation was found to be applied to 54.5% of those in the high bilirubin group, compared to 43.5% and 38.3% of patients with mild and normal bilirubin groups; where the difference was not statistically significant (P >0.05). These groups either did not differ with respect to the renal replacement therapy or total parenteral nutrition administered. The length of hospital stay was also detected to be similar between patients with different bilirubin levels (P >0.05). Length of stay at intensive care unit was found to be shorter in patients with normal bilirubin levels (P <0.05). Mortality rate in high, mild and normal bilirubin groups at admission were found to be 54.5%, 34.8% and 38.3%, where the difference was not statistically significant (P >0.05; Table 2).

DISCUSSION
This study shows that patients with higher levels of bilirubin were more likely to have infection during admission to ICU. Similarly, these patients had higher levels of APACHE II and SOFA scores. There was no relationship between bilirubin levels and mortality, but high levels of bilirubin were found to be associated with long-term ICU stay.

The threshold values for hyperbilirubinemia were found to vary among different studies. Brienza et al reported to accept the threshold of bilirubin level in critically ill postoperative or sepsis patients as 2 mg/dL, showing poorer prognosis above this level[11]. Field et al considered the threshold level of bilirubin to be higher than 3 mg/dL within the first 48 hours of admission to surgical ICU[8]. Kramer et al reported that bilirubin levels of 2 mg/dL and above was an early predictor of hepatic dysfunction in critically ill patients[4]. In this study, we used the threshold values used by Pierrakos et al[10]. Accordingly, we did not include patients with bilirubin levels 6 mg/dL and

Table 2: Comparison of patients’ comorbidities, supportive therapies, length of hospitalization and mortality

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Bilirubin levels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤1 mg/dL</td>
</tr>
<tr>
<td></td>
<td>(n=261, 79.3%)</td>
</tr>
<tr>
<td>Comorbid conditions</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>71 (27.2)</td>
</tr>
<tr>
<td>Neurologic diseases</td>
<td>66 (25.3)</td>
</tr>
<tr>
<td>Endocrine diseases</td>
<td>13 (5.0)</td>
</tr>
<tr>
<td>Renal diseases</td>
<td>31 (11.9)</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>43 (16.5)</td>
</tr>
<tr>
<td>Hematological diseases</td>
<td>6 (2.3)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>46 (17.6)</td>
</tr>
<tr>
<td>Others</td>
<td>16 (6.2)</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>100 (38.3)</td>
</tr>
<tr>
<td>Renal replacement therapy</td>
<td>26 (10.0)</td>
</tr>
<tr>
<td>Total parenteral nutrition</td>
<td>50 (19.2)</td>
</tr>
<tr>
<td>Length of stay at intensive care unit (days)</td>
<td>11.4±18.4</td>
</tr>
<tr>
<td>Length of hospital stay (days)</td>
<td>19.6±22.5</td>
</tr>
<tr>
<td>Fatal events at intensive care units</td>
<td>100 (38.3)</td>
</tr>
</tbody>
</table>

Results are demonstrated as mean ± standard deviation or n (%). There was no statistically significant difference by bilirubin level groups; where the difference was not statistically significant (P >0.05). These groups either did not differ with respect to the renal replacement therapy or total parenteral nutrition administered. The length of hospital stay was also detected to be similar between patients with different bilirubin levels (P >0.05). Length of stay at intensive care unit was found to be shorter in patients with normal bilirubin levels (P <0.05). Mortality rate in high, mild and normal bilirubin groups at admission were found to be 54.5%, 34.8% and 38.3%, where the difference was not statistically significant (P >0.05; Table 2).
above, as this might be accompanied with marked hepatic dysfunction. We regarded the patients with bilirubin values between 2.1 and 6 mg/dL as having high bilirubin level. Patients with bilirubin levels below 1 mg/dL were found to constitute 79% of our study population.

The impact of high bilirubin levels on the body and its association with infection is not clearly established, though it is known to be accompanied with increased mortality and morbidity. Owing to its anti-oxidative effect, bilirubin is thought to disturb bactericidal effect of neutrophils, improve endothelial functions and decrease organ injury by protecting against oxidative stress\[12,13\]. In this study, although the comorbidities of our patients are similar, 40.9% of patients with high bilirubin levels at admission to ICU had a primary diagnosis of infection. These patients also had higher SOFA and APACHE II scores that we used for assessing organ functions, and calculated within the first 24 hours of admission, respectively. There were no differences between the groups in terms of clinical course (number of days of mechanical ventilation or stay at ICU, or renal replacement therapy) and mortality. We thought that absence of increased mortality rate despite elevated APACHE II and SOFA scores in the group with the high bilirubin group might be explained by such protective effects of bilirubin. Although increased levels of bilirubin caused by infection may be associated with such protective mechanisms, it may also be associated with secondary cholestasis secondary to the toxicity of the infectious microorganism and consequently with the host response. In addition, hemolysis that occurs during infection could also be a contributing factor\[14-17\]. Kramer et al reported that 11% of patients had bilirubin levels higher than 2 mg/dL, within the first 48 hours of admission to ICU, and the mortality rates were higher in this subgroup\[4\]. Field et al reported an association between bilirubin levels higher than 3 mg/dL and infection, and positive correlation of bilirubin level to the risk of infection\[19\]. Patel et al showed that severe sepsis led to hyperbilirubinemia, which was related to cholestasis, concluding with relation of bilirubin elevation to mortality\[10\]. Vanwijaerden et al suggested hyperbilirubinemia to be an adaptive response to critical illness, and even to protect against harmful cellular effects\[18\]. We detected that the infection and organ function deterioration associated with bilirubin elevation could be controlled and had no effect on mortality.

In critically ill patients, devastating clinical picture secondary to multi-organ failure accompanied with respiratory, cardiovascular or renal impairment may mask newly-emerging hepatic dysfunction. Furthermore, serial monitoring of bilirubin levels is not a routine practice in critically ill patients. While half of the patients with hepatic dysfunction had sepsis, bilirubin elevation was reported to be 3-fold higher in ICU patients when admitted due to sepsis. It is likely that dysfunction of intrahepatic cells and their impaired interactions to each other in sepsis influence liver functions\[13,14\]. Yamano et al reported elevated bilirubin levels to be associated with poor prognosis in prolonged sepsis\[19\]. However, we did not assess the impact of hyperbilirubinemia that developed after ICU admission, as our aim was to investigate the effects of bilirubin elevation that existed at admission.

Liver has a high blood supply, both from hepatic artery and the portal venous system. Hepatic dysfunction can be driven by a decrease in hepatic blood flow and failure to meet metabolic needs. Such conditions that may reduce visceral blood flow, including parenteral nutrition, sepsis, trauma, major surgery, shock, antibiotic use, high positive end-expiratory pressure as well as use of mechanical ventilation may disrupt portal and hepatic arterial hemodynamics, and hence underlie impaired liver function\[20-24\]. It has been reported that hepatic dysfunction that developed in post-injury setting had higher mortality\[25\]. In contrast to our study, Kramer et al reported a linear relationship between elevated bilirubin levels and mortality\[4\]. Fuhrmann et al reported hypoxic hepatitis in 11% of patients admitted to medical ICU. Patients with hypoxic hepatitis had a longer length of ICU stay and shorter ICU survival\[26\]. Jaundice increases rates of complications and mortality in patients with hypoxic hepatitis\[27\]. Pierrakos et al, in their one-day international prevalence study of adult patients admitted to ICU, reported that hospital mortality linearly increased as long as the bilirubin level raised, among patients who had bilirubin level between 1.1 to 6 mg/dL. Serum bilirubin level higher than 1 mg/dL was reported to be an independent risk factor for mortality\[19\].

**Limitations of the study**

Small sample size might reduce the likelihood of the available findings to reflect actual outcomes. Actual sepsis incidence was not found in inpatients due to infection because no diagnosis of sepsis was found in the ICD-9 coding system. In addition, the retrospective study design mostly hampers consideration of many confounding factors, which may influence observed patient outcomes.

**CONCLUSION**

Patients who were admitted to ICU due to infection were likely to have more elevated bilirubin levels and higher APACHE II and SOFA scores. Although the mortality rate was higher in the high-level bilirubin
group, the difference between the groups was not significant. We conclude that bilirubin levels were associated with infection but not mortality in critically ill patients. Nonetheless, we believe that prospective studies are warranted on this subject.

ACKNOWLEDGMENT

Conflict of interest: None

Financial support: None

Author contributions: Belgin Akan designed the study and wrote the manuscript; Derya Gokcinar was in charge of study design; Gucin Ceran performed study and wrote the manuscript; Isil Ozkocak Turan finalized the manuscript.

REFERENCES


Original Article

Evaluation of the flexible laryngeal mask airway in 120 patients undergoing tympanoplasty

Guo Ran1#, Yan Wu2#, Lijun Wang1, Jie Jia1
1Department of Anesthesiology, Ear Eye Nose and Throat Hospital of Fudan University, Shanghai 200031, China
2Huangdu Community Service Center, Anting Town, Jiading District, Shanghai, China

Kuwait Medical Journal 2021; 53 (4): 441 - 446

ABSTRACT

Objective: Although the flexible laryngeal mask airway (FLMA) has been used widely in dental, head and neck-related surgery, information regarding its use during tympanoplasty has been limited. The study was done to evaluate the FLMA in patients undergoing tympanoplasty.

Design: A prospective clinical trial was conducted.

Setting: Department of Anesthesiology, EENT Hospital of Fudan University, Shanghai, China.

Subjects: Current study included 120 patients undergoing elective tympanoplasty after informed written consent.

Intervention: After the induction of anesthesia, the FLMA was inserted using an index finger. Fiberoptic assessment was performed to assess optimal placement.

Main outcome measures: We recorded the number of attempts required to successfully insert the FLMA, cuff pressure, tidal volume <15 cmH2O airway pressure, fiberoptic assessment before/after the head position, the partial pressure of carbon dioxide at the end of expiration during tidal breathing, duration of anesthesia and complications.

Results: FLMA insertion was successful at the first attempt in 109 patients and required a second attempt in 11. The cuff pressure and/or fiberoptic assessment did not differ between the frontal and lateral head positions. The tidal volume was significantly lower in the lateral than in the frontal head position (men: 408.78±56.73 vs. 453.35±68.66 mL, respectively; women: 362.41±59.78 vs. 396.58±63.82 mL, respectively, P<.05). Of note, 9.2%, 1.7%, 1.7%, 2.5%, 5.83% and 4.17% of patients reported a sore throat, hoarseness, dysphagia, tongue numbness, headache, and postoperative nausea and vomiting, respectively.

Conclusions: Use of FLMA was effective and safe during tympanoplasty and showed a high success and a low complication rate.

KEY WORDS: complications, cuff pressure, flexible laryngeal mask airway, tidal volume, tympanoplasty

INTRODUCTION

The laryngeal mask airway (LMA) has gained wide acceptance as an alternative to traditional tracheal tube intubation owing to the ease of insertion and a possibly lower risk of tracheal trauma[1]. Lately, the LMA (LMA Flexible, Laryngeal Mask Co. Limited, Mahe, Seychelles) is used worldwide in millions of patients undergoing dental, head and neck-related surgery[2,3]. The flexible laryngeal mask airway (FLMA) enables more hands-free anesthesia than a facemask, and omits the use of a laryngoscope, thereby reducing morbidities/stress associated with tracheal intubation and ensures faster recovery that does not require muscle relaxation[4]. Several studies have shown its advantages such as a lower incidence of hoarseness, coughing and oxygen desaturation[5,6]; however, a few others have emphasized that the results of the LMA were related to the method of selection of the device size and cuff inflation[7]. Surgical procedures requiring muscle relaxation require mechanical positive-pressure ventilation to secure airway ventilation[8], and various types of LMAs have been developed for better convenience[9]. The FLMA was first used successfully in 1990 during tonsillectomies and dental surgeries to
MATERIALS AND METHODS
Inclusion and exclusion criteria
Ethical approval was obtained from the Institutional Review Board of Shanghai Eye, Ear, Nose and Throat Hospital (No.KY2014-036) prior to the start of the study, and informed consent was obtained from all patients enrolled in the study. We studied 120 patients who underwent elective tympanoplasty between June 2016 and December 2016. Patients aged 18-65 years, belonging to the American Society of Anesthesiologists category 1-2, with expected uncomplicated airway upon assessment, and with no gastroesophageal reflux disease or other known risk factors for aspiration were included. Patients with a preoperative sore throat, hoarseness, dysphagia, obesity (body mass index >30 kg/m²), symptoms of upper respiratory infection two weeks prior to surgery, or with history of previous surgeries of the oral cavity or pharynx were excluded. The study included 63 women and 57 men. The FLMA was inserted in all patients by a single anesthetist who was not involved in the data collection or analysis and had at least three years’ experience with using LMAs, including an FLMA. The size of the FLMA was chosen based on a patient’s body weight - in patients weighing <50 kg, 50-70 kg and >70 kg, the FLMA sizes chosen were 3, 4 and 5, respectively.

Surgical procedure
No patient received any preoperative premedication. Upon arrival at the operating room, patients underwent standard monitoring, including electrocardiography, noninvasive arterial pressure assessment and pulse oximetry. Pre-oxygenation was performed for three minutes. Subsequently, intravenous access was established, and all patients were administered sufentanil 0.3 µg/kg and propofol 2-3 mg/kg for induction of anesthesia followed by cisatracurium 0.2 mg/kg to facilitate muscle relaxation. The mean arterial pressure and the heart rate were recorded at one minute intervals during induction of anesthesia and five minute intervals intraoperatively. Anesthesia was maintained using sevoflurane at a minimal alveolar concentration of 0.9-1.1 in an oxygen-air mixture and remifentanil 0.1 µg/kg/min to maintain a bispectral index (10083122 Rev A, COVIDIEN, USA) of 40-60. The heart rate and mean blood pressure were maintained within 20% of their preoperative values. Additional sufentanil and cisatracurium were administered as required.

The FLMA was inserted with the cuff fully deflated and digital pressure was applied at the flexometallic tube near its cuff, flattening it against the hard palate and advancing it along the posterior palatopharyngeal curve with the operator’s index finger placed at the junction of the mask and the tube until resistance could be felt against the finger. The cuff was then inflated with air to achieve an intracuff pressure <40 cmH₂O using a hand pressure gauge (VBM Medizintechnik GmbH, Germany, 5-118X). The ventilator (Dräger Fabius® Plus) was set to a pressure-controlled ventilation mode with pressure maintained at 15 cmH₂O. Successful ventilation was defined as visible chest movements, a square-wave capnogram and the ability to achieve an expired tidal volume of 6 mL/kg. A tympanoplasty procedure requires the patient’s head to be turned to the healthy (contralateral) side. Thus, after the head was rotated, the cuff pressure measurement was repeated and the tidal volume is determined. If the initial attempt at insertion was unsuccessful, we discontinued further attempts temporarily, and the patient’s lungs were manually ventilated before re-attempting FLMA insertion. Tracheal intubation was performed in patients after three failed attempts at FLMA insertion, and these patients were excluded from the study.

An ideal anatomical positioning of the LMA minimizes the need for intraoperative airway adjustment. Fiberoptic assessment provides an objective confirmation of FLMA placement. It was performed before surgery by passing a flexible fiberoptic bronchoscope (Olympus LF-GP, Olympus Optical Co. Ltd., Tokyo, Japan) through the flexometallic tube of the LMA to a position 1 cm proximal to the end of the tube and was also assessed at any arbitrary point intraoperatively at the discretion of the supervising anesthetist. The laryngeal view was classified based on a previously described scoring system: Grade 1: clear view of the vocal cords; Grade 2: view of only the arytenoids; Grade 3: view of only the epiglottis; and Grade 4: no laryngeal structures visible. Fiberoptic assessment was performed in both, the frontal and the lateral head positions.
The number of attempts required to insert the FLMA, the cuff pressure, tidal volume <15 cmH₂O, airway pressure, fiberoptic assessment before and after the required head position, partial pressure of carbon dioxide at the end of expiration during tidal breathing and the duration of anesthesia were recorded.

Postoperatively, the residual neuromuscular blockade was reversed using neostigmine 0.04 mg/kg and atropine 0.02 mg/kg. Extubation was performed after gentle suctioning of the oral cavity and deflation of the cuff when the patient had completely recovered and was awake. Patients were then transferred to the post-anesthesia care unit. Pain scores were assessed by nurses who had been blinded to the proposal immediately prior to discharge in all patients using the visual analog scale (VAS 1-10). Patients were asked to rate their degree of sore throat, jaw and/or neck soreness and any other complications were also recorded.

**Statistical analysis**

Statistical analyses were performed using the SPSS software version 11.5 (SPSS, Chicago, IL). Continuous data were presented as mean±standard deviation and compared using the Student’s *t*-test. Categorical data were analyzed using the Pearson’s Chi-square test. A *P* value <.05 was considered statistically significant.

**RESULTS**

**General information**

All 120 patients completed the study and the ventilation mode was not changed intraoperatively in any patient. Demographic information such as age, gender, weight, body mass index and other information such as type and duration of anesthesia, FLMA-related parameters and complications have been shown in Table 1. We studied 57 men and 63 women. The FLMA and subsequent ventilation could be performed successfully in all 120 patients. The FLMA was successfully inserted at the first attempt in 109 (50 men, 59 women) and at the second attempt in 11 patients (7 men, 4 women). No patient required a third attempt for FLMA insertion.

**Surgical indices**

Patients undergoing tympanoplasty need to have their head rotated 80 degrees toward the contralateral side. We observed that the cuff pressure did not significantly differ in the frontal and lateral head positions. Tidal volume was significantly lower in the lateral than in the frontal head position (453.35±68.66 mL respectively in men and 362.41±59.78 mL respectively in women, *P* <0.5). An expired tidal volume of 6 mL/kg, a square-wave capnogram and stable arterial oxygen saturations were observed in all patients.

**Complications of surgery**

Early postoperative complications were reported in 37 patients. Sore throat was reported in 9.2% patients (5 men, 6 women) and the mean VAS was <4. Hoarseness was reported in 1.7% patients (1 man, 1 woman), dysphagia in 1.7% (1 man, 1 woman), tongue numbness in 2.5% (2 men, 1 woman), headache in 5.83% (3 men, 4 women) and postoperative nausea and vomiting (PONV) in 4.17% (2 men, 3 women). When interviewed 24 hours post procedure, all patients reported that these early complications were self-limited in nature.

**Results of fiberoptic assessment**

Fiberoptic assessment through the flexometallic tube was performed in all patients. The vocal cords were visible in 61.7% (frontal head position) and 55.8% patients (lateral head position). Details of the fiberoptic

<table>
<thead>
<tr>
<th>Table 1: Patient characteristics and results for all flexible laryngeal mask airways</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Index</strong></td>
</tr>
<tr>
<td>Number</td>
</tr>
<tr>
<td>Age (year)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Body mass index</td>
</tr>
<tr>
<td>Anesthesia duration (min)</td>
</tr>
<tr>
<td>LMA size (No.)</td>
</tr>
<tr>
<td>Size 3</td>
</tr>
<tr>
<td>Size 4</td>
</tr>
<tr>
<td>Size 5</td>
</tr>
<tr>
<td>Insertion</td>
</tr>
<tr>
<td>1st attempt</td>
</tr>
<tr>
<td>2nd attempt</td>
</tr>
<tr>
<td>≥3rd attempt</td>
</tr>
<tr>
<td>Cuff pressure (cmH₂O)</td>
</tr>
<tr>
<td>Frontal head position</td>
</tr>
<tr>
<td>Lateral head position</td>
</tr>
<tr>
<td>Tidal volume (mL)</td>
</tr>
<tr>
<td>Frontal head position</td>
</tr>
<tr>
<td>Lateral head position</td>
</tr>
<tr>
<td>End-tidal CO₂ pressure (mmHg)</td>
</tr>
<tr>
<td>Overall pain score (VAS)</td>
</tr>
<tr>
<td>Sore throat</td>
</tr>
<tr>
<td>No.</td>
</tr>
<tr>
<td>VAS</td>
</tr>
<tr>
<td>Hoarseness</td>
</tr>
<tr>
<td>Dysphagia</td>
</tr>
<tr>
<td>Tongue numbness</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>PONV</td>
</tr>
</tbody>
</table>

*Compared to frontal head position, *P* <.05. LMA: laryngeal mask airway; VAS: visual analog scale; PONV: postoperative nausea and vomiting.
assessments have been presented in Table 2. No significant differences were observed between the frontal and lateral head positions.

DISCUSSION

The FLMA has been widely used in cleft palate, nasal, upper chest, as well as head and neck oncplastic surgery[15,12]. Reportedly, the insertion of an FLMA is technically more difficult than that associated with the standard LMA Classic because pressure cannot be directly transmitted along the soft flexometallic shaft[13]. Various techniques suggested for FLMA insertion include the use of a stylet[14], a spatula introducer[15], a Bosworth introducer[16] and a flexiguide introducer[17]. In our study, the FLMA was inserted using an index finger, and we observed positive results with this technique. Insertion of the FLMA was easy in most patients. The first-time insertion success rate was 90.8% (109/120) and the overall insertion success rate was 100%.

The LMA is easy to insert in patients who are placed in the supine position; however, in patients undergoing tympanoplasty, the patient’s head needs to rotate 80 degrees toward the contralateral side. Reportedly, this change in head position is known to reduce the sealing and ventilation effect of the laryngeal mask such that it might not optimally meet the clinical needs[18,19]. The FLMA does not affect the surgeon because it is a sturdy device that is easy to place, and it can be easily inserted and effectively used for airway management even in children with obesity undergoing minor surgery[20].

The results of this study showed that although the tidal volume was significantly lower in the lateral than in the frontal head position, it could adequately meet the clinical ventilation requirements (>6 mL), which would be attributable to the change in head position. Fiberoptic examination revealed a Grade 1 or 2 view of the larynx in 85% of patients (35 men, 39 women) in the frontal head position and in 83% (31 men, 36 women) in the lateral head position. Although head rotation diminished the laryngeal exposure (the Grade 1 or 2 view was not as clearly visible), no significant difference was observed between the two positions.

Sore throat is a common postoperative complaint following tracheal intubation, use of an LMA, oral airway insertion as well as mask ventilation. An LMA is known to reduce the incidence of postoperative sore throat after general anesthesia compared with an endotracheal tube[7,21]. The incidence of sore throat is highly dependent on the cuff pressure within the LMA (b). High LMA cuff pressures exert a variable pressure on pharyngeal structures[22,23]. Notably, high cuff pressures are associated not only with sore throat but a higher incidence of all complications[24-26]. Although the manufacturer guidelines for the use of the LMA propose/set a maximum recommended inflation volume, the use of the recommended maximum volume is associated with a high risk of hyperinflation and increased leakage around the LMA cuff[18]. The development of a sore throat with high cuff pressures is likely secondary to ischemic injury to the pharynx, which occurs when the laryngeal mask pressures exceed pharyngeal wall perfusion pressures[18]. Brimacombe et al have reported that no instances of sore throat were observed when cuff pressures were <40 cmH2O, which is a value at which cuff pressures are unlikely to exceed the pharyngeal perfusion pressure[11]. William et al showed a 3.3% overall rate of sore throat with a cuff pressure <60 cmH2O[27]. A previous study performed by the same research group reported that sore throat did not occur at a cuff pressure <40 cmH2O and that the incidence of sore throat was 4.6% when the cuff pressure was 40-60 cmH2O[28]. The results of our study demonstrated that the incidence of sore throat was 9.2% (5 men, 6 women) when the cuff pressures (measured using a hand pressure gauge) were <40 cmH2O. These results show a higher incidence of sore throat than in previous studies[28]. This difference could be attributed to the fact that the lateral head position adopted during a tympanoplasty caused compression of the pharyngeal tissues by the laryngeal mask precipitating a sore throat.

Hoarseness has been reported in approximately 50% of intubated patients and 15% of patients undergoing LMA insertion[29]. Hoarseness is associated with low levels of patient satisfaction. Apfelbaum et al[29] suggested that the most common cause of vocal
cord paralysis could be attributed to compression of the recurrent laryngeal nerve by the endotracheal tube cuff within the endolarynx. An FLMA is positioned superior to the larynx and is rarely associated with recurrent laryngeal nerve injury. The incidence of hoarseness in our study was 1.7%, which was in agreement with previous reports[31]. Other complications included dysphagia, tongue numbness, headache and PONV. The pressure exerted by the LMA on the vocal cords and the tongue intraoperatively might lead to dysphagia and tongue numbness. Use of a postoperative head band might cause headaches. PONV is a common general anesthesia-induced complication. Fortunately, in our study, the incidence of all complications was low and no patient demonstrated severe symptoms.

**Limitations of the present study**

Firstly, our study included patients belonging to the American Society of Anesthesiologists category 1-2; thus, our results may not be applicable to other patients with significant comorbidities. We studied only low-risk patients who showed normal airways and most patients had not been diagnosed with obesity. Our results might not apply to patients who are diagnosed with morbid obesity and present with a potential difficulty with maneuverability in their airway or require other types of surgery. Second, we did not compare the performance of the FLMA with other likely alternatives/substitutes. This study can be regarded a feasibility study and randomized controlled studies to compare these devices are warranted. Third, post-tympanoplasty laryngopharyngeal symptoms were evaluated only through a short-term postoperative follow-up. Further studies are warranted to evaluate the long-term effects following the use of an FLMA. Lastly, the sample size of this study was relatively small. Further large-scale cohort studies comprising a greater volume of data are required in this context.

**CONCLUSION**

Although the heads of patients undergoing tympanoplasty need to rotate 80 degrees toward the contralateral side, the use of the LMA flexible is a good option in those undergoing tympanoplasty owing to the advantages of better placement of the airway device, decreased incidence of postoperative complications and satisfactory ventilation effects.

**ACKNOWLEDGMENT**

The authors declare no conflict of interest.

**REFERENCES**


Original Article

Diagnostic value of TIMP-1, TIMP-2, TGF-β1, YKL-40 in the evaluation of liver fibrosis in patients with chronic hepatitis B

Kader Arslan1, Cigdem A Hatipoglu1, Cemal Bulut2, Mehmet A Gonultas3, Sami Kinikli1
1Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
2Department of Infectious Diseases and Clinical Microbiology, Gülhane Training and Research Hospital, Ankara, Turkey
3Department of Pathology, Ankara Training and Research Hospital, Ankara, Turkey

ABSTRACT

Objectives: To evaluate the diagnostic accuracy of noninvasive serological parameters to predict liver fibrosis in chronic hepatitis B patients

Design: Prospective clinical study

Setting: Ankara Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey

Subjects: This study included 88 patients with chronic hepatitis B

Intervention: Liver biopsy was performed in all patients. Fibrosis stage was determined using Ishak’s scoring system. In group I, there were cases with mild or no fibrosis and group II had patients with severe fibrosis.

Main outcome measures: Serum YKL-40, TIMP-1, TIMP-2, MMP-2 and TGF-β1 were measured by ELISA. Serological parameters were compared with histopathological fibrosis scores.

Results: Group I included 55 patients (62.5%) and group II had 33 patients (37.5%). Serum YKL-40 were found higher in group II than group I (P=0.034). There was no statistical difference in other serological parameters. We demonstrated that YKL-40 has highest area under the receiver operating characteristic for predicting ≥F3 fibrosis. Based on the results, TIMP-1, TIMP-2, MMP-2, TGF-β1 levels are not useful in determining liver fibrosis in patients with chronic hepatitis B. However, YKL-40 values revealed correlation with histopathological parameters.

Conclusion: We found that serum YKL-40 values can be used as an important non-invasive test for diagnosis of fibrosis in patients with chronic hepatitis B. However, we think that it was not yet enough to replace liver biopsy clinically.

KEY WORDS: chronic hepatitis B, liver fibrosis, non-invasive, YKL-40

INTRODUCTION

Infections of hepatitis B virus (HBV) lead to important public health problems in Turkey, as in the rest of the world. The World Health Organization has estimated that about two billion people in the world have been exposed to HBV and are seropositive, while an average of 250 million people are currently infected with HBV. Every year, about 600,000 people in the world die from cirrhosis and hepatocellular carcinoma caused by chronic hepatitis B (CHB). In patients with chronic hepatitis B (CHB), the decision for therapy is generally made according to the serum HBV-DNA and alanine aminotransferase levels, the degree of necroinflammation and the stage of fibrosis in the liver biopsy[2,3].

In liver diseases, liver biopsy is the gold standard method for diagnosing fibrosis[4]. Although liver biopsy is generally accepted to be a simple and reliable procedure, its application is debatable as this procedure is an invasive method, has contraindications, may lead to complications, requires hospitalization and may cause sampling errors; it is also difficult to be replicated.

Address correspondence to:
Kader Arslan, Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey.
Tel: +90 5326103803; Fax: +90 3123637445; E-mail: kaderdogan@gmail.com
SUBJECTS AND METHODS
The study comprised patients with HBV infection who were admitted to the Infectious Diseases and Clinical Microbiology Clinic between the dates of January 16, 2013 and July 16, 2013, who had been HBsAg positive for longer than six months and had not been treated previously. Patients with anti-HAV IgM, anti-HIV, anti-HCV or anti-HDV positivity with a chronic liver disease other than HBV (toxic hepatitis, granulomatous hepatitis, autoimmune hepatitis, cholestatic liver disease, alcoholic liver disease, Wilson’s disease, alpha-1 antitrypsin deficiency and hemochromatosis), and with signs and findings of hepatocellular carcinoma (abdominal pain, weight loss, anorexia, fever, jaundice, and ascites and palpable mass at physical examination) were excluded from the study. Prior to biopsy, blood samples were collected from the patients included in the study for evaluating non-invasive serological markers. All patients underwent a percutaneous fine-needle liver biopsy using a 16-G biopsy needle. During histopathological investigations, staging and grading were made according to the Modified Knodell ‘Ishak’ Scoring System. Using the Ishak scoring system, stage 0 was defined as the absence of fibrosis, stages 1-2 were defined as mild fibrosis, and stages 3-4 were defined as intermediate/severe fibrosis. The patients were divided into two groups according to the degree of fibrosis as follows: Group I comprised cases with stages 0-1-2 (no fibrosis, mild fibrosis) and Group II with stages 3-4 (intermediate/severe fibrosis). The serum levels of the non-invasive serological markers MMP-2, TIMP-1, TIMP-2, TGF-B1 and YKL-40 were evaluated using the commercially available ELISA kits (EIAab Science CO, CHINA and Aviscera Bioscience, Inc., USA), and the analyses were conducted in line with the manufacturer’s instructions. The non-invasive serological markers were compared with the histopathological fibrosis scores revealed following the liver biopsy, in terms of hepatic fibrosis.

Ethical approval and consent to participate
The study was approved by our institutional review board and study number was 4097/405. Consent for publication was obtained from all the patients.

Statistical analyses
The SPSS 16.0 for Windows program was used for statistical analysis. The descriptive statistical data were expressed as percentage distribution, mean, standard deviation and median. Comparison of percentages was made using the Chi-square test and the Fisher’s exact test was used where necessary. Student’s t test was used to compare two continuous variables that fit normal distribution, and Mann Whitney U test was used to compare two continuous variables that did not fit normal distribution. The correlations between these variables were evaluated using the Kendall’s tau-b correlation test. A P-value less than 0.05 was accepted to be statistically significant. The receiver operating characteristic curves were drawn in order to test the efficiencies of non-invasive markers of fibrosis to indicate liver fibrosis, and the area under the receiver operating characteristic (AUROC) was calculated.

RESULTS
The study comprised 88 patients with CHB followed-up in the Infectious Diseases and Clinical Microbiology Clinic. Of the patients, 41 (46.6%) were male and 47 (53.4%) were female; the mean age of the patients was 40.03±11.9 (17-67) years. Age and gender were not found to differ significantly between the patients in Group I and Group II (P=.391 and P=.783).

The histopathological evaluation of liver biopsies conducted in line with Ishak scoring indicated that 10 (11.4%) patients were at stage 0, 45 (51.1%) were at stages 1-2 and 33 (37.5%) were at stages 3-4. No cirrhotic patients at stages 5-6 were detected. The patients’ mean Knodell score and the mean stage of fibrosis were determined as 4.4 and 2.1, respectively. The distribution of the patients in according to fibrosis scores is indicated in Table 1.

<table>
<thead>
<tr>
<th>Fibrosis scores</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>No fibrosis (0)</td>
<td>10</td>
<td>11.4</td>
</tr>
<tr>
<td>Mild fibrosis (1-2)</td>
<td>45</td>
<td>51.1</td>
</tr>
<tr>
<td>Intermediate-severe fibrosis (3-4)</td>
<td>33</td>
<td>37.5</td>
</tr>
<tr>
<td>Total</td>
<td>88</td>
<td>100</td>
</tr>
</tbody>
</table>

Patients with no/mild fibrosis were compared with patients with intermediate/severe fibrosis in terms of levels of the non-invasive serological markers such as YKL-40, TIMP-1, TIMP-2, MMP-2 and TGF-β1 (Table 2). A statistically significant difference in serum YKL-40 levels was detected in Group II patients. In this group, patients had a significantly higher YKL-40 level.
(P = .029). There was no statistical difference in other serological parameters.

The correlations between the stages of liver fibrosis and serum YKL-40, TIMP-1, TIMP-2, MMP-2 and TGF-B1 levels in the patients were investigated (Table 3). A positive correlation was detected between the serum YKL-40 level and stage of fibrosis (r = 0.235, P = .029).

The values of the AUROC related to serum YKL-40, TIMP-1, TIMP-2, MMP-2 and TGF-B1 levels that determine the existence of fibrosis were assessed as 0.636, 0.540, 0.575, 0.480 and 0.407, respectively. YKL-40 provided the best diagnostic value for the detection of liver fibrosis. The receiver operating characteristic curves of the tests are presented in Figure 1.

**DISCUSSION**

Assessment of the stage of liver fibrosis in patients with CHB is paramount in determining treatment and prognosis. Liver biopsy is the gold standard method for evaluating liver fibrosis. However, over recent years, studies have been undertaken with the objective of developing biochemical and other non-invasive diagnostic methods that can replace histopathological evaluation. By evaluating several parameters in combination, indices (such as Bonacini, Forns and APRI indices, ALT/AST ratio, FibroTest and ActiTest) which might be more sensitive, have been developed. Furthermore, in recent years, some novel markers (such as laminin, hyaluronic acid, YKL-40, TIMP-1 and 2, PIIINP, MMP 1,2,3 and 9, PDGF-BB,}

---

| Table 2: Comparison of serum levels of non-invasive fibrosis markers of Group I and Group II patients |
|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Noninvasive serological markers** | **Group I** (mean ± SD) | **Group II** (mean ± SD) | **P** |
| YKL-40 (0.25-16 ng/mL) | 6.08 ± 5.18 | 8.82 ± 6.18 | .029 |
| TIMP-1 (62.5-4000 pg/mL) | 2841 ± 440 | 2880 ± 428 | .690 |
| TIMP-2 (0.3-20 ng/mL) | 2.78 ± 1.8 | 3.43 ± 2.57 | .215 |
| MMP-2 (0.31-20 ng/mL) | 3.58 ± 2.98 | 3.47 ± 2.99 | .865 |
| TGF-β1 (15.6-1000 pg/mL) | 446.8 ± 317.5 | 362.8 ± 305.8 | .228 |

*YKL-40: Condrex, TIMP-1: Tissue inhibitor metalloproteinase-1, TIMP-2: Tissue inhibitor metalloproteinase-2, MMP-2: Matriks metallocroproteinaz-2, TGF-β1: Transforming growth factor-beta 1

| Table 3: Correlation between fibrosis stages and noninvasive fibrosis markers |
|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Noninvasive serological markers** | **R** | **P** |
| YKL-40 (ng/mL) | 0.188 | .034 |
| TIMP-1 (pg/mL) | 0.055 | .532 |
| TIMP-2 (ng/mL) | 0.096 | .276 |
| MMP-2 (ng/mL) | -0.028 | .750 |
| TGF-β1 (pg/mL) | -0.128 | .149 |

*YKL-40: Condrex, TIMP-1: Tissue inhibitor metalloproteinase-1, TIMP-2: Tissue inhibitor metalloproteinase-2, MMP-2: Matriks metallocroproteinaz-2, TGF-β1: Transforming growth factor-beta 1

---

Fig 1: Receiver operating characteristic curve demonstrating diagnostic strength of non-invasive fibrosis markers on signaling fibrosis presence
TGF-B1, type 4 collagen and fibronectin), which have been linked with tissue fibrosis, have also been produced for use as commercial kits[11-13].

There are studies investigating the correlation between the level of TIMP-1, one of the non-invasive markers of fibrosis and the severity of fibrosis in patients with chronic liver disease. In a study by Zhu et al consisting of 159 patients with CHB, a positive correlation was determined between the stage of fibrosis and serum TIMP-1 levels (r=0.695, P < .01); when the threshold value was accepted as ≥174.5 ng/mL, the sensitivity, specificity, positive predictive value and negative predictive value were found to be 89.4%, 83.6%, 91.2% and 80.1%, respectively[14]. In the study of El Kamery et al conducted with 355 patients with chronic hepatitis C, it was revealed that the serum TIMP-1 levels increased as the stage of fibrosis advanced in a way that was statistically significant[P<.05]. In a study by Seven et al, a positive correlation was identified between the serum TIMP-1 level and the stage of fibrosis in 109 patients with CHB, 33 of whom were coinfected with HDV. In this study, the AUROC for TIMP-1 has been assessed as 0.747, and it was asserted that TIMP-1 could be a good non-invasive marker of fibrosis in the patients with CHB[16]. In our study, the serum TIMP-1 level was slightly higher in the group with an intermediate/severe stage of fibrosis compared with the other group, but this difference was not found to be statistically significant (P=.690).

TIMP-2 was another marker evaluated in our study. In a study by Liang et al comprising 101 patients with CHB, the serum TIMP-2 level was found to be significantly higher in the group with a stage of fibrosis ≥2, compared with the group with stage 0-1[17]. In two separate studies comparing patients with chronic hepatitis C to healthy control groups, the serum TIMP-2 levels in the patient groups were found to be significantly higher compared with healthy groups, and no significant correlation was identified between the stage of fibrosis and serum TIMP-2 levels[18,19]. In our study, the serum TIMP-2 level was also determined to be higher in the group with an advanced stage of fibrosis; nevertheless, this difference was not statistically significant (P=.215) and no significant correlation was detected between the stage of fibrosis and serum TIMP-2 levels (r=0.096, P=.276).

There are studies demonstrating that the serum matrix metalloproteinase-2 level increases with chronic liver disease. In the study of El Kamery et al conducted with 355 patients with chronic hepatitis C, it was shown that the serum MMP-2 levels also increased as the stage of fibrosis increased in a way that was statistically significant[15]. The study by Liang et al of 101 patients with CHB, found that the serum MMP-2 level was significantly higher in the group with a stage of fibrosis ≥2, when compared with the group with stage 0-1[17]. In the same study, 101 patients with CHB were compared to 54 healthy controls and the serum MMP-2 level was found to be significantly higher in the patient group[17]. In two different studies comprising patients with chronic hepatitis, the serum MMP-2 levels were likewise assessed to be significantly higher in the patient groups with a stage of fibrosis ≥2, compared with the groups with stages of ≤1[16,20]. In our study, no statistically significant difference was detected between the cases with no fibrosis/mild fibrosis and those with intermediate/severe fibrosis in terms of the serum MMP-2 levels (P=.865).

The TGF-B1 was the other non-invasive marker of fibrosis that we evaluated in our study. In the study of Valva et al that examined patients with chronic hepatitis C, the serum TGF-B1 levels were found to be significantly higher both in the adult and pediatric patient groups, when compared with healthy group. In the pediatric patient group, the serum TGF-B1 level did not differ significantly between the group with a high stage of fibrosis and the group with a low stage. In the adult patient group, the serum TGF-B1 level was seen to be significantly lower in the group with an advanced stage of fibrosis[21]. In the study by Guo et al comprising 131 patients with CHB, the serum TGF-B1 level was determined to be significantly lower in the group with advanced stages of fibrosis compared with the group with stage 0[22]. In another study conducted by Zhang et al, no statistically significant difference was identified between patients with CHB and a healthy control group in terms of serum TGF-B1 levels[23]. In our study, the serum TGF-B1 levels were also found to be lower in the group with an advanced stage of fibrosis. However, this result was not statistically significant (P=.228).

In recent years, the value of YKL-40 has been investigated as a marker to indicate inflammation and fibrosis. In the study of Saitou et al involving 109 cases of chronic hepatitis C, the YKL-40 was determined to be more sensitive than the other non-invasive parameters of fibrosis in serum, in terms of demonstrating advanced stages of fibrosis[24]. When the threshold value for YKL-40 was established as 284±8 ng/ml, the sensitivity and specificity was found to be 80% and 77%, respectively. Following antiviral treatment, the serum YKL-40 level was seen to decrease more significantly than those of the other markers. This result emphasized that the serum YKL-40 level, in addition to the severity of disease, could also be helpful for evaluating the response to therapy[24]. In a study by Nojgaard et al comprising 370 patients with alcohol-related chronic liver disease, the serum YKL-40 level was found to be low in the patients without steatosis and cirrhosis, whereas it was high in the patients with...
fibrosis.[25] In our study, the serum YKL-40 level was seen to be higher in the group with an advanced stage of fibrosis, and this difference was found to be statistically significant ($P=0.029$). A positive correlation was determined between the stage of fibrosis and serum YKL-40 level ($r=0.188$, $P=0.034$).

Furthermore, in our study, the serum YKL-40 possessed the highest AUROC level and thus had the highest diagnostic value in demonstrating the presence of stage 3 and more severe fibrosis, and also that the YKL-40 levels were correlated with the histopathological parameters. It was considered that the evaluation of serum TIMP-1, TIMP-2, MMP-2 and TGF-B1 levels was not sufficiently effective in demonstrating the presence of fibrosis in the patients with CHB.

**CONCLUSION**

In conclusion, the present study suggests that the serum YKL-40 level could be used as an effective non-invasive marker of fibrosis, in terms of revealing the presence of fibrosis in the patients with CHB. Nevertheless, without more detailed and comprehensive studies, it is clear that it will not be sufficient to replace liver biopsy alone. We consider that more comprehensive studies involving the cirrhotic patient group are needed on this subject, in patients with chronic hepatitis.

**ACKNOWLEDGMENTS**

This study was presented as a poster in ECMID congress, 10-13 May 2014, Barcelona-Spain.

**Funding:** This study has received no financial support.

**Conflicts of Interest:** There are no conflicts of interest in connection with this paper.

**Author’s contribution:** Kader Arslan designed the study, carried out all the lab work and wrote the manuscript. Cigdem A Hatipoglu, Cemal Bulut and Sami Kinikli participated in the design, execution and analysis of the paper, and they approved the final version. Mehmet A Gonultas performed pathological examination of biopsy materials.

**REFERENCES**


Can diabetes insipidus be used as a marker for multisystemic and progressive disease in Langerhans cell histiocytosis?

Nizameddin Koca1, Soner Cander2, Ozen Oz Gul2
1Department of Internal Medicine, University of Health Sciences, Bursa Yuksek Ihtisas Training & Research Hospital, Bursa, Turkey
2Department of Internal Medicine, Division of Endocrinology & Metabolism, Uludag University Medical School, Bursa, Turkey


ABSTRACT

Langerhans cell histiocytosis (LCH) is a rare disease with an yearly incidence of nine cases per a million in children and 1-2 cases per a million adults. 68.6% of LCH presented with multisystem involvement. A 40-year-old woman who was admitted to endocrinology outpatient clinic with symptoms of polyuria, polydipsia and headache was diagnosed with diabetes insipidus (DI). Desmopressin treatment was initiated, but six months after therapy, re-evaluation revealed progression in hypophyseal mass. Thoracoscopic biopsy shows LCH with multisystemic involvement. She did not respond clinically to systemic chemotherapy and external radiotherapy and died due to pneumonia.

LCH should be taken into consideration in patients diagnosed with DI. DI is almost always the hallmark of hypothalamic pituitary axis involvement and a sign of multisystemic involvement.

KEY WORDS: diabetes insipidus, Langerhans cell histiocytosis, multisystemic disease

INTRODUCTION

Langerhans cell histiocytosis (LCH) is a rare disease in childhood and adulthood which is a part of diseases caused by infiltration of Langerhans cells across multiple organs, such as the lungs, bones, skin, pituitary gland and lymph nodes[1]. The yearly incidence is 3-5 cases per million between 1 and 3 years of age[2] and 9 cases per a million in children[3]. LCH is rarer in adults with the yearly incidence of 1-2 cases per a million[4,5].

The exact pathogenesis of LCH is still not defined, but identified tumor-associated mutation (BRAFV600E) indicates that LCH is more a neoplastic disease rather than a reactive disorder, although it exhibits a strong inflammatory component[6,7]. Presence of Birbeck granules in electron microscopy or S100/ CD1a positivity in immunohistochemical staining confirms the diagnosis of LCH[7].

The International LCH Study of the Histiocyte Society categorized LCH into localized (single-system disease) and disseminated forms (multisystem disease[8]. According to International Histiocyte Society Registry from January 2000 to June 2001, 68.6% of LCH presented with multisystem involvement[9].

The most commonly involved organs are lungs (58.4%) and bones (57.3%). Local pain (34%), weight loss (11%) and fever (10%) are the most common symptoms at presentation[9]. The most common endocrine manifestation of LCH in adults is diabetes insipidus (DI, 29.6%)[9].

CASE REPORT

A 40-year-old woman was admitted to endocrinology outpatient clinic with symptoms of polyuria, polydipsia and headache. In the initial examinations, there was no feature except for
hypoosmolar urine in routine tests. No hormonal insufficiency was detected in anterior pituitary function tests. Thirst test was compatible with DI without anterior hypophysis failure. Magnetic resonance imaging (MRI) of the hypophysis shows an area of approximately 4x4 mm focal thickening with contrast enhancement at the distal portion of the infundibular stalk (Figure 1). Chest X-ray was considered as normal. She was followed-up under desmopressin treatment for six months.

She was re-evaluated with symptoms such as lethargy, diplopia, menstrual irregularity, headache and forgetfulness. Control hypophysis MRI shows heterogeneous, contrast enhanced, 18x15 mm nodular thickness that extends through hypothalamus (Figure 2). Hormonal evaluation reveals that her prolactin level was elevated to 92 ng/mL, cortisol response to ACTH stimulation test was normal with 33 mcg/dL highest value of cortisol response and she had secondary hypogonadism. Serum angiotensin converting enzyme, 24 hours’ urine calcium excretion, complete blood count, erythrocyte sedimentation rate, ferritin, progesterone, alpha-feto protein and beta-HCG levels were within normal limits.

High resolution computed tomography scanning of the lungs showed multiple, irregularly shaped cystic lesions at the posterior and upper lobes of both lungs, posterior reticulonodular opacities and multiple lymph nodes with max 20 mm diameter at the right paratracheal, pre-carinal region (Figure 3). Positron emission tomography scan for differential diagnosis of lymphoma reveals increased osteoblastic activity at the 6th, 8th and 9th right ribs and in the central part of the left femoral shaft (Figure 4). Bone marrow biopsy was reported as normocellular. Biopsy through thoracoscopic surgery revealed pulmonary Langerhans cell histiocytosis on histopathologic examination with positive CD68, S100 and CD1a staining. No complication was observed during and after the procedure. The thickness progressed to 2.5 cm diameter in control MRI during these diagnostic processes, which lasted six months (Figure 5).
External radiotherapy and six-cycle of chemotherapy (vinblastine + prednisolone) was planned. In the follow-up, panhypopituitarism was well established and replacement therapy with levothyroxine and prednisolone was added in addition to desmopressin treatment. However, she did not respond clinically to systemic chemotherapy and external radiotherapy and she died due to pneumonia that developed several times.

DISCUSSION

LCH is most often multisystemic and pituitary gland involvement is particularly frequent in adults\cite{10}. Anterior pituitary dysfunction is found in nearly 20% of patients with LCH, and is almost always associated with DI\cite{10}. In case of pituitary gland involvement, DI is the most common endocrine abnormality, occurring in 12% of children and 30% of adults with LCH\cite{10}. In one of the largest series which included 274 adult patients with biopsy-proven LCH, DI existed in 81 of 188 (43.1%) patients with multisystemic involvement\cite{9}.

In a retrospective study recruited during a 50-year period with 314 LCH patients, 44 patients with pituitary-thalamic axis (HPA) LCH was observed and all of them had DI\cite{11}. Kaltsas et al\cite{12} followed-up 12 adult multisystemic LCH patients with HPA involvement for 20 years. While eight of them developed some anterior pituitary hormonal deficiencies during the follow-up, they all had DI, which is considered as the earliest hormonal deficiency. Isoo et al reported two patients who had DI as the first noted abnormality\cite{13}. Asano T et al\cite{14} reported a patient

Fig 4: PET-scan for differential diagnosis of lymphoma reveals increased osteoblastic activity at the 6th, 8th and 9th right ribs and in the central part of the left femoral shaft
in whom DI was the only HPA abnormality. There are several cases presented in the literature that had DI and anterior pituitary deficiencies (APD) at the time of LCH diagnosis\[15,16\]. APD occurred almost exclusively with DI in the series of seven cases \[17\]. Radojkovic \textit{et al} \[18\] and Tabarin \textit{et al} \[19\] reported a case that has pituitary LCH and hypothalamic LCH without any sign and symptoms of DI, respectively. In our case, the patient was diagnosed and treated, but DI progressed rapidly as a multisystemic and progressive disease. Established DI is generally permanent\[9,10\]. In a study evaluating the efficacy of chemotherapy in childhood LCH, preexisting central DI persisted after chemotherapy in 23 patients, with the exception of two cases of partial central DI, in which the disappearance of pituitary stalk thickening was observed on MRI and desmopressin was no longer required (complete remission)\[20\]. This emphasizes the need for early intervention before DI is fully established. It is hypothesized that the pathogenesis of DI is related to autoantibodies against antiuretic hormone or scarring/infiltration of the HPA\[21\]. In autopsy series, granulomatous tissue has been determined on the pituitary gland and stalk, which suggests HPA axis involvement leading to pituitary hormone deficiencies\[22\]. The progression of hypophyseal mass can also lead to APD, as in our case.

APD is almost always seen in patients with multisystem disease. Arico \textit{et al} \[23\] reported that while all patients with DI had multisystemic disease, 43.1% of multisystemic patients had DI. Hence, it is logical to extend diagnostic approach in LCH patients with DI.

DI may be the first clinical finding in LCH patients with systemic involvement. Kurtulmus \textit{et al} \[23\] reported that seven of nine patients had DI initially and the other two cases developed DI within three years. Kaltsas \textit{et al} \[24\] published that while four of 12 LCH patients had DI initially, the remaining eight patients developed DI over the next 1-20 years (median: 2 years). These studies prove that DI can be used as a clue for investigation of multisystemic disease.

**CONCLUSION**

LCH should be taken into consideration in patients diagnosed with DI. DI is almost always the hallmark of HPA involvement and a sign of multisystemic involvement. Since there are some cases with isolated DI in LCH, it is usually associated with multisystemic and progressive disease in which early diagnosis and appropriate treatment can affect quality of life and can also prolong life expectancy.

Infilitrative diseases should be considered in the cases presenting with diabetes insipidus. Histioctosis is a disease with poor prognosis; therefore, early diagnosis is important. It should be kept in mind that lung involvement, one of the typical sites of involvement, cannot be ruled out by X-ray alone.

**ACKNOWLEDGMENT**

Special thanks to Ozlem Sengoren Dikis, MD for kind participation in patient management. All authors state that there is no conflict of interest. Each author has contributed to patient’s follow-up, literature search and manuscript writing process.

**REFERENCES**


Case Report

Parapharyngeal spindle cell rhabdomyosarcoma presenting as infra-auricular pain with vocal cord paralysis

Ching-Yuan Wang1,2, Liang-Yu Chen1,2, Teik-Ying Ng1,2
1Department of Otorhinolaryngology Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan
2School of Medicine, China Medical University, Taichung, Taiwan

Kuwait Medical Journal 2021; 53 (4): 458 - 460

ABSTRACT

Spindle cell rhabdomyosarcoma is currently difficult to diagnose and is a therapeutic challenge. We report a case of parapharyngeal tumour, spindle cell rhabdomyosarcoma in a 23-year-old woman with a one-month history of infra-auricular pain, who was discovered to have vocal paralysis. Vocal paralysis due to spindle cell rhabdomyosarcoma can be a rare laryngeal problem. To the best of our knowledge, we report the first case of vocal cord paralysis in parapharyngeal spindle cell rhabdomyosarcoma to be treated successfully after surgical intervention. Our experience with this patient also highlights the importance of performing a detailed oral examination in any patient with infra-auricular pain. The unusual clinical presentation of infra-auricular pain could increase the difficulty of a clinical diagnosis. Clinicians should remember that infra-auricular pain can be a symptom of spindle cell rhabdomyosarcoma. An early, correct diagnosis can improve the patient’s quality of life and may even save the patient’s life.

KEY WORDS: computed tomography, diagnosis, malignant, surgical, tumour

INTRODUCTION

Spindle cell rhabdomyosarcoma (RMS) is a variant of embryonic rhabdomyosarcoma. Spindle cell RMS is a rare and aggressive malignant tumour in adults. The head and neck areas are the most commonly affected regions in adults[1]. Even though the spindle cell RMS in head and neck region had some isolated reports, parapharyngeal spindle cell RMS is a rare entity. The most common initial clinical presentation of spindle cell RMS is a painless, rapidly growing neck mass[2]. In the present report, we discuss a parapharyngeal spindle cell RMS presenting as infra-auricular pain with vocal cord paralysis successfully treated after surgical intervention.

CASE REPORT

A 23-year-old Chinese female with a medical history of glucose-6-phosphate dehydrogenase deficiency was referred to our hospital due to left infra-auricular pain (duration of one month). The patient had been well until one month before admission, when she had left infra-auricular pain, especially when swallowing. Acute parotiditis was initially diagnosed by her primary physician. Oral antibiotics and analgesic medication were prescribed by her primary physician. One month later, she still had left infra-auricular pain with increased pain severity. She was referred to our hospital. A physical examination revealed left infra-auricular tenderness. It revealed no neck swelling and no erythematous skin. Upon oral examination, medial displacement of the left, lateral pharyngeal wall was noted. The laboratory tests were within normal limits. No leukocytosis or anemia was noted, but the differential white blood cell count showed elevated neutrophil segments up to 82.8% (the healthy range is 40%-74%). The C-reactive protein concentration was within the normal limit. Two weeks later, she developed progressive hoarseness and was easily choked. A laryngoscopy revealed left vocal cord paralysis.

A computed tomography scan was performed, which revealed a space occupying lesion in the left parapharyngeal space. The hypo-intense tumour was approximately 3.3*5.2*4.0 cm in size and infiltrated the surrounding structures (Figure 1). No enlarged
lymph nodes were found in the head or neck region. The left parapharyngeal tumour connected to the deep lobe of the parotid gland. The patient received surgical intervention with a left total parotidectomy, and an external cervical approach extirpated the left parapharyngeal tumour. The operative findings revealed an elastic, fragile tumour located in the left parapharyngeal space and extending toward the skull base. The vagus nerve and hypoglossal nerve were identified and were not involved with the tumour. The parotid gland was not adhered to the tumour. All branches of the facial nerve were preserved with nerve monitoring.

The pathological findings revealed that the whole parotid gland appeared normal and free of tumour invasion. The main tumour was fragile and elastic. Focal haemorrhage and tumour necrosis were observed. Microscopically, the tumour was composed of spindle-shaped cells with hyperchromatic, moderately atypical nuclei with evidence of increased mitotic activity (13/10 high power field, HPF) and a lot of eosinophilic cytoplasm (Figure 2). The arrangement was short-fasciculated or solid architecture with focally hemangiopericytoma-like vasculature. The immunohistochemical studies revealed that the tumour cells were vimentin and desmin positive. The Myo-D1 stain resulted in moderately positive nuclei, and the myogenin stain resulted in positively scattered nuclei. The other stains were negative for myosin, cytokeratin, CK8, CD34, CD99, EMA, S-100. Ki-67 staining revealed that the increased proliferative fraction was approximately 40%. Phosphahistone 3 staining resulted in 13 counts/10 HPF. Pathology confirmed the diagnosis of grade 3 spindle cell RMS (Fedreation Nationale des Centres de Lutte Contre le Cancer, FNCLCC grading).

The postoperative course was uneventful. One week after the operation, the patient no longer had infra-auricular pain. There was no facial paralysis after the operation. Left vocal paralysis recovered after the operation. She received postoperative radiotherapy.

DISCUSSION

Rhabdomyosarcoma is now classified into three histologic subtypes (embryonic, alveolar and pleomorphic) according to the characteristics. Spindle cell RMS is a variant of embryonic RMS and was first described in 1992 in the paediatric population by the German-Italian Cooperative Sarcoma Study[3]. This subtype presents mainly in children and in some adults, especially males. It occurs predominantly in the paratesticular area followed by the head and neck region. The retroperitoneum, thigh, hand, uvula, heart, thoracic wall, abdominal wall, ureter and uterus have also been reported[1,4,5]. Following the description of this variant, a few small studies reported this tumour in the adult population, and a more invasive clinical course and poor prognosis was noted[1,6]. The clinical presentation is a rapidly growing, painless, soft tissue mass with specific symptoms related to the location and infringement on surrounding structures[2]. In the head and neck region, spindle cell RMS can present with the following symptoms: lump throat, hoarseness, dysphagia, obstructive sleep apnea syndrome, diplopia, unilateral deafness, proptosis and sinusitis[2]. However, intolerable infra-aureicular pain with vocal paralysis had not been previously reported.

The parapharyngeal tumours account for approximately 0.5% of head and neck tumours. Of these, 80% are benign and 20% are malignant[6]. The
parapharyngeal space is a deep neck space extending from the skull base to the hyoid bone. The space is divided into two compartments by the styloid process and muscles. The bony structures, including the skull base, mandible and vertebrae, confine the space and the tumour only can grow in a medial and inferior direction[7]. The common symptoms of parapharyngeal tumours are lump throat, dysphagia, hoarseness, dyspnea and a painless mass[7].

The spindle cell RMS tumour is typically a firm, white to tan mass with a whorled appearance[2]. However, in this patient, the tumour was fragile and elastic. This atypical finding may have been due to the massive tumour necrosis (40%) and haemorrhage. Microscopically, the spindle cell RMS was composed of long fascicles with elongated spindle cells with hyperchromatic nuclei and pale eosinophilic cytoplasm and occasional rhabdomyoblasts[7]. Spindle cell RMS (especially in the head and neck region) should be considered during the differential diagnosis of nodular fascitis, malignant nerve sheath tumour, spindle cell sarcoma, spindle cell malignant melanoma, leiomyosarcoma and myofibrosarcoma. The spindle cell RMS originated from the skeletal muscle, and the tumour reacted with myogenic markers such as desmin, myogenin and MyoD1. Negative reactivity for S-100, CD-99, CD-34, h-caldesmon and glial fibrillary acidic protein facilitated the differential diagnosis from other sarcomas[2].

The prognosis of patients with spindle cell RMS varies in adults and paediatric patients. The standard treatment protocol is a combination of surgery, chemotherapy and adjuvant radiotherapy[2,8]. Paediatric spindle cell RMS usually arises in the paratesticular region. With early detection and adequate surgical margins, paediatric patients have a good prognosis. However, in adults, spindle cell RMS usually arises from the head and neck region, and the patients have a poor prognosis due to difficulties in obtaining adequate surgical margins[1,2]. Adult spindle cell RMS with uncontrolled local recurrence and distant metastasis has been noted postoperatively[2]. The one-year survival rate for adults with spindle cell RMS is only 53%[1,4].

CONCLUSION
A Pubmed search (1970 to the present) revealed no reports of scenario and management similar to this patient. To the best of our knowledge, we herein report the first case of parapharyngeal spindle cell RMS presenting as infra-auricular pain with vocal cord paralysis to be treated successfully after surgical intervention. The unusual clinical presentation of infra-auricular pain could increase the difficulty of a clinical diagnosis. Patients should be carefully examined in the oral and oropharynx when presenting with intolerable infra-auricular pain to accurately diagnose these patients. Clinicians should remember that infra-auricular pain can be a symptom of spindle cell RMS. Our patient highlights the importance of performing a detailed oral examination in patients with infra-auricular pain. An early, correct diagnosis can improve the patient’s quality of life and may even save the patient’s life.

ACKNOWLEDGMENT

Author’s Contribution:
First and second authors contributed equally to this work.

Ching-Yuan Wang and Liang-Yu Chen contributed substantially to the conception and design of the study, final approval of the version to publish and agreed to be accountable for all aspects of the work. Liang-Yu Chen drafted the article. Ching-Yuan Wang and Teik-Ying Ng provided critical revision of the article.

Disclosure: The case has not been presented or submitted elsewhere.

Conflict of Interests: None

Funding source: None

Ethics approval and consent to participate: Institutional review board approval was obtained (CMUH105-REC1-074)

REFERENCES

Case Report

Treatment of bilateral patellar dislocation after bilateral total knee arthroplasty of a patient with Parkinson’s disease: A case report

Kursad Aytekin, Cem Zeki Esenyel

1Department of Orthopaedics and Traumatology, University of Giresun, School of Medicine, Giresun, Turkey

ABSTRACT

We present a case of a Parkinson’s disease (PD) patient who sustained bilateral lateral patellar dislocation shortly after bilateral total knee arthroplasty (TKA). Prior to admission to our hospital, he underwent several surgical reduction attempts in other health centers. His Modified Hoehn and Yahr scale was 4. Surgical procedures included medial patellofemoral ligament (MPFL) reconstruction and Insall procedure. Non-absorbable polyethylene multifilament suture was used to repair the soft tissue. Two months postoperatively, the patient sustained fracture of the right patella due to falling. Patella fracture occurred at the tunnel level that was drilled for MPFL reconstruction. The fracture was treated with the tension band technique. After two years of follow-up, he was able to walk with the help of a walker. His Knee Society Score and Womac Score improved from preoperatively 6 to postoperatively 52, and from preoperatively 5.5 to postoperatively 52.3, respectively. PD may negatively affect the medial retinaculum and tendon healing because of muscular rigidity, weakness and imbalance. Use of non-absorbable polyethylene multifilament sutures may be more helpful for healing of medial structures of patella in TKA surgery in patients with neurodegenerative diseases such as PD.

KEY WORDS: bilateral patellar dislocation, bilateral total knee arthroplasty, Parkinson’s Disease, patellar fracture

INTRODUCTION

Patellar dislocation after total knee arthroplasty (TKA) surgery is a rare disease which causes difficulty in walking[1]. Dislocation of the patella may be due to insufficient surgical technique and component malposition, disruption of the extensor mechanism, high Q angle and neuromuscular disorders[2]. Patellar dislocation is one of the revision surgery causes in TKA[3]. In their study with 142 patients, Pećina et al reported that revision surgery was performed in three patients because of patellar instability[3]. Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called substantia nigra. Tremor (mainly at rest), bradykinesia, limb rigidity, muscle weakness, gait and balance problems are the most common symptoms that patients suffer from[4]. As it is very well known, patella is stabilized in knee joint by vastus medialis, vastus lateralis muscles and the medial patellofemoral ligament (MPFL). During TKA surgery, medial structures of patella as patellar insertion of MPFL, medial retinaculum and vastus medialis muscle tendon are cut and sutured routinely with absorbable sutures. In this study, we present a report with two years follow up of a PD patient who was surgically treated with the diagnosis of bilateral lateral patellar dislocation after TKA, and patellar fracture complication after our patella reduction surgery.

CASE REPORT

A 61-year old male patient with PD for 12 years was admitted to Orthopedics and Traumatology polyclinic with complaints of inability to walk, limited range of
motion (ROM) of both knees, inability to lift straight legs and pain. He had bilateral TKA nine months ago (Smith & Nephew, TC-PLUS™ PRIMARY). There was no history of trauma. Within one month of TKA surgery, patellar dislocation in both knees occurred. He never had patellar dislocation prior to TKA. Due to bilateral patellar dislocation, the patient had soft tissue interventions performed for the right knee twice and to the left knee once. It was noted in his discharge summary that he had TKA in the same surgical session via medial parapatellar approach to both knees. After one month, he had medial retinacular repair in both knees. One month later, he again had patellar dislocation at his right knee. Therefore, the medial retinacular repair surgery was repeated, but his patellar dislocation at both knees repeated again within one month. As stated in his discharge summaries, the medial retinacular repairs were done via absorbable suture no:2 vicryl surgery as a routine application.

During examination, the patient could not lift his legs straight. Both patellas were laterally dislocated (Fig 1a). Passive ROM of his knees was between 30°-100° and the active ROM was 50°-90°. Passive and active ROM of the patient was observed to be painful. In clinical (Fig 1a) and radiological (Fig 1b) examinations, the patellas were fixed at lateral side of the knee. With palpation, there was a gap between the tendo vastus medialis and the patella. Based on the normal clinical examination results and laboratory values, we did not think of infection at the knees. The valgus malalignment and rotational malalignment are frequently the causes of the patella dislocation after TKA. During preoperative examinations, we observed that the patient was not able to extend his knees because of patellar dislocation and pain sensation. For this reason, we could not take a full-length X-ray of the lower limb of the patient. However, we evaluated the possible rotational malalignment through computed tomography of his knees. In radiological examination, we observed no malrotation at the components of arthroplasty. Being a PD patient for 12 years, he had tremor, bradykinesia and limb rigidity. He did not use his medications regularly. His Modified Hoehn and Yahr scale value, a scale to present the stage of PD, was 4 (Table 1)[5]. Before surgery, his Knee Society Score was 6 and Womac Score was 5.5.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No sign of disease</td>
</tr>
<tr>
<td>1</td>
<td>Unilateral disease</td>
</tr>
<tr>
<td>1.5</td>
<td>Unilateral plus axial involvement</td>
</tr>
<tr>
<td>2</td>
<td>Bilateral disease without involvement of balance</td>
</tr>
<tr>
<td>2.5</td>
<td>Mild bilateral disease, with recovery on pull test</td>
</tr>
<tr>
<td>3</td>
<td>Mild to moderate bilateral disease, some postural instability, physically independent</td>
</tr>
<tr>
<td>4</td>
<td>Severe disability, still able to walk or stand unassisted</td>
</tr>
<tr>
<td>5</td>
<td>Wheel chair bound or bed ridden unless aided</td>
</tr>
</tbody>
</table>

Table 1: Modified Hoehn and Yahr Scale staging of Parkinson’s disease[5]

Under spinal anesthesia, both knees were entered through the prior incisions. It was observed that the musculus vastus medialis was not inserted into the patella. Both patellas had lateral retinacular release. After the lateral release, patella was placed into the trochlear groove of femoral component. Then, the Q angle between the quadriceps tendon and the patellar tendon was measured (Fig 2). The possible malalignment of lower extremity was evaluated by cable method under fluoroscopy intraoperatively[6]. We observed the alignment of lower extremities within the normal limits. Then, proximal soft tissue realignment surgery previously described by Insall et al[7] and Efe et al[8], and MPFL reconstruction were conducted. Medial parapatellar incision was performed around the patella from the upper edge of the tendo vastus medialis in the quadriceps tendon to the tibial tubercle. During the examination of patella, we noticed that the central and medial facets of the patella were crushed (Fig 1b). The thickness of...
the patella was measured as 17 mm with the help of calipers intraoperatively.

The patella was placed into the groove. A fresh frozen allograft (Community Tissue Services, USA) of tibialis anterior tendon was prepared in “Y” shape (Fig 2). A tunnel was opened under fluoroscopy in the femur between the adductor tubercule and medial collateral ligament in accordance with inserting the medial collateral ligament. Two tunnels were opened to the patella for fixing it by the branches of the tendon allograft. The tendon allograft was fixed in the femoral tunnel with a bioabsorbable screw (Biorci screw, 10*25 mm, Smith & Nephew, USA).

The branches of the tendon were passed through the tunnels opened in the patella and fixed with a nonabsorbable polyethylene multifilament suture (no:2, Smith & Nephew, USA). MPFL reconstruction was performed with tibialis anterior tendon allograft. Then, medial retinaculum and tendon vastus medialis were pulled laterally and distally for at least 1-1.5 cm. Tendo vastus medialis repair was done via one 6.5 mm titanium anchor (Smith & Nephew, USA) to the patella and nonabsorbable polyethylene multifilament suture (no:2, Smith & Nephew, USA) (Fig 3). It was observed that the patella was in the groove, no maltracking was seen,
and there was no lateral or medial tilt (Fig 3). After surgery, rehabilitation involved an angle adjustable brace. After the surgery, knee ROM were free for rehabilitation except while walking. He was able to walk with a walker while the brace was locked at knees in extension. After the 6th week, the angle-adjustable brace was removed and he was able to walk with the walker.

Two months after the operation, the patient was referred to the polyclinic after falling on his right knee. The patient had swelling, redness and inability to lift a straight leg of the right knee. Radiological tests revealed patella fracture. The fracture line of the patella was observed to be at the tunnel level opened for the graft (Fig 4a). A tension band surgery was performed for the patella (Fig 4a, b). After the surgery, free ROM of knee was allowed. The patient was mobilized with a brace while the knee is in extension and with a walker. After six weeks, the angle-adjustable knee brace was removed.

After two-year follow-up, the patient was ambulating with a walker. Passive knee ROM was 0-110 degrees and the active knee ROM was 10-100 degrees. On the last follow-up, Knee Society Score was 52 and Womac Score was 52.3.

DISCUSSION

In the present case, medial retianculum, tendo vastus medialis and MPFL, those ensure that the patella remains in the trochlear groove, were separated from the patella, after bilateral TKA surgery. Based on laboratory and radiological findings, there was no malalignment of lower extremity, malposition of components and infection. Our patient had idiopathic PD for 12 years. PD is known for muscle weakness and imbalance[4,9]. Since medial parapatellar approach was used in TKA surgery of our patient, the force of medial vectors depended on the sutures only until the medial retinaculum and vastus medialis tendon healed.

According to discharge summary, the suture used in the TKA surgery for closing the medial structures was no:2 vicryl, and it is absorbed before complete wound healing. The patient was operated twice previously because of patellar dislocation. The technique used in previous patella reduction surgeries was only medial retinaculum repair done with no:2 vicryl. The cause of fail at these surgeries may be because the no:2 vicryl was resolved before the healing of medial retinaculum and tendo vastus medialis. However, in patella reduction surgeries, non-absorbable no:2 Ethibond, which is known to be biomechanically stronger than vicryl[10], was used. The cause of fail at the patella reduction surgeries may be related to the soft tissue problems as decreased soft tissue volume is not enough for tightening. Another possible cause of fail at medial retinaculum repair may be the short intervals (one month) between surgeries because at the early period of tissue repairs, the soft tissue weakens and its quality decreases[11]. We did not face any tissue quality decrease because we did patellar realignment surgery seven months after the last patella reduction surgery.

Based on the anamnesis and discharge summary, we decided to use MPFL reconstruction and proximal realignment surgery at the presurgical planning period as previously described[7,12], by using nonabsorbable polyethylene multifilament suture. Additionally, we used anchor for the fixation of vastus medialis tendon to patella. After the surgery, the anchor failed and dissociated from patella as seen on X-ray films (Fig 4a, b). This dissociated anchor may be related to the muscle imbalance at PD.

TKA is not commonly suggested for PD patients with Modified Hoehn and Yahr scale score over 3[9]. In our case, however, Modified Hoehn and Yahr scale score was 4 and the surgery for reconstruction was indicated because of the extensor mechanism failure. In this case report, we present two years follow-up of the treatment of a patient with bilateral patellar dislocation after bilateral TKA in the presence of muscle imbalance accompanied by PD. Patellar dislocation or refracure of patella did not occur. The patient was able to move with a walker. A clear improvement was observed in Knee Society Score (from 6 to 52) and Womac knee score (from 5.5 to 52.3). PD is a serious disease and if the patient has this diagnosis, TKA surgery decision must be taken both by the patient and by the neurologist. A previous case report from Croatia presented a periprosthetic knee recurrent dislocation at a PD patient nine months after surgery[4]. Erceg et al interpreted the dislocation of knee due to muscle weakness caused by PD and the authors treated the patient with a revision surgery[4]. We could not find any information about what sutures were used in primary and revision surgeries for closing the wound in their case report.

In our literature search, we did not encounter any report of a patient with both patella dislocated after TKA linked to muscle weakness after the neurodegenerative disease of PD and the surgical treatment results. We believe our report of the bilateral patella dislocation after TKA is a rare case presentation comparing to currently accessible literature. This case emphasizes the importance of soft tissue balance and the sturdy repair with nonabsorbable sutures in TKA surgery with PD.

CONCLUSION

Using nonabsorbable polyethylene multifilament sutures for repairing the medial patellar structures such as retinaculum/tendon during TKA surgeries on
patients with neurodegenerative diseases such as PD, may be more helpful during healing process.

ACKNOWLEDGMENT

Conflicts of interest: The authors declare no conflict of interest.

Author contributions in the manuscript: KA: treatment, writing; CZE: treatment, critical revision

REFERENCES

Case Report

Oliver Sacks syndrome treated with adaptation to hearing aid

Ebru Sahan1, Ismet Kırpınar2
1Department of Psychiatry, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey
2Department of Psychiatry, Bezmialem Foundation University Medical Faculty, Istanbul, Turkey

ABSTRACT

An eighty-year-old woman was diagnosed with bilateral severe sensorineural hearing loss in audiometric examination and recommended to use hearing aids. The patient could not adapt to the device and was reluctant to wear it. In the psychiatric examination, it was difficult to communicate with the patient due to hearing loss. No delusions were found in the thought content. When hallucinations were asked about, she noted resonance and humming in the early periods that later turned to helicopter, airplane sound, and as hearing loss progressed, she heard wedding music. The patient had full insight that the sound was coming from her head. The psychiatric treatment was useful for adjustment to hearing aid and maintaining acoustic stimulation. As hearing devices were used, the ambient sounds increased, and the musical hallucinations were slowed down and communication with her relatives increased.

KEY WORDS: audiometry, hearing aid, hearing loss, musical hallucination

INTRODUCTION

Auditory hallucinations can be seen either in elementary forms such as resonance and buzzing or in complex forms such as human voices or music. Musical hallucinations have been defined as Oliver Sacks syndrome; they are a form of cortical release phenomenon in hearing loss and in this context they are also described as auditory Charles Bonnet syndrome[1].

CASE REPORT

An eighty-year-old woman was brought to the psychiatry outpatient unit of the health board by her children for investigation about disability. On the wheelchair, she seemed a little bit surly. She was overweight and had been diagnosed with diabetes mellitus, essential hypertension and gonarthrosis during the last 25 years. She was well controlled with antidiabetic and antihypertensive drugs. For the past three years, she could not hear what others were saying in conversations properly and she had the television on a high volume all the time. She was brought to an otorhinolaryngologist three months ago and was diagnosed with bilateral severe sensorineural hearing loss according to the audiometry tests and it was suggested to use hearing aids. The patient could not adapt to the device and did not want to wear it. Her children noticed that she had recently become more uncomfortable and stubborn, talked less with her relatives, occasionally cried and had difficulty sleeping at night. There was no previous history of psychiatric disorders. She lost her husband five years ago. She lived with her children, their spouses and her grandchildren. Her appearance seemed compatible with her chronological age. It was difficult to communicate with the patient during the mental status examination due to hearing loss. When she could hear and understand the questions asked, she was responding a little bit reluctantly. She was oriented to place, person and time. No delusions were found in her thought content. When hallucinations were questioned, she confirmed that there were noises in
her ears. When she was asked about the voices, it was learned that in the early periods of the hearing loss, the voices were in the form of resonating and humming. Later, they converted to a helicopter, airplane noise and progressively to halay music which is composed of drum and clarion sounds played at the weddings in the region she lived in. She said that the sounds were heard from both ears, increasing at quieter times such as nighttime.

A detailed audiometric examination including Bekesy and Sisi scores was done. Bekesy audiometry is based on a comparison of thresholds for constant and intermittent tones. Clinical importance has been attached to the measurement of the threshold excursions. Short Increment Sensitivity Index test measures the ability of a subject to detect a 1 dB change in intensity at a level 20 dB above threshold. This test can be used at any frequency in either ear, regardless of the asymmetry of the hearing loss[2]. There was severe sensorineural hearing loss in both ears plus air conduction deficits were noted on the left (right ear speech reception threshold [SRT] 65 dB, discrimination 40% dB 90; left ear SRT 80 dB, discrimination 40% dB 100). Tympanograms were type A and acoustic reflexes were absent bilaterally. The music was less with hearing aids, but the device was very uncomfortable. The music noise could be suppressed by television or radio noise. Different melodies and folk songs were able to change her musical hallucination temporarily. Halay sound was not as uncomfortable as the device’s. The patient had good insight that the sound was coming from inside her head.

The cranial magnetic resonance imaging of the patient revealed mild cortical atrophy and widening of the sulci. Routine hemogram and biochemistry values were in the normal range. Hepatitis, AIDS, syphilis, and brucellosis were excluded by serological tests. The electroencephalogram was normal. In neuropsychological tests, simple attention can be considered immediate memory or very short-term memory. Complex attention defines functions based on sustaining attention; in the event of deterioration, there is deterioration in persistence (persistence), perseverations, distractibility, reduced resistance to interference, and difficulty in suppressing the immediate, but unfavorable, tendency to react. These functions, which are based on complex considerations, are called executive or executive functions[3]. Short-term memory, simple and complex attention were preserved in our patient. There was minimal age-compatible cognitive impairment. She had a depressed mood most of the day, nearly every day, diminished interest and pleasure in almost all activities, psychomotor retardation, fatigue and insomnia, yet she did not have suicidal thoughts or tendencies. Thus, she was diagnosed with major depressive disorder according to DSM-V. In order to exclude malingering, confirm the diagnosis of depression and to learn antidepressant treatment response, the decision of the board was postponed for six months with once a month outpatient follow-up visits.

Escitalopram 5 mg/day and trazodone 50 mg/day were prescribed for the treatment of depression and insomnia respectively. She was supported by her family to wear her hearing aids starting with one hour a day and to increase gradually. At the third-month outpatient visit, the trazodone was discontinued because the sleeping problem had disappeared. As hearing devices were used, the ambient sounds increased; thereby the sensory input suppressed myriads of nonessential information, including previously acquired memories. The musical hallucinations regressed and communication with her relatives increased. At the sixth-month follow-up visit, escitalopram was discontinued.

DISCUSSION

The diagnosis of dementia was ruled out because the patient’s cognitive changes were compatible with her age. Psychotic depression was ruled out as a differential diagnosis due to the fact that the musical hallucinations reflecting past experiences were not congruent with depressive mood (Halay voice did not include a sad, pessimistic, critical or accusative theme), though she had major depressive disorder with melancholic features. It was thought that auditory hallucinations were due to hearing loss because they started at similar times with the hearing loss and they increased as the hearing loss progressed.

Sensory inputs suppress much of the information that is not necessary, such as previous memories. The ‘Perceptual Release Theory’ of West[4] influenced by Hughlings-Jackson’s concept of disinhibition suggests that when a certain amount of external sensory stimulation does not go to the area of the cerebral cortex responsible for hearing (in the temporal region of the non-dominant hemisphere) due to deafness or isolation, the acoustic stimuli of recorded memories are transmitted and perceived again with familiar or new and strange forms[5].

Peripheral sensory organ damage by anatomical and physiologic pathways may cause central perceptions which can also be seen in Charles Bonnet and Phantom Limb syndromes. Charles Bonnet Syndrome, in which visual hallucinations occur due to loss of sight, is more similar by its origin to auditory hallucinations of patients with hearing loss. In addition, it has been reported that musical hallucinations are lateralized to the ear that cannot hear in a person with unilateral deafness[6].
The two-factor theorists who advocate that both peripheral and central dysfunction should be present, as evidence, suggest that such hallucinations occur more frequently in older adults with a high incidence of brain pathology[7].

The main risk factors for musical hallucinations are impaired hearing, tinnitus, advanced age and, perhaps, also female sex; however, the latter finding may be due to an overrepresentation of females in the literature[8].

There is no consensus for the treatment of disturbing musical hallucinations and decision is made usually according to underlying etiology. In a review, among pharmacological treatment methods investigated, antidepressants were found to be possibly more helpful than antiepileptics (which are still better than antipsychotics)[9]. The limited use of acetylcholinesterase inhibitors was promising[10]. Musical hallucinations experienced in the context of brain injuries and epilepsy tend to respond well to antiepileptics. Musical hallucinations occurring as part of a psychiatric disorder tend to respond well to psychopharmacological treatments targeting the underlying disorder.

As in our case, the hypoacusis etiological group appears to respond to hearing impairment treatment. More acoustic stimulation suppresses the hallucination (e.g. our patient increased the volume of the television or music)[9].

Not all adults provided with hearing aids use them, wear them regularly, or are satisfied with them[11].

We used antidepressant treatment in this patient for depressive disorder and easing adjustment to hearing aid use thereafter. In contrast to the report by Serrador-García et al, our patient had a complete response; musical hallucination did not occur when taking hearing aid out at night[12].

CONCLUSION
Adjustment to hearing loss and hearing aids become much more difficult with increasing age and psychiatrists can help these people by means of dealing with this adjustment disorder.

ACKNOWLEDGMENT
None to declare.

REFERENCES
3. Öktem Ö. Nöropsikolojik Testler ve Nöropsikolojik Değerlendirme. Türk Psikoloji Dergisi -33:(33)9 ;1994 44.
Case Report

Hyalinizing trabecular tumor of the thyroid gland:
A case report and review of the literature

Mohammed Alswayyed
Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia

Kuwait Medical Journal 2021; 53 (4): 469 - 472

ABSTRACT

A hyalinizing trabecular tumor (HTT) is a rare and controversial thyroid gland tumor with an extremely low malignant potential. Its cytological and histological features overlap with those of papillary thyroid carcinomas (PTCs) and medullary thyroid carcinomas (MTCs). Hence, diagnosis of this entity can be challenging, especially when diagnosis is based on fine needle aspiration cytology (FNAC). Herein, we report the case of a 52-year-old woman with HTT along with the cytological, histological and immunohistochemical studies performed. A follicular origin for the tumor was confirmed based on immunohistochemistry, which showed that the tumor cells were positive for thyroglobulin and TTF-1 and negative for calcitonin. The tumor cells were also negative for HBME-1, galactin-3 and CK19, but they were positive for CD56. The preferred diagnosis based on the histological and immunohistochemistry studies was an HTT. The patient is currently undergoing regular follow-up visits and has shown no evidence of residual tumor or metastasis. This case highlights the importance of considering HTT when interpreting FNAC results when the cytological features are those of PTC or MTC, but the ultrasonography findings are not worrisome.

KEY WORDS: carcinoma, cytology, immunohistochemistry, papillary, trabecular

INTRODUCTION

The thyroid gland is commonly studied by researchers, especially after the announcement in 2016 of the new entity called non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)[3]. A hyalinizing trabecular tumor (HTT) of the thyroid gland is a rare non-invasive follicular cell-derived thyroid neoplasm with papillary-like nuclear features (NIFTP)[3]. HTT is included in the WHO classification of tumors of the endocrine organs, which defines this lesion as a tumor with a trabecular pattern of growth and intra-trabecular hyalinization[3]. While a RAS mutation is the most common mutation associated with NIFTP[4], a rearranged during transfection / papillary thyroid carcinoma (RET/PTC) mutation is more likely to be identified in HTT[3]. The cytological identification of this tumor based on fine needle aspiration cytology (FNAC) is extremely difficult and even impossible in some cases, as these tumors share major cytopathological features with papillary thyroid carcinomas (PTCs) and medullary thyroid carcinomas (MTCs), such as nuclear grooves, pseudo-inclusions and abundant cytoplasm. Here, I describe my experience with a case of HTT and the process by which it was diagnosed.

CASE REPORT

The patient was a 52-year-old woman with a six-year history of hypothyroidism, for which she was receiving treatment. Two years previously, she presented with a large anterior neck mass that caused difficulty in breathing and swallowing. An ultrasonography scan revealed a well-circumscribed vascular nodule in the left lobe that measured 1.8 cm. Follow-up ultrasonography performed one-and-a-half years later showed that the nodule had increased in size to 2.5 cm. A nuclear medicine thyroid scan showed a hot nodule corresponding to the nodule identified on ultrasonography. FNAC was performed, and the obtained material was prepared for air-dried and wet fixation staining with Diff-Quik and Papanicolaou.
stain, respectively. The stained smears were moderately cellular with a lymphocytic background and nonspecific hemorrhaging. Epithelial cells formed cohesive clusters of variable sizes with prominent cytoplasm. The nuclei were round to oval-shaped with dispersed chromatin and several pseudo-inclusions and grooves (Figure 1). No papillary architectures or significant stromal material was observed. Based on these findings, a possible diagnosis of PTC was suggested. The patient then underwent total thyroidectomy. Gross examination of the excised thyroid revealed a well-defined, firm white nodule measuring 1*1*0.9 cm with an adjacent hemorrhagic area. Histological examination showed that the nodule was well-circumscribed, thinly encapsulated and had a smooth border on a background of chronic lymphocytic thyroiditis. The tumor showed a trabecular and nested pattern with a hyalinized stroma. The cells were large with abundant eosinophilic cytoplasm. The nuclei were round or elongated with frequent nuclear pseudo-inclusions and grooves (Figure 2). No calcification or psammoma bodies were seen. A follicular origin for the tumor was confirmed based on immunohistochemistry, which showed that the tumor cells were positive for thyroglobulin and TTF-1 and negative for calcitonin. The tumor cells were also negative for HBME-1, galactin-3 and CK19, but they were positive for CD56 (Figure 3). Congo red staining was negative. No gene mutation or rearrangement studies were performed. The preferred diagnosis based on the histological and immunohistochemistry studies was HTT. The patient is currently undergoing regular follow-up visits and has shown no evidence of residual tumor or metastasis.

DISCUSSION

HTT is a rare follicular cell-derived thyroid neoplasm with a trabecular growth pattern and hyalinization. It is a controversial entity that is markedly predominant in women. The lesion was first described in 1987 by Carney and colleagues, who called it a hyalinizing trabecular adenoma [2]. Four years later, one of a series of nine cases with a trabecular pattern and hyalinization showed a lymph node metastasis. Thus, the terminology used for the entity changed from “adenoma” to the now-preferred “tumor” [6]. There is controversy surrounding HTTs with respect to their potential malignant behavior and their possible relationship with PTC. The confusion exists due to its overlapping morphology with PTC.

Fig 1 A, B & C: Light microscopy photographs of fine needle aspiration cytology from the left lobe of the thyroid gland nodule shows groups of thyroid follicular cells arranged in three-dimensional clusters in a haemorrhagic background. Some cells display nuclear overlapping and grooving (arrowheads), and some show nuclear pseudo-inclusions (arrows). (A. Diff-Quik stain; ×200; B. Diff-Quik stain; ×400; and C. Papanicolaou stain; ×400).

Fig 2 A, B & C: (A) Light microscopy photographs of the left lobe thyroid gland lesion shows an encapsulated nodule on a background of lymphocytic thyroiditis (star). (B and C) Higher magnifications show neoplastic follicular cells arranged in a trabecular pattern with intervening stromal hyalinization (plus). Several nuclear pseudo-inclusions (arrows) and nuclear grooves (arrowheads) are noted. (Hematoxylin and eosin stain; A ×20; B ×200; and C ×400).
and the discovery of RET/PTC oncogene rearrangements in some cases of HTT, which is the most common genetic alteration in PTC. In a large series of HTT by Dell’Aquilla and his colleagues, they support the fact that HTT is a benign neoplasm[7]. Furthermore, most experts consider this tumor to be benign[5,8-9].

HTT’s cytological features are indefinite and could lead to erroneous diagnoses of either PTC or MTC. These features include elongated cells, ill-defined cell borders, an eosinophilic cytoplasm, nuclei with prominent grooves and frequent pseudo-inclusions, hyaline material in the background, and a lack of papillary architecture[9]. Some authors have suggested that the combination of a bloody background, radially oriented cohesive cells, an abundant cytoplasm, nuclei with very frequent pseudo-inclusions and grooves, and the presence of hyaline should raise the possibility of an HTT[4]. Nonetheless, a cytological diagnosis remains challenging[10-11].

With regard to immunohistochemistry, HTTs are positive for thyroglobulin and TTF-1. They are generally negative for cytokeratin-19, whereas they show a variable pattern of galectin-3 expression[9]. Their unusual pattern of cytoplasmic immunoreactivity with MIB-1 (Ki-67) (which is prepared at room temperature) is useful in distinguishing them from PTCs[12,13]. HBME-1 negativity and CD56 positivity can be useful for confirming the benign nature of this tumor[14], and calcitonin and Congo red staining negativity can be of great value for excluding MTC[15].

It is recommended that physicians use ultrasonography to confirm the tumor’s shape, margins, consistency and echogenicity. Additionally, HTT should be considered as a differential diagnosis when a tumor’s cytological features are suggestive of PTC but ultrasonography results are not worrisome[16].

In this case, the tumor’s nuclear features in the cytological material were the main reason for considering the diagnosis of PTC. However, a papillary configuration and psammoma bodies, which are usually seen in PTC, were not seen. In contrast to MTCs, granular nuclear chromatin and amyloid-like amorphous material were not observed in the cytological material of this tumor.

CONCLUSION
It is difficult to impossible to differentiate HTTs from papillary and medullary thyroid carcinomas based on FNAC alone. The cytological diagnosis of HTT should be considered for thyroid lesions with nuclear grooves and pseudo-inclusions that lack other diagnostic criteria for PTCs. Histological examination is superior to cytological studies in making a diagnosis of HTT.

ACKNOWLEDGMENT
Conflict of interest: The author declares no conflict of interest.
REFERENCES


Address correspondence to:
Erkan Somuncu, MD, Atakent, Halkalı Altınşehir İstanbul Cd. No:1, 34303, Küçükçekmece, Istanbul, Turkey. Tel: +90 5352383977; E-mail: dr.somuncu@gmail.com

Kuwait Medical Journal 2021; 53 (4): 473 - 476

Case Report

Emergency parathyroidectomy under combined superficial and intermediate cervical plexus block: A fatal case of hypercalcemic crisis due to parathyroid carcinoma

Erkan Somuncu¹, Fethi Akyol²
¹Department of General Surgery, University of Health Sciences, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
²Department of Anesthesiology, University of Erzincan, Mengücek Gazi Training and Research Hospital, Erzincan, Turkey

ABSTRACT

Hypercalcemic crisis is a rare but fatal condition. This condition may occur primarily due to primary hyperparathyroidism caused by parathyroid adenoma or rarely parathyroid carcinoma. In surgical treatment, parathyroidectomy and additional procedures are often performed with general, local and regional anesthesia. We present a case of a 71-year-old white woman with a hypercalcemic crisis associated with a possible preoperative parathyroid carcinoma. Serum calcium and parathyroid hormone levels were 18.8 mg/dl and >1900 pg/ml, respectively. Emergency left lower parathyroidectomy was performed only under locoregional anesthesia because of existing comorbidities. There was a rapid decrease in parathyroid hormone levels immediately after surgery. Histology revealed a 3 cm parathyroid carcinoma in our patient. Definitive surgery was planned and the patient was discharged. Excision in hypercalcemic crisis due to parathyroid adenoma, ipsilateral thyroid lobectomy and removal of abnormal lymph nodes in case of carcinoma is recommended. In our patient, emergency parathyroidectomy was preferred instead of definitive surgery in the first stage because of comorbidities. This case raises awareness of the life-threatening hypercalcemic crisis and emphasizes the importance and benefit of emergency parathyroidectomy and alternative anesthesia techniques in hypercalcemic crisis.

KEY WORDS: malignant hypercalcemia, minimal invasive parathyroidectomy, parathyroid carcinoma

INTRODUCTION

Hypercalcemic crisis caused by primary hyperparathyroidism is a rare but life-threatening condition. Symptoms of hypercalcemic crisis, also interpreted as malignant hypercalcemia, are often non-specific and may occur with multiple organ involvement. Hypercalcemic crisis of primary hyperparathyroidism should be considered in acute patients with deep dehydration, gastrointestinal symptoms, urinary symptoms, altered mental status or cardiac arrhythmias. Among these pathologies, parathyroid carcinoma is a rare malignancy with 0.5-4% of reported primary hyperparathyroidism cases[1,2]. Surgery is the most curative treatment in parathyroid carcinoma with a high rate of 98%[1-4]. The most appropriate surgical procedure is ipsilateral thyroid lobectomy and anblock parathyroidectomy, as well as removal of enlarged or abnormal lymph nodes[3].

In this study, we present a case of emergency parathyroidectomy in hypercalcemia crisis due to primary hyperparathyroidism under superficial and intermediate cervical plexus block.

CASE REPORT

A 71-year-old female was admitted to the Emergency Department with flutter, spasm, weakness and poor general condition. The patient who previously had chronic obstructive pulmonary disease, hypertension,
cardiac failure and hyperthyroidism was hospitalized by our Endocrine Department. Laboratory results showed urea: 62 mg/dl (17-43), creatinin: 1.60 mg/dl (0.66-1.09), albumin: 2.6 g/dl (3.5-5.2), calcium: 18.8 mg/dl (8.8-10.6), phosphor: 3.2 mg/dl (2.5-4.5), free T3: 5.4 pg/ml (2.3-4.2), free T4: 4.5 ng/dl (0.89-1.76), thyroid stimulating hormone: 0.130 µU/ml (0.55-4.78) and parathyroid hormone (PTH): >1900.0 pg/ml (11.1-79.5). Neck and thyroid ultrasound showed nodular lesions smaller than 2 cm in thyroid gland and a noduler lesion approximately 3 cm was located posteroinferior of left thyroid gland. This nodular lesion was described as a parathyroid adenoma by our radiology department. Our endocrine team thought it may be a malignancy, but we did not have the option for exploration under general anesthesia due to her other co-morbidities. Due to her co-morbid factors, she did not have another option. Her hypercalcemia was under control with medical management for a short time. Immediately after, we planned the minimal invasive parathyroidectomy under locoregional anesthesia. We marked the parathyroid location with the aid of ultrasound on the operating day (Fig. 1). She was evaluated ASA-3 for operating by Anesthesia Department. Initially our anesthesia team established vascular access and began isotonic infusion over 10 ml/kg/hour. IV midazolam was applied for premedication by anesthetist. Following positioning, anesthesia team placed ultrasound probe (10-15 Ghz) and viewed investing prevertebral fascia that is located between sternocleidomastoid and middle scalene muscles (Fig. 2). Local anesthesia was applied to skin and subcuteneous tissue. Following that, they injected 20 ml 0.5% bupivacaine to infiltrate the prevertebral fascia and injected 5 ml 0.5% bupivacain through pretracheal area with the purpose of blockage of contralateral cervical nerve fibers.

Approximately twenty minutes later, we started the surgery. We did nearly five cm incision from marked area with ultrasound. In addition, 0.025 mg/kg midazolam was administered during operating time, but we did not need another anesthetic drug. We could find the parathyroid gland (Fig. 3) from this incision (Fig. 4) and parathyroidectomy was performed in about thirty minutes. Following operation, she was taken into service. She did not need to stay in intensive care. Six hours later, laboratory studies showed that PTH was 800 pg/ml and the day after, PTH was 73 pg/ml.
She was discharged the day after operation and she recovered fully in approximately fourteen days. Meanwhile, the parathyroid gland’s definitive pathological result was described as parathyroid carcinoma by our Pathology Department and we planned further operation for carcinoma. However, her co-morbid factors should be taken into consideration.

**DISCUSSION**

Hypercalcemia crisis caused by primary hyperparathyroidism has been named as parathyroid storm. Hypercalcemia which develops into hypercalcemic crisis can be seen between 1% and 6%\(^4\)\(^-\)\(^6\). Nowadays, being able to easily detect hypercalcemia during routine blood analysis enables us to plan diagnosis and treatment without allowing the disease to enter into crisis. Malignancy is the most common cause of hypercalcemia in the case of decompensated hypercalcemic crisis\(^7\). The most common malignancies associated with hypercalcemia are squamous cell carcinoma of the lung, breast cancer, renal cell carcinoma, bladder cancer and multiple myeloma disease. The mechanism of hypercalcemia in malignancy is due to tumor production of parathyroid hormone-related polypeptides or other osteolytic factors. Bone resorption occurs due to primary disease and bone metastases\(^6\)\(^,\)\(^8\).

In patients with primary hyperparathyroidism with chronic hypercalcemia, hypercalcemic crisis may develop suddenly. Sudden increase of hypercalcemia can be life-threatening. Therefore, just as in our case, hypercalcemia due to primary hyperparathyroidism should be treated quickly, as an emergency parathyroidectomy should be performed without delaying. Although the mechanism is not yet fully understood, several factors have been blamed. The most important of these are infection, trauma, surgery and the use of calcium antagonists. A high mortality rate of 93.5% has been reported in patients who had not undergone parathyroidectomy in the hypercalcemic crisis, but this rate was reduced to 6.7% by an experienced endocrine surgeon\(^8\)\(^,\)\(^9\).

Vital steps are recommended in the hypercalcemic crisis. Firstly, medical treatment is necessary to decrease serum calcium and stabilize the patient, the etiology of hyperparathyroidism must then be determined by measuring parathyroid hormone level and finally, emergency parathyroidectomy must be planned quickly. In case of hypercalcemic crisis, saline diuresis, bisphosphonate, glucorticoid and/or calcitonin treatments can be tried to decrease the calcium values of patients and stabilize them for surgery. If it fails, it can be considered in calcium-free dialysis\(^10\)\(^-\)\(^12\).

Removing abnormal parathyroid gland is the basic surgical procedure in primary hyperparathyroidism. Until 1990, bilateral cervical exploration of four parathyroid glands was the gold standard procedure. However, because of the extended operating time and postoperative hypocalcemia rates, this procedure was abandoned by physicians. Nowadays, minimal invasive parathyroidectomy has become popular. Evolution of parathyroid gland imaging techniques can assure a well satisfactory parathyroid surgery\(^13\). In addition, the evolution of local and general anesthesia increases the success of operations. In recent years, minimal invasive parathyroidectomy can often be performed under local anesthesia successfully. The elderly population especially have many healthy problems such as cardiopulmonary diseases, renal or neural disorders. Many elderly patients who have primary hyperparathyroidism are treated surgically. In this way, the hospital stay and hospital costs are markedly reduced with minimal morbidity and mortality rates\(^14\).

**CONCLUSION**

We present a case of emergency and minimally invasive parathyroidectomy due to primary hyperparathyroidism in hypercalcemic crisis. We aimed to show that the primary hypercalcemic crisis can be resolved in a very short time in some co-morbid patients with this combination of local anesthesia technique and surgical procedure.

**ACKNOWLEDGMENT**

Conflict of interest: The authors declare that there is no conflict of interest.
REFERENCES


The experience of Oman with establishing a field hospital during COVID-19 pandemic

Zainab Al Lawati¹, Alaa Al Lawati²
¹Emergency Medicine Physician (MBBCh, OMSB EM, ABEM), Ministry of Health (MOH), Muscat, Oman
²Medical Officer (MBBS), Ministry of Health (MOH), Muscat, Oman

Kuwait Medical Journal 2021; 53 (4): 477 - 481

ABSTRACT

Over the past fourteen months, services in various countries across the globe have been hit hard by the COVID-19 pandemic. The outbreak of corona virus has been overwhelming on healthcare systems in particular; and this is likely to have a lasting impact on health ventures and delivery models over the coming few years.

On 31st December 2019, the World Health Organization reported the first case of COVID-19, and since then 179,553,288 cases have been reported across the sphere. In Oman, the total number of cases reported reached 250,572 as of 21st June 2021. This is against a hospital ward bed capacity of 6,034 beds across all government and private hospitals in the country. Due to the healthcare system becoming overwhelmed by the load of cases detected, a field hospital was established to act as a main hub of care for COVID-19 cases in the country.

The aim of this article is to highlight the process involved in establishing and operating the field hospital. The main aspects that will be covered are the objectives of establishing the hospital, operation, components, in addition to the management and provision of cadres in its departments. The objective is to enlighten healthcare providers and the public about this service and share the experience of establishing a field hospital during this period.

KEY WORDS: corona virus, flu pandemic, health services administration, health unit, mobile

INTRODUCTION

On the eve of the year 2020, the World Health Organisation (WHO) reported the first case of COVID-19 disease after cases of pneumonia of unknown aetiology were reported in Wuhan city, located at Hubei Province of China. In the following month, the causative agent of this newly emerging disease was identified and named as Corona-Sars-2 virus, and during the same month, the WHO declared the global situation as a public health emergency of international concern. Ten weeks following this declaration, COVID-19 disease was categorised as a global pandemic[1].

The global toll at that stage had reached 318,941 for detected cases and 10,191 for deceased ones[2]. Figure 1 summarises the main declarations made by the WHO and the country regarding COVID 19 pandemic from December 2019 up until March 2020.

Over the past twenty years, some members of the Corona family have caused coronavirus-associated diseases before, including Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome-related Coronavirus. However, Corona-SARS-2 virus is a newly identified member of this unwelcome family, and it is the first time for this strain of novel agents to be reported to cause ailments in the human race. Corona-SARS-2 virus causes a spectrum of symptoms, ranging from mild to moderate (80%), severe (15%) and critical (5%)[3]. The majority of patients infected appear to have an uneventful recovery (80%), without requiring further medical care. However, symptoms progress and worsen in around one out of every five people infected with the virus[1]. This group makes around 20% of all infections, and it is this group that has been overwhelming the healthcare systems across the globe[3].

In Oman, the virus was discerned for the first time on February 24th 2020, after the return of two females...
from abroad and testing positive for it[4]. Following that, His Majesty issued royal orders to stipulate the formation of the Supreme Committee to study scopes for a mechanism to handle developments resulting from COVID-19 disease. The biggest burden of the virus was on the healthcare system, as it created a significant load on the Ministry of Health as well as the tertiary hospitals, following the surge in the number of confirmed and admitted cases. The surplus of patients requiring medical care created a challenge on the hospitals in terms of providing additional care for patients with COVID-19 along with the usual care for other patients with long-term illnesses. This necessitated the need to establish a field hospital as a temporary shelter for that group of patients. The aim of this article is to discuss the process involved in establishing and operating the field hospital. The main aspects that will be highlighted are the objectives of establishing the hospital, its components, in addition to the management and provision of cadres in its departments. The objective is to educate physicians, health care workers and the public about the service, and likewise share the experience of establishing a field hospital during this period. Figures obtained in this report have been taken from WHO global dashboard, global surveillance bodies and national surveillance data reports.

DISCUSSION

Over the last few months, the number of cases diagnosed with COVID-19 has been rising locally, regionally and globally, with some countries being affected more than others. Sustaining healthcare organizations, consequently, has become a worldwide concern[9]. Up until 21st June 2021, the total number of confirmed cases in the world reached 179,553,288[2]. Of the total number of cases reported globally, 45.9% were noted to be from only three countries: United States of America, India and Brazil[2]. In Oman, the overall figure reached 250,572, out of those 220,171 recovered (87.9%) while 2,741 passed away (12.1%)[4]. This is against a hospital ward bed capacity of 6,034 beds across all government and private hospitals in the country[6].

Following the global and local surge in the number of COVID-19 cases, the supreme committee deemed it necessary to take additional measures in order to mitigate the impacts locally. A combination of proactive containment measures and suppression interventions were implemented. The former involved travel restrictions, case finding, contact tracing, isolation of confirmed cases and quarantine of exposed individuals. The latter comprised lock down measures, social distancing, closure of educational institutions and prohibition of large-scale public gatherings[4]. In addition, an electronic surveillance system was launched, named Tarassud Plus to track the cases in the country, and ensure isolation measures are adhered to[4]. The WHO described it as one of the most powerful technological solutions deployed in the Middle East to track movement and spread of COVID-19[7].

These public health measures were improbable months ago, but the government deemed it necessary to implement them at that stage to control the situation locally. Following attenuation of control measures, another surge appeared to surface with case numbers and, consequently, the death toll making another ascent. The increase in demand on the health care system led the supreme committee to re-evaluate the role of the country’s government hospitals as the main sites of care. Consequently, the committee released a decision on July 5, 2020 to establish a field hospital[9]. The Ministry of Health then made a ministerial decision (95/2020) to formulate a task force for supervising the establishment, preparation and operation of the field hospital for patients infected with COVID-19 disease[8].

During the COVID era, several countries opted to establish field hospitals, being either as seclusion sites for cases with mild to moderate severity, sites with capabilities of an Intensive Care Unit to care for severe cases, or as step-down units to provide care for recovering cases[9]. The government of Oman established a field hospital for the latter reason, with the main objective of accommodating patients infected with COVID-19 disease in one institute, following the shortage of beds in the local hospitals. This was to ultimately decrease the burden on other health care institutes in the country, and enable them to resume their usual daily services, along with provision of care to other patients with long-standing illnesses[10].

The Field Hospital established in Oman was designed to encompass two zones: Zone A and Zone B. The former has multiple departments, including medium dependency, high dependency and female zone, in addition to radiology, laboratory and pharmacy sections. The latter comprises general quarantine beds for both genders[11]. Figure 2 represents the distribution of beds in Zone A.

The total bed capacity in the field hospital is 312 beds. A plan was set to operate it over three phases, phase one encompassing 100 beds, phase two 200 beds, and phase three covering the full hospital capacity, i.e. 312 beds. The first phase of the hospital was inaugurated on 5th October 2020, under the auspices of The Minister of State and Governor of Muscat[11]. It started to operate on the same day of the opening ceremony. The hospital was not receiving patients directly, but only cases referred from other health care institutions and requiring intermediate level of care. The critical and
severe cases were sent directly to the referral hospitals in the region\textsuperscript{[12]}. An admission criterion was prepared and distributed to all primary, secondary and tertiary healthcare institutions.

Table 1 outlines the bed distribution in the field hospital\textsuperscript{[10-12]}. Among the sites that were proposed for establishing the hospital was Oman Convention and Exhibition Centre, Sultan Qaboos Football Stadium and Old Muscat Airport Building. The latter was ultimately selected for the project due to the site being located at the heart of the city, existing spacious building, availability of space for future expansion, ease of modifying the internal design to suit the facility and possibility of providing additional services to accommodate the new requirements\textsuperscript{[6,10]}. It was planned to utilize the existing building as a temporary hospital and a shelter centre, where the latter can be converted to a hospital if the need did arise. The assigned engineering company along with the supervising committee studied the design in depth in order to ensure on utilizing the space provided and allocating the beds and services in the most convenient location, and to ease movement and transfer of patients between different departments during their stay there. The hospital was run by a medical team seconded from the Ministry’s various institutes, including 30 doctors, 115 male and female nurses, 7 lab technicians, 7 pharmacist assistants, 4 radiologists and 2 physiotherapists, in addition to administrative personnel and ambulance drivers\textsuperscript{[13]}. Establishing and equipping the hospital with beds, medical equipment and logistic support was achieved in collaboration with multiple authorities, including the Ministry of Health, Civil Aviation Authority, Oman Airport, Petroleum Development Oman, Royal Court Affairs and Royal Oman Police, as a means of collaborating with the committee for the public’s best interest\textsuperscript{[13,14]}.

From the start of operating the field hospital and

Table 1: Bed distribution in the field hospital

<table>
<thead>
<tr>
<th>Zone</th>
<th>Sections</th>
<th>Number of beds</th>
<th>Total bed capacity</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (Hospital)</td>
<td>Medium dependency</td>
<td>261</td>
<td>312</td>
<td>6,100 m\textsuperscript{2}</td>
</tr>
<tr>
<td></td>
<td>High dependency</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female zone</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B (Shelter Centre)</td>
<td>General beds</td>
<td>314</td>
<td>384</td>
<td>10,000 m\textsuperscript{2}</td>
</tr>
<tr>
<td></td>
<td>Female zone</td>
<td>70</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig 1: The main declarations made by the WHO and the country regarding COVID-19 pandemic, from December 2019 up until March 2020. Courtesy Dr. Z Allawati, Muscat, Oman (January, 2021)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline?gclid=CjwKCAiAu8SABAhAxEiwAsodSZP5gy0toe4l9XF06EdUdl1XVy6laY4njZ-El36eYS-Tqb7lJN-OVhxoChvMQAvD_BwE#event-7
[Accessed 28.01.2021]
up until this day, the majority of patients admitted there underwent an uneventful course and were discharged from the hospital. Some cases did show a clinical deterioration and were transferred to other healthcare facilities to receive appropriate level of care, as there is no intensive care unit in the hospital[14].

Figure 3 highlights the main actions that were taken by the government to combat the spread of COVID-19 disease[13-15].

The experience Oman has witnessed with regards to responding to this pandemic has emphasized some of the strategies that should be accentuated in the sector of healthcare management, to ensure keeping the healthcare system robust, sustainable and innovative during onerous periods. These stratagems include having agile leaders, clear emergency management plans, creating makeshift hospitals during a short timeframe and subsidizing the healthcare sector[16].

CONCLUSION

This report provided a succinct summary of the experience Oman has encountered with regards to establishing a field hospital during the COVID-19 pandemic. A significant proportion of this information lies within news agency reports, thus such an article is vital to validate and document the information pertaining to this critical milestone during this era. This experience has highlighted the importance of re-evaluating the role of hospitals as main centers for care, and the lessons learnt should be reminisced after the calamity period. With the establishment of the field hospital and increased immunity among society from the vaccination programs, the load on the government is bound to decline with time. However, the battle against this virus will continue to exist and will require long-lasting harmony, both locally and internationally, to control the situation and return to normality.

ACKNOWLEDGMENT

Disclosure: The authors declare no conflicts of interest. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author statement: The authors contributed equally in the conception, drafting and approval of the final version of this manuscript. Both authors are accountable for all aspects of the work, and information has been checked for accuracy in the best possible and comprehensive manner.

The authors would like to thank Mr. Asaad Al Qasmi (MOH, DGSMC, Quality Department) for his assistance in validating local figures.

REFERENCES

Overview on outbreak investigations of 2019 novel Coronavirus disease

Asad Khan
Department of Anesthesia Medical Teaching Institution, College of Medical Technology, Bacha Khan Medical College, Mardan, Pakistan

Kuwait Medical Journal 2021; 53 (4): 482 - 484

ABSTRACT

The therapy of “post-COVID-19 syndrome” requires a multidisciplinary team, an individualized approach and long-term rehabilitation. Recovery and rehabilitation after COVID-19 is aimed specifically at overcoming the consequences of the disease by strengthening the respiratory, nervous and cardiovascular systems through treatment and rehabilitation procedures. The complex program includes pulmonary rehabilitation to increase lung capacity and overall metabolic effects. Complex rehabilitation is part of the whole treatment plan and includes many physical and rehabilitation activities, health care, healthy behavior, training and prevention of complications in patients after infection.

KEY WORDS: coronavirus infection, treatment plan

Dear Editor,

As like other coronavirus pneumonias such as Middle East Respiratory Disease (MERS) and Severe Acute Respiratory Syndrome (SARS), COVID-19 can also lead to acute Respiratory Distress Syndrome. This viral pneumonia was reported in early December 2019 and initially, it was linked to exposure at Huanan Seafood Market, Wuhan, Hubei province, China[1]. Data as of February 16, 2020 showed that the virus had caused 70,548 infections and 1,770 deaths in mainland China and 413 infections in Japan[2].

On 21st January 2020, a 50-year-old man was admitted in clinic for fever with other symptoms of cough, shortness of breath (SOB), chills and fatigue. On day nine of his illness, 22nd January 2020, the patient was confirmed by Beijing Centers for Disease Control through reverse real-time PCR assay to be positive for COVID-19[3].

On 21st January 2020, a 50-year-old man was admitted in clinic for fever with other symptoms of cough, shortness of breath (SOB), chills and fatigue. On day nine of his illness, 22nd January 2020, the patient was confirmed by Beijing Centers for Disease Control through reverse real-time PCR assay to be positive for COVID-19[3].

Since the onset of the COVID-19 outbreak, infection prevention control system has played a major role in preventive and mitigation measures. In the 24-hour survey of confirmed and suspected cases of COVID-19 reported by provinces, regions and cities in China on March 13, 2020, 11 of them were confirmed cases of COVID-19, seven deaths occurred and 33 of them were suspected[4]. This outbreak of COVID-19 was then continuously under investigation with new and confirmed cases increasing day by day. On March 15, 2020, the same outbreak within the same region and same population was investigated for 24 hours and this time, the confirmed cases of COVID-19 rose to 27 individuals, deaths reached 10, and 39 individuals were suspected cases[5].

The Director General of the World Health Organization described the situation of COVID-19 as a pandemic on 16th of March 2020. A study suggested that elderly people, particularly those older than 80 years, and people with comorbidities such as cardiac disease, respiratory disease and diabetes, are at greatest risk of serious disease and increased chance of mortality[6].

Another study conducted in China reported that pregnant women with COVID-19 associated pneumonia showed a similar pattern of clinical features.
to non-pregnant adult patients. Common symptoms at the onset of COVID-19 pneumonia in these women were fever and cough, whereas less common symptoms were myalgia, malaise, sore throat, diarrhea and SOB. Laboratory tests indicated that lymphopenia is also likely to occur[7]. COVID-19 is a respiratory illness that can spread from person to person and having common symptoms of fever, cough and SOB[8,9]. However, there is no evidence of person to person transmission from asymptomatic carriers with normal chest computed tomography[10]. The four genera of this viral disease are alpha, beta, gamma and delta corona virus[11]. The signs and symptoms and other pathological features of this COVID-19 is greatly similar to SARS and MERS coronavirus infections[3].

Studies in China on COVID-19 patients showed the following clinical features in them: fever in 98% of patients, cough in 76% of patients, fatigue in 44% of patients, and dyspnea and SOB. Other less common symptoms were sputum production, headache, haemoptysis and diarrhea. The blood samples of patients showed leucopenia and lymphopenia[1].

The most essential measures for prevention and control from COVID-19 was addressed by Washington State Department of Health on 13th March 2020, which were the following:

- Stay at home in a separate room, except to get medical care
- Isolate yourself from people and animals in your home
- Call your doctor just before visiting
- Wearing face mask
- Cover your mouth when sneezing or coughing
- Frequently cleaning hands
- Do not share any personal domestic items
- Clean high touch surfaces all day
- Monitor symptoms in yourself (most commonly fever, cough and SOB)
- Request your doctor to call the “state health department” for discussing your situation

The public were advised to discontinue home isolation in the following cases:

i. If you had a fever, three days after the fever ends and you see an improvement in your initial symptoms (e.g. cough, SOB);

ii. If you did not have a fever, three days after you see an improvement in your initial symptoms (e.g. cough, SOB)

In cases where fever persists with cough or SOB but the person has not been exposed to somebody with COVID-19 and have not tested positive for COVID-19, then you should stay at home away from others until 72 hours after the fever and other symptoms are relieved[9]. China multicenter clinical trials reveal that an old drug chloroquine, which is used for the treatment of malaria, had also demonstrated marked efficacy and a possible safety in treating pneumonia associated with COVID-19. Different vitro studies suggest that chloroquine can block infection in COVID19 at low-micromolar concentrations[2].

However, the Emergency Use Authorization (EUA) mechanism permits the US Food and Drug Administration to respond fast to novel threats by approving new instrumentations and drugs. Pfizer became the first company to succeed in its pursuit of approval for its COVID-19 vaccine on 13th November 2020, making it the first sample of EUA approval for vaccine[12]. In addition to the Pfizer vaccine, on 20th January 2021, the Corona-Vac vaccine was also approved by Public Health Institute of Chile, China for emergency use[13].

Since COVID-19 is caused by an emerging new type of enveloped RNA virus, treatment is yet to be developed and needs further studies. The case fatality ratio in children and elderly people was more because of underdeveloped and degenerated immune systems respectively. However, this case fatality ratio was demonstrated from lack of data availability and the case fatality ratio might be fluctuating. On laboratory findings, lymphopenia was also common.

ACKNOWLEDGMENT

As a primary author, I would like to appreciate all the medical staff including doctors, nurses and Allied Health sciences workers for their great efforts to combat the COVID-19.

REFERENCES


Handling missing data in a rheumatoid arthritis registry using random forest approach

Ahmad Alsaber¹, Adeeba Al-Herz², Jiazhu Pan¹, Ahmad T Al-Sultan³, Divya Mishra⁴, KRRD Group²
¹Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.
²Department of Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait.
³Department of Community Medicine and Behavioral Sciences, Kuwait University, Kuwait City, Kuwait.
⁴Department of Plant Pathology, Kansas State University, Kansas, MN, USA.


Missing data in clinical epidemiological research violate the intention-to-treat principle, reduce the power of statistical analysis, and can introduce bias if the cause of missing data is related to a patient’s response to treatment. Multiple imputation provides a solution to predict the values of missing data. The main objective of this study is to estimate and impute missing values in patient records. The data from the Kuwait Registry for Rheumatic Diseases was used to deal with missing values among patient records. A number of methods were implemented to deal with missing data; however, choosing the best imputation method was judged by the lowest root mean square error (RMSE). Among 1735 rheumatoid arthritis patients, we found missing values vary from 5% to 65.5% of the total observations. The results show that sequential random forest method can estimate these missing values with a high level of accuracy. The RMSE varied between 2.5 and 5.0. missForest had the lowest imputation error for both continuous and categorical variables under each missing data rate (10%, 20%, and 30%) and had the smallest prediction error difference when the models used the imputed laboratory values.

Endoscopic internal drainage by double pigtail stents in the management of laparoscopic sleeve gastrectomy leaks

Iqbal Siddique¹, Waleed Alazmi¹, Salman K Al-Sabah²
¹Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait; Thunayan Al-Ghanim Gastroenterology Center, Al-Amiri Hospital, Kuwait City, Kuwait.
²Department of Surgery, Faculty of Medicine, Kuwait University, Safat, Kuwait; Department of Surgery, Al-Amiri Hospital, Kuwait City, Kuwait. Electronic address: salman.alsabah@hsc.edu.kw.


BACKGROUND
Leaks and fistulas after laparoscopic sleeve gastrectomy (SG) are major adverse events of bariatric surgery. Endoscopic management of post-SG leaks has evolved from closure with covered self-expanding metallic stents to endoscopic internal drainage (EID).

OBJECTIVE
To report our experience with the management of post-SG leaks treated with EID, either as primary therapy or after failure of closure therapy with self-expanding metallic stents.

SETTING
Single-center observational study.
Physical activity and sedentary behaviors among active college students in Kuwait relative to gender status

Mohammed Alkatan1, Khaled Alsharji1, Abdullah Akbar1, Amal Alshareefi1, Sanabel Alkhalaf1, Kholoud Alabduljader1, Hazzaa M Al-Hazzaa2

1Department of Physical Education & Sports, College of Basic Education, Public Authority for Applied Education & Training, Kuwait.
2Lifestyle and Health Research Center, Health Sciences Research Center, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.


OBJECTIVES
To determine the prevalence of physical activity (PA), sedentary behaviors (SB) and sleep duration and the associations between those variables among Kuwaiti Physical Education (PE) College students.

METHODS
A total of 418 participants (220 females) were randomly selected from the Basic Education College in the Public Authority for Applied Education and Training in Kuwait. Body weight and height were measured, and body mass index (BMI) was calculated. A validated questionnaire was used to assess lifestyle behaviors.

RESULTS
Based on BMI classification, the prevalence of overweight or obesity among males (34.9%) was significantly higher than that of females (16.7%). However, the mean (SD) of body fat percentage using bioelectrical impedance analysis was 21.3 (9.0) for males and 32.3 (7.7) for females. The proportions of highly active (> 1,200 METs-min/week) males (85.9%) and females (64.3%) were significantly (p < 0.005) different. The participants exceeding 3 hours of screen viewing time/day and insufficient sleep duration (< 7 hours/night) were 76.8% and 65.1%, respectively, with no gender differences. Logistic regression, adjusted for confounders, showed that highly active PE students had a higher proportion of SB. However, neither sleep duration nor body fat percentage exhibited any significant difference relative to PA.

CONCLUSIONS
Despite having high PA, Kuwaiti PE College students had a high prevalence of SB and insufficient sleep. Gender differences were found in PA but not in screen time or sleep duration. Efforts toward reducing SB and insufficient sleep among Kuwaiti PE College students are needed to reduce unhealthy lifestyle behaviors and promote health and well-being.
Forthcoming Conferences and Meetings

Compiled and edited by

Vineetha Elizabeth Mammen

Kuwait Medical Journal 2021; 53 (4): 487 - 495

International Research Conference on COVID-19 and its Impact on Mental Health
Dec 01, 2021
India, Kerala
Email: info.researchconferences@gmail.com
Event website: http://researchconferences.in/Conference/1310/IRCCIMH/

International Conference on Oncology & Cancer Research
Dec 03, 2021
United Kingdom, Liverpool
Email: papers.scienceplus@gmail.com
Event website: http://scienceplus.us/Conference/14881/ICOCR/

International Conference on Medical Health Science, Pharmacology & Biotechnology
Dec 01, 2021
United States, New York
Email: papers.issrd@gmail.com
Event website: http://issrd.org/Conference/10491/ICMPB/

World Conference on Pharma Industry and Medical Devices
Dec 03, 2021
United Arab Emirates, Dubai
Email: info.iferp@gmail.com
Event website: http://iferp.org/Conference/4724/WCPIMD/

World Disability & Rehabilitation Conference
Dec 02, 2021
China, Beijing
Email: papers.asar@gmail.com
Event website: http://asar.org.in/Conference/18630/WDRC/

International Conference on Medical Ethics and Professionalism
Dec 04, 2021
South Korea, Busan
Email: info.sciencefora@gmail.com
Event website: http://sciencefora.org/Conference/9756/ICMEP/

International Conference on Healthcare and Clinical Gerontology
Dec 02, 2021
United Arab Emirates, Dubai
Email: info.sciencefora@gmail.com
Event website: http://sciencefora.org/Conference/9729/ICHCG/

125th International Conference on Advances in Health and Medical Science
Dec 04, 2021
United Kingdom, Glasgow
Email: info.saard.org@gmail.com
Event website: http://saard.org/Conference2021/12/UK/ICAHMS/

International Conference on Oncology & Cancer Research
Dec 05, 2021
United States, Boston
Email: papers.scienceplus@gmail.com
Event website: http://scienceplus.us/Conference/14905/ICOCR/

1219th International Conference on Recent Advances in Medical Science
Dec 03, 2021
Germany, Munich
Email: info@theiier.org
Event website: http://theiier.org/Conference2021/Germany/6/ICRAMS/

1170th International Conference on Science, Health and Medicine
Dec 05, 2021
Australia, Sydney
Email: info@iser.co
Event website: http://iser.co/Conference2021/Australia/8/ICSHM/

International Conference on Recent Advances in Medical, Medicine and Health Sciences
Dec 03, 2021
United States, Houston
Email: contact.wrfer@gmail.com
Event website: http://wrfer.org/Conference/15628/ICRAMMHS/
International Conference on Medical, Medicine and Health Sciences
Dec 05, 2021
Turkey, Istanbul
Email: contact.iierd@gmail.com
Event website: http://iierd.com/Conference/1158/ICCMH/

International Conference on Healthcare and Clinical Gerontology
Dec 06, 2021
Australia, Adelaide
Email: info.sciencefora@gmail.com
Event website: http://sciencefora.org/Conference/9781/ICHCG/

International Conference on Biological and Medical Sciences
Dec 06, 2021
Japan, Tokyo
Email: info.arsss@gmail.com
Event website: http://arsss.org/Conference/14121/ICBMS/

International Conference on Cell and Tissue Science
Dec 06, 2021
Russia, Yekaterinburg
Email: info@conferencefora.org
Event website: http://conferencefora.org/Conference/27926/ICCTS/

1188th International Conference on Recent Advances in Medical and Health Sciences
Dec 07, 2021
United Kingdom, Edinburgh
Email: info@academicsworld.org
Event website: http://www.academicsworld.org/Conference2021/UK/10/ICRAMHS/

1086th International Conference on Food Microbiology and Food Safety
Dec 07, 2021
Japan, Kobe
Email: info@theires.org
Event website: http://theires.org/Conference2021/Japan/12/ICFMFS/

International Conference on Recent Advances in Medical, Medicine and Health Sciences
Dec 08, 2021
Thailand, Phuket
Email: contact.wrfer@gmail.com
Event website: http://wrfer.org/Conference/15652/ICRAMMHS/

International Conference on Medical, Medicine and Health Sciences
Dec 09, 2021
United Kingdom, George Town
Email: contact.iierd@gmail.com
Event website: http://iierd.com/Conference/1169/ICCMH/

1190th International Conference on Recent Advances in Medical and Health Sciences
Dec 10, 2021
Bahrain, Manama
Email: info@academicsworld.org
Event website: http://www.academicsworld.org/Conference2021/Bahrain/2/ICPAF/

International Conference on Medical, Medicine and Health Sciences
Dec 10, 2021
Egypt, Cairo
Email: contact.iierd@gmail.com
Event website: http://iierd.com/Conference/1173/ICCMH/

1044th International Conference on Pharma and Food
Dec 10, 2021
Qatar, Doha
Email: info@academicsera.com
Event website: http://academicsera.com/Conference2021/Qatar/2/ICPAF/

1174th International Conference on Science, Health and Medicine
Dec 11, 2021
Spain, Barcelona
Email: info@iser.co
Event website: http://iser.co/Conference2021/Spain/5/ICSHM/

1089th International Conference on Food Microbiology and Food Safety
Dec 11, 2021
Iran, Tehran
Email: info@theires.org

1175th International Conference on Science, Health and Medicine
Dec 12, 2021
Egypt, Cairo
Email: info@iser.co
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Location/Region</th>
<th>Email</th>
<th>Event website</th>
</tr>
</thead>
<tbody>
<tr>
<td>1196th International Conference on Medical, Biological and Pharmaceutical Sciences</td>
<td>Dec 12, 2021</td>
<td>Morocco, Marrakesh</td>
<td><a href="mailto:info@iastem.org">info@iastem.org</a></td>
<td><a href="http://iastem.org/Conference2021/Morocco/3/ICMBPS/">http://iastem.org/Conference2021/Morocco/3/ICMBPS/</a></td>
</tr>
<tr>
<td>1213th International Conferences on Medical and Health Science</td>
<td>Dec 14, 2021</td>
<td>United Arab Emirates, Dubai</td>
<td><a href="mailto:info@theires.org">info@theires.org</a></td>
<td><a href="http://theires.org/Conference2021/UAE/10/ICMHS/">http://theires.org/Conference2021/UAE/10/ICMHS/</a></td>
</tr>
<tr>
<td>1193rd International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Dec 15, 2021</td>
<td>Saudi Arabia, Mecca</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://www.academicsworld.org/Conference2021/SaudiArabia/9/ICRAMHS/">http://www.academicsworld.org/Conference2021/SaudiArabia/9/ICRAMHS/</a></td>
</tr>
<tr>
<td>International Conference on Healthcare and Clinical Gerontology</td>
<td>Dec 16, 2021</td>
<td>Switzerland, Geneva</td>
<td><a href="mailto:info.sciencefora@gmail.com">info.sciencefora@gmail.com</a></td>
<td><a href="http://sciencefora.org/Conference/9898/ICHCG/">http://sciencefora.org/Conference/9898/ICHCG/</a></td>
</tr>
<tr>
<td>1092nd International Conference on Food Microbiology and Food Safety</td>
<td>Dec 16, 2021</td>
<td>United States, Boston</td>
<td><a href="mailto:info@theires.org">info@theires.org</a></td>
<td><a href="http://theires.org/Conference2021/USA/16/ICFMFS/">http://theires.org/Conference2021/USA/16/ICFMFS/</a></td>
</tr>
<tr>
<td>1012th International Conference on Medical &amp; Health Science</td>
<td>Dec 17, 2021</td>
<td>United States, Orlando</td>
<td><a href="mailto:info@researchfora.com">info@researchfora.com</a></td>
<td><a href="http://researchfora.com/Conference2021/USA/20/ICMHS/">http://researchfora.com/Conference2021/USA/20/ICMHS/</a></td>
</tr>
<tr>
<td>International Conference on Nutrition &amp; Health</td>
<td>Dec 18, 2021</td>
<td>United Arab Emirates, Dubai</td>
<td><a href="mailto:info.conferenceonline@gmail.com">info.conferenceonline@gmail.com</a></td>
<td><a href="http://www.conferenceonline.net/Conference/74/ICNH/">http://www.conferenceonline.net/Conference/74/ICNH/</a></td>
</tr>
<tr>
<td>International Conference on Recent Advances in Medical, Medicine and Health Sciences</td>
<td>Dec 19, 2021</td>
<td>Ireland, Dublin</td>
<td><a href="mailto:contact.wrfer@gmail.com">contact.wrfer@gmail.com</a></td>
<td><a href="http://wrfer.org/Conference/15727/ICRAMMHS/">http://wrfer.org/Conference/15727/ICRAMMHS/</a></td>
</tr>
<tr>
<td>1231st International Conference on Recent Advances in Medical Science</td>
<td>Dec 21, 2021</td>
<td>Italy, Venice</td>
<td><a href="mailto:info@theieri.org">info@theieri.org</a></td>
<td><a href="http://theieri.org/Conference2021/Italy/8/ICRAMS/">http://theieri.org/Conference2021/Italy/8/ICRAMS/</a></td>
</tr>
<tr>
<td>International Conference on Cell and Tissue Science</td>
<td>Dec 21, 2021</td>
<td>United States, Oklahoma City</td>
<td><a href="mailto:info@conferencefora.org">info@conferencefora.org</a></td>
<td><a href="http://conferencefora.org/Conference/28626/ICCTS/">http://conferencefora.org/Conference/28626/ICCTS/</a></td>
</tr>
<tr>
<td>1198th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Dec 22, 2021</td>
<td>United States, Chicago</td>
<td><a href="mailto:info.gsr@gmail.com">info.gsr@gmail.com</a></td>
<td><a href="http://gsrd.co/Conference2021/12/Thailand/2/ICMPH/">http://gsrd.co/Conference2021/12/Thailand/2/ICMPH/</a></td>
</tr>
<tr>
<td>597th International Conference on Medical, Pharmaceutical and Health Sciences</td>
<td>Dec 22, 2021</td>
<td>Thailand, Pattaya</td>
<td><a href="mailto:info.gsr@gmail.com">info.gsr@gmail.com</a></td>
<td><a href="http://gsrd.co/Conference2021/12/Thailand/2/ICMPH/">http://gsrd.co/Conference2021/12/Thailand/2/ICMPH/</a></td>
</tr>
<tr>
<td>1183rd International Conference on Science, Health and Medicine</td>
<td>Dec 23, 2021</td>
<td>United States, Miami</td>
<td><a href="mailto:info@iser.co">info@iser.co</a></td>
<td><a href="http://iser.co/Conference2021/USA/17/ICSHM/">http://iser.co/Conference2021/USA/17/ICSHM/</a></td>
</tr>
</tbody>
</table>
International Conference on **Biological and Medical Sciences**  
Dec 26, 2021  
*Italy*, Milan  
Email: info.arsss@gmail.com  
Event website: http://arsss.org/Conference/14264/ICBMS/  

International Conference on **Nutrition & Health**  
Dec 26, 2021  
*Thailand*, Bangkok  
Email: submit@conferenceonline.net  
Event website: http://www.conferenceonline.net/Conference/88/ICNH/  

1201<sup>st</sup> International Conference on Recent Advances in **Medical and Health Sciences**  
Dec 27, 2021  
*Canada*, Ottawa  
Email: info@academicsworld.org  

1207<sup>th</sup> International Conference on **Medical, Biological and Pharmaceutical Sciences**  
Dec 29, 2021  
*China*, Beijing  
Email: info@iastem.org  
Event website: http://iastem.org/Conference2021/China/10/ICMBPS/  

International Conference on **Medical and Health Sciences**  
Dec 30, 2021  
*Canada*, Montreal  
Email: papers.academicsconference@gmail.com  
Event website: http://academicsconference.com/Conference/14028/ICMHS/  

1200<sup>th</sup> International Conference on **Medical and Biosciences**  
Jan 01, 2022  
*United Arab Emirates*, Dubai  
Email: info@researchworld.org  
Event website: http://researchworld.org/Conference2022/UAE/1/ICMBS/  

1203<sup>rd</sup> International Conference on Recent Advances in **Medical and Health Sciences**  
Jan 02, 2022  
*Germany*, Berlin  
Email: info@academicsworld.org  
Event website: http://academicsworld.org/Conference2022/Germany/1/ICRAMHS/  

1201<sup>st</sup> International Conference on **Medical and Biosciences**  
Jan 03, 2022  
*Germany*, Munich  
Email: info@researchworld.org  
Event website: http://researchworld.org/Conference2022/Germany/1/ICMBS/  

1211<sup>th</sup> International Conference on **Medical, Biological and Pharmaceutical Sciences**  
Jan 05, 2022  
*Australia*, Sydney  
Email: info@iastem.org  

International Conference on **Medical Ethics and Professionalism**  
Jan 06, 2022  
*Australia*, Adelaide  
Email: info.sciencefora@gmail.com  
Event website: http://sciencefora.org/Conference/10625/ICMEP/  

1227<sup>th</sup> International Conferences on **Medical and Health Science**  
Jan 07, 2022  
*United Kingdom*, Edinburgh  
Email: info@theires.org  
Event website: http://theires.org/Conference2022/UK/1/ICMHS/  

International Conference on **Medical and Health Sciences**  
Jan 07, 2022  
*New Zealand*, Wellington  
Email: papers.academicsconference@gmail.com  
Event website: http://academicsconference.com/Conference/18570/ICMHS/  

1025<sup>th</sup> International Conference on **Medical & Health Science**  
Jan 08, 2022  
*Japan*, Osaka  
Email: info@researchfora.com  
Event website: http://researchfora.com/Conference2022/Japan/2/ICMHS/
<table>
<thead>
<tr>
<th>Conference</th>
<th>Date</th>
<th>Location</th>
<th>Email</th>
<th>Event Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Conference on Recent Advances in Medical, Medicine and Health Sciences</td>
<td>Jan 09, 2022</td>
<td>Singapore, Singapore</td>
<td><a href="mailto:contact.wrfer@gmail.com">contact.wrfer@gmail.com</a></td>
<td><a href="http://wrfer.org/Conference/18679/ICRAMMHS/">http://wrfer.org/Conference/18679/ICRAMMHS/</a></td>
</tr>
<tr>
<td>1107th International Conference on Food Microbiology and Food Safety</td>
<td>Jan 10, 2022</td>
<td>Bahrain, Manama</td>
<td><a href="mailto:info@theires.org">info@theires.org</a></td>
<td><a href="http://theires.org/Conference/2022/Bahrain/1/ICFMFS/">http://theires.org/Conference/2022/Bahrain/1/ICFMFS/</a></td>
</tr>
<tr>
<td>World Conference on Pharma Industry and Medical Devices</td>
<td>Jan 10, 2022</td>
<td>Egypt, Luxor</td>
<td>info@<a href="mailto:iferp@gmail.com">iferp@gmail.com</a></td>
<td><a href="http://iferp.org/Conference/4868/WCPIMD/">http://iferp.org/Conference/4868/WCPIMD/</a></td>
</tr>
<tr>
<td>1243rd International Conference on Recent Advances in Medical Science</td>
<td>Jan 11, 2022</td>
<td>Iran, Tehran</td>
<td><a href="mailto:info@theiier.org">info@theiier.org</a></td>
<td><a href="http://theiier.org/Conference/2022/Iran/1/ICRAMS/">http://theiier.org/Conference/2022/Iran/1/ICRAMS/</a></td>
</tr>
<tr>
<td>International Conference on Recent Advances in Medical, Medicine and Health Sciences</td>
<td>Jan 12, 2022</td>
<td>Qatar, Doha</td>
<td><a href="mailto:contact.wrfer@gmail.com">contact.wrfer@gmail.com</a></td>
<td><a href="http://wrfer.org/Conference/18799/ICRAMMHS/">http://wrfer.org/Conference/18799/ICRAMMHS/</a></td>
</tr>
<tr>
<td>1109th International Conference on Food Microbiology and Food Safety</td>
<td>Jan 13, 2022</td>
<td>Saudi Arabia, Dammam</td>
<td><a href="mailto:info@theires.org">info@theires.org</a></td>
<td><a href="http://theires.org/Conference/2022/SaudiArabia/1/ICFMFS/">http://theires.org/Conference/2022/SaudiArabia/1/ICFMFS/</a></td>
</tr>
<tr>
<td>International Conference on Cell and Tissue Science</td>
<td>Jan 13, 2022</td>
<td>China, Changsha</td>
<td><a href="mailto:info@conferencefora.org">info@conferencefora.org</a></td>
<td><a href="http://conferencefora.org/Conference/29187/ICCTS/">http://conferencefora.org/Conference/29187/ICCTS/</a></td>
</tr>
<tr>
<td>International Conference on Recent Advances in Medical, Medicine and Health Sciences</td>
<td>Jan 14, 2022</td>
<td>Saudi Arabia, Medina</td>
<td><a href="mailto:contact.wrfer@gmail.com">contact.wrfer@gmail.com</a></td>
<td><a href="http://wrfer.org/Conference/18879/ICRAMMHS/">http://wrfer.org/Conference/18879/ICRAMMHS/</a></td>
</tr>
<tr>
<td>1246th International Conference on Recent Advances in Medical Science</td>
<td>Jan 16, 2022</td>
<td>United States, Boston</td>
<td><a href="mailto:info@theiier.org">info@theiier.org</a></td>
<td><a href="http://theiier.org/Conference/2022/USA/1/ICRAMS/">http://theiier.org/Conference/2022/USA/1/ICRAMS/</a></td>
</tr>
<tr>
<td>1210th International Conference on Medical and Biosciences</td>
<td>Jan 17, 2022</td>
<td>United States, Las Vegas</td>
<td><a href="mailto:info@researchworld.org">info@researchworld.org</a></td>
<td><a href="http://researchworld.org/Conference2022/USA/1/ICMB5/">http://researchworld.org/Conference2022/USA/1/ICMB5/</a></td>
</tr>
<tr>
<td>1067th International Conference on Sports Nutrition and Supplements</td>
<td>Jan 17, 2022</td>
<td>Ukraine, Kiev</td>
<td><a href="mailto:info@academicsera.com">info@academicsera.com</a></td>
<td><a href="http://academicsera.com/Conference2022/Ukraine/1/ICSNS/">http://academicsera.com/Conference2022/Ukraine/1/ICSNS/</a></td>
</tr>
<tr>
<td>1220th International Conference on Medical, Biological and Pharmaceutical Sciences</td>
<td>Jan 18, 2022</td>
<td>Malaysia, Langkawi</td>
<td><a href="mailto:info@iastem.org">info@iastem.org</a></td>
<td><a href="http://iastem.org/Conference/2022/Malaysia/1/ICMB5/">http://iastem.org/Conference/2022/Malaysia/1/ICMB5/</a></td>
</tr>
<tr>
<td>1214th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Jan 19, 2022</td>
<td>Italy, Florence</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/Italy/1/ICRAMHS/">http://academicsworld.org/Conference2022/Italy/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>1212th International Conference on Medical and Biosciences</td>
<td>Jan 20, 2022</td>
<td>Italy, Rome</td>
<td><a href="mailto:info@researchworld.org">info@researchworld.org</a></td>
<td><a href="http://researchworld.org/Conference2022/Italy/1/ICMB5/">http://researchworld.org/Conference2022/Italy/1/ICMB5/</a></td>
</tr>
</tbody>
</table>
1214th International Conference on Medical and Biosciences  
Jan 23, 2022  
Spain, Barcelona  
Email: info@researchworld.org  
Event website: http://researchworld.org/Conference2022/Spain/1/ICMBS/

International Conference on Medical Health Science, Pharmacology & Bio Technology  
Jan 24, 2022  
Italy, Rome  
Email: papers.issrd@gmail.com  
Event website: http://issrd.org/Conference/10618/ICMPB/

International Conference on Medical Ethics and Professionalism  
Jan 26, 2022  
China, Macao  
Email: info.sciencefora@gmail.com  
Event website: http://sciencefora.org/Conference/1122/ICMEP/

International Conference on Oncolytic Virus Therapeutics  
Jan 27, 2022  
United States, New York  
Email: info.conferenceonline@gmail.com  
Event website: http://www.conferenceonline.net/Conference/232/ICOVT/

International Virtual Conference on COVID-19 and its Effect  
Jan 29, 2022  
Russia, Moscow  
Email: info.conferenceonline@gmail.com  
Event website: http://www.conferenceonline.net/Conference/230/IVCCE/

International Conference on Medical Health Science, Pharmacology & Bio Technology  
Jan 30, 2022  
Canada, Ottawa  
Email: papers.issrd@gmail.com  
Event website: http://issrd.org/Conference/10639/ICMPB/

World Disability & Rehabilitation Conference  
Jan 31, 2022  
India, West Bengal  
Email: papers.asar@gmail.com  
Event website: http://asar.org.in/Conference/26592/WDRC/

1258th International Conference on Recent Advances in Medical Science  
Feb 06, 2022  
Turkey, Istanbul  
Email: info@theiier.org  
Event website: http://theiier.org/Conference2022/Turkey/2/ICRAMS/

1259th International Conference on Recent Advances in Medical Science  
Feb 07, 2022  
United Kingdom, Edinburgh  
Email: info@theiier.org  
Event website: http://theiier.org/Conference2022/UK/3/ICRAMS/

1223rd International Conference on Medical and Biosciences  
Feb 09, 2022  
Japan, Kyoto  
Email: info@researchworld.org  
Event website: http://researchworld.org/Conference2022/Japan/2/ICMBS/

1247th International Conferences on Medical and Health Science  
Feb 10, 2022  
Qatar, Doha  
Email: info@theires.org  
Event website: http://theires.org/Conference2022/Qatar/1/ICMHS/

International Conference on Obesity and Chronic Diseases  
Feb 12, 2022  
Singapore, Singapore  
Email: info.iared.org@gmail.com  
Event website: http://iared.org/Conference/102/ICOCD/

1229th International Conference on Recent Advances in Medical and Health Sciences  
Feb 14, 2022  
Brazil, Sao Paulo  
Email: info@academicsworld.org  
Event website: http://academicsworld.org/Conference2022/Brazil/1/ICRAMHS/

International Conference on Medical Ethics and Professionalism  
Feb 15, 2022  
Switzerland, Bern  
Email: info.sciencefora@gmail.com  
Event website: http://sciencefora.org/Conference/11582/ICMEP/
<table>
<thead>
<tr>
<th>Conference Name</th>
<th>Date</th>
<th>Country</th>
<th>City</th>
<th>Email</th>
<th>Event website</th>
</tr>
</thead>
<tbody>
<tr>
<td>1233rd International Conference on Medical and Health Sciences</td>
<td>Feb 20, 2022</td>
<td>Turkey</td>
<td>Istanbul</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/Turkey/1/ICRAMHS/">http://academicsworld.org/Conference2022/Turkey/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>International Conference on Medical and Biological Engineering</td>
<td>Feb 20, 2022</td>
<td>United Kingdom</td>
<td>Edinburgh</td>
<td><a href="mailto:papers.techno@gmail.com">papers.techno@gmail.com</a></td>
<td><a href="http://technoarete.com/Conference/6959/ICMBE/">http://technoarete.com/Conference/6959/ICMBE/</a></td>
</tr>
<tr>
<td>1231st International Conference on Medical and Biosciences</td>
<td>Feb 21, 2022</td>
<td>Turkey</td>
<td>Antalya</td>
<td><a href="mailto:info@researchworld.org">info@researchworld.org</a></td>
<td><a href="http://researchworld.org/Conference2022/Turkey/1/ICMBS/">http://researchworld.org/Conference2022/Turkey/1/ICMBS/</a></td>
</tr>
<tr>
<td>1235th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Feb 23, 2022</td>
<td>India</td>
<td>Chennai</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/India/1/ICRAMHS/">http://academicsworld.org/Conference2022/India/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>1055th International Conference on Medical &amp; Health Science</td>
<td>Feb 24, 2022</td>
<td>Australia</td>
<td>Melbourne</td>
<td><a href="mailto:info@researchfora.com">info@researchfora.com</a></td>
<td><a href="http://researchfora.com/Conference2022/Australia/1/ICMHS/">http://researchfora.com/Conference2022/Australia/1/ICMHS/</a></td>
</tr>
<tr>
<td>1247th International Conference on Medical, Biological and Pharmaceutical Sciences</td>
<td>Feb 27, 2022</td>
<td>Saudi Arabia</td>
<td>Riyadh</td>
<td><a href="mailto:info@iastem.org">info@iastem.org</a></td>
<td><a href="http://iastem.org/Conference2022/SaudiArabia/2/ICMBPS/">http://iastem.org/Conference2022/SaudiArabia/2/ICMBPS/</a></td>
</tr>
<tr>
<td>1238th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Feb 27, 2022</td>
<td>Kuwait</td>
<td>Kuwait City</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/Kuwait/1/ICRAMHS/">http://academicsworld.org/Conference2022/Kuwait/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>1066th International Conference on Medical &amp; Health Science</td>
<td>Mar 13, 2022</td>
<td>Saudi Arabia</td>
<td>Riyadh</td>
<td><a href="mailto:info@researchfora.com">info@researchfora.com</a></td>
<td><a href="http://researchfora.com/Conference2022/SaudiArabia/1/ICMHS/">http://researchfora.com/Conference2022/SaudiArabia/1/ICMHS/</a></td>
</tr>
<tr>
<td>1247th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Mar 11, 2022</td>
<td>Spain</td>
<td>Barcelona</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/Spain/1/ICRAMHS/">http://academicsworld.org/Conference2022/Spain/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>International Conference on Cell and Tissue Science</td>
<td>Feb 28, 2022</td>
<td>New Zealand</td>
<td>Dunedin</td>
<td><a href="mailto:info@conferencefora.org">info@conferencefora.org</a></td>
<td><a href="http://conferencefora.org/Conference/30011/ICCTS/">http://conferencefora.org/Conference/30011/ICCTS/</a></td>
</tr>
<tr>
<td>1260th International Conferences on Medical and Health Science</td>
<td>Mar 01, 2022</td>
<td>Ireland</td>
<td>Dublin</td>
<td><a href="mailto:info@theires.org">info@theires.org</a></td>
<td><a href="http://theires.org/Conference2022/Ireland/1/ICMHS/">http://theires.org/Conference2022/Ireland/1/ICMHS/</a></td>
</tr>
<tr>
<td>World Disability &amp; Rehabilitation Conference</td>
<td>Mar 06, 2022</td>
<td>Vietnam</td>
<td>Hanoi</td>
<td><a href="mailto:papers.asar@gmail.com">papers.asar@gmail.com</a></td>
<td><a href="http://asar.org.in/Conference/25514/WDRC/">http://asar.org.in/Conference/25514/WDRC/</a></td>
</tr>
<tr>
<td>1102nd International Conference on Sports Nutrition and Supplements</td>
<td>Mar 10, 2022</td>
<td>Russia</td>
<td>Moscow</td>
<td><a href="mailto:info@academicsera.com">info@academicsera.com</a></td>
<td><a href="http://academicsera.com/Conference2022/Russia/1/ICSNS/">http://academicsera.com/Conference2022/Russia/1/ICSNS/</a></td>
</tr>
<tr>
<td>1247th International Conference on Recent Advances in Medical and Health Sciences</td>
<td>Mar 11, 2022</td>
<td>Spain</td>
<td>Barcelona</td>
<td><a href="mailto:info@academicsworld.org">info@academicsworld.org</a></td>
<td><a href="http://academicsworld.org/Conference2022/Spain/1/ICRAMHS/">http://academicsworld.org/Conference2022/Spain/1/ICRAMHS/</a></td>
</tr>
<tr>
<td>1066th International Conference on Medical &amp; Health Science</td>
<td>Mar 13, 2022</td>
<td>Saudi Arabia</td>
<td>Riyadh</td>
<td><a href="mailto:info@researchfora.com">info@researchfora.com</a></td>
<td><a href="http://researchfora.com/Conference2022/SaudiArabia/1/ICMHS/">http://researchfora.com/Conference2022/SaudiArabia/1/ICMHS/</a></td>
</tr>
</tbody>
</table>
World Conference on Pharma Industry and Medical Devices
Mar 13, 2022
*India*, New Delhi
Email: info.iferp@gmail.com

1106th International Conference on Pharma and Food
Mar 15, 2022
*Denmark*, Copenhagen
Email: info@academicsera.com
Event website: http://academicsera.com/Conference2022/Denmark/1/ICPAF/

World Disability & Rehabilitation Conference
Mar 16, 2022
*Japan*, Tokyo
Email: papers.asar@gmail.com
Event website: http://asar.org.in/Conference25902/WDRC/

1252nd International Conference on Recent Advances in Medical and Health Sciences
Mar 18, 2022
*Malaysia*, Langkawi
Email: info@academicsworld.org
Event website: http://academicsworld.org/Conference2022/Malaysia/2/ICRAMHS/

World Conference on Pharma Industry and Medical Devices
Mar 19, 2022
*Turkey*, Antalya
Email: info.iferp@gmail.com
Event website: http://iferp.org/Conference2022/5853/WCPIMD/

World Disability & Rehabilitation Conference
Mar 20, 2022
*New Zealand*, Auckland
Email: papers.asar@gmail.com
Event website: http://asar.org.in/Conference25957/WDRC/

International Conference on Medical and Health Sciences
Mar 26, 2022
*Greece*, Crete
Email: papers.academicsconference@gmail.com
Event website: http://academicsconference.com/Conference/19776/ICMHS/

International Conference on Medical and Biological Engineering
Mar 28, 2022
*Indonesia*, Bali
Email: papers.techno@gmail.com
Event website: http://technoarete.com/Conference/7004/ICMBE/

International Conference on Medical Health Science, Pharmacology & Bio Technology
Mar 31, 2022
*India*, Hyderabad
Email: papers.issrd@gmail.com

1292nd International Conference on Recent Advances in Medical Science
Apr 01, 2022
*Ireland*, Dublin
Email: info@theiier.org
Event website: http://theiier.org/Conference2022/Ireland/1/ICRAMS/

1263rd International Conference on Recent Advances in Medical and Health Sciences
Apr 05, 2022
*Sweden*, Stockholm
Email: info@academicsworld.org
Event website: http://academicsworld.org/Conference2022/Sweden/1/ICRAMHS/

1122nd International Conference on Pharma and Food
Apr 08, 2022
*Japan*, Nagoya
Email: info@academicsera.com
Event website: http://academicsera.com/Conference2022/Japan/2/ICPAF/

International Conference on Science, Health and Medicine
Mar 25, 2022
*Canada*, Vancouver
Email: info@iser.co
Event website: http://iser.co/Conference2022/Canada/15/ICSHM/

International Conference on Cell and Tissue Science
Apr 10, 2022
*Bolivia*, Sucre
Email: info@conferencefora.org
Event website: http://conferencefora.org/Conference/30809/ICCTS/
1124th International Conference on **Pharma and Food**
Apr 11, 2022  
*Egypt, Cairo*  
Email: info@academicsera.com  
Event website: http://academicsera.com/Conference2022/Egypt/2/ICPAF/

1277th International Conference on **Medical, Biological and Pharmaceutical Sciences**
Apr 14, 2022  
*Nigeria, Lagos*  
Email: info@iastem.org  
Event website: http://iastem.org/Conference2022/Nigeria/1/ICMBPS/

1127th International Conference on **Pharma and Food**
Apr 16, 2022  
*United States, New York*  
Email: info@academicsera.com  
Event website: http://academicsera.com/Conference2022/USA/6/ICPAF/

1302nd International Conference on **Recent Advances in Medical Science**
Apr 17, 2022  
*Ukraine, Kiev*  
Email: info@theiier.org  
Event website: http://theiier.org/Conference2022/Ukraine/1/ICRAMS/

1090th International Conference on **Medical & Health Science**
Apr 21, 2022  
*Czech Republic, Prague*  
Email: info@researchfora.com  
Event website: http://researchfora.com/Conference2022/CzechRepublic/1/ICMHS/

1278th International Conference on **Recent Advances in Medical and Health Sciences**
Apr 26, 2022  
*Japan, Tokyo*  
Email: info@academicsworld.org  
Event website: http://academicsworld.org/Conference2022/Japan/1/ICRAMHS/

1285th International Conference on **Medical, Biological and Pharmaceutical Sciences**
Apr 27, 2022  
*United Arab Emirates, Abu Dhabi*  
Email: info@iastem.org  
http://iastem.org/Conference2022/UAE/3/ICMBPS/

International Conference on **Oncolytic Virus Therapeutics**
Apr 30, 2022  
*China, Beijing*  
Email: info.conferenceonline@gmail.com  
Event website: http://www.conferenceonline.net/Conference/293/ICOVT/
WHO-Facts Sheet

1. Brucellosis
2. Children: new threats to health
3. Endometriosis
4. Hepatitis C
5. Meningitis

Compiled and edited by
Vineetha E Mammen

Kuwait Medical Journal 2021; 53 (4): 496 - 507

1. BRUCELLOSIS

KEY FACTS

• Brucellosis is found globally and is a reportable disease in most countries
• The disease causes flu-like symptoms, including fever, weakness, malaise and weight loss
• Person-to-person transmission is rare
• Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs

Brucellosis is a bacterial disease caused by various Brucella species, which mainly infect cattle, swine, goats, sheep and dogs. Humans generally acquire the disease through direct contact with infected animals, by eating or drinking contaminated animal products or by inhaling airborne agents. Most cases are caused by ingesting unpasteurized milk or cheese from infected goats or sheep.

Brucellosis is one of the most widespread zoonoses transmitted by animals and in endemic areas, human brucellosis has serious public health consequences. Expansion of animal industries and urbanization, and the lack of hygienic measures in animal husbandry and in food handling, partly account for brucellosis remaining a public health hazard.

Who is at risk?

Brucellosis is found globally and is a reportable disease in most countries. It affects people of all ages and both sexes. In the general population, most cases are caused by the consumption of raw milk or its derivatives such as fresh cheese. Most of these cases are from sheep and goat products.

The disease is also considered an occupational hazard for people who work in the livestock sector. People who work with animals and are in contact with blood, placenta, foetuses and uterine secretions have an increased risk of contracting the disease. This method of transmission primarily affects farmers, butchers, hunters, veterinarians and laboratory personnel.

Worldwide, Brucella melitensis is the most prevalent species causing human brucellosis, owing in part to difficulties in immunizing free-ranging goats and sheep.

Human-to-human transmission is very rare.

Prevention and control

Prevention of brucellosis is based on surveillance and the prevention of risk factors. The most effective prevention strategy is the elimination of infection in animals. Vaccination of cattle, goats and sheep is recommended in enzootic areas with high prevalence rates. Serological or other testing and culling can also be effective in areas with low prevalence. In countries where eradication in animals through vaccination or elimination of infected animals is not feasible, prevention of human infection is primarily based on raising awareness, food-safety measures, occupational hygiene and laboratory safety.

Pasteurization of milk for direct consumption and for creating derivatives such as cheese is an important step to preventing transmission from animals to humans. Education campaigns about avoiding unpasteurized milk products can be effective, as well as policies on its sale.

In agricultural work and meat-processing, protective barriers and correct handling and disposal of afterbirths, animal carcasses and internal organs is an important prevention strategy.
Treatment and care

Brucellosis typically causes flu-like symptoms, including fever, weakness, malaise and weight loss. However, the disease may present in many atypical forms. In many patients the symptoms are mild and, therefore, the diagnosis may not be considered. The incubation period of the disease can be highly variable, ranging from 1 week to 2 months, but usually 2–4 weeks.

Treatment options include doxycycline 100 mg twice a day for 45 days, plus streptomycin 1 g daily for 15 days. The main alternative therapy is doxycycline at 100 mg, twice a day for 45 days, plus rifampicin at 15mg/kg/day (600-900mg) for 45 days. Experience suggests that streptomycin may be substituted with gentamicin 5mg/kg/daily for 7–10 days, but no study directly comparing the two regimes is currently available. The optimal treatment for pregnant women, neonates and children under 8 is not yet determined; for children, options include trimethoprim/sulfamethoxazole (co-trimoxazole) combined with an aminoglycoside (streptomycin, gentamycin) or rifampicin.

WHO response

WHO provides technical advice to member states through provision of standards, information and guidance for the management of brucellosis in humans and animals. The Organization works to support the coordination and sharing of information between the public health and animal health sectors. In collaboration with the Food and Agricultural Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the Mediterranean Zoonoses Control Programme (MZCP), WHO supports countries in the prevention and management of the disease through the Global Early Warning System for Major Animal Diseases (GLEWS).

2. CHILDREN: NEW THREATS TO HEALTH

KEY FACTS

- Greenhouse gas emissions leading to climate change and ecological degradation existentially threaten the lives of all children.
- Children are vulnerable to adverse health effects from indoor and outdoor air pollution which causes an estimated 7 million deaths per year (2016).
- Over 250 million children are at risk of not meeting their development potential (2017).
- There are 124 million children and adolescents affected by obesity (2016).
- Children are frequently exposed to commercial marketing promoting addictive substances and unhealthy commodities.
- Road injury is the leading cause of death for children and young people; more than 1 billion children are exposed to violence every year.

Overview

Children’s survival, nutrition and education have improved dramatically over recent decades. But progress on indicators of child health and well-being is currently stalled across the Sustainable Development Goal (SDGs). No country is currently providing the conditions needed to support every child to grow up and have a healthy future.

Children (aged 0 to 18 years) today face a host of new threats linked to climate change, pollution, harmful commercial marketing, unhealthy lifestyles and diets, injury and violence, conflict, migration and inequality. Their very future is uncertain, and urgent action is needed to address these threats.

Some of the most important actions needed to protect children and ensure their future are: centering the child in every policy linked to the Sustainable Development Goal agenda;

- urgently reducing greenhouse gas emissions to fight the climate crisis;
- taking multisectoral action, coordinated at the highest levels of government;
- increasing funding and political prioritization of children; involving children and youth in the design of their future;
- enacting new national and international regulations to curb harmful commercial marketing, including an Optional Protocol to the UN Convention on the Rights of the Child; and
- improving reporting of data on children’s health and well-being.

Investing in children’s health, education and well-being brings substantial returns for societies. For every dollar invested in children, there is a benefit of around US$ 10 for many interventions and up to US$ 20 for some. Each dollar invested in health brings 20 times that in benefit in lower-middle income countries and nine times the benefit in low-income countries. Improving health and well-being in childhood benefits the individual throughout the life course and for generations to come.

Main health risks

Environmental threats

The lives of all children are existentially threatened by greenhouse gas emissions leading to climate change. Children’s lives today, and future existence, are at risk from rising sea levels, extreme weather events, water and food insecurity, heat stress, emerging infectious diseases and large-scale population
migration. These issues are already affecting hundreds of millions of children today.

Urgent action is needed to reduce carbon emissions in order to keep warming below 1.5 °C and implement the provisions of the 2015 Paris Agreement on climate change.

Indoor and ambient (outdoor) air pollution are both responsible for an estimated 7 million deaths (2016). Air pollution is associated with poor childhood respiratory health; it impairs the lungs and the brain and increases the risk of cardiovascular disease, obesity, type 2 diabetes and metabolic syndrome across the child’s lifespan.

Climate-related health risks are compounded amongst the 40% of the world’s children who live in informal settlements where substandard housing, overcrowding, hazardous locations, unhealthy living conditions, poverty and poor access to basic services can harm their health and well-being.

Obesity and non-communicable diseases

The rapid rise in childhood obesity is one of the most serious public health challenges of the 21st century, with the number of children and adolescents affected by obesity increasing more than ten times from 11 million in 1975 to 124 million in 2016.

Children are frequently exposed to harmful commercial marketing, typically seeing tens of thousands of advertisements a year for addictive substances and unhealthy commodities including fast food and sugar-sweetened beverages which contribute to obesity and chronic diseases, as well as online gambling services, which can harm their relationships, school achievement, and mental health.

The marketing and inappropriate use of breastmilk substitutes (formula milk)— a US$ 70 billion industry — is associated with lowered intelligence, obesity, increased risk of diabetes and other non-communicable diseases, accounting for an estimated loss to society of US$ 302 billion.

• Evidence suggests that children in some countries see as many as 30,000 advertisements on television alone in a single year, many for harmful products.
• A review of 23 studies in Latin America reported that advertising exposure was associated with a preference for and purchase of unhealthy foods by families and children who are overweight and obese.
• In a sample of five- and six-year-olds in Brazil, China, India, Nigeria and Pakistan, 68% could identify at least one cigarette brand logo; 50% could do so in Russia and 86% in China.
• In a study of 11- to 14-year-olds from Los Angeles, United States, African-American youth were exposed to an average of four to one alcohol advertisements per day.
• In Iran, food advertising during children’s programs is dominated by food items that are potentially harmful to oral health, as are almost two thirds of food adverts during children’s television in the United Kingdom.

The commercial threats to children’s health are dangerously underappreciated. Children’s high online exposure can also harm them when companies buy and sell their profiles for the purposes of commercial targeting. Children are also exposed to via bullying, exploitation, and contact with criminals and sexual predators.

Injuries, violence and conflict

Road injury is the leading cause of death for children and young people aged five to 29 years. And more than 1 billion children — half of all children — are exposed to violence every year.

In 2018, 1 billion people had moved or were on the move either as internally displaced persons, international migrants or refugees, including many children, as a result of conflict, violence or inequity and lack of opportunities.

WHO response

In 2010, the World Health Assembly, passed Resolution WHA63.14 Marketing of food and non-alcoholic beverages to children. In so doing, the Assembly endorsed a set of 12 recommendations which call for global action on marketing to children of food and drinks high in saturated fats, trans fatty acids, free sugars or salt.

In 2017, the WHO Western Pacific Region passed Resolution WPR/RC68.R3 Protecting children from the harmful impact of food marketing. It calls for accelerated, multisectoral and multi-stakeholder action; sharing of best practices; provision of technical support and advocacy; and more collaboration among countries on measuring and mitigating harmful impacts of food marketing.

In 2020, a WHO-UNICEF-Lancet Commission published the report A future for the world’s children?, which is based on the expertise of more than 40 child health specialists from around the world. The report sets out new threats to child health and well-being and provides recommendations to ensure children’s health today and in the future.

WHO and UNICEF are providing technical support to countries as well as communication and advocacy on the report’s findings and messages globally. WHO will, inter alia:

• Work with Member States to foster a new legally binding and regularly monitored Optional Protocol to the Convention on the Rights of the Child to curb...
harmful commercial marketing of fast foods, sugar-sweetened beverages, inappropriate use of breastmilk substitutes, alcohol and tobacco, and collate best practices;
• Develop a package of child health interventions involving other sectors as needed;
• Adopt a systematic process to generate and capture evidence for policy and programming;
• Provide integrated technical support to country child health programmes; and
• Develop a scorecard with partners for monitoring the implementation of the recommendations of the report.

3. ENDOMETRIOSIS

KEY FACTS
• Endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility (1).
• Endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally (2).
• It is a chronic disease associated with severe, life-impacting pain during periods, sexual intercourse, bowel movements and/or urination, chronic pelvic pain, abdominal bloating, nausea, fatigue, and sometimes depression, anxiety, and infertility.
• The variable and broad symptoms of endometriosis mean that healthcare workers do not easily diagnose it and many individuals suffering from it have limited awareness of the condition. This can cause a lengthy delay between onset of symptoms and diagnosis (3).
• At present, there is no known cure for endometriosis, and treatment is usually aimed at controlling symptoms (4).
• Access to early diagnosis and effective treatment of endometriosis is important, but is limited in many settings, including in low- and middle-income countries.
• There is a need for more research and awareness raising around the world to ensure effective prevention, early diagnosis, and improved management of the disease (2,5).

Introduction and definition
Endometriosis is a disease characterized by the presence of tissue resembling endometrium (the lining of the uterus) outside the uterus (1). It causes a chronic inflammatory reaction that may result in the formation of scar tissue (adhesions, fibrosis) within the pelvis and other parts of the body. Several lesion types have been described (1,6):
• superficial endometriosis found mainly on the pelvic peritoneum
• cystic ovarian endometriosis (endometrioma) found in the ovaries
• deep endometriosis found in the recto-vaginal septum, bladder, and bowel
• in rare cases, endometriosis has also been found outside the pelvis

Symptoms associated with endometriosis vary, and include a combination of:
• painful periods
• chronic pelvic pain
• pain during and/or after sexual intercourse
• painful bowel movements
• painful urination
• fatigue
• depression or anxiety
• abdominal bloating and nausea

In addition to the above, endometriosis can cause infertility. Infertility occurs due to the probable effects of endometriosis on the pelvic cavity, ovaries, fallopian tubes or uterus. There is little correlation between the extent of endometrial lesions and severity or duration of symptoms: some individuals with visibly large lesions have mild symptoms, and others with few lesions have severe symptoms. Symptoms often improve after menopause, but in some cases painful symptoms can persist. Chronic pain may be due to pain centres in the brain becoming hyper-responsive over time (central sensitisation), which can occur at any point throughout the life course of endometriosis, including treated, insufficiently treated, and untreated endometriosis, and may persist even when endometriosis lesions are no longer visible. In some cases, endometriosis can be asymptomatic.

What is the cause of endometriosis?
Endometriosis is a complex disease that affects some women globally, from the onset of their first period (menarche) through menopause regardless of ethnic origin or social status. The exact origins of endometriosis are thought to be multifactorial, meaning that many different factors contribute to its development. Several hypotheses have been proposed to explain origins of endometriosis. At present endometriosis is thought to arise due to:
• Retrograde menstruation, which is when menstrual blood containing endometrial cells flows back through the fallopian tubes and into the pelvic cavity at the time that blood is flowing out of the body through the cervix and vagina during periods. Retrograde menstruation can result in endometrial-like cells being deposited outside the uterus where they can implant and grow.
• Cellular metaplasia, which is when cells change from one form to another. Cells outside the uterus change into endometrial-like cells and start to
Early suspicion of endometriosis is a key factor for or populations that are most likely to have the disease. Validated to accurately identify or predict individuals, tests have been proposed and tested, none are currently available. Although several screening tools and chronic pelvic pain provides the basis for suspecting endometriosis. Several other factors are thought to promote the development, growth, and maintenance of endometriosis lesions. These include altered or impaired immunity, localized complex hormonal influences, genetics and potentially, environmental contaminants.

Health, social and economic benefits of addressing endometriosis

Endometriosis has significant social, public health and economic implications. It can decrease quality of life due to severe pain, fatigue, depression, anxiety, and infertility. Some individuals with endometriosis experience debilitating endometriosis-associated pain that prevents them from going to work or school. In these situations, addressing endometriosis can reduce absence from school or increase an individual’s ability to contribute to the labour force. Painful sex due to endometriosis can lead to interruption or avoidance of intercourse and affect the sexual health of affected individuals and/or their partners. Addressing endometriosis will empower those affected by it, by supporting their human right to the highest standard of sexual and reproductive health, quality of life, and overall well-being.

Prevention

At present, there is no known way to prevent endometriosis. Enhanced awareness, followed by early diagnosis and management may slow or halt the natural progression of the disease and reduce the long-term burden of its symptoms, including possibly the risk of central nervous system pain sensitisation, but currently there is no cure.

Diagnosis

A careful history of menstrual symptoms and chronic pelvic pain provides the basis for suspecting endometriosis. Although several screening tools and tests have been proposed and tested, none are currently validated to accurately identify or predict individuals or populations that are most likely to have the disease. Early suspicion of endometriosis is a key factor for early diagnosis, as endometriosis can often present symptoms that mimic other conditions and contribute to a diagnostic delay. In addition to medical history, referral from the primary health care level to secondary centers where additional investigations are available may be needed. For instance, ovarian endometrioma, adhesions and deep nodular forms of disease often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming diagnosis, particularly for the most common superficial lesions. The need for histologic/laparoscopic confirmation should not prevent the commencement of empirical medical treatment.

Treatment

Treatment can be with medications and/or surgery depending on symptoms, lesions, desired outcome, and patient choice. Contraceptive steroids, non-steroidal anti-inflammatory medications, and analgesics (painkillers) are common therapies. All must be carefully prescribed and monitored to avoid potentially problematic side effects. Medical treatments for endometriosis focus on either lowering estrogen or increasing progesterone in order to alter hormonal environments that promote endometriosis. These medical therapies include the combined oral contraceptive pill, progestins, and GnRH-analogues. However, none of these treatments eradicates the disease, they are associated with side effects, and endometriosis-related symptoms can sometimes - but not always - reappear after therapy discontinuation. The choice of treatment depends on effectiveness in the individual, adverse side effects, long-term safety, costs, and availability. Most current hormonal management is not suitable for persons suffering from endometriosis who wish to get pregnant, since they affect ovulation.

Surgery can remove endometriosis lesions, adhesions, and scar tissue. However, success in reducing pain symptoms and increasing pregnancy rates are often dependent on the extent of disease. In addition, lesions may recur even after successful eradication, and pelvic floor muscle abnormalities can contribute to chronic pelvic pain. Secondary changes of the pelvis, including the pelvic floor, and central sensitisation may benefit from physiotherapy and complementary treatments in some patients. Treatment options for infertility due to endometriosis include laparoscopic surgical removal of endometriosis, ovarian stimulation with intrauterine insemination (IUI), and in vitro fertilization (IVF), but success rates vary. Other comorbidities may occur alongside
Addressing current challenges and priorities

In many countries, the general public and most front-line healthcare providers are not aware that distressing and life-altering pelvic pain is not normal, leading to a normalisation and stigmatisation of symptoms and significant diagnostic delay (2,3). Patients who could benefit from medical symptomatic management are not always provided with treatments due to limited awareness of endometriosis among primary healthcare providers. Due to diagnostic delays, prompt access to available treatment methods, including non-steroidal analgesics (painkillers), oral contraceptives and progestin-based contraceptives is often not achieved. Due to limited capacity of health systems in many countries, access to specialised surgery for those who need it is sub-optimal. In addition, and especially in low and middle-income countries, there is a lack of multi-disciplinary teams with the wide range of skills and equipment needed for the early diagnosis and effective treatment of endometriosis. Although primary health care professionals should play a role in screening and basic management of endometriosis, tools to screen and accurately predict patients and populations who are most likely to have the disease are lacking. In addition, many knowledge gaps exist, and there is need for non-invasive diagnostic methods as well as medical treatments that do not prevent pregnancy.

Subsequently, some of the current priorities related to endometriosis include:

• Ensuring that primary health care plays a role in screening, identifying and providing basic pain management of endometriosis, in situations where gynaecologists or advanced multidisciplinary specialists are unavailable.
• Advocating for health policies that ensure access to at least a minimum level of treatment and support for patients with endometriosis.
• Setting up referral systems and care pathways consisting of well-linked primary healthcare centres and secondary and tertiary centres with advanced imaging, pharmacologic, surgical, fertility and multi-disciplinary interventions.
• Strengthening capacity of health systems to achieve early diagnosis and management of endometriosis by enhancing availability of equipment (e.g. ultrasound or magnetic resonance imaging) and pharmaceuticals (e.g. non-steroidal analgesics, combined oral contraceptives and progestin-based contraceptives).
• Increasing research on the pathogenesis, pathophysiology, natural progression, genetic and environmental risk factors, prognosis, disease classification, non-invasive diagnostic biomarkers, personalized treatments and other treatment paradigms, role of surgery, novel targeted therapeutics, curative therapies, and preventive interventions in endometriosis (2,5).
• Accelerating collaborative global action to improve access to reproductive health care for women globally, including in low- and middle-income countries.

WHO response

The World Health Organization (WHO) recognizes the importance of endometriosis and its impact on people’s sexual and reproductive health, quality of life, and overall well-being. WHO aims to stimulate and support the adoption of effective policies and interventions to address endometriosis globally, especially in low and middle-income countries. WHO is partnering with multiple stakeholders, including academic institutions, non-state actors and other organizations that are actively involved in research to identify effective models of endometriosis prevention, diagnosis, treatment, and care. WHO recognises the importance of advocating for increased awareness, policies and services for endometriosis, and collaborates with civil society and endometriosis patient support groups in this regard. WHO is also collaborating with relevant stakeholders to facilitate and support the collection and analysis of country- and region-specific endometriosis prevalence data for decision making.
REFERENCES


4. HEPATITIS C

KEY FACTS

- Hepatitis C is an inflammation of the liver caused by the hepatitis C virus.
- The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including liver cirrhosis and cancer.
- The hepatitis C virus is a bloodborne virus and most infection occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusions, injection drug use and sexual practices that lead to exposure to blood.
- Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.
- WHO estimated that in 2019, approximately 290 000 people died from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).
- Antiviral medicines can cure more than 95% of persons with hepatitis C infection, but access to diagnosis and treatment is low.
- There is currently no effective vaccine against hepatitis C.

Overview

Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infections are usually asymptomatic and most do not lead to a life-threatening disease. Around 30% (15–45%) of infected persons spontaneously clear the virus within 6 months of infection without any treatment.

The remaining 70% (55–85%) of persons will develop chronic HCV infection. Of those with chronic HCV infection, the risk of cirrhosis ranges from 15% to 30% within 20 years.

Geographical distribution

HCV occurs in all WHO regions. The highest burden of disease is in the Eastern Mediterranean Region and European Region, with 12 million people chronically infected in each region. In the South-East Asia Region and the Western Pacific Region, an estimated 10 million people in each region are chronically infected. Nine million people are chronically infected in the African Region and 5 million the Region of the Americas.

Transmission

The hepatitis C virus is a bloodborne virus. It is most commonly transmitted through:

- the reuse or inadequate sterilization of medical equipment, especially syringes and needles in healthcare settings;
- the transfusion of unscreened blood and blood products; and
- injecting drug use through the sharing of injection equipment.

HCV can be passed from an infected mother to her baby and via sexual practices that lead to exposure to blood (for example, people with multiple sexual partners and among men who have sex with men); however, these modes of transmission are less common.

Hepatitis C is not spread through breast milk, food, water or casual contact such as hugging, kissing and sharing food or drinks with an infected person.

Symptoms

The incubation period for hepatitis C ranges from 2 weeks to 6 months. Following initial infection, approximately 80% of people do not exhibit any
symptoms. Those who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, pale faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes).

Testing and diagnosis

Because new HCV infections are usually asymptomatic, few people are diagnosed when the infection is recent. In those people who go on to develop chronic HCV infection, the infection is often undiagnosed because it remains asymptomatic until decades after infection when symptoms develop secondary to serious liver damage.

HCV infection is diagnosed in 2 steps:
1. Testing for anti-HCV antibodies with a serological test identifies people who have been infected with the virus.
2. If the test is positive for anti-HCV antibodies, a nucleic acid test for HCV ribonucleic acid (RNA) is needed to confirm chronic infection because about 30% of people infected with HCV spontaneously clear the infection by a strong immune response without the need for treatment. Although no longer infected, they will still test positive for anti-HCV antibodies.

After a person has been diagnosed with chronic HCV infection, an assessment should be conducted to determine the degree of liver damage (fibrosis and cirrhosis). This can be done by liver biopsy or through a variety of non-invasive tests. The degree of liver damage is used to guide treatment decisions and management of the disease.

Early diagnosis can prevent health problems that may result from infection and prevent transmission of the virus. WHO recommends testing people who may be at increased risk of infection.

In settings with high HCV antibody seroprevalence in the general population (defined as >2% or >5% HCV antibody seroprevalence), WHO recommends that all adults have access to and be offered HCV testing with linkage to prevention, care and treatment services.

About 2.3 million people (6.2%) of the estimated 37.7 million living with HIV globally have serological evidence of past or present HCV infection. Chronic liver disease represents a major cause of morbidity and mortality among persons living with HIV globally.

Prevention

There is no effective vaccine against hepatitis C so prevention depends on reducing the risk of exposure to the virus in health care settings and in higher risk populations. This includes people who inject drugs and men who have sex with men, particularly those infected with HIV or those who are taking pre-exposure prophylaxis against HIV.

Primary prevention interventions recommended by WHO include:
- safe and appropriate use of health care injections;
- safe handling and disposal of sharps and waste;
- provision of comprehensive harm-reduction services to people who inject drugs;
- testing of donated blood for HBV and HCV (as well as HIV and syphilis);
- training of health personnel; and
- prevention of exposure to blood during sex.

WHO response

In May 2016, the World Health Assembly adopted the first *Global health sector strategy on viral hepatitis, 2016-2021*. The strategy highlights the critical role of universal health coverage and sets targets that align with those of the Sustainable Development Goals. The strategy aims to eliminate viral hepatitis as a public health problem by reducing new viral hepatitis infections by 90% and reduce deaths due to viral hepatitis by 65% by 2030.

WHO is working in the following areas to support countries in moving towards achieving the global hepatitis goals under the Sustainable Development Agenda 2030:
- raising awareness, promoting partnerships and mobilizing resources;
- formulating evidence-based policy and data for...
• increase health equities within the hepatitis response;
• preventing transmission; and
• scaling up screening, care and treatment services.

WHO organizes the annual World Hepatitis Day campaign (as 1 of its 9 flagship annual health campaigns) to increase awareness and understanding of viral hepatitis. For World Hepatitis Day 2021, WHO is focusing on the theme “Hepatitis Can’t wait” to highlight the urgency of hepatitis elimination with a view to achieving the 2030 elimination targets.

5. MENINGITIS

KEY FACTS

• Meningitis is a devastating disease with a high case fatality rate and leading to serious long-term complications (sequelae).
• Meningitis remains a major global public-health challenge.
• Epidemics of meningitis are seen across the world, particularly in sub-Saharan Africa.
• Many organisms can cause meningitis including bacteria, viruses, fungi, and parasites.
• Bacterial meningitis is of particular concern. Around 1 in 10 people who get this type of meningitis die and 1 in 5 have severe complications.
• Safe affordable vaccines are the most effective way to deliver long-lasting protection.

The focus of this fact sheet is on the four main causes of acute bacterial meningitis:
• *Neisseria meningitidis* (meningococcus)
• *Streptococcus pneumoniae* (pneumococcus)
• *Haemophilus influenzae*
• *Streptococcus agalactiae* (group B streptococcus)

These bacteria are responsible for more than half of the deaths from meningitis globally and they cause other severe diseases like sepsis and pneumonia.

Other bacteria e.g., *Mycobacterium tuberculosis*, Salmonella, Listeria, Streptococcus and Staphylococcus, viruses such as enteroviruses and mumps, fungi especially Cryptococcus, and parasites like Amoeba are also important causes of meningitis.

Who is at risk?

Although meningitis affects all ages, young children are most at risk. Newborn babies are at most risk from Group B streptococcus, young children are at higher risk from meningococcus, pneumococcus and *Haemophilus influenzae*. Adolescents and young adults are at particular risk of meningococcal disease while the elderly are at particular risk of pneumococcal disease.

People all over the world are at risk of meningitis. The highest burden of disease is seen in a region of sub-Saharan Africa, known as the African Meningitis Belt, especially recognised to be at high risk of epidemics of meningococcal but also pneumococcal meningitis.

Higher risk is seen when people are living in close proximity, for example at mass gatherings, in refugee camps, in overcrowded households or in student, military and other occupational settings. Immune deficiencies such as HIV infection or complement deficiency, immunosuppression, and active or passive smoking can also raise the risk of different types of meningitis.

Transmission

The route of transmission varies by organism. Most bacteria that cause meningitis such as meningococcus, pneumococcus and *Haemophilus influenzae* are carried in the human nose and throat. They spread from person to person by respiratory droplets or throat secretions. Group B streptococcus is often carried in the human gut or vagina and can spread from mother to child around the time of birth.

Carriage of these organisms is usually harmless and helps build up immunity against infection, but the bacteria occasionally invade the body causing meningitis and sepsis.

Signs and symptoms

The incubation period is different for each organism and can range between two and 10 days for bacterial meningitis. Since bacterial meningitis is often accompanied by sepsis, the signs and symptoms cover both conditions.

Signs and symptoms can include:

• severe headache
• stiff or painful neck
• high fever
• avoiding bright light
• drowsy, confused, comatose
• convulsions
• rash
• joint pains
• cold hands and feet
• vomiting

In babies, signs can include:

• poor feeding
• sleepy, difficult to wake, comatose
• irritable, crying when handled
• difficulty breathing, grunting
• fever
• neck rigidity
• bulging soft spot on top of head (fontanelle)
• high pitched cry
• convulsions
Prevention

Preventing meningitis through vaccination is the most effective way to reduce the burden and impact of the disease by delivering long-lasting protection.

Antibiotics are also used to help prevent infection in those at high risk of meningococcal and group B streptococcal disease. Controlling epidemics of meningococcal meningitis relies on both vaccination and antibiotics.

1. Vaccination

Licensed vaccines against meningococcal, pneumococcal and *Haemophilus influenzae* disease have been available for many years. These bacteria have several different strains (known as serotypes or serogroups) and vaccines are designed to protect against the most harmful strains. Over time, there have been major improvements in strain coverage and vaccine availability, but no universal vaccine against these infections exists.

Meningococcus

The meningococcus has 12 serogroups, with A,B,C,W,X and Y causing most meningitis.

There are three types of vaccine available:

- Polysaccharide-protein conjugate vaccines (conjugate vaccines) are used in prevention and outbreak response:
  - They confer longer-lasting immunity, and also prevent carriage, thereby reducing transmission and leading to herd protection.
  - They are effective in protecting children under two years of age.
  - Vaccines are available in different formulations:
    - monovalent vaccines (serogroup A or C)
    - tetravalent vaccines (serogroups A, C, W, Y).
    - in combination (serogroup C and *Haemophilus influenzae* type b)
- Protein based vaccines against serogroup B. These vaccines protect against meningitis in all ages but are not thought to prevent carriage and transmission so do not lead to herd protection.
- Polysaccharide vaccines are safe and effective in children and adults, but weakly protective in infants. Protection is short-lived and they do not lead to herd protection as they do not prevent carriage. They are still used for outbreak control but are being replaced by conjugate vaccines.

Global public health response – elimination of meningococcal A meningitis epidemics in the African meningitis belt

In the African meningitis belt, meningococcus serogroup A accounted for 80–85% of meningitis epidemics before the introduction of a meningococcal A conjugate vaccine through mass preventive campaigns (since 2010) and into routine immunization programmes (since 2016). As of April 2021, 24 of the 26 countries in the meningitis belt have conducted mass preventive campaigns targeting 1-29 year olds (nationwide or in high-risk areas), and half of them have introduced this vaccine into their national routine immunization schedules. Among vaccinated populations, incidence of serogroup A meningitis has declined by more than 99% - no serogroup A case has been confirmed since 2017. Continuing introduction into routine immunization programmes and maintaining high coverage is critical to avoid the resurgence of epidemics.

Cases of meningitis and outbreaks due to other meningococcal serogroups, apart from serogroup B, continue to strike. The roll out of multivalent meningococcal conjugate vaccines is a public health priority to eliminate bacterial meningitis epidemics in the African Meningitis Belt.

Pneumococcus

The pneumococcus has over 97 serotypes, 23 causing most disease.

- Conjugate vaccines are effective from 6 weeks of age at preventing meningitis and other severe pneumococcal infections and are recommended for infants and children up to the age of 5 years, and in some countries for adults aged over 65 years, as well as individuals from certain risk groups. Two different conjugate vaccines are in use that protect against 10 and 13 serotypes. New conjugate vaccines designed to protect against more pneumococcal serotypes are either in development or have been approved for use in adults. Research continues into protein based vaccines.

- A polysaccharide vaccine against 23 serotypes is available but, as for other polysaccharide vaccines, this type of vaccine is considered less effective than conjugate vaccines. It is used mostly in those aged over 65 years to protect against pneumonia, as well as in individuals from certain risk groups. It is not used in children under 2 years of age and is less useful in protecting against meningitis.

*Haemophilus influenzae*

*Haemophilus influenzae* has 6 serotypes, serotype b causing most meningitis.

- Conjugate vaccines protect specifically against *Haemophilus influenzae* serotype b (Hib). They are highly effective in preventing Hib disease and are recommended for routine use in infant vaccine schedules.
Group B streptococcus
Group B streptococcus has 10 serotypes, 1a, 1b, II, III, IV and V causing most disease.
• Conjugate and protein vaccines designed to protect against group B streptococcal disease in mothers and babies are in clinical development.

2. Antibiotics for prevention (chemoprophylaxis)

Meningococcus
Antibiotics for close contacts of those with meningococcal disease, when given promptly, decreases the risk of transmission. Outside the African meningitis belt, chemoprophylaxis is recommended for close contacts within the household. Within the meningitis belt, chemoprophylaxis for close contacts is recommended in non-epidemic situations. Ciprofloxacin is the antibiotic of choice, and ceftriaxone an alternative.

Group B streptococcus
Identifying mothers whose babies are at risk of getting Group B streptococcal disease is recommended in many countries. One way to do this is by universal screening for carriage of Group B streptococcus in pregnancy. Mothers at risk are offered intravenous penicillin during labour to prevent their babies developing Group B streptococcal infection.

Diagnosis
Initial diagnosis of meningitis can be made by clinical examination followed by a lumbar puncture. The bacteria can sometimes be seen in microscopic examinations of the spinal fluid. The diagnosis is supported or confirmed by growing the bacteria from specimens of cerebrospinal fluid or blood, by rapid diagnostic tests or by polymerase chain reaction (PCR). The identification of the serogroups and susceptibility to antibiotics are important to define control measures. Molecular typing and whole genome sequencing identify more differences between strains and inform public health responses.

Treatment
Meningitis is fatal in up to half of patients, when left untreated, and should always be viewed as a medical emergency. Admission to a hospital or health centre is necessary. Isolation of the patient is not usually advised after 24 hours of treatment.

Appropriate antibiotic treatment must be started as soon as possible in bacterial meningitis. Ideally, lumbar puncture should be done first as antibiotics can make it more difficult to grow bacteria from the spinal fluid. However, blood sampling can also help to identify the cause and the priority is to start treatment without delay. A range of antibiotics is used to treat meningitis, including penicillin, ampicillin, and ceftriaxone. During epidemics of meningococcal and pneumococcal meningitis, ceftriaxone is the drug of choice.

Complications and sequelae
One in five people surviving an episode of bacterial meningitis may have long lasting after-effects. These after-effects include hearing loss, seizures, limb weakness, difficulties with vision, speech, language, memory, and communication, as well as scarring and limb amputations after sepsis.

Support and after-care
Meningitis sequelae can have an enormous impact on individuals, families and communities, both financially and emotionally. Sometimes, complications such as deafness, learning impairment or behavioural problems are not recognized by carers and healthcare workers and therefore go untreated.

Those who have lived through meningitis often have health-care needs requiring long-term medical treatments. The ongoing psychosocial impacts of disability from meningitis can have medical, educational, social and human rights-based implications. Despite the high burden of meningitis sequelae on people with meningitis, their families and the community, access to both services and support for these conditions is often insufficient, especially in low and middle income countries. Individuals and families with members disabled by meningitis should be encouraged to seek services and guidance from local and national Organizations of Disabled People (ODPs) and other disability focused organizations, which can provide vital advice about legal rights, economic opportunities and social engagement to ensure people disabled by meningitis are able to live full and rewarding lives.

Surveillance
Surveillance, from case detection to investigation and laboratory confirmation is essential to the control of meningitis. Main objectives include:
• Detect and confirm outbreaks.
• Monitor the incidence trends, including the distribution and evolution of serogroups and serotypes.
• Estimate the disease burden.
• Monitor the antibiotic resistance profile.
• Monitor the circulation, distribution, and evolution of specific strains (clones).
• Estimate the impact of meningitis control strategies, particularly preventive vaccination programmes.
WHO response

The global roadmap “Defeating Meningitis by 2030” was developed by WHO with the support of many partners. The strategy was approved in the first ever resolution on meningitis by the World Health Assembly in 2020 and endorsed unanimously by WHO member states.

The roadmap sets a comprehensive vision “Towards a world free of meningitis” and has three visionary goals:

- Elimination of bacterial meningitis epidemics.
- Reduction of cases of vaccine-preventable bacterial meningitis by 50% and deaths by 70%.
- Reduction of disability and improvement of quality of life after meningitis due to any cause.

It sets a path to achieve goals, through concerted actions across five interconnected pillars:

- Prevention and epidemic control focused on the development of new affordable vaccines, achievement of high immunization coverage, improvement of prevention strategies and response to epidemics.
- Diagnosis and treatment, focused on speedy confirmation of meningitis and optimal patient care.
- Disease surveillance to guide meningitis prevention and control.
- Care and support of those affected by meningitis, focusing on early recognition and improved access to care and support for complications from meningitis, and
- Advocacy and engagement, to ensure high awareness of meningitis, to promote country engagement and to affirm the right to prevention, care, and after-care services.

In a complementary initiative, the WHO is working on the Intersectoral global action plan on epilepsy and other neurological disorders in consultation with Member States to address many challenges and gaps in providing care and services for people with epilepsy and other neurological disorders that exist worldwide. Human rights for people affected by disability are also recognised and addressed in the WHO Global Disability Action Plan in alignment with the Convention on the Rights of the Child and the Convention on the Rights of Persons with Disability (CRPD) and in a landmark resolution on attaining the highest standard of health for persons with disabilities adopted at the 74th World Health Assembly.

While the road map on defeating meningitis addresses all meningitis regardless of the cause, it primarily focuses on the main causes of acute bacterial meningitis (meningococcus, pneumococcus, Haemophilus influenzae and group B streptococcus). These bacteria were responsible for over 50% of the 250,000 deaths from all-cause meningitis in 2019. They also cause other severe diseases like sepsis and pneumonia. For each of these infections, vaccines are either available, or in the case of group B streptococcus, likely to become available in the next few years.
# Yearly Author Index

**Kuwait Medical Journal**  
2021; Volume 53

Kuwait Medical Journal 2021, 53 (4) : 508 - 510

<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdelghani S</td>
<td>25</td>
</tr>
<tr>
<td>Abdulaziz AA</td>
<td>312</td>
</tr>
<tr>
<td>Abunaja MH</td>
<td>265</td>
</tr>
<tr>
<td>Abu-Sini M</td>
<td>265</td>
</tr>
<tr>
<td>Acar A</td>
<td>402</td>
</tr>
<tr>
<td>Agin M</td>
<td>239</td>
</tr>
<tr>
<td>Ahmad S</td>
<td>124</td>
</tr>
<tr>
<td>Ak G</td>
<td>74</td>
</tr>
<tr>
<td>Akan B</td>
<td>436</td>
</tr>
<tr>
<td>Akdag T</td>
<td>337</td>
</tr>
<tr>
<td>Akyol F</td>
<td>473</td>
</tr>
<tr>
<td>Al Lawati A</td>
<td>477</td>
</tr>
<tr>
<td>Al Lawati Z</td>
<td>477</td>
</tr>
<tr>
<td>Al Maraghi NM</td>
<td>421</td>
</tr>
<tr>
<td>Al-Adsani W</td>
<td>1</td>
</tr>
<tr>
<td>Al-Ajmi M</td>
<td>340</td>
</tr>
<tr>
<td>Alalem F</td>
<td>408</td>
</tr>
<tr>
<td>Alali AM</td>
<td>421</td>
</tr>
<tr>
<td>Al-Bader S</td>
<td>8</td>
</tr>
<tr>
<td>Albayrak L</td>
<td>69</td>
</tr>
<tr>
<td>Al-Essa L</td>
<td>265</td>
</tr>
<tr>
<td>Algethami AM</td>
<td>312</td>
</tr>
<tr>
<td>Alghonaim M</td>
<td>140</td>
</tr>
<tr>
<td>Aljofri HE</td>
<td>179</td>
</tr>
<tr>
<td>Alkhowaiter M</td>
<td>140</td>
</tr>
<tr>
<td>Almehashi K</td>
<td>408</td>
</tr>
<tr>
<td>Al-Mutairi NM</td>
<td>124</td>
</tr>
<tr>
<td>Alobaid K</td>
<td>81</td>
</tr>
<tr>
<td>Al Omar RS</td>
<td>179</td>
</tr>
<tr>
<td>Al-Othman N</td>
<td>340</td>
</tr>
<tr>
<td>Alper S</td>
<td>402</td>
</tr>
<tr>
<td>Alqahtani MS</td>
<td>408</td>
</tr>
<tr>
<td>Alsagheir M</td>
<td>408</td>
</tr>
<tr>
<td>Alsaif FA</td>
<td>408</td>
</tr>
<tr>
<td>Alswayyed M</td>
<td>469</td>
</tr>
<tr>
<td>Altawfeeq M</td>
<td>408</td>
</tr>
<tr>
<td>Alwakeel J</td>
<td>140</td>
</tr>
<tr>
<td>Alzahrani AA</td>
<td>312</td>
</tr>
<tr>
<td>Alzahrani KM</td>
<td>312</td>
</tr>
<tr>
<td>Aras M</td>
<td>212</td>
</tr>
<tr>
<td>Arsen U</td>
<td>388</td>
</tr>
<tr>
<td>Arslan K</td>
<td>447</td>
</tr>
<tr>
<td>Asil E</td>
<td>84</td>
</tr>
<tr>
<td>Atik A</td>
<td>87</td>
</tr>
<tr>
<td>Atik YT</td>
<td>162</td>
</tr>
<tr>
<td>Ayan A</td>
<td>395</td>
</tr>
<tr>
<td>Aydogdu S</td>
<td>239</td>
</tr>
<tr>
<td>Aylanc N</td>
<td>90</td>
</tr>
<tr>
<td>Aytekin K</td>
<td>461</td>
</tr>
<tr>
<td>Baran H</td>
<td>51</td>
</tr>
<tr>
<td>Baran I</td>
<td>184</td>
</tr>
<tr>
<td>Baris A</td>
<td>167</td>
</tr>
<tr>
<td>Barutcuoglu B</td>
<td>74</td>
</tr>
<tr>
<td>Basdelioglu K</td>
<td>87</td>
</tr>
<tr>
<td>Basmaci I</td>
<td>259, 306</td>
</tr>
<tr>
<td>Baydilli N</td>
<td>162</td>
</tr>
<tr>
<td>Bozkurt A</td>
<td>402</td>
</tr>
<tr>
<td>Bozkurt IH</td>
<td>259, 306</td>
</tr>
<tr>
<td>Bozkurt S</td>
<td>344</td>
</tr>
<tr>
<td>Bulbul M</td>
<td>324</td>
</tr>
<tr>
<td>Bulut C</td>
<td>447</td>
</tr>
<tr>
<td>Caltekin I</td>
<td>69</td>
</tr>
<tr>
<td>Canda AE</td>
<td>84</td>
</tr>
<tr>
<td>Cander S</td>
<td>453</td>
</tr>
<tr>
<td>Carkci E</td>
<td>429</td>
</tr>
<tr>
<td>Cayir S</td>
<td>51</td>
</tr>
<tr>
<td>Celik S</td>
<td>259, 306</td>
</tr>
<tr>
<td>Cevik B</td>
<td>282</td>
</tr>
<tr>
<td>Ceylan C</td>
<td>402</td>
</tr>
<tr>
<td>Chao C-C</td>
<td>199</td>
</tr>
<tr>
<td>Chen L-Y</td>
<td>458</td>
</tr>
<tr>
<td>Cigdem UK</td>
<td>13</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Cil H</td>
<td>173</td>
</tr>
<tr>
<td>Cimen HI</td>
<td>162</td>
</tr>
<tr>
<td>Cizmeci EA</td>
<td>173</td>
</tr>
<tr>
<td>Daher J</td>
<td>329</td>
</tr>
<tr>
<td>Damar IH</td>
<td>131</td>
</tr>
<tr>
<td>Dahtsi AA</td>
<td>421</td>
</tr>
<tr>
<td>Degirmenci T</td>
<td>259, 306</td>
</tr>
<tr>
<td>Demir B</td>
<td>69</td>
</tr>
<tr>
<td>Demir ME</td>
<td>301</td>
</tr>
<tr>
<td>Dere HH</td>
<td>51</td>
</tr>
<tr>
<td>Dolanbay T</td>
<td>212</td>
</tr>
<tr>
<td>Donmez A</td>
<td>184</td>
</tr>
<tr>
<td>Duman T</td>
<td>56</td>
</tr>
<tr>
<td>Dursun I</td>
<td>251</td>
</tr>
<tr>
<td>Eid SM</td>
<td>97</td>
</tr>
<tr>
<td>Eid T</td>
<td>329</td>
</tr>
<tr>
<td>Eker N</td>
<td>90</td>
</tr>
<tr>
<td>Ekhmimi AS</td>
<td>291</td>
</tr>
<tr>
<td>Elamin E</td>
<td>25</td>
</tr>
<tr>
<td>Electricwala QY</td>
<td>421</td>
</tr>
<tr>
<td>El-Hamshary O</td>
<td>291</td>
</tr>
<tr>
<td>El-Reshaih K</td>
<td>8</td>
</tr>
<tr>
<td>Elshaikh N</td>
<td>25</td>
</tr>
<tr>
<td>Eltayeb LB</td>
<td>25</td>
</tr>
<tr>
<td>Engin M</td>
<td>411</td>
</tr>
<tr>
<td>Ensari S</td>
<td>51</td>
</tr>
<tr>
<td>Erenler BH</td>
<td>332</td>
</tr>
<tr>
<td>Ergani B</td>
<td>136, 145</td>
</tr>
<tr>
<td>Ergil J</td>
<td>184</td>
</tr>
<tr>
<td>Ermutlu C</td>
<td>167</td>
</tr>
<tr>
<td>Eroz R</td>
<td>131</td>
</tr>
<tr>
<td>Ersoy O</td>
<td>271</td>
</tr>
<tr>
<td>Esenel CZ</td>
<td>461</td>
</tr>
<tr>
<td>Gamze T</td>
<td>13</td>
</tr>
<tr>
<td>Gencer M</td>
<td>317</td>
</tr>
<tr>
<td>Ghunaim MY</td>
<td>97</td>
</tr>
<tr>
<td>Gok B</td>
<td>84</td>
</tr>
<tr>
<td>Gokce A</td>
<td>162</td>
</tr>
<tr>
<td>Gokcen E</td>
<td>69</td>
</tr>
<tr>
<td>Gokcinar D</td>
<td>436</td>
</tr>
<tr>
<td>Gonultas MA</td>
<td>447</td>
</tr>
<tr>
<td>Gul HF</td>
<td>212</td>
</tr>
<tr>
<td>Gul OO</td>
<td>453</td>
</tr>
<tr>
<td>Gulten A</td>
<td>31</td>
</tr>
<tr>
<td>Gumus M</td>
<td>239</td>
</tr>
<tr>
<td>Guner E</td>
<td>209</td>
</tr>
<tr>
<td>Gunluosoy B</td>
<td>259</td>
</tr>
<tr>
<td>Gura M</td>
<td>150</td>
</tr>
<tr>
<td>Gurpinar T</td>
<td>429</td>
</tr>
<tr>
<td>Halis F</td>
<td>162</td>
</tr>
<tr>
<td>Hamadneh L</td>
<td>265</td>
</tr>
<tr>
<td>Hamamri A</td>
<td>369</td>
</tr>
<tr>
<td>Hasirci E</td>
<td>38</td>
</tr>
<tr>
<td>Hatipoglu CA</td>
<td>447</td>
</tr>
<tr>
<td>Hattab S</td>
<td>369</td>
</tr>
<tr>
<td>Haznedarooglu CI</td>
<td>344</td>
</tr>
<tr>
<td>Hendi OM</td>
<td>312</td>
</tr>
<tr>
<td>Hui C</td>
<td>191</td>
</tr>
<tr>
<td>Ilbey YO</td>
<td>136, 145</td>
</tr>
<tr>
<td>Ince C</td>
<td>173</td>
</tr>
<tr>
<td>Jalali A</td>
<td>44</td>
</tr>
<tr>
<td>Karabacak M</td>
<td>136, 145</td>
</tr>
<tr>
<td>Karacor T</td>
<td>324</td>
</tr>
<tr>
<td>Kasnakova P</td>
<td>346</td>
</tr>
<tr>
<td>Kassiri H</td>
<td>44</td>
</tr>
<tr>
<td>Kataki MM</td>
<td>44</td>
</tr>
<tr>
<td>Kervancioglu E</td>
<td>38</td>
</tr>
<tr>
<td>Kesici S</td>
<td>150, 195</td>
</tr>
<tr>
<td>Kesici U</td>
<td>195</td>
</tr>
<tr>
<td>Khan A</td>
<td>482</td>
</tr>
<tr>
<td>Khreesha LA</td>
<td>97</td>
</tr>
<tr>
<td>Kilicaslan B</td>
<td>173</td>
</tr>
<tr>
<td>Kilova K</td>
<td>346</td>
</tr>
<tr>
<td>Kinc MF</td>
<td>18</td>
</tr>
<tr>
<td>Kinci OS</td>
<td>18</td>
</tr>
<tr>
<td>Kinikli S</td>
<td>447</td>
</tr>
<tr>
<td>Kirpınar I</td>
<td>466</td>
</tr>
<tr>
<td>Kirteke F</td>
<td>56</td>
</tr>
<tr>
<td>Kettana N</td>
<td>369</td>
</tr>
<tr>
<td>Koc G</td>
<td>136, 145</td>
</tr>
<tr>
<td>Koca N</td>
<td>453</td>
</tr>
<tr>
<td>Kokanali MK</td>
<td>18</td>
</tr>
<tr>
<td>Korkmaz H</td>
<td>69</td>
</tr>
<tr>
<td>Koseoglu D</td>
<td>332</td>
</tr>
<tr>
<td>Koseoglu H</td>
<td>271</td>
</tr>
<tr>
<td>Kovalak E</td>
<td>167</td>
</tr>
<tr>
<td>Kozacioglu Z</td>
<td>136, 145</td>
</tr>
<tr>
<td>Kucukler FK</td>
<td>332</td>
</tr>
<tr>
<td>Kuo S-C</td>
<td>199</td>
</tr>
<tr>
<td>Li S-J</td>
<td>199</td>
</tr>
<tr>
<td>Lotfi M</td>
<td>44</td>
</tr>
<tr>
<td>Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Madani M</td>
<td>25</td>
</tr>
<tr>
<td>Mirka L-S</td>
<td>388</td>
</tr>
<tr>
<td>Mohammed AA</td>
<td>312</td>
</tr>
<tr>
<td>Mohammed EL</td>
<td>246</td>
</tr>
<tr>
<td>Mohanan K</td>
<td>157</td>
</tr>
<tr>
<td>Mohsen A</td>
<td>329</td>
</tr>
<tr>
<td>Mokaddas E</td>
<td>124</td>
</tr>
<tr>
<td>Nacar MC</td>
<td>324</td>
</tr>
<tr>
<td>Nagy E</td>
<td>232</td>
</tr>
<tr>
<td>Nair D</td>
<td>81</td>
</tr>
<tr>
<td>Nalbant B</td>
<td>184</td>
</tr>
<tr>
<td>Ng T-Y</td>
<td>458</td>
</tr>
<tr>
<td>Obut A</td>
<td>167</td>
</tr>
<tr>
<td>Oguz U</td>
<td>162</td>
</tr>
<tr>
<td>Okay M</td>
<td>344</td>
</tr>
<tr>
<td>Oommen A</td>
<td>179</td>
</tr>
<tr>
<td>Orhan O</td>
<td>150</td>
</tr>
<tr>
<td>Ortatati M</td>
<td>395</td>
</tr>
<tr>
<td>Oruc N</td>
<td>74</td>
</tr>
<tr>
<td>Ozcekeic AN</td>
<td>150</td>
</tr>
<tr>
<td>Ozkan D</td>
<td>184</td>
</tr>
<tr>
<td>Ozkan NK</td>
<td>150</td>
</tr>
<tr>
<td>Ozkardes H</td>
<td>38</td>
</tr>
<tr>
<td>Ozsoy IE</td>
<td>93</td>
</tr>
<tr>
<td>Ozturkmen Y</td>
<td>429</td>
</tr>
<tr>
<td>Oztemiz AO</td>
<td>74</td>
</tr>
<tr>
<td>Parayil SM</td>
<td>81</td>
</tr>
<tr>
<td>Parildar Z</td>
<td>74</td>
</tr>
<tr>
<td>Pehlivanoglu T</td>
<td>429</td>
</tr>
<tr>
<td>Polat AE</td>
<td>429</td>
</tr>
<tr>
<td>Polat B</td>
<td>429</td>
</tr>
<tr>
<td>Qarasniq BK</td>
<td>63</td>
</tr>
<tr>
<td>Radmila P</td>
<td>388</td>
</tr>
<tr>
<td>Ran G</td>
<td>441</td>
</tr>
<tr>
<td>Ranko Z</td>
<td>388</td>
</tr>
<tr>
<td>Resorlu M</td>
<td>90</td>
</tr>
<tr>
<td>Sahan E</td>
<td>204, 466</td>
</tr>
<tr>
<td>Sahin DA</td>
<td>383</td>
</tr>
<tr>
<td>Sahin Y</td>
<td>383</td>
</tr>
<tr>
<td>Salama I</td>
<td>369</td>
</tr>
<tr>
<td>Sanja V</td>
<td>388</td>
</tr>
<tr>
<td>Sankararaman N</td>
<td>340</td>
</tr>
<tr>
<td>Sargin S</td>
<td>87</td>
</tr>
<tr>
<td>Sari C</td>
<td>271</td>
</tr>
<tr>
<td>Sari SO</td>
<td>271</td>
</tr>
<tr>
<td>Savrun A</td>
<td>69</td>
</tr>
<tr>
<td>Sayin MM</td>
<td>184</td>
</tr>
<tr>
<td>Sefik E</td>
<td>259, 306</td>
</tr>
<tr>
<td>Seker KG</td>
<td>209</td>
</tr>
<tr>
<td>Sezen O</td>
<td>282</td>
</tr>
<tr>
<td>Sheashaa H</td>
<td>232</td>
</tr>
<tr>
<td>Shemies RS</td>
<td>232</td>
</tr>
<tr>
<td>Sipahi M</td>
<td>317</td>
</tr>
<tr>
<td>Sivri S</td>
<td>271</td>
</tr>
<tr>
<td>Somuncu E</td>
<td>473</td>
</tr>
<tr>
<td>Srinivasan C</td>
<td>157</td>
</tr>
<tr>
<td>Taha TH</td>
<td>1</td>
</tr>
<tr>
<td>Tangilntiz A</td>
<td>204</td>
</tr>
<tr>
<td>Tao L</td>
<td>191</td>
</tr>
<tr>
<td>Tarakji A</td>
<td>140</td>
</tr>
<tr>
<td>Tasci Y</td>
<td>18</td>
</tr>
<tr>
<td>Tawgoz F</td>
<td>63</td>
</tr>
<tr>
<td>Telatar A</td>
<td>167</td>
</tr>
<tr>
<td>Teodora B</td>
<td>388</td>
</tr>
<tr>
<td>Tezcan MA</td>
<td>93</td>
</tr>
<tr>
<td>Tork SE</td>
<td>291</td>
</tr>
<tr>
<td>Tumgor G</td>
<td>239</td>
</tr>
<tr>
<td>Turan IO</td>
<td>436</td>
</tr>
<tr>
<td>Turk H</td>
<td>136, 145</td>
</tr>
<tr>
<td>Tuzuner T</td>
<td>167</td>
</tr>
<tr>
<td>Ugur R</td>
<td>209</td>
</tr>
<tr>
<td>Unal NG</td>
<td>74</td>
</tr>
<tr>
<td>Usama S</td>
<td>140</td>
</tr>
<tr>
<td>Venkataraman SK</td>
<td>157</td>
</tr>
<tr>
<td>Waggialah HA</td>
<td>25, 246</td>
</tr>
<tr>
<td>Wang C-Y</td>
<td>458</td>
</tr>
<tr>
<td>Wang L</td>
<td>441</td>
</tr>
<tr>
<td>Wu Y</td>
<td>441</td>
</tr>
<tr>
<td>Yalcinkaya S</td>
<td>417</td>
</tr>
<tr>
<td>Yarimoglu S</td>
<td>306</td>
</tr>
<tr>
<td>Yenipazar G K</td>
<td>402</td>
</tr>
<tr>
<td>Yilmaz KB</td>
<td>337</td>
</tr>
<tr>
<td>Yilmaz O</td>
<td>251</td>
</tr>
<tr>
<td>Yongbao W</td>
<td>191</td>
</tr>
<tr>
<td>Younan H</td>
<td>1</td>
</tr>
<tr>
<td>Younis D</td>
<td>232</td>
</tr>
<tr>
<td>Yucel A</td>
<td>239</td>
</tr>
<tr>
<td>Yuuskekayya HA</td>
<td>239</td>
</tr>
<tr>
<td>Yuekeli OT</td>
<td>271</td>
</tr>
<tr>
<td>Zighan L</td>
<td>271</td>
</tr>
<tr>
<td>Zieghe L</td>
<td>369</td>
</tr>
</tbody>
</table>
A case with Fahr’s syndrome who applied to the Emergency Department with convulsion complaint. 53(2):212-214

A total hip arthroplasty practice in a coxarthrosis case with hereditary multiple exostoses. 53(1):87-89

Acute hypertriglyceridemia and hyperglycemia related to mirtazapine: A case report. 53(2):204-208

An unexpected sign on mammography: Air hole. 53(3):337-339

Anesthesia and postoperative complications in sleeve gastrectomy operations performed in morbid obesity surgery. 53(3):317-323

Arthroscopic Bankart repair by using the antero-superior portal for visualization. 53(4):429-435

Can diabetes insipidus be used as a marker for multisystemic and progressive disease in Langerhans cell histiocytosis? 53(4):453-457

Can we detect index tumor using transrectal ultrasound-guided prostate biopsy? 53(2):136-139

Case series of pancreas transplant in Kingdom of Saudi Arabia. 53(4):408-410

Comparison of diagnostic tests performed in patients with suspected acute osteomyelitis. 53(4):395-401

Comparison of equal doses of bupivacaine and levobupivacaine in terms of efficiency in lateral approach to popliteal sciatic nerve blocks: a randomized controlled trial. 53(2):150-156

Comparison of psoriasis area and severity index and physician’s global assessment in determining psoriasis severity. 53(4):402-407

Considering the effect of Stapes Footplate’s macroscopic vision on surgical complication rate. 53(1):51-55


Diagnostic value of TIMP-1, TIMP-2, TGF-β1, YKL-40 in the evaluation of liver fibrosis in patients with chronic hepatitis B. 53(4):447-452

Do all Familial Mediterranean Fever (FMF) patients with recurrent chest pain have cardiac problems? 53(2):131-135

Does bipolar transuretral resection of prostate increase the incidence of urethral stricture? 53(1):38-43

Effect of BMI on outcome in peritoneal dialysis patients: a single Saudi center review. 53(2):140-144

Effects of 5α-reductase inhibitor therapy with dutasteride on bone metabolism in patients with benign prostatic hyperplasia. 53(2):162-166

Effects of sevoflurane and desflurane on microcirculation during non-cardiac surgery. 53(2):173-178

Emergency parathyroidectomy under combined superficial and intermediate cervical plexus block: A fatal case of hypercalcemic crisis due to parathyroid carcinoma. 53(4):473-476

Evaluation of Speed-oligo Mycobacteria assay for rapid differentiation and identification of Mycobacterium tuberculosis and nontuberculous mycobacteria in MGIT 960 system cultures from human clinical samples. 53(2):124-130
Evaluation of the flexible laryngeal mask airway in 120 patients undergoing tympanoplasty. 53(4):441-446

External validation of a new nomogram for prediction of cancer specific and all-cause mortality in bladder cancer patients undergoing radical cystectomy. 53(3):306-311

First report of t(1;15)(q21;q11.2) and t(1;21)(q21;q11.2) anomalies in Burkitt Lymphoma. 53(3):344-345

Functional independence level of Wagner grade 3 diabetic foot ulcer patients using diabetic foot ulcer scale. 53(2):157-161

Fusariosis as a cause of subcutaneous infection in immune-compromised patient. 53(1):81-83

Gamma-glutamyltransferase and lactic acid as markers of oxidative stress in carbon monoxide poisoning. 53(1):69-73

Genetic studies on glucose-6-phosphate dehydrogenase deficiency in neonates suffering from hemolytic anemia. 53(3):291-300

Hyalinizing trabecular tumor of the thyroid gland: A case report and review of the literature. 53(4):469-472

Impact of dialyzer membrane’s flow characteristics on parathormone levels and its association with anemia in maintenance hemodialysis patients. 53(3):301-305

Intubating conditions with articulating vs. intubating stylet during video laryngoscope intubation in anticipated difficult airway patients. 53(2):184-190

Invasive fungal rhinosinusitis in a chronic kidney disease patient. 53(1):97-100

Is Gleason score in transrectal ultrasound guided prostate biopsy consistent with Gleason score in radical prostatectomy? 53(2):145-149

Langerhans cell histiocytosis: diagnosis on thyroid aspirate and effective treatment with systemic chemotherapy. 53(3):332-336

Mapping the intensive care unit environment and health care workers for methicillin-resistant Staphylococcus aureus with mecA gene confirmation and antibacterial resistance pattern identification in a district hospital in Amman. 53(3):265-270

Molecular epidemiology of Mycobacterium tuberculosis and rifampicin resistance among pulmonary tuberculosis patients in Erbil City, Kurdistan Region, Iraq. 53(1):63-68


Oliver Sacks syndrome treated with adaptation to hearing aid. 53(4):466-468

Oral hygiene habits and storage method impact on toothbrush contamination among participants in Kuwait. 53(4):421-428

Overview of PCSK9 inhibitor use: Local and regional implications for the treatment of dyslipidemia. 53(1):1-7

Overview on outbreak investigations of 2019 novel Coronavirus disease. 53(4):482-484

Parapharyngeal spindle cell rhabdomyosarcoma presenting as infra-auricular pain with vocal cord paralysis. 53(4):458-460

Patellar tendon ganglion cyst with Osgood Schlatter disease: A rare coexistence. 53(1):90-92


Preliminary findings: Functionality in patients with migraine. 53(1):56-62

Prevalence of vitamin D deficiency among patients attending orthopedic clinic in Taif, Saudi Arabia: A single center study. 53(3):312-316

Primary mucinous adenocarcinoma of the renal pelvis with signet ring cell formation. 53(2):191-194

Pseudohyperkalemia in a neonate with hyperleukocytosis due to transient myeloproliferative disorder. 53(3):340-343

Pyelonephritis due to spontaneous massive steinstrasse and its treatment: A rare case report. 53(2):209-211
Radiological findings from patients with COVID-19: A meta-analysis of clinical studies. 53(2):117-123

Rare etiology of ischemic colitis in an Emergency Department: Phlebosclerotic colitis. 53(2):199-203


Relationship with serum bilirubin levels and mortality in critically ill patients. 53(4):436-440

Retrospective evaluation of cancer patients in Intensive Care Unit. 53(1):31-37

Robotic radical prostatectomy in patients with cerebrovascular disease history: safe but epilepsy. 53(1):84-86


Serous cystadenoma of fallopian tube: A case report of a rare pathology presented as an isolated tubal torsion. 53(3):329-331

Short-term prognostic importance of ambulatory blood pressure variability in patients with acute ST elevation myocardial infarction. 53(3):251-258

Spontaneous submucosal hematoma in the sigmoid colon causing complete intestinal obstruction in a patient with cerebral palsy. 53(2):195-198

Ten years clinical and epidemiological picture of cutaneous Leishmaniasis in the Dasht-e-Azadegan County, Southwestern Iran. 53(1):44-50

Testing the depth of anesthesia in total intravenous and balanced anesthesia. 53(4):388-394

The effect of disease activity on cardiac autonomic functions in inflammatory bowel disease. 53(3):271-281

The effect of neutrophil lymphocyte ratio and monocyte HDL ratio in indicating additional arterial disease in patients scheduled to undergo elective coronary bypass operation. 53(4):411-416

The experience of Oman with establishing a field hospital during COVID-19 pandemic. 53(4):477-481

The frequency of celiac disease in children with chronic constipation. 53(4):383-387

The pattern of skin diseases in a multidisciplinary medical unit. 53(1):8-12

The relationship between different types of nutritional supportive treatment and infection in patients with diagnosis of Chronic Obstructive Pulmonary Disease. 53(1):13-17

The relationship between nutritional status and Fetuin-A in Inflammatory Bowel Disease patients. 53(1):74-80

The role of ultrasonographic measurement of bladder and detrusor wall thickness in diagnosis of urinary incontinence. 53(1):18-24

The value of integrated pulmonary index monitoring in pediatric endoscopic interventions under sedation. 53(3):282-290

Thrombotic tendency in Sudanese juvenile acute lymphoblastic leukemia patients: 81 cases without leukemia treatment. 53(3):246-250

Treatment of acute postpartum uterine inversion case with a different compression suture technique. 53(3):324-328


Unusual location of the hydatid cyst: Coexistence of serratus anterior muscle and lung. 53(1):93-96

Ursodeoxycholic acid treatment for duodenogastric reflux in childhood. 53(3):239-245

Validity of Paprosky and Saleh acetabular bone loss classifications for CLS expansion cup revision surgery. 53(2):167-172

Vitamin D deficient diet and autism. 53(2):179-183

What is the best cut-off time to prevent worsening prognosis in muscle-invasive bladder cancer? 53(3):259-264